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Abstract 
 
The purpose of this doctoral project was to investigate the effects of aerobic 
exercise on breast cancer risk biomarkers such as endogenous sex hormone levels and 
urinary estrogen metabolites in premenopausal women. In this study, 391 healthy, 
sedentary, young eumenorrheic women were randomized to either an exercise 
intervention of 30 minutes of moderate-to-vigorous aerobic exercise five times a week for 
approximately 16 weeks (n = 212) or a usual-lifestyle sedentary control group (n = 179). 
Outcome measures were taken at baseline and follow-up. 
The study described in Chapter 2 evaluated changes in serum levels of estradiol, 
estrone sulfate, testosterone, progesterone, and sex hormone-binding globulin (SHBG) 
via radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA) 
methods. As expected, the intervention resulted in significant increases in aerobic fitness, 
lean body mass, and decreases in percent body fat in women in the exercise group. No 
significant changes in body weight were observed between or within groups. The major 
finding of this study was a significant decrease in progesterone in the exercise group, 
albeit this change was similar to that of the control group. The lack of significant changes 
in sex hormone or SHBG levels due to the intervention (without a concomitant weight 
change) between or within groups suggest this may not be a plausible mechanism by 
which physical activity decreases breast cancer risk in premenopausal women. 
The second study described in Chapter 3 measured changes in urinary levels of 
estrogens (estrone [E1], and estradiol [E2]), and ten estrogen metabolites via liquid 
chromatography/tandem mass spectrometry (LC-MS/MS). In addition, the ratios of 2-
 iv 
hydroxyestrone to 16α-hydroxyestrone (2-OHE1/16α-OHE1) and 2-hydroxyestrone to 4-
hydroxyestrone (2-OHE1/4-OHE1) were calculated. Although no significant changes in 
urinary estrogens or their metabolites were found between groups, the 2-OHE1/16α-OHE1 
ratio in exercisers increased significantly (P = 0.043) compared to the control group (P = 
0.045), even after adjustment for baseline values. 
Collectively, the results of this doctoral project suggest the positive effects 
aerobic exercise allegedly has on premenopausal breast cancer risk may be mediated 
through hormonal mechanisms that involve changes in estrogen metabolism but not 
necessarily changes in endogenous sex hormone levels. 
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I. BREAST CANCER 
A. Relevance 
Breast cancer continues to be the most widely diagnosed disease and second leading 
cause of death in women in the United States. In 2014, breast cancer is expected to 
account for 29% of all newly diagnosed cancer cases in women and 15% female 
mortality, which translates into 232,670 new cases of breast cancer and 40,000 deaths [1]. 
Despite significant improvements in the last three decades in 5-year survival rates (90% 
survival rate in 2003-09 vs. 75% survival rate in 1975-77), the incidence of breast cancer 
has remained stable since 2003 [1]. These statistics suggest great advances have been 
made in the diagnosis and treatment of breast cancer but much improvement is still 
needed in the prevention of the disease. 
B. Risk Factors 
As in the case with most cancers, age is one of the best predictors of breast cancer 
risk. The probability a woman will develop breast cancer within her lifetime is 1 in 8 or 
12.3%, and the risk increases rapidly with each passing decade of life after 50 [1]. 
Specifically, the probability of being diagnosed with breast cancer at age younger than 50 
is 1 in 53 and the odds increase to 21%, 84%, and 350% at age 50, 60, and 70 years old 
or older, respectively [1]. Other well-established risk factors include specific hereditary, 
genetic, environmental, reproductive, hormonal, and lifestyle factors. 
For instance, positive family history of breast cancer, number and type of relatives 
(1st and 2nd degree) with breast cancer, and age at which these relatives became affected 
are hereditary risk factors associated with 5-10% of the total breast cancer burden [2]. Of 
  3
the breast cancer cases considered to be hereditary, at least 30% have been attributed to 
mutations in two major breast cancer susceptibility genes known as BRCA1 [3] and 
BRCA2 [4] genes. Although the prevalence of BRCA1 and BRCA2 gene mutations in the 
general population is 1 in 1000, accounting for less than 5% of all breast cancer cases, 
women with these mutations are 60-85% more likely to develop the disease [5, 6]. The 
likelihood of carrying a mutation in these susceptibility genes has been linked to early-
onset breast cancer, breast and ovarian cancer, and Ashkenazi Jewish ancestry [7, 8]. 
Rare germline mutations in other high penetrance genes (relative risk > 5) such as 
TP53, PTEN, SKT-11, MMR genes, and CDH1 have been recently associated with breast 
cancer syndromes such as Li-Fraumeni syndrome, Cowden/PTEN hamartoma tumor 
syndrome, Peutz-Jeghers syndrome, Lynch syndrome, and hereditary diffuse gastric 
cancer, respectively [9]. Although these syndromes are associated with less than 1% of 
all breast cancer cases, breast cancer is the most common malignancy among females 
carrying these mutations [9]. 
Another well-established but uncommon risk factor for breast cancer in women 
involves radiation exposure to the chest. Data from a newly published study suggests this 
risk is much larger than originally thought. Specifically, the study found women who had 
received radiation to the chest as children to treat cancers such as Hodgkin lymphoma 
and non-Hodgkin lymphoma, were 20 times more likely to develop breast cancer than 
average women [10]. In addition, 30% of women in the study developed breast cancer by 
the time they were 50 years old, and approximately 20% of those affected died of the 
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disease within ten years of being diagnosed [10]. Because of this deleterious side effect, 
high-dose radiation is no longer used to treat childhood Hodgkin lymphoma. 
Reproductive characteristics such as early age at menarche (< 12 years old), older age 
at menopause (≥ 55 years old), nulliparity, and older age at first live birth (> 30 years old) 
have been shown to put women at higher risk for breast cancer [11]. Similarly, women 
with benign breast disease such as atypical hyperplasia [12] and history of one or more 
breast biopsies are considered to be at higher risk for breast cancer [11, 13, 14]. 
The use of exogenous sex hormones has long been associated with an increased risk 
for breast cancer. This is particularly the case of postmenopausal women who have used 
estrogen-plus-progestin hormone replacement therapy (HRT) [15]. The Women’s Health 
Initiative, a very large randomized clinical trial (n = 16,608) reported postmenopausal 
women who had used a combined estrogen-progestin HRT had a significantly higher 
hazard ratio (HR) for total (HR = 1.24, P < 0.001) and invasive breast cancer (HR = 1.24, 
P = 0.003) than women who did not use any kind of HRT [16]. 
In premenopausal women, the use of exogenous sex hormones in the form of 
combined estrogen and progestin oral contraceptives (OC) has not been regarded as an 
established risk factor. Results of case-control and cohort studies have either reported 
borderline effects or no association at all with breast cancer. For instance, a recent meta-
analysis of 66 case-control and cohort studies (totaling 35,527 breast cancer cases and 
180,318 controls) found premenopausal women who had ever taken OC had a slightly 
higher odds ratio (OR) (OR = 1.10, 95% confidence interval (CI): 1.03-1.18) than those 
who had never taken OC [17]. In addition, women who took OC the longest (> 10 years 
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vs. < 5 years) were at 17% greater risk, although non-significantly. In the Nurses’ Health 
Study (NHS), the largest prospective cohort to investigate the association between OC 
and female mortality, the use of OC by premenopausal women was found to be not 
significantly associated with a higher risk for breast cancer after 24 [18] or even 36 years 
of follow-up [19]. 
Lifestyle behaviors associated with breast cancer risk that are particularly amenable 
for intervention include alcohol consumption, physical inactivity, excess body weight, 
and breastfeeding. 
The consumption of alcohol in habitual to moderate quantities, that is, up to one drink 
per day in women, has been associated with lower rates of mortality, coronary artery 
disease, diabetes mellitus, and stroke [20]. However, even in these low quantities, alcohol 
consumption has also been associated with a significantly higher risk for breast cancer. 
Specifically, a meta-analysis of 65 studies reported that women, regardless of whether 
they had ever smoked or not, increased their relative risk (RR) for breast cancer by 7.1% 
with each additional 10g per day of alcohol consumed (95% CI: 5.5-8.7%; P < 0.0001) 
[21]. 
With a global prevalence of 39%, physical inactivity is estimated to be responsible for 
10% of the incidence of breast cancer worldwide [22]. This is extremely relevant given 
that in a review of 73 studies conducted worldwide, women who were the most 
physically active compared to those who were inactive had a significant average risk 
reduction of 25% of breast cancer [23]. 
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Similarly, excess body weight (mostly due to physical inactivity) has been strongly 
associated with breast cancer in women. Observational studies have revealed this 
association is mediated by menopausal status. For instance, in postmenopausal women, 
most large case-control studies (but only some cohort studies) have found a clear positive 
association between body mass index (BMI) and breast cancer risk, while in 
premenopausal women, most cohort studies have found the association to be inverse [24, 
25].  
Consistent with these observations, a meta-analysis of seven prospective studies 
totaling 337, 819 women and 4, 385 incident cases of invasive breast cancer, found 
nonlinear positive and inverse associations with breast cancer in post- and premenopausal 
women, respectively [26]. Specifically, postmenopausal women with a BMI greater than 
31 had a 29% higher risk for breast cancer (95% CI: 1.03-1.60, Ptrend = 0.001) than 
women with a BMI of less than 21. In postmenopausal women, the main source of 
estrogen production comes from the aromatization of androgens in adipose tissue and 
therefore, higher fat mass levels (associated with higher BMI levels) are associated with 
higher estrogen levels [27]. In addition, in postmenopausal women excess weight is 
associated with lower levels of SHBG [28], which also leads to higher circulating levels 
of biologically active estrogens [29]. In contrast, premenopausal women with a BMI 
greater than 31 had a 56% lower risk (95% CI: 0.34-0.85, Ptrend = 0.007) for breast cancer 
than women with a BMI of less than 21. It has been hypothesized that obesity in young 
women is protective against breast cancer by inducing more frequent anovulatory 
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menstrual cycles and luteal phase defects [30, 31], which ultimately result in lower levels 
of estradiol and progesterone [32]. 
Unlike the other modifiable lifestyle choices, breastfeeding has been consistently 
associated with numerous and long-lasting benefits for both babies and mothers, 
especially as breastfeeding duration increases. Point-in-case, a meta-analysis of 32 
studies (n = 134,767) found women who had ever breastfed were 14% less likely (95% 
CI: 0.84-0.89) to be at risk for breast cancer than women who never breastfed, even after 
the adjustment for parity [17]. Furthermore, the protective effect of breastfeeding on 
breast cancer risk increased to 28% (95% CI: 0.58-0.89) when mothers breastfed ≥ 12 
months relative to non-breastfeeding women [17]. 
Finally, factors not yet considered to be established risk factors for breast cancer but 
that are currently being investigated include mammographic density, bone density, 
fracture risk, and endogenous sex hormone levels. In 1976, John N. Wolfe proposed a 
system of four categories based on mammographic density in which higher density 
correlated with higher risk [33, 34]. In fact, a recent study involving 2,392,998 women 
found a RR of 4.09 (95% CI: 3.6-4.6) for women in the extremely dense category [35]. 
Currently, the use of mammographic density to assess breast cancer risk has been limited 
and controversial due to possible “masking” of breast cancer by dense breast tissue [15]. 
Masking occurs when tumors in dense breast tissue are missed at a woman’s first 
mammographic examination but are eventually detected at subsequent follow-up 
examinations, creating the impression of a higher risk associated with mammographic 
density. 
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Bone density and fracture risk are also considered potential risk factors since they are 
believed to be surrogate markers for increased estrogen exposure. Higher estrogen 
exposure, in turn, is thought to be associated with increased risk for breast cancer. In 
general, studies in women have shown a positive and inverse association between breast 
cancer risk and bone density and bone fractures, respectively [15]. 
Evidence in support of using endogenous sex hormone levels to predict breast cancer 
risk continues to accumulate, especially for postmenopausal women. In this population, a 
positive association between breast cancer risk and endogenous sex hormone levels has 
been identified. For instance, in a current re-analysis of 18 prospective studies, the OR 
for postmenopausal women in the highest quintile for estradiol, estrone, and testosterone, 
compared to women in the lowest quintile, was 2.15 (95% CI: 1.87-2.46), 1.81 (95% CI: 
1.56-2.10), and 2.04 (95% CI: 1.76-2.37), respectively [36]. Evidence of an association 
between endogenous sex hormones and breast cancer risk in premenopausal women will 
be reviewed in the following section. 
 
II. BREAST CANCER RISK 
A. Biomarkers 
Due to the long latency of cancer, there are currently no prevention studies in which 
breast cancer is the measured outcome. The undertaking of this type of study would not 
only require an extraordinarily large study sample and long follow up time, but it would 
also be extremely costly. Alternatively, current research uses biomarkers for breast 
cancer risk as surrogate outcomes rather than the disease itself. 
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Biomarkers are biological factors thought to be involved in the casual pathway 
between exposure and cancer development. To date, the most well-studied biomarkers in 
breast cancer prevention research are endogenous sex hormones such as estrogens 
(estradiol, estrone, estrogen metabolites), progesterone, testosterone, and sex hormone-
binding globulin (SHBG). 
Other non-hormonal biomarkers of interest include insulin and insulin resistance, 
levels of metabolic hormones (i.e., leptin, adipokines), inflammatory markers (i.e., 
prostaglandins, C-reactive protein), immune function markers (i.e., natural killer cells, 
leukocytes, T helper cells), and oxidative stress markers (i.e., F2-isoprostanes, reactive 
oxygen species) [37]. 
B. Endogenous Sex Hormones and SHBG 
In women of reproductive age, the ovaries are the main source of sex hormones. 
Steroidogenesis in peripheral tissues such as subcutaneous fat and skin, and physiologic 
and pathologic target sites such as the hypothalamus and cells of the breast and 
endometriosis are also important, especially in postmenopausal women and anovulatory 
premenopausal women [38]. 
In general, the ovaries secrete three major classes of sex hormones, namely the C18-
steroids estrone (E1) and estradiol (E2), the C21-steroids pregnenolone, progesterone, and 
17α-hydroxyprogesterone, and the C19-steroids dehydroepiandrosterone, 
androstenedione, and testosterone, [39]. The main precursor for all of these sex hormones 
is cholesterol. In the preovulatory follicle, cholesterol can be derived from dietary plasma 
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lipoprotein cholesterol and de novo synthesis, while in the corpus luteum, cholesterol is 
derived from intracellular cholesterol esters stores within lipid droplets [38]. 
The first and rate-limiting step in ovarian steroidogenesis involves the translocation 
of cholesterol into the mitochondrion of ovarian theca cells by the steroidogenic acute 
regulatory protein known as StAR [40]. Once inside the mitochondrion, cholesterol is 
converted into pregnenolone by the cholesterol side-chain cleavage enzyme or P450scc 
[40]. Pregnenolone is then converted to progesterone, which in turn is converted to 
androstenedione by the action of enzymes 3β–hydroxysteroid dehydrogenase Δ 5, 4 
isomerase type II (3β-HSD-II) and 17α-hydroxylase/17,20-lyase (P450c17), respectively 
[41]. 
Androstenedione can then diffuse out of the theca cells into the granulosa cells where 
it is transformed to estrone by aromatase (P450arom) [42]. Alternatively, androstenedione 
diffuses into the circulation and reaches extraglandular tissues where it can mainly be 
converted into estrone by P450arom or (to a much lesser extent) into testosterone by 17β-
hydroxysteroid dehydrogenase type 1 (17β-HSD-1) [27]. The conversion of 
androstenedione to estrone and the entry of cholesterol in mitochondrial thecal cells, are 
both critical steps in the formation of ovarian estradiol. 
Finally, estrone is converted into biologically active estradiol by the action of 17β-
HSD-1. It should be noted there are at least seven enzymes in the 17β-HSD family with 
overlapping activities, which are capable of converting E1 into E2 in both the ovary and 
peripheral tissues [43]. 
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Once formed, estradiol and testosterone can enter the circulation in either their free 
(non-bound) form or bound to a protein like albumin or SHBG. SHBG is a plasma 
glycoprotein synthesized and secreted by the liver [44] that regulates the bioavailability 
of these two sex hormones by binding two molecules of steroid ligand at a time [29]. 
Figure 1.1 shows the steroidogenic pathway in the ovary. 
1. Experimental Evidence 
The role of estradiol and other sex hormones in the etiology of breast cancer has been 
substantiated by a plethora of studies in animals and human in vitro studies. For instance, 
in ovariectomized adult mice, administration of E2 increased DNA synthesis of mammary 
epithelial cells [45]. Similarly, exposure of E2 to human breast cancer cell lines Michigan 
Cancer Foundation-7 (MCF-7) [46] and ZR-75-1 [47] caused a marked increase in cell 
proliferation. Likewise, in the Noble rat model, administration of E1 increased cell 
proliferation of mammary epithelium two-fold and perturbed cell kinetics leading to 
genetic instability [48]. 
Depending on the model used, the role of progesterone in breast carcinogenesis has 
been either supported or questioned. For example, in ovariectomized adult mice, the 
combined administration of E2 and progesterone resulted in greater DNA synthesis than 
with either hormone alone [49] while in mouse mammary tumors, sole administration of 
progesterone was necessary to increase cell proliferation [50]. On the other hand, 
progesterone has been observed to decrease proliferation in primary cultures of normal 
human breast epithelium and breast cancer cells [51]. 
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Studies on testosterone, similarly to progesterone, have provided evidence of both 
agonist and antagonist roles in mammary cell proliferation. For instance, in a study of 
mouse CH11 cell line, testosterone treatment significantly increased mammary epithelial 
growth, possibly through stimulation of the androgen receptor (AR) [52]. In contrast, in 
ovariectomized rhesus monkeys, the combined treatment of E2 and testosterone resulted 
in approximately 40% reduction in E2-induced proliferation (P < 0.002) as well as 
abolishment of E2-induced augmentation of estrogen receptor alpha (ER-α) expression 
[53]. 
The opposing effects of testosterone can be explained by noting that at low estrogen 
levels (such as it is the case of postmenopausal women), testosterone and other androgens 
may have proliferative effects on mammary epithelial and cancer cells by direct binding 
to the ER-α and thus, mediate estrogenic functions. In contrast, at high estrogen levels 
(such as in the case of most premenopausal women), androgens may exert mainly 
antiestrogenic effects via binding to the AR resulting in the suppression of estrogen 
stimulation of breast epithelial and cancer cells [54]. 
Lastly, SHBG is thought to play a role in breast cancer etiology by regulating the 
amount of bioavailable (i.e., biologically active) fraction of estradiol and testosterone that 
can reach target cells [55]. More directly, SHBG has been reported to inhibit estradiol’s 
positive effect on cell proliferation [56, 57] while also completely reversing estradiol’s 
anti-apoptotic effect on MCF-7 cells [58]. 
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2. Observational Evidence 
Observational studies have shown a well-established positive association between 
endogenous levels of estrogens and testosterone and breast cancer risk in postmenopausal 
women [36]. This is not the case in premenopausal women. 
To date, 14 prospective nested case-control studies have evaluated the association 
between breast cancer risk and premenopausal levels of estrogens, progesterone, 
testosterone, and SHBG. Most of these studies, especially those conducted in the 1980’s 
and 90’s, had limited statistical power as less than 100 cases of breast cancer were 
included. More recent updates to three of the four largest studies have greatly improved 
the ability to detect significant differences by extending the number of cases by 
approximately eight-fold.  
a. Estradiol 
To date, 12 nested case-control studies have investigated the association between 
premenopausal E2 and breast cancer risk, making it the most well-studied sex hormone in 
the etiology of breast cancer. Of these studies, 11 have reported results based on levels of 
total E2 [59-69], while four [60, 61, 64, 70] and two [59, 65] have additionally reported 
breast cancer risk based on free and bioavailable E2, respectively. Most recently, updates 
in the number of breast cancer cases in three large cohort studies have allowed a more in-
depth look at breast cancer risk based on cancer type (overall, invasive, and in situ) and 
hormone receptor subtype (ER+, ER-, ER+/progesterone receptor (PR)+, and ER-/PR-) 
[60, 61, 64]. 
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Despite the large amount of data now available, overall conclusions have been 
difficult to formulate given the different approaches studies have used to account for 
estrogen level fluctuations across the menstrual cycle. This variability is critical to 
consider given E2 levels have been shown to differ by more than hundred-fold over the 
duration of the menstrual cycle [71]. Therefore, results from studies in which no 
menstrual cycle matching or model adjustment was made, such as those of Bulbrook et 
al. [70] and Kabuto et al. [65], should be considered of low quality and unsuitable to 
determine whether or not an association exists between estradiol levels and breast cancer 
risk. 
The remaining prospective studies have used different approaches to deal with 
menstrual cycle variation including: matching to exact menstrual cycle day [67-69], 
matching plus spline regression adjustment [59, 63, 66], and matching plus separate 
analysis of follicular and luteal samples [60-62, 64]. 
Among the studies that only used exact menstrual cycle day matching, only one 
reported significantly higher levels of estradiol in breast cancer women compared to 
controls and a non-significant positive association with breast cancer [68], while the other 
two observed the exact opposite associations [67, 69]. 
In contrast, all the studies that used a spline regression of estradiol levels on day of 
cycle (in addition to matching), showed breast cancer cases had higher levels of estradiol 
than controls, which in turn translated into a non-significant increase in breast cancer risk 
[59, 63, 66]. 
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Finally, in studies in which follicular and luteal estradiol samples were analyzed 
separately, the results have been inconsistent. For instance, two [60, 62] studies reported 
higher risk for all breast cancers with higher follicular levels of E2 but two others found 
no association at all [61, 64]. Similarly, higher levels of luteal E2 have been associated 
with lower risk for all types of breast cancer in three studies [61, 62, 67]; higher risk in 
one study [64], and no risk at all in another [60]. 
Conflicting results have also been reported for the risk of invasive, in situ, ER+, and 
ER+/PR+ breast carcinomas and follicular and luteal levels of E2. For example, the risk 
of invasive breast cancer has been associated with higher follicular [60] and luteal [61] 
levels of E2, lower levels of luteal E2 [60] or not at all [61]. Similarly, the risk for 
ER+/PR+ breast cancer has been associated with higher levels of follicular [60] and luteal 
[60, 61] E2 or not all associated with follicular E2 levels [61].  
For in situ breast carcinomas, Fortner et al. found a positive association with 
follicular E2 levels and an inverse association with luteal E2 levels [61]. Finally, in the 
case of hormone subtype cancers, Kaaks et al. reported the risk of ER+ breast cancers to 
increase with not only increasing levels of follicular E2 but luteal E2 levels as well [64]. 
The association between breast cancer risk and premenopausal levels of bioavailable 
and free estradiol has been investigated in two and four studies, respectively. As 
previously discussed, the results of Kabuto et al. and Bulbrook et al. provide questionable 
data due to the lack of control or adjustment for menstrual cycle variability in estradiol 
levels [65, 70]. In the remaining study, where matching and spline regression was used, 
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both follicular and luteal levels of bioavailable E2 were found to be non-significantly 
associated with an increase for breast cancer [59]. 
In the case of free estradiol, three studies have yielded consistent results in terms of 
risk for developing ER+, ER+/PR+, and in situ breast carcinomas. More specifically, 
increasing levels of both follicular and luteal free E2 levels were associated not only with 
an increased risk for ER+ and ER+/PR+ breast cancer, but also with a decrease for in situ 
breast carcinomas. 
While the results of Fortner et al. and Eliassen et al. agree on a positive association 
between invasive breast cancer and luteal free E2 levels, they differ in the direction of the 
association with follicular free E2 levels [60, 61]. Similarly, opposite associations have 
been reported between follicular and luteal free E2 levels and risk for all types of breast 
cancer [60, 61]. 
The disagreement in the results for overall and invasive breast cancer risk between 
the studies of Eliassen et al. and Fortner et al. is troublesome considering both used data 
from the Nurses’ Health Study II cohort (NHS-II), and the latter used an updated and 
considerably larger number of breast cancer cases than the former (514 cases vs. 197 
cases). 
In a 2011 meta-analysis of seven of the earliest prospective studies, the estimated 
breast cancer OR for a doubling of premenopausal E2 was found to be non-significant 
regardless of whether follicular or luteal data was included in the analyses [72]. In 2013, 
another meta-analysis of seven prospective studies including two of the largest cohorts 
followed to date, namely the New York University Women’s Health study (NYU-WSH) 
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and NHS-II cohorts, found total and free E2 levels to be significantly associated with 
premenopausal breast cancer risk [73]. Specifically, the relative risk for a doubling of 
total and free E2 levels was 1.19 (95% CI: 1.06-1.35, Ptrend = 0.042) and 1.17 (95% CI: 
1.03-1.33, Ptrend = 0.014), respectively. 
It is important to keep in mind the more recent meta-analysis restricted data to only 
premenopausal cases in which breast cancer was diagnosed before age 50 and pooled 
together follicular and luteal E2 measures to calculate the estimated odds ratio for breast 
cancer risk. While the updated reports of two of the other large prospective studies were 
not available at the time this meta-analysis was conducted, it is unlikely the inclusion of 
their data would have significantly changed the previously reported associations. 
First of all, data from the updated Hormones and Diet in the Etiology of Breast 
Cancer (ORDET) study would have not been included in the meta-analysis considering 
the mean age at blood draw in the ORDET study was 43 years old, and the median 
follow-up time was 15.4 years, suggesting a postmenopausal and not premenopausal 
status at breast cancer diagnosis. Furthermore, when breast cancer cases in the updated 
European Prospective Investigation into Cancer and Nutrition (EPIC) study were 
restricted to those diagnosed before 50 years old, the positive associations between breast 
cancer risk and total and free E2 levels were not found to be statistically significant any 
longer [64]. 
In conclusion, the results from 12 prospective, nested case-control studies and two 
meta-analyses do not provide significantly convincing evidence of a positive association 
between premenopausal total, free, or bioavailable E2 levels and breast cancer risk. 
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b. Estrone 
Due to its less estrogenic activity, estrone has received far less consideration in the 
etiology of breast cancer compared to estradiol. In fact, only five [60-63, 69] of the 14 
prospective, nested case-control studies investigating the association between 
premenopausal endogenous sex hormones and breast cancer risk have included E1 in their 
analyses. 
Results from two earlier studies nested both in the Campaign Against Cancer and 
Stroke cohort from Washington County, MD provided conflicting results. Specifically, 
while Wysowski et al. showed women with breast cancer had lower levels of estrone than 
controls [69], Helzlsouer et al. reported no significant differences in the levels of 
follicular and luteal estrone between cases and controls [62]. Both of these studies were 
very small, and with less than 25 cases, it is unlikely they were able to detect any 
statistical differences. In fact, Breslow and Day estimated a minimum of 250 case-control 
sets (1:3 matching ratio) would be necessary to detect a significant difference at 0.05 
level and 80% power [74]. 
In the EPIC study of 801 cases and 1,132 controls, a non-significant increase in risk 
was associated with higher levels of E1 [63]. Similarly, in the NHS-II study, follicular E1 
levels were associated with a non-significant increase in breast cancer risk, but luteal 
levels were found to have the opposite association [60]. When the number of cases in the 
NHS-II study was updated from 197 to 514 in 2013, information on breast cancer overall 
and by hormone receptor subtype further elucidated the differences in risk based on 
menstrual cycle phase estrone levels [61]. 
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In this updated study, Fortner et al. reported a non-significantly higher risk for 
ER+/PR+ and in situ breast cancer with higher levels of follicular E1 and lower levels of 
luteal E1. The risk for invasive breast cancer, on the other hand, was observed to decrease 
with both higher levels of follicular and luteal E1. Similarly, a recent meta-analysis using 
all but the study by Wysowski et al. showed higher levels of follicular E1 in 
premenopausal women to be associated with a significant increase in breast cancer risk 
overall [73]. Specifically, a doubling of follicular E1 levels in premenopausal women 
translated into 27% higher risk for breast cancer (OR = 1.27, 95% CI: 1.05-1.54, Ptrend = 
0.014). Unfortunately, this meta-analysis did not include data for luteal E1 levels, so the 
pooled estimate effect of follicular E1 levels on breast cancer risk is currently unavailable. 
c. Progesterone 
Results from observational studies have not provided clear evidence of an association 
between premenopausal luteal progesterone levels and breast cancer risk. For instance, in 
four nested case-control studies, women with breast cancer had non-significantly higher 
levels of luteal progesterone than controls, which translated into a non-significant 
increase in risk for breast cancer including ER+/PR+ subtype [60, 62, 64, 67].  
In contrast, in seven other nested case-control studies [60, 61, 63, 64, 68, 69, 75], an 
inverse relationship with breast cancer risk was found, although the association was only 
significant in the ORDET study of Micheli et al. (OR = 0.12, 95% CI: 0.03-0.52, Ptrend = 
0.005) [75]. However, when Micheli et al. restricted their analysis to women with menses 
without marked irregularities, the inverse association lost statistical significance (Ptrend = 
0.077). Furthermore, when the number of breast cancer cases in the ORDET cohort was 
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updated in 2013, the association not only ceased to be significant but also reversed 
direction (OR = 1.16, 95% CI: 0.6-2.3, Ptrend = 0.75) [67]. 
When the NHS-II and EPIC cohorts were updated in 2013 and 2014, respectively, no 
change in direction of the association previously reported was evident. The magnitude of 
the association, however, was attenuated but the inverse association remained non-
significant. Finally, a meta-analysis by the Endogenous Hormones and Breast Cancer 
Collaborative Group in 2013 concluded premenopausal, luteal progesterone levels were 
not associated at all with the risk for breast cancer (OR = 1.00 95% CI: 0.92-1.09, Ptrend = 
0.93) [73]. 
d. Testosterone 
While the evidence implicating premenopausal progesterone levels in the etiology of 
breast cancer has been weak and inconclusive, data on testosterone has consistently 
shown a positive and statistically significant association. In fact, of the ten prospective, 
nested case-control studies conducted to date [59-61, 63, 64, 67-69, 75, 76], only two [60, 
69] have failed to show a difference in risk between cases and controls based on the 
levels of total, free, and bioavailable testosterone. 
The majority of the studies showing women with breast cancer with higher levels of 
total [59, 63, 64, 76], free [64, 67, 76], and bioavailable testosterone [59] found the 
associations to be statistically significant. Specifically, the relative risk of breast cancer 
reported with highest vs. lowest levels of total testosterone in these studies has ranged 
from OR = 1.73 (95% CI: 1.2-2.6; Ptrend  = 0.01) to 3.3 (95% CI: 1.5-7.5; Ptrend = 0.006). 
The relative risk reported by studies for women in the highest vs. lowest levels of free 
  21
testosterone has ranged from OR = 1.13 (95% CI: 1.01-1.26, Ptrend = 0.04) to 2.4 (95% 
CI: 1.1 to 5.1; Ptrend = 0.03). Finally, the relative risk for women in the highest vs. lowest 
quartiles of bioavailable testosterone levels reported by Dorgan et al. was OR = 4.2 (95% 
CI: 1.6-10.9, Ptrend = 0.002) [59]. 
In terms of invasive, in situ, ER+, and ER+/PR+ breast cancer, only three studies 
have investigated the association with testosterone levels. In all of these studies, higher 
levels of total and free testosterone were associated with higher risk for invasive [61, 76], 
in situ [61], ER+ [64, 76], ER- [64], ER+/PR+ [64], and ER-/PR- [64] breast carcinomas. 
However, only Zeleniuch-Jacquotte et al. were able to report a statistically significant 
association for total and free testosterone with invasive (OR = 1.5, 95% CI: 1.1-2.2, Ptrend 
= 0.03 and OR = 1.2, 95% CI: 1.0-1.4, Ptrend = 0.02, respectively) and ER+ (OR = 2.4, 
95% CI: 1.2-4.6, Ptrend = 0.01 and OR = 1.6, 95% CI: 1.2-2.2, Ptrend = 0.003, respectively) 
cancers. 
With the exception of the most updated data from the EPIC and ORDET cohorts, a 
recent meta-analysis found a doubling of total and free testosterone levels to be 
associated with an OR= 1.18 (95% CI: 1.03-1.35, Ptrend = 0.018) and OR= 1.14 (95% CI: 
1.01-1.28, Ptrend = 0.031), respectively [73]. In the EPIC study, the inclusion of new 
breast cancer cases resulted in the attenuation of the positive association between breast 
cancer risk and total and free testosterone levels (OR = 1.14, 95% CI: 1.02-1.28, Ptrend = 
0.02 and OR = 1.13, 95% CI: 1.01-1.26, Ptrend = 0.04, respectively) although it remained 
significant [64]. In the case of the ORDET study, the previously non-significant 
association reported between breast cancer risk and total testosterone remained non-
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significant, while that of free testosterone reached statistical significance (OR = 2.4, 95% 
CI: 1.5-5.1, Ptrend = 0.03 [67]. 
Overall, data from prospective studies and results from one meta-analysis clearly 
support the positive, significant association between breast cancer risk and 
premenopausal total and free testosterone levels. 
e. SHBG 
The effect of SHBG on premenopausal breast cancer risk has been evaluated in six 
small [59, 62, 65, 68, 70, 75] and six large [60, 61, 63, 64, 67, 76] nested case-control 
studies. In three of these studies, women with breast cancer had similar levels of SHBG 
than controls and therefore, no association with breast cancer risk was found [62, 64, 65]. 
In four other studies, breast cancer cases had higher levels of SHBG than controls as well 
as a non-significant risk increase for invasive, ER-, ER+/PR+, and ER-/PR- breast 
cancers [60, 61, 64, 68]. In contrast, three small [59, 70, 75] and five large [61, 63, 64, 
67, 76] studies reported women with breast cancer had non-significantly lower levels of 
SHBG than controls which correlated with a non-significant risk reduction of 5-52% for 
overall breast cancer, 7% for ER+ breast cancer, and 20% for in situ breast cancer. 
Finally, in a recent meta-analysis [73] of eight prospective studies, including 767 
cases of breast cancer and 1699 controls, premenopausal SHBG levels were not 
associated with breast cancer risk (OR= 1.07, 95% CI: 0.94-1.23). Since the time this 
meta-analysis was published, updated data from the ORDET [67] and EPIC [64] cohorts 
have become available, and their results support the evidence of an inverse association 
with breast cancer risk, albeit not statistically significant. 
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Overall, data from most prospective studies and this meta-analysis seem to suggest 
there is an inverse association between premenopausal levels of SHBG and breast cancer 
risk; however, to date, not one study has reported a statistical significant association. 
C. Estrogen Metabolites 
In the human body, native E2 undergoes biotransformation to E1 through oxidation at 
the C17 position. While this process is reversible, the formation of E1 is largely favored 
as it occurs rapidly compared to the reduction of E1 to E2. 
Phase I metabolism of estrogens involves irreversible oxidation at either the A-ring or 
D-ring. Hydroxylation of E1 and E2 at the A-ring in C2 position yields 2-hydroxyestone 
(2-OHE1) and 2-hydroxyestradiol (2-OHE2), respectively. Similarly, hydroxylation of E1 
and E2 at the A-ring in C4 position yields 4-hydroxyestone (4-OHE1) and 4-
hydroxyestradiol (4-OHE2), respectively. Alternatively, oxidation at the D-ring in C16α 
position yields 16α-hydroxyestrone (16α-OHE1) and estriol (E3), respectively. Figure 1.1 
shows the steroidogenic pathway in the human ovary. 
The tissue-specific hydroxylases responsible for these oxidations belong to the 
cytochrome P450-dependent family. Specifically, CYP1A1, CYP1B1 (breast), and 
CYP1A2 (liver) catalyze the oxidation of E1 into 2-OHE1 and 2-OHE2 while CYP1A1, 
CYP3A5 (breast), CYP3A4, and CYP3A7 facilitate the 16α-hydroxylation [77]. In 
contrast, a much smaller fraction of E1 is hydroxylated at the 4C position by CYP1B1 
(breast) and CYP1A2 (liver) enzymes [77]. 
Further oxidative metabolism of these hydroxyestrogens leads to the formation of 2- 
and 4-quinones that can cause DNA damage. In particular, 4-quinones form unstable 
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depurinating adducts with adenine and guanine. These adducts undergo spontaneous 
depurination causing the formation of apurinic sites, which in turn undergo error prone 
DNA repair with resultant point mutations [78]. In contrast, the 2-quinones form 
relatively stable DNA adducts and depurination rarely occurs [79]. Additionally, the 2- 
and 4-quinones can be reduced to semiquinones by cytochrome P450 reductase resulting in 
a redox cycle that generates reactive oxygen species such as superoxide, which causes 
oxidative DNA damage [80]. 
Phase II metabolism involves the methylation of 2- and 4-hydroxyestrogens by the 
catechol-O-methyltransferase (COMT) enzyme into the 2-methoxyestrogens (2-
methoxyestrone [2-MeOE1) and 2-methoxyestradiol (2-MeOE2)] and the 4-
methoxyestrogens (4-methoxyestrone [4-MeOE1) and 4-methoxyestradiol (4-MeOE2)], 
respectively. Finally, parent estrogens (E2 and E1) and hydroxyestrogens can undergo 
detoxification through glucuronidation, sulfonation, and/or O-methylation with the 
resulting products becoming water-soluble and therefore excretable in urine or feces [81, 
82]. 
1. Experimental Evidence 
The first suggestion that the manner in which estrogens are metabolized had an 
etiological significance in breast cancer was first introduced by Thomas Dao in 1979 
[83]. In vitro studies using human breast cancer tissue, as well as animal studies in mice 
and rats, have provided supporting evidence that estrogen metabolites may in fact play a 
role in the initiation and progression of breast cancer. 
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For instance, the 2-hydroxyestrogens, due to their reduced binding affinity to the ER 
compared to E2, are capable of exhibiting both weak agonist and partial antagonistic roles 
[84, 85]. Specifically, in estrogen receptor-dependent MCF-7 and T47D cell lines, both 2-
OHE1 and 2-OHE2 induce cell proliferation rate [86-88] while also suppressing the 
mitogenic effect of E2 on these cells [86, 89, 90]. 
Conversely, 16α-OHE1 binds tightly and covalently to the ER [91] and increases cell 
proliferation in MCF-7 [86, 89] and T47D cell lines [86]. In comparison, 4-OHE2 
exhibits a higher affinity for the ER than 2-OHE2 (but less than E2) [84, 85, 88] and can 
induce tumor cell proliferation in MCF-7 cell line [88]. 
While both the 2-hydroxyestrogens (2-OHE) and 4-hydroxyestrogens (4-OHE) can 
undergo metabolic redox cycling and cause oxidative damage to both DNA and other 
cellular constituents, the 2-OHE have not shown the carcinogenic activity that has been 
reported for 4-OHE2 [92]. This difference can be explained in part by the fact 2-OHE 
have a faster clearance in vivo [93], are more readily inactivated by COMT [89, 90, 94], 
are less hormonally potent  [84, 88-90], and dissociate away from ER more rapidly than 
the 4-OHE [95]. 
In contrast, the 2-methylestrogens (2-MeOE) and 4-methylestrogens (4-MeOE) bind 
weakly to the ER and exhibit < 3% of the affinity of E2 [85]. Interestingly, in MCF-7 cell 
line, 2-MeOE1 did not have a significant effect on tumor cell growth [90], while 2-
MeOE2 was a potent inhibitor of cell growth [87, 96] and angiogenesis [96]. Finally, in 
MCF-7 cells, E3 promoted tumor cell proliferation with slightly less potency than E2 [89], 
while in the T47D cell line, its potency was much more than E2 [86]. 
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2. Observational Evidence 
The association between estrogen metabolism and breast cancer risk in 
postmenopausal women has been mixed. For instance, one case-cohort [97] and one 
nested case-control study found some significant associations [97, 98] while another 
nested case-control study found none [99]. Furthermore, a combined analysis [100] and a 
systematic review [101] found postmenopausal women with the highest 2-OHE1/16α-
OHE1 ratio to have virtually the same risk as those with the lowest 2-OHE1/16α-OHE1 
ratio. 
In premenopausal women, five prospective studies have investigated the association 
between breast cancer risk and estrogen metabolism using blood [102] and urine samples 
[60, 103-105]. The earliest investigation, a case-cohort study of 38 cases and 597 controls 
conducted in the Island of Guernsey, found women with breast cancer had lower levels of 
urinary parent estrogens and E3 than controls, which were associated with a non-
significant 60% and 30% reduction in breast cancer risk, respectively [103]. Similarly, in 
the much larger case-control NHS-II study, women with breast cancer had significantly 
lower levels of urinary parent estrogens than controls while the 50% reduction in breast 
cancer risk was found to be non-significant [60]. 
In the case of 2-OHE1, two nested case-control studies found a slight positive 
association between breast cancer risk and urinary [105] and serum [102] levels of 2-
OHE1, respectively. In contrast, the same two studies found higher urinary and serum 
levels of 16α-OHE1 to be associated with a greater risk of breast cancer, albeit also non-
significantly. 
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When looking at the ratio of 2-OHE1 to 16α-OHE1, all [60, 104, 105] but one [102] 
study, have associated a higher 2-OHE1/16α-OHE1 ratio with a lower risk for breast 
cancer. Specifically, a higher urinary 2-OHE1/16α-OHE1 ratio was non-significantly 
associated with a 10% [60], 25% [104], or even 45% [105] risk reduction in breast 
cancer. Of these estimates, the one by Eliassen et al. is likely to be the most accurate as it 
analyzed considerably more breast cancer cases (n = 247) than either of the Island of 
Guernsey studies (n = 38 and n = 60) and used a newer lab method based on high-
performance liquid chromatography-tandem mass spectrometry assay (HPLC-MS/MS). 
In contrast to enzyme immunoassays (EIA), HPLC-MS/MS has shown to be a more 
sensitive, specific, accurate, and reproducible assay method [106]. With the use of this 
new lab technology, Eliassen and colleagues were able to analyze not only the parent 
estrogens, 2-OHE1 and 16α-OHE1 but also ten other urinary metabolites including 2-
OHE2, 4-OHE1, 2-MeOE2, 2-MeOE1, 4-MeOE2, 4-MeOE1, 2-Hydroxyestrone-3-methyl 
ether, 16-Ketoestriadiol, 16-Epiestriol, E3, and 17-Epiestriol. 
Results from this study show that in control women the most abundant parent 
estrogen is estrone (15% of total estrogen metabolites), while the most abundant estrogen 
metabolites are 2-OHE1 (27%) and AÆ E3 (18%) [60]. None of these metabolites were 
individually associated with a significant decrease or increase in breast cancer risk. 
However, a significant positive association was found between breast cancer risk and the 
ratio of 16-pathway metabolites to parent estrogens (top vs. bottom quartile RR = 1.61; 
95% CI: 0.99-2.62). None of the other ratios that were calculated such as 2-
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pathway/parent estrogens, 4-pathway/parent estrogens, and 2-OHE1/16a-OHE1 showed a 
statistical significant association with breast cancer risk [60]. 
As has been the case with retrospective case-control studies, most prospective studies 
have relied on the 2-OHE1/16α-OHE1 ratio to assess the effect of estrogen metabolism on 
breast cancer risk. The fact most studies have restricted their analysis to only these two 
estrogen metabolites has been due in part to laboratory convenience as a new commercial 
EIA became available in the mid-1990s. At the time, this assay allowed separate 
measurement of 2-OHE1 and 16α-OHE1 and manual calculation of their ratio while 
avoiding the complicated and invasive measurement of previously used radiolabel tracers 
[107]. 
EIA methods have gradually been replaced by HPLC-MS/MS methods as studies 
have sought to improve the scope and accuracy of estrogen metabolism analyses. This, 
however, has not been translated into a more frequent detection of statistically significant 
associations. Aside from methodological advances, no statistical relevance has been 
found in any prospective studies regardless of study size and type (case-cohort vs. nested 
case-control), bio-specimen used (serum vs. urine), duration of urine collection (spot 
sample [60, 104], 12-hr sample [105], and 24-hr sample [103]), or type of statistical 
analyses employed (model adjustment for menstrual cycle phase [103], case-control 
matched on menstrual cycle phase [102, 104], and specific collection on luteal phase [60, 
105]). 
  29
Overall, prospective studies in premenopausal women have failed to find statistically 
significant associations between estrogen metabolite levels and breast cancer risk and 
therefore, the association remains weakly suggestive. 
D. Genetic Variation in Estrogen Biosynthesis and Metabolism 
Polymorphisms in genes encoding for the enzymes involved in estrogen biosynthesis 
and metabolism, namely the cytochrome P450 oxygenases, the hydroxysteroid 
dehydrogenases, and COMT, have been associated with breast cancer risk. While 
polymorphisms in these genes may be associated with breast cancer risk by altering the 
expression levels of sex hormones and estrogen metabolites, evidence of this association 
for most of them has been inconclusive, largely due to small sample sizes and variability 
between populations [108].  
Despite encoding for the mitochondrial enzyme responsible for the initial and rate-
limiting step in ovarian steroidogenesis, genetic variation in the CYP11A1 gene has not 
been extensively studied. To date, most studies have concentrated on pentanucleotide 
[(TAAAA)n] repeat polymorphisms in Chinese women. The first study to assess breast 
cancer risk based on the number of TAAAA repeats in the CYP11A1 gene was the 
Shanghai Breast Cancer Study, a population-based case-control study of 1015 breast 
cancer cases and 1082 controls [109]. In this study, three common alleles with 4, 6, and 8 
repeats were identified, accounting for nearly 99% of total alleles detected in the study 
population. Compared to women homozygous for the 4-repeat allele, women carrying the 
8-repeat allele had an elevated risk of breast cancer (OR= 1.8, 95% CI: 1.2-2.7) and the 
risk was even greater for those who were homozygous for the risk allele (OR= 3.4, 95% 
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CI: 1.4-8.4). Furthermore, this study showed a positive association between CYP11A1 
genotypes and breast cancer risk in both premenopausal and postmenopausal women. 
Since then, other studies have reveled breast cancer risk may be also be related to other 
variants located upstream of the coding region in Chinese women [110] and CYP11A1 
haplotypes in a study of multiethnic populations [111]. Furthermore, in another study of 
Chinese women, those who were homozygous carriers of the 4-repeat allele relative to 
non-carriers were at a decrease risk for breast cancer (OR= 0.61, 95% CI: 0.39-0.96), 
while those homozygous carriers of the 6-repeat allele relative to non-carriers were at a 
significant increased risk (OR= 1.42, 95% CI: 1.03-1.97). [112]. 
Genetic variation in CYP17A1, the gene encoding for the enzyme converting 
progesterone to 17β-hydroxyprogesterone and subsequently to androstenedione, has been 
associated with breast cancer risk in some ethnic populations but not in others. For 
instance, increased breast cancer risk and single nucleotide polymorphisms (SNPs) in the 
CYP17A1 gene have been reported in studies of Thai [113], Canadian [114], German 
[115], Swedish [116], and American-Asian, African-American, and Latino women [117]. 
In contrast, there have been studies conducted in German [118], Swedish [119], 
Portuguese [120], Australian [121], and American [122] women that have not found 
evidence of an association with breast cancer risk.  
Similarly, inconclusive results have been reported in studies investigating genetic 
variations in the gene CYP19A1 responsible for encoding for aromatase – the enzyme 
that catalyzes the conversion of androgens androstenedione and testosterone to estrone 
and estradiol, respectively. One SNP believed to interfere with RNA stability, namely the 
  31
rs10046 polymorphism, has been associated with increased breast cancer risk in three 
small studies [123-125], but not in other larger studies like the Shanghai Breast Cancer 
and the NHS-II study [126, 127]. Furthermore, no association was found in two meta-
analyses involving Caucasian European (5,356 cases, 7,129 controls) and multiethnic 
populations (7,998 cases, 12,100 controls) [128, 129]. In contrast, the polymorphisms 
W39R, T201M, R264C, and M364T have been reported to be associated with decreased 
enzymatic activity and thus, increased breast cancer risk [130]. Specifically, the R39 
allele has been associated with breast cancer risk in premenopausal Japanese women with 
late-age parity or high BMI [131], while increased risk was observed in Korean women 
who carried the variant C264 and consumed alcohol regularly [132]. Interestingly, a 
meta-analysis of 22 studies involving 10,592 cases and 11,720 in Asian and Caucasian 
women however, did not find a significant association between any of these SNPs and 
breast cancer risk [133]. Finally, numerous studies have investigated the association 
between an intronic tetranucleotide repeat (TTTA)n in the CYP19A1 gene and breast 
cancer risk. Some studies have found a significant association in Caucasian, Japanese, 
Chinese, Brazilian, and Nigerian women [134-140] while other studies have not found a 
similar association in Asian and American women [141-143]. Two large meta-analyses 
however, did find an association between (TTTA)12 and decreased breast cancer risk and 
(TTTA)10  and increased risk [133, 144]. 
Other enzymes of importance in the biosynthesis of estrogen include the 
hydroxysteroid dehydrogenases 3β-HSD, which convert pregnenolone to progesterone, 
and 17β-HSD, which converts androstenedione to testosterone and estrone to estradiol. 
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Currently, no studies have substantiated a possible role for 3β-HSD polymorphisms in 
breast cancer susceptibility. In contrast, a particular polymorphism in the HSD17β gene 
has been associated with decreased risk for breast cancer. Specifically, a polymorphism 
(A to G, rs605059) in exon 6 leads to an amino acid substitution of Ser to Gly [145]. A 
recent meta-analysis of 9 studies involving 13,987 cases and 17,066 controls found no 
significant association between this SNP and breast cancer risk [146]. However, a 
subgroup analysis of this data revealed a significant inverse association in Caucasians for 
G/G vs. A/A (OR= 0.91, 95% CI: 0.83-1.00), G/A vs. A/A (OR= 0.92, 95% CI: 0.85-
0.99), and G/G +G/A vs. A/A (OR= 0.92, 95% CI: 0.86-0.98). Although this meta-
analysis did not find a publication bias or significant heterogeneity, it had some important 
limitations including small samples of Asian and African-American women and lack of 
stratification based on other risk factors (age, smoking status, etc.). 
Similar to the CYP genes involved in estrogen biosynthesis, genetic variation in the 
CYP genes involved in estrogen metabolism such as CYP1A1, CYP1A2, CYP3A4, and 
CYP1B1 have been studied extensively in terms of their association with breast cancer 
risk.  
As previously mentioned, CYP1A1 is a monooxygenase that catalyzes the 
conversion of estrogens predominantly to their 2-catechol estrogens in extrahepatic 
tissues. While several variant alleles have been identified, two of them (T3801C and 
A2455G) have been reported to increase the risk for breast cancer by significantly 
elevating enzymatic activity compared to the wild-type genotype [147, 148]. However, a 
recent meta-analysis of 23 studies involving 10,520 cases and 14,567 controls found no 
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significant associations between those heterozygous or homozygous for the T allele and 
breast cancer risk regardless of ethnicity and menopausal status [149]. Similarly, another 
meta-analysis reported no association between breast cancer risk and the variant T3801C 
or the polymorphisms T3205C and C2453A[150]. The only significant association found 
in this meta-analysis was for Caucasian women who were homozygous carriers for the 
A2455G G allele. Specifically, women of Caucasian origin carrying this SNP were found 
to be at significantly higher risk for developing breast cancer (pooled OR= 2.2, 95% CI: 
1.3-3.8). 
Mixed results have also been reported in studies of polymorphisms in the CYP1A2 
and CYP3A4 genes, which are mainly expressed in the liver and favor 2-hydroxylation of 
estrogen. For example, in one multiethnic cohort study, women who were homozygote 
carriers of rs762551 A  C in the CYP1A2 gene showed increased risk for breast cancer 
[151], while women carrying this SNP were not found to be at higher risk in the Shanghai 
Breast study [152]. Consistent with the null results found in the Shanghai Breast Study, a 
meta-analysis of nine studies comprising 7,580 cases and 10,020 controls found no 
association between this SNP and breast cancer risk [153]. Likewise, the Human Genome 
Epidemiology review and meta-analysis of 11 studies (3,810 cases and 3,173 controls) 
found the G allele and G carrier of the CYP3A4 polymorphism not to be significantly 
associated with breast cancer risk [154]. 
In contrast to the relative few polymorphisms found in other CYP genes, more than 
300 polymorphisms have been identified for CYP1B1. In particular, the R48G, A119S, 
V432L, and N453 SNPs have been associated with higher 4-hydroxylation activity 
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compared to the wild-type CYP1B1 [155]. In case-control studies, these SNPs have been 
associated with increased breast cancer risk in Polish [156], French [157], Chinese [158], 
and American white and black women [159], while three meta-analyses did not found an 
association with breast cancer risk [160-162].  
Finally, COMT has been extensively studied, as it is responsible for the inactivation 
of catechol estrogens through esterification and thus, the prevention of estrogen quinone-
DNA adducts and reactive oxygen species. The polymorphism occurring at codon 158 of 
COMT results in the substitution of Val for Met, which seems to determine high- and 
low-activity alleles of the enzyme [163]. Specifically, in a in vitro study, the Met allele 
(GG vs. AA) coding for the low-activity and heat-labile enzyme was found to be four to 
five times less effective in methylating the catechol estrogens than the Val allele [164]. 
The numerous meta-analyses that have investigated the association between this 
SNP and breast cancer risk have reported conflicting results, mainly due to the ethnicities 
of the populations investigated. For example, in two meta-analyses restricted to Chinese 
women (4,626 cases, 5637 controls), significant risk for breast cancer was associated 
with the genetic models A/A vs. G/G (OR = 1.59, 95% CI: 1.12-2.27); A/A vs. G/A + 
G/G (OR = 1.62, 95% CI: 1.14-2.29); and A vs. G (OR = 1.15, 95% CI: 1.00-2.32) [165, 
166]. Only one of these meta-analyses performed a subgroup analysis based on 
menopausal status and found the SNP presented a significant increased risk in the 
premenopausal group (A/A vs. G/A +G/G: OR = 1.94, 95% CI: 1.03-3.63) whereas in 
postmenopausal women, no significant increase in risk was associated with any of these 
genetic models [166]. In contrast, another meta-analysis including studies conducted in 
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Asian populations other than Chinese (i.e., Korean, Indian, Thai, and Asian American) 
found no association between this SNP and breast cancer risk [167].  
Lastly, the most comprehensive meta-analysis to date, including 33 studies in 
Caucasians, 18 in Asians, and 5 in mixed ethnicities totaling 34,358 cases and 45429 
controls, found no overall positive relationship between the COMT polymorphism and 
breast cancer risk [168]. Subgroup analyses revealed no significant associations 
regardless of ethnicity, menopausal status, or the source of controls.  
Overall, further studies employing more homogenous populations and larger sample 
sizes are needed to substantiate the role of genetic variation in any of the genes involved 
in estrogen biosynthesis and metabolism and breast cancer pathogenesis. 
 
III.PHYSICAL ACTIVITY AND BREAST CANCER RISK 
The observation that physically active women, compared to sedentary or less active 
women, had a lower prevalence of breast cancer was first reported by Frisch and 
colleagues in 1985 in a study of young, female college athletes [169]. Since then more 
than 90 studies worldwide have studied the association between physical activity and 
breast cancer risk in women [23, 170, 171]. Overall, these studies provide convincing 
evidence of an inverse relationship between physical activity (PA) and breast cancer risk. 
For instance, in a recent literature review, 33 cohort and 40 case-control studies found 
all physically active women (pre- and postmenopausal women combined), compared to 
the least active women, had a 30% and 20% average reduction in risk for breast cancer, 
respectively [23]. Of the 73 studies reviewed, 29 found a statistically significant risk 
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reduction [172-200]; eight found a borderline significant risk reduction [201-208]; 14 
observed a non-significant risk reduction [209-222]; 19 reported null results [174, 223-
240]; and only three found a non-significant increased risk for breast cancer among the 
most physically active women [241-243]. 
Among the types of physical activity reported, engagement in recreational and 
household activity resulted in the greatest breast cancer risk reduction (21% average), 
followed by transportation (walking/cycling) and occupational activities (18% and 13%, 
respectively). 
In terms of intensity, moderate physical activity was associated with a risk reduction 
of 15% while vigorous physical activity was associated with a slightly greater risk 
reduction of 18%. Similarly, increasing duration of physical activity was found to offer 
the most risk protection. Specifically, 2-3 hours per week of moderate-to-vigorous 
physical activity was associated with a 9% risk reduction while 6.5 hours per week was 
associated with a 30% risk reduction. 
On the effect of physical activity performed during different periods of life, breast 
cancer risk decreased by 16% during adolescence; 8% during early adulthood (20s); 15% 
during middle adulthood (30s/40s); and 17% during late adulthood (older than 50 years). 
Finally, a smaller portion of these studies has investigated the effect modification of 
menopausal status. Specifically, 25 studies have analyzed data from premenopausal and 
postmenopausal women separately, while nine and 14 studies have exclusively focused 
on premenopausal and postmenopausal women, respectively. Data from these studies 
suggest a much stronger, inverse association between PA and breast cancer risk in 
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postmenopausal women than premenopausal women. In postmenopausal women, 87% of 
these studies found an inverse association between PA and breast cancer risk and 13% 
found no association at all. In contrast, 73% of the studies in premenopausal women the 
association between PA and breast cancer risk to be inverse; 24% found no association, 
and 3% of them the association to be positive albeit non-significantly. 
Furthermore, a greater proportion of studies reporting an inverse association between 
PA and breast cancer risk have found the association to be statistically significant in 
postmenopausal women than in premenopausal women. For example, four of 16 cohort 
studies and 11 of 23 case-control studies found a significant risk reduction with 
increasing PA levels, while only two cohort and four case-control studies found the 
association to be statistically significant in premenopausal women. 
A recent review in 2014 of 14 case-control and seven cohort studies further support 
these findings by reporting the only three studies that did not find a significant reduction 
in breast cancer risk with increasing PA were those in which the sample population was 
exclusively premenopausal [244]. However, when pre- and postmenopausal data that was 
analyzed separately was included, the overall odds ratio for case-control and cohort 
studies in premenopausal women was found to be statistically significant (OR = 0.84, 
95% CI: 0.81-0.88 and OR = 0.61, 95% CI: 0.59-0.63, respectively). 
Overall, there is enough evidence to suggest and support the observation that 
increasing levels of PA, especially of moderate-to-vigorous intensity, result in significant 
decreases in breast cancer risk in both premenopausal and postmenopausal women. 
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IV. PHYSICAL ACTIVITY AND HORMONAL RISK FACTORS  
A. Endogenous Sex Hormones and SHBG 
One of the proposed mechanisms by which physical activity is thought to mediate 
breast cancer risk is through changes in endogenous levels of sex hormones and SHBG. 
In the case of postmenopausal women, evidence from a re-analysis of 18 prospective 
studies has shown a significant association exists between higher serum levels of 
estradiol, estrone, and testosterone and postmenopausal breast cancer risk [36]. Evidence 
of a similar association in premenopausal women is scarce. To date, three cross-sectional 
[245-247], three prospective [248-250], and one clinical study [251] have investigated the 
associations and effects of physical activity in premenopausal women. 
1. Observational Studies 
The earliest of such studies was one of 50 collegiate Japanese premenopausal women, 
in which physical activity performed during early adolescence, i.e., 13-15 years old, was 
found to be significantly and inversely associated with follicular (but not luteal) levels of 
E2 [245]. Physical activity during late adolescence (16-18 years old) or activity performed 
in the year prior to the study was not correlated at all with either follicular or luteal levels 
of E2. Similarly, follicular and luteal levels of SHBG were not associated with physical 
activity at any of the life periods assessed by the study. Although this study analyzed 
samples in both menstrual cycle phases and provided adjustment for age, cycle length, 
BMI, and birth month, the study sample was very small and no adjustment was made for 
day of menstrual cycle since no date for the onset of subsequent menstruation was 
available. 
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In a much larger cross-sectional study of 636 premenopausal women, vigorous 
physical activity was significantly associated with lower plasma concentrations of E2 
taken across the menstrual cycle (P = 0.043) [247]. In this study, plasma levels of SHBG 
and luteal progesterone, however, were not associated with either occupational or 
vigorous physical activity.  
Similarly, a cross-sectional analysis of 565 premenopausal women based on the NHS-
II study, found a significant inverse association between moderate-to-vigorous PA and 
luteal levels of free E2, E1, and free testosterone (P = 0.04, 0.01, and 0.02, respectively) 
[246]. Specifically, women who exercised more than 42 MET-hours/week (equivalent to 
seven hours of vigorous physical activity) had 14% lower luteal free E2, 10% lower luteal 
E1, and 10% lower luteal free testosterone levels than women exercising less than 3 
MET-hours/week (equivalent to one hour of walking). When women with anovulatory 
and irregular menstrual cycles were excluded from these analyses, the trends became 
significantly attenuated (8% lower luteal free E2, 2% lower luteal E1, and 5% lower luteal 
free testosterone) and ceased to be statistically significant. Finally, this study reported 
levels of vigorous physical activity, walking, and sitting/standing were not associated 
with follicular or luteal plasma levels of E2, free E2, E1, estrone sulfate (E1SO4), SHBG, 
testosterone, free testosterone, and progesterone. 
Overall, cross-sectional data consistently suggests higher moderate-to-vigorous 
physical activity levels in premenopausal women are inversely associated with plasma 
levels of estrogen and free testosterone but not associated with any other sex hormones or 
SHBG. 
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2. Clinical Studies 
In comparison, only one of three prospective studies has found an association 
between physical activity and premenopausal sex hormone levels. In the Tromso Study, a 
single-center, population-based prospective study in Northern Norway, untimed plasma 
levels of 205 premenopausal women were not associated with moderate-to-vigorous 
physical activity [248]. 
In the Penn Ovarian Aging Study, 391 women provided a follicular sample during 
two consecutive menstrual cycles at four different assessment periods (baseline, 30 
months later, 54 months later, 78 months later) and reported physical activity up to four 
times over 10 years through the Paffenbarger Physical Activity survey [250]. In this 
study, leisure-time physical activity of pre- and postmenopausal women was not 
associated with follicular plasma levels of E2 and total testosterone. Interestingly, 
significant associations were only observed in women undergoing transmenopause, that 
is those experiencing amenorrhea for 3 to 11 months. 
In contrast to these two studies, a Polish study of 139 eumenorrheic, premenopausal 
women found mean salivary E2 levels collected daily over one menstrual cycle to be 
significantly and inversely associated with higher habitual physical activity [249]. 
Women in the highest tertile for habitual physical activity had significantly lower salivary 
mid-cycle, follicular, and luteal levels of E2 (P = 0.0001 for all) than women in the lowest 
tertile. Furthermore, this study observed women in the highest tertile of habitual physical 
activity spent significantly more time (min/day) in occupational, housework, 
sport/exercise, and overall daily activities than women in the other tertiles. 
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Lastly, the strongest evidence on the effects of physical activity on premenopausal 
estrogen levels comes from a recent, small clinical study of 35 sedentary, eumenorrheic 
women assigned to either a light conditioning intervention (n = 9) or an exercise 
intervention coupled with caloric restriction (n = 24)[251]. The exercise prescription 
consisted of 40-90 minutes of supervised aerobic activity at 80% of maximum heart rate 
for four menstrual cycles for 1-2 days a week for the light conditioning (LC) group and 
four times per week for the exercise/diet group (EX+CR). The diet prescription for the 
LC group remained eucaloric while that of the EX+CR group targeted a reduction of 20-
35% of baseline energy requirements. Both groups had excellent compliance to the 
nutrition counseling sessions (95-99%) and exercise sessions (92-95%). Blood samples 
for serum E2 were collected every 2-3 days totaling ten samples during the baseline cycle 
and ten samples during intervention cycle 4. Blood samples for SHBG were obtained 
during follicular days 1-7 for baseline, intervention cycles 1-4, and the post-study cycle. 
First morning void samples were taken daily during the baseline and intervention cycles 
and were used to assess estrone-1-glucuronide (E1G) and pregnanediol glucuronide 
(PdG). 
The total area under the curve (AUC) for E2 (representing the entire menstrual cycle) 
at intervention cycle 4 was significantly lower than at baseline in the EX+ CR group (P = 
0.004). Similarly, urinary E1G and PdG AUCs across the menstrual cycle for the EX 
+CR group decreased significantly from baseline values (P = 0.004 and 0.011, 
respectively). The effect of the intervention on SHGB levels in the EX+ CR group 
showed a biphasic response; SHBG increased significantly by intervention cycle 2 and 
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then decreased gradually by intervention cycle 4 such that post-intervention levels were 
not statistically different from baseline levels. In comparison, the LC group experienced 
no significant changes from baseline in urinary levels of E1G and PdG, or serum levels of 
E2 and SHBG. 
In conclusion, data in premenopausal women collectively and consistently suggests 
physical activity, especially of moderate-to-vigorous intensity, has an inverse effect on E2 
and E1 levels and no effect on SHBG levels. Currently, such a conclusion cannot be 
extended to testosterone (free or total) or progesterone due to inconclusive or insufficient 
data. 
B. Estrogen Metabolites 
While there is limited data on the association between physical activity and 
endogenous sex hormones in premenopausal women, there is an abundance of 
observational but not experimental evidence in support of an association between 
physical activity and premenopausal estrogen metabolism. 
1. Observational Studies 
The earliest observations that physical activity led to changes in estrogen metabolism 
came from small, cross-sectional studies in young female athletes in the mid 1980’s. 
Specifically, Russell et al. observed that both oligomenorrheic competitive swimmers and 
eumenorrheic runners had significantly higher urinary levels of 2-OHE1 and lower levels 
of E2 at baseline than non-exercising women [252]. In these athletes, levels of 2-OHE1 
were significantly elevated after exercise compared to their pre-exercise levels. In another 
study, Russell et al. reported young competitive swimmers who developed 
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oligomenorrhea after switching from a moderate to a strenuous training program 
experienced a significant increase in serum levels of 2-OHE1 (but not E2) [253]. 
Interestingly, the levels of 2-OHE1 during moderate training were similar to those of non-
athlete controls. 
Similarly, using radiolabeled tracers, Snow and colleagues showed elite oarswomen 
with menstrual irregularities metabolized a greater fraction of E2 by 2-hydroxylase 
oxidation than both oarswomen with normal menstrual function and control women 
[254]. No significant differences in 2-hydroxylase oxidation were observed between 
oarswomen with normal menstrual function and controls. The extent of 16α-hydroxylase 
oxidation, however, remained unchanged and similar in both oarswomen and controls. 
Collectively, results from these earlier studies suggest higher levels or increased intensity 
of chronic exercise promotes a shift in estrogen metabolism that favors C2-hydroxylation. 
Cross-sectional studies conducted more than two decades later also suggest physical 
activity may favorably mediate estrogen metabolism in premenopausal women. For 
instance, a Chinese study found premenopausal women in the highest quartile of leisure-
time physical activity (measured in MET per hour/day) had significantly higher urinary 
2-OHE1/16α-OHE1 ratio than women in the lowest quartile after adjustment for age, soy 
protein, and Brassica vegetable intake [255]. Interestingly, a significant positive 
interaction was observed between 2-OHE1/16α-OHE1 ratio and BMI among the most 
active women but not among the least physically active. 
In another study, regression analyses adjusted for age and BMI showed the average 
daily MET-hours of physical activity of 77 eumenorrheic premenopausal women to be 
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significantly associated with higher luteal levels of 2-OHE1 and 2-OHE1/16α-OHE1 ratio 
but not 16α-OHE1 levels [256]. 
The results of another study with a larger sample size (n = 603), better lab 
methodology (liquid chromatography-tandem mass spectrometry (LC/MS-MS)), timed 
luteal urine samples, and a previously tested and confirmed reliable physical activity 
assessment instrument also support the idea that physical activity can mediate estrogen 
metabolism in premenopausal women [257]. Specifically, high overall physical activity 
in adulthood (42+ MET-hour/week vs. < 3 MET-hour/week) was associated with a 15% 
reduction in urinary luteal levels of both E2 and 2-MeOE1 and a 24% reduction in16α-
OHE1 levels after adjusting for age, BMI, alcohol consumption, luteal day at collection, 
and menstrual cycle length. In addition, high overall physical activity was positively 
associated with 2-OHE1 /16α-OHE1, 2-OHE/parent estrogens, and 2-OHE/2-MeOE 
ratios. Significant associations were also observed for walking and vigorous physical 
activity in adulthood, but there was little evidence of an association with adolescent 
physical activity or sedentary behavior in adolescence or adulthood. 
In contrast, a study in which aerobic fitness was used as an objective indicator of 
chronic physical activity, follicular and luteal levels of 2-OHE1, 16α-OHE1, and 2-
OHE1/16α-OHE1 ratio of highly fit premenopausal women (maximum oxygen 
consumption (VO2 max) ≥ 48mL.kg.min-1) were found to be similar to those of average 
fit women (VO2 max ≤ 40 mL.kg.min-1) [258]. 
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Overall, observational studies highly suggest physical activity, whether as purposeful 
exercise or recreational activity, can mediate changes in estrogen metabolism of 
premenopausal women. 
2. Clinical Studies 
The first experimental studies in premenopausal women initially focused on the 
effects of acute not chronic exercise on estrogen metabolism. The knowledge derived 
from these studies is almost due entirely to the work of Carl De Cree and colleagues in 
the late1990’s. In one of many studies, De Cree and colleagues studied nine normally 
menstruating, untrained young women who underwent a standardized incremental 
exercise test during the follicular and the luteal phase [259]. Results from this study 
showed baseline serum levels of total estrogens (E), 2-hydroxyestrogens, and 2-
methoxyestrogens to be significantly higher in the luteal phase than in the follicular 
phase. However, with the exception of total E (which only increased significantly in the 
luteal phase), incremental exercise intensity did not result in significant changes in total 
2-OHE, total 2-MeOE, catechol estrogen (CE) formation (expressed as 2-OHE/E ratio), 
or CE activity (expressed as 2-MeOE/2-OHE ratio) in either menstrual phase [259]. 
In a subsequent study, nine untrained eumenorrheic women were tested in the 
follicular and luteal phase of a control (pre-training) cycle and also after a 5-day 
exhaustive training program. Similar to their previous study, De Cree et al. confirmed 
total plasma levels of E, 2-OHE, and 2-MeOE were significantly higher in the luteal 
phase than in the follicular phase [260]. Compared to pre-training levels, luteal post-
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training levels of E, 2-OHE, and 2-MeOE were significantly lower while CE formation 
and CE activity were significantly higher. 
In a third study, nine healthy, eumenorrheic, untrained women underwent a pre- and 
post-training incremental exercise test during the follicular and luteal phase [261]. 
Results showed follicular and luteal levels of E decreased significantly after five days of 
intense training compared to pre-training levels while exercise at all intensities increased 
estrogen levels significantly from those at rest. In the case of 2-OHE and 2-MeOE, 
plasma post-training levels decreased significantly compared to pre-training levels 
regardless of intensity but only during the luteal phase, especially for 2-OHE. 
Conversely, CE formation and CE activity in the luteal phase increased significantly from 
pre-training levels while decreasing with exercise intensity. 
While at face value the results reported by De Cree and colleagues (i.e., exercise 
induces CE formation) and those by Russell et al. (i.e., exercise increases 2-OHE plasma 
levels) seem to contradict each other, the results can be reconciled when one calculates 
the CE formation in the studies of the latter. In this manner, De Cree and colleagues 
found the CE formation in Russell’s controls to be 0.13 ± 0.03; 0.77 ± 0.30 in 
eumenorrheic swimmers training 55 km/week; and 1.20 ± 0.21 in oligomenorrheic 
swimmers training 90 km/week [261]. Based on these calculations, De Cree and 
colleagues speculate that as long as a subject is euestrogenemic, a higher formation of CE 
may not be accompanied by increases in absolute levels of CE. One obvious argument 
against this conclusion however, is that it is based on data obtained by indirect methods, 
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that is, CE formation was calculated arithmetically by dividing the concentration of 
plasma 2-OHE levels by E levels. 
In another study, De Cree et al. was able to address this criticism indirectly by 
measuring O-methylation of 2-hydroxyestrogens directly in human erythrocytes. This 
method has been shown to be an accurate measure of COMT activity in other tissues and 
significant for the in vivo methylation rate of CE [262]. Therefore, a direct method for 
measuring CE activity (not CE formation) was used. In this study, levels of plasma 2-
MeOE and 4-MeOE of 15 healthy, eumenorrheic untrained women following similar 
training protocols as in the previous studies increased significantly after training in both 
menstrual phases [263]. However, the effect of incremental exercise was only apparent in 
the formation of 4-MeOE, especially in the luteal phase. 
In a later study and consistent with previous results, De Cree et al. showed plasma 
levels of 4-OHE and 4-MeOE of untrained, healthy, eumenorrheic women increased with 
incremental exercise [264]. Specifically, 4-OHE levels increased substantially more in 
the pre-training state while 4-MeOE levels increased more so after training. Furthermore, 
the ratio of 4-MeOE to 4-OHE, a measure of CE activity, increased significantly with 
progressive training. 
Collectively, the work of De Cree and colleagues suggest acute exercise in 
eumenorrheic women shifts estrogen metabolism in favor of 2- vs. 16α-hydroxylation and 
CE activity through increased COMT activity leading to higher levels of 2- and 4-
methoxyestrogens. 
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While data on the effect of acute exercise is valuable, it has limited application to the 
general female population, as women do not engage in enough physical activity and/or 
high intensity exercise as the athletes or women in these acute exercise studies did. In that 
regard, current studies have focused on the chronic effect of usual, recreational physical 
activity on estrogen metabolism. To date, five exercise intervention studies [265-269] 
have investigated the effects of chronic aerobic exercise on the estrogen metabolism of 
premenopausal women. 
In the Women’s Healthy Lifestyle Project study, 84 healthy premenopausal women 
followed a diet and exercise intervention for six months while 90 women were 
randomized into an assessment-only control group [266]. The diet/exercise intervention 
was designed to induce a 5- to 15-lb weight loss by decreasing dietary cholesterol to ≤ 
100 mg/day, limiting total fat and saturated fat intake to ≤ 25% and ≤ 7% of calories, 
respectively; and increasing moderately intensity physical activity. In the treatment 
group, the intervention resulted in a significant increase in urinary 2-OHE1/16α-OHE1 
ratio compared to baseline values. The control group, however, also experienced 
(inexplicably) a positive change from baseline values. Ultimately, the difference between 
groups in the change from baseline in 2-OHE1/16α-OHE1 ratio was not statistically 
different. Limitations of this study include untimed spot urine samples, retrospective 
assessment of physical activity through a questionnaire, and unexplained observation of a 
significant increase in 2-OHE1/16α-OHE1 ratio in the control group. 
In another diet and exercise study, 24 eumenorrheic premenopausal women followed 
an exercise intervention lasting four menstrual cycles seeking to increase caloric 
  49
expenditure by 20% while also reducing daily caloric intake by 20-35% [269]. Subjects 
had supervised exercise sessions four times per week during which they exercised 
aerobically on a treadmill, stationary bike, or stair stepper for approximately 40-90 
minutes at 60-90% of their maximum heart rate (max HR). Additionally, subjects were 
instructed to track their daily food consumption for seven days at a time, every two 
weeks, and review these records every other week with a study dietitian. Estrogen 
metabolite values were assessed via EIA from first morning voids collected daily during 
a one-month baseline cycle and the subsequent four intervention cycles. Women in the 
study showed high adherence to the exercise protocol (96% compliance) and diet 
intervention (22% reduction in daily caloric intake) resulting in significant improvements 
in aerobic fitness and significant decreases in body weight (3.8 kg) and body fat 
percentage (4.6%). In addition, levels of 2-OHE1 and 16α-OHE1 were reported to be 
significantly higher in the luteal phase compared to the follicular phase. However, urinary 
levels of 2-OHE1 and 2-OHE1 /16α-OHE1 ratio did not change significantly over the 
course of the study or between menstrual cycle phases, while levels of luteal 16α-OHE1 
increased significantly in a non-linear (cubic) fashion. 
Interestingly, when women in this study were divided into tertiles according to their 
baseline 2-OHE1/16α-OHE1 ratio, those in the lowest tertile experienced the greatest 
percent changes (increases) in follicular and luteal 2-OHE1/16α-OHE1 ratio and absolute 
changes in the luteal phase that women in the second and third tertiles did. Importantly, 
women in the lowest tertile did not differ from women in the other tertiles in baseline 
weight, percent body fat, or aerobic fitness, or in the amount of weight or fat loss and 
  50
improvement in aerobic fitness during the intervention suggesting baseline 2-OHE1/16α-
OHE1 ratio could be a major determinant of changes in 2-OHE1/16α-OHE1 ratio. The 
study design, however, makes it impossible to determine whether the significant changes 
in 2-OHE1/16α-OHE1 ratio were due to the exercise intervention, calorie restriction, 
weight/fat loss, or a combination of these factors. 
In an exercise-only intervention, 15 young, eumenorrheic, sedentary, premenopausal 
women exercised aerobically at an incrementally higher intensity (70% max HR to 85% 
max HR) for 30 minutes on a treadmill or elliptical machine five times a week, for three 
to four menstrual cycles [268]. During the study, subjects were asked to avoid changes in 
diet or weight and to collect their urine for three consecutive 24-hr periods corresponding 
to menstrual cycle days 7, 8, and 9 of a pre- and post-intervention cycle. Urine was 
pooled and analyzed as a single sample via modified gas chromatography-tandem mass 
spectrometry (GC-MS/MS). Results from this study show that approximately 15 weeks of 
moderate-to-vigorous intensity aerobic exercise in premenopausal women did not result 
in statistically significant changes from baseline on follicular levels of E1, E2, 2-OHE, 4-
OHE, 16α-OHE1, E3, 2-OHE1/16α-OHE1 ratio and 2-OHE/4-OHE ratio. 
In a similarly small but much longer exercise-only intervention, 20 young, sedentary 
premenopausal women were asked to exercise aerobically at 60-70% of their max HR for 
at least 60 minutes three days a week for six months [267]. First morning urine was 
collected on menstrual cycle day 3 and also before and after the afternoon exercise 
program and analyzed via GC/MS-MS. Urinary follicular levels of E1, E2, and E3 did not 
change significantly after the intervention when compared to pre-intervention levels. 
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To date, only one randomized exercise-controlled clinical trial in premenopausal 
women has been conducted. This study also failed to find significant changes in estrogen 
metabolism due to exercise. Specifically, Campbell et al. recruited and randomized 32 
young, sedentary, healthy, eumenorrheic women into either a 12-week aerobic exercise 
program (n = 14) or a usual lifestyle intervention (n = 15) [265]. Randomization was 
stratified on BMI (< 25 or ≥ 25) and occurred once baseline measurements were obtained 
during a control cycle. 
During weeks 1-4, exercise participants trained aerobically for 20-40 minutes on a 
stationary bike three times a week at an intensity of approximately 25% higher than the 
power output recorded at a baseline fitness assessment. During weeks 5-8, participants 
did two aerobic sessions for 30-45 minutes as in weeks 1-4 and two 40-minute session of 
interval training. Finally, during weeks 9 to 12, participants did two base aerobic training 
sessions for 30-45 minutes and two interval sessions similar to weeks 5 to 8. 
First morning urine samples were collected during menstrual cycle days 20 and 22 
over four consecutive menstrual cycles (one baseline and three intervention cycles) and 
analyzed via EIA methods. 
At baseline, there were no differences in the luteal levels of 2-OHE1, 16α-OHE1, and 
2-OHE1/16α-OHE1 ratio between exercisers and control women. Similarly, there were no 
significant differences within- and between-groups in the levels of 2-OHE1, 16α-OHE1, 
and 2-OHE1/16α-OHE1 ratio due to the exercise intervention. While the intervention 
resulted in no changes in body weight, BMI, waist and hip circumference, exercise 
participants lost a significant amount of body fat (1.2 kg) and gained lean mass (0.9 kg) 
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when compared to control women. Lean body mass was found to be positively and 
significantly associated with the 2-OHE1/16α-OHE1 ratio (r = 0.43; P = 0.015). 
Although the exercise intervention by Campbell et al. used a robust study design, it 
does have some limitations that could have compromised their ability to detect significant 
changes on estrogen metabolism including small sample size (14-15 women per group) 
and difficulty standardizing urine sample collection across the menstrual cycle. 
Overall, exercise interventions in premenopausal women (whether coupled with a diet 
intervention or not) do not support the hypothesis that aerobic exercise is capable of 
inducing significant changes in estrogen metabolism. 
The discrepancy observed between observational studies and exercise interventions 
may be due in part to the inherent limitations of the observational design and 
methodology. For instance, in the earlier cross-sectional studies [252-254], sample sizes 
were very small (5-7 participants per group), menstrual function was not standardized 
(comparison between eumenorrheic and oligomenorrheic women), reproductive age 
among subjects varied widely, physical activity was assessed via self-reported measures, 
and lab methods used an older version of radioimmunoassay [252, 253] or administration 
of radiolabeled tracer [254] to measure estrogen metabolites, which are not as accurate as 
the newer solid-phase EIA [107]. In contrast, the more recent studies [255-258] have 
used larger sample sizes, adjusted or controlled for menstrual cycle phase, and used an 
improved [270] EIA method [255, 256, 258]or GC-MS/MS methodology [257]. With the 
exception of one study [258], all of the recent observational studies [255-257] have also 
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relied on self-reports of physical activity, which are susceptible to recall bias and over 
reporting of frequency, duration, and intensity [271]. 
Future exercise interventions should use a control group, be designed to have enough 
statistical power to detect a minimum difference in estrogen metabolite concentrations, 
account for menstrual cycle differences, and expand the scope of estrogen metabolite 
analyses to include the 4-hydroxyestrogens, 2- and 4-methoxyestrogens and their 
metabolite ratios. 
 
V. DISSERTATION RATIONALE 
Most risk factors for breast cancer are not or not easily modifiable. Physical inactivity 
is one of few risk factors that are reasonably amenable for intervention, and as a result, it 
has become a primary target for behavior modification in breast cancer prevention 
research. 
Cohort and case-control studies have been instrumental in providing compelling 
evidence of an inverse association between physical activity and breast cancer risk. 
Observational data, however, has important limitations. First of all, the use of self-
reported, mostly retrospectively, physical activity is subject to recall bias. Secondly, and 
most importantly, observational studies are not designed to determine the exact biological 
mechanisms by which physical activity (and its optimal modality, intensity, frequency, 
duration) mediate breast cancer risk. In this regard, an exercise randomized clinical trial 
is necessary to address both of these issues. 
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The doctoral project presented in this dissertation used some of the data generated by 
the Women In Steady Exercise Research (WISER) study conducted at the University of 
Minnesota. The WISER study is the first randomized, exercise-controlled, clinical trial 
investigating the effects of aerobic exercise (30 minutes a day, five times a week for four 
menstrual cycles) on a myriad of breast cancer risk biomarkers of sedentary, healthy, 
premenopausal women. Circulating levels of F2-isoprostanes, IGF-1, IGFBP-1, IGFBP-2, 
and IGFBP-3, insulin, fasting glucose, endogenous sex hormones, estrogen metabolite 
excretion, body composition parameters, and dietary intake were measured both at 
baseline and post-intervention. Based on the results of a pilot study [268], 4 menstrual 
cycles (average of 16 weeks) was the minimum amount of weight-bearing aerobic 
exercise needed to observe significant changes in the levels of the aforementioned breast 
cancer biomarkers. In addition, the specific exercise protocol sought to follow the current 
public health recommendations by the American College of Sports Medicine to promote 
and maintain health and prevent chronic disease and that of the International Agency for 
Research in Cancer to prevent breast cancer. 
In particular, this doctoral project sought to test the hypothesis that 150 minutes of 
moderate-to-vigorous aerobic physical activity per week for 16 weeks would reduce 
circulating levels of sex hormones and shift estrogen metabolism in premenopausal 
women in a matter consistent with decreased breast cancer risk. The specific hormonal 
endpoints analyzed include serum levels of E2, E1SO4, progesterone, testosterone, and 
SHBG via RIA and ELISA methods and urinary levels of parent estrogens and ten 
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estrogen metabolites (2-OHE1, 2-OHE2, 4-OHE1, 4-OHE2, 16a-OHE1, E3, 2-MeOE1, 2-
MeOE2, 4-MeOE1, and 4-MeOE2) via LC/MS-MS. 
The study intervention focused exclusively on premenopausal women to address the 
possibility that physiological changes associated with breast cancer may take place before 
menopause. This is important to consider given it is well accepted that cancer initiation 
and its development may occur over a long period of time. 
The WISER study was designed to address many of the shortcomings of previous 
exercise interventions in premenopausal women, which are currently very few. For 
instance, the sample size of the WISER study (n = 320) is roughly an order of magnitude 
greater than other studies. Secondly, confounding effects were optimally minimized by 
the use of a control group chosen at random. Thirdly, the WISER study was designed to 
analyze a much broader hormonal profile using a more accurate and sensitive lab 
methodology than the one chosen by previous studies.  
Given these methodological advantages, the WISER study is better equipped to 
address the scientific question of whether or not the hormonal changes (if any) associated 
with aerobic exercise are consistent with those deemed to decrease breast cancer risk in 
premenopausal women. 
  
  56
 
    
Figure 1.1. Steroidogenic Pathway in the Ovary. Abbreviations: StAR, steroidogenic acute 
regulatory protein; CYP11A1, side-chain cleavage of P450; CYP17A1, 17-hydroxylase/17,20- 
lyase; HSD3B2, 3β-hydroxysteroid dehydrogenase-Δ5,4 isomerase type 2; CYP19A1, aromatase; 
HSD17B1, 17β-hydroxysteroid dehydrogenase type 1 [32]. 
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CHAPTER 2: 
 
ENDOGENOUS SEX HORMONES AND SHBG 
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I. SUMMARY 
Background. It is hypothesized that exercise can lead to a decrease in breast cancer risk 
through several hormonal and non-hormonal mechanisms. The Women in Steady 
Exercise Research (WISER) study investigated the effects of aerobic exercise on 
premenopausal sex hormone levels. 
Methods. 391 sedentary, healthy, young eumenorrheic women were randomized into an 
exercise intervention of 30 minutes of aerobic exercise 5 times a week for approximately 
16 weeks (n = 212), or into a control group (n = 179). Serum levels of estradiol, estrone 
sulfate, testosterone, and sex hormone binding globulin (SHBG), all in the midfollicular 
phase, and of progesterone, in the midluteal phase, were measured at baseline and at the 
end of the 16-week period. 
Results. Compared to the controls (n = 153), exercisers (n = 166) experienced significant 
increases in aerobic fitness, lean body mass, and decreases in percent body fat. There 
were no significant changes in body weight and menstrual cycle length between or within 
groups. Progesterone decreased significantly in exercisers; however, this reduction was 
similar to that of the control group. No significant changes between or within groups 
were found for any of the other sex hormones or SHBG. 
Conclusions. In premenopausal women, 16 weeks of 150 minutes per week of moderate 
aerobic exercise in young women did not significantly alter sex hormone or SHBG levels. 
Impact. Any favorable effects that moderate aerobic exercise without an associated 
weight change may have on breast cancer risk in premenopausal women are unlikely to 
be a consequence of changes in levels of sex hormones or SHBG. 
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II. INTRODUCTION 
 Despite steady decreases in breast cancer mortality rates, breast cancer continues to 
be the most frequently diagnosed non-skin cancer and second leading cause of cancer 
death among women[272]. Well-established risk factors for breast cancer include early 
age at menarche, late age at menopause and first childbirth, nulliparity, family history of 
breast cancer, benign breast disease, and non-reproductive factors such as hormone-
replacement therapy use and physical inactivity [273, 274]. Collectively, these factors 
increase the lifetime exposure of breast tissue to circulating sex hormones, which have 
been implicated, both experimentally and observationally, in the etiology of breast 
cancer. 
In cultured mammary cancer cells, estrogen has been shown to promote cell 
proliferation [86, 275]. Furthermore, although the role of progesterone in breast cancer is 
unclear, there is evidence progesterone can potentiate the mitogenic effect of estradiol 
[276]. Although not a steroid hormone, the glycoprotein sex hormone binding globulin 
(SHBG) is also thought to play a role in breast carcinogenesis not only by regulating the 
bioavailability of estradiol and testosterone in circulation [277], but also by inhibiting 
estradiol-mediated cell growth and anti-apoptosis in estrogen-dependent breast cancer 
cells [278]. 
In observational studies, elevated levels of circulating sex hormones are strongly 
associated with decreased risk for breast cancer. In a re-analysis of 13 prospective 
studies, postmenopausal women with the highest levels of estradiol, estrone, and 
testosterone had a two-fold increase in breast cancer risk, and those with the highest 
  60
SHBG levels had a 34% decreased risk [279]. Similarly, studies in premenopausal 
women have shown associations between increases in breast cancer risk with higher 
levels of estrogens and androgens and lower levels of progesterone and SHBG [60, 62, 
63, 65, 66, 69, 75, 280-284]. Importantly, premenopausal levels of estradiol have been 
associated with postmenopausal breast cancer [65], suggesting exposures during this 
period may very well play a role in the initiation and promotion of breast cancer. 
Physical activity is a modifiable lifestyle that has been associated with reductions in 
breast cancer risk of approximately 25-30% [285]. Although many mechanisms have 
been suggested for the protective effect of exercise on breast cancer, reduction of 
circulating levels of sex steroid hormones is one that has been widely suggested [286]. 
This has not been substantially studied in clinical trials, although in a recent, small 
clinical study of sedentary premenopausal women reported by Williams et al. [287], a 
four-cycle intervention consisting of moderate-intensity aerobic exercise in combination 
with a caloric restrictive diet resulted in significant decreases in serum estradiol and 
urinary estrone-1-glucuronide (E1G) and pregnanediol glucuronide (PdG) levels. 
In contrast, our study, the Women In Steady Exercise Research (WISER) study, was a 
randomized trial of premenopausal women that investigated the effects of a moderate-to-
vigorous exercise intervention independent of diet restriction and weight loss. We 
specifically sought to determine if the exercise intervention would lead to alterations in 
levels of sex hormones and SHBG that would be consistent with a decreased risk of 
breast cancer. 
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III. MATERIALS AND METHODS 
The WISER study was a randomized, controlled, parallel-arm study that investigated 
the effects of a 16-week, moderate-to-vigorous intensity, aerobic exercise intervention on 
breast cancer biomarkers in young, healthy, sedentary, eumenorrheic women. The study 
was approved by the Human Subjects Review Committee at the University of Minnesota 
(Institutional Review Board; IRB ID#0505M69867). Written informed consent was 
obtained from each participant prior to participation. Details of the study design and 
methods have been described previously [288]. 
Briefly, 391 non-smoking women aged 18-30 years residing in the Minneapolis-St. 
Paul metropolitan area with a body mass index (BMI) of 18-40 kg/m2 (inclusive), having 
a self-reported menstrual cycle length of 24 to 35 days and a sedentary lifestyle (two or 
less weekly sessions of moderate intensity exercise) were randomized into the WISER 
study. Exclusion criteria included use of hormonal contraceptives in the past three 
months of any form or depot-medroxyprogesterone acetate in the past 12 months, 
gynecological problems, metabolic or endocrine-related diseases, non-melanoma cancer 
in the past 5 years, alcohol consumption of > 7 servings per week, current or recent (past 
6 months) pregnancy, and body weight changes greater than 10% over the past year. A 
total of 391 women started the study by completing baseline measurements during the 
luteal phase of menstrual cycle 1 and the follicular phase of cycle 2. 
Randomization to either an exercise intervention or a no-exercise control group 
occurred after both baseline measurements were taken. Women with menstrual cycles 
averaging 25-31 days concluded the study with follow-up measurements during the luteal 
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phase of cycle 5 and the follicular phase of cycle 6. Women with menstrual cycle lengths 
outside this range had follow-up measurements scheduled such that study duration after 
randomization was no less than 14 weeks and no more than 18 weeks. Specifically, 
women with menstrual cycle lengths of less than 25 days provided follow-up 
measurements during the luteal phase of menstrual cycle 6 and the follicular phase of 
cycle 7, while women with menstrual cycle lengths of more than 31 days completed these 
measurements during the follicular and luteal phases of cycle 5. 
Randomization was stratified on baseline BMI tertiles (≤ 22.8, 22.8-26.3, ≥ 26.3) 
based on the 50th and 75th percentiles from NHANES I data and age (18-24 vs. 25-30). 
Initially, the randomization ratio (exercise:control) was 1:1 but due to the higher dropout 
rate in the treatment group it was later changed to 60:40 to ensure adequate sample size in 
both groups was achieved within the projected study timeline. While failure to return for 
follow-up measures resulted in being dropped out of the study, exercisers were 
additionally subject to study exclusion if they missed 15 or more exercise sessions. 
Figure 2.1 shows the screening, randomization, retention, and completion of WISER 
participants. 
Exercise Intervention 
Women randomized to the exercise intervention trained aerobically five times a week 
for 30 minutes on a treadmill, stair-stepper, or elliptical machine, at a specified intensity 
based on age-predicted maximal heart rate (max HR) for 4 menstrual cycles (14-18 
weeks). All training sessions took place at the University of Minnesota’s Recreation 
Center. However, under special circumstances (housing relocation, time constrains, or 
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traveling issues) participants were allowed to work out at another exercise facility. The 
exercise intensity was initially set at 65%-70% of the age-predicted max HR and was 
gradually increased by 5% every four weeks until 80%-85% of age-predicted max HR 
was reached (stage 1 = 65-70%; stage 2 = 70-75%; stage 3 = 75-80%; stage 4 = 80-85%). 
A certified personal trainer provided instruction on how to properly use the exercise 
machines and thoroughly complete an exercise log after each workout. Trainers 
supervised exercise sessions and reviewed the exercise logs at least once weekly to 
monitor adherence and safety. When not meeting with a trainer, participants were 
expected to complete the remaining of the workout sessions on their own at the specified 
training facility. Exercise adherence was monitored by a heart rate monitor (Polar Electro 
Inc., Lake Success, NY) and exercise logs. When the trainer detected a missed exercise 
session in the exercise logs, she contacted the participant to determine the reason for the 
missed session and to encourage compliance with the study protocol. Any physical 
activity performed after randomization and outside the prescribed exercise intervention 
was assessed with a physical activity questionnaire by a research member at the end of 
the study. 
All participants, regardless of randomization outcome, were advised to maintain their 
baseline body weight. Control participants were asked to maintain their usual level of 
physical activity and to not change their eating habits. A thorough description of the 
exercise intervention has been described previously [288]. 
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Outcome Measures  
All biological, anthropometric, and body composition measures were taken at the 
General Clinical Research Center at the University of Minnesota. Body weight was 
measured four times during the study (baseline, cycle 3, cycle 4, and at follow up) to the 
nearest 0.1 kg, using an electronic scale (Scale Tronix, White Plains, NY). Height was 
measured by a stadiometer at baseline without shoes to the nearest 0.1 cm (Scale Tronix, 
White Plains, NY).  Body mass index was calculated by dividing weight in kg by height 
in meters squared (kg/m2). Body composition was assessed at baseline and follow-up 
luteal phase clinic visits by dual energy x-ray absorptiometry (DXA) using a Lunar 
Prodigy DXA apparatus (Lunar Radiation Corp., Madison, WI). 
A sub-maximal treadmill test was used to assess aerobic fitness at baseline and 
immediately after the intervention. This workload was then converted to metabolic 
equivalents (METs) by using a standard conversion formula [289]. Details of the fitness 
protocol have been described previously [288]. Self-reported physical activity performed 
a year prior to the study and during the 4-month follow-up period was assessed by 
research staff via a modified version of the Modifiable Activity Questionnaire [290]. This 
information was transformed into MET-hours per week (MET-hrs/wk) using commonly 
accepted MET values [291].  Dietary intake was assessed through self-reported, 3-day 
food records at baseline and follow-up. Nutrient intake was determined using The Food 
Processor SQL® by ESHA Research (Salem, OR). 
Timing and occurrence of ovulation was assessed using a commercial 9-day Assure 
LHTM ovulation kit (Conception Technologies, San Diego, CA). This kit assesses for 
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luteinizing hormone (LH) surge via ELISA, with a 96% accuracy rate with home use. For 
purposes of the study, day of ovulation was considered to be the day after a positive LH 
surge result. Participants were asked to inform research staff of positive LH surge results 
each month either by email or phone. 
Hormone and SHBG Analysis 
Blood samples were drawn between 6:45 and 11:00 am after an overnight fast, 
centrifuged for 15 minutes (4oC at 1000 x g); serum was separated, aliquoted, and stored 
frozen at -70oC.  Baseline and follow-up blood draws took place during specific days of 
the menstrual cycles. Midluteal phase blood draws were scheduled 6-9 days after 
ovulation for analysis of progesterone during cycles 1 and 5 (cycle 6 for women with 
menstrual cycle lengths of less than 25 days) while midfollicular phase blood draws were 
on cycle days 7-10 for the analysis of all other sex hormones and SHBG during cycles 2 
and 6 (cycle 5 and cycle 7 for women with menstrual cycle lengths of less than 25 days 
and more than 31 days, respectively). 
Serum concentrations of estradiol, estrone sulfate, testosterone, progesterone, and 
SHBG were measured by laboratory personnel blinded to the intervention status. 
Commercially available RIA kits (Diagnostic System La2oratories, Webster, TX) were 
used to measure estradiol (DSL-4400), estrone sulfate (DSL-5400), testosterone (DSL-
4100), and progesterone (DSL-3900). An ELISA method (Immuno-Biological 
Laboratories-America, Minneapolis, MN) was used to measure SHBG (IBL-59106). Free 
and bioavailable fractions of estradiol and testosterone were calculated using the 
equations by Vermeulen et al. [292] and association constants estimated by Mazer [293].  
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Although not a sex hormone, SHBG will be referred as such in the remainder of the text 
for ease of expression. 
Samples were assayed in duplicate and in batches such that each batch contained both 
baseline and follow-up samples from each participant and an equal number of exercise 
and control participants. Two quality control blood samples were included in each batch. 
The mean intra-assay and inter-assay CVs were 5.7% and 16.6% for estradiol; 3.7% and 
12.7% for estrone sulfate; 6.1 and 23.2% for testosterone; 8.6% and 11.7% for 
progesterone; and 4.9 and 5.2% for SHBG. 
Statistical Analysis 
Unadjusted comparisons of baseline characteristics were performed by using 
Student’s t-tests for continuous variables and chi-square tests for categorical variables. 
Baseline associations between sex hormones and measures of body composition, 
adiposity, fitness, reproductive characteristics, and diet were determined using Spearman 
correlation coefficients. The main trial analysis assessed the intervention effect on 
hormones on an intent-to-treat basis such that all samples from participants who 
completed at least one follow-up blood measure were included in the analysis regardless 
of compliance level. Comparison of sex hormone levels at baseline, follow-up, and 
changes from baseline were adjusted for age and BMI strata with a general linear model. 
Baseline and follow-up analyses were conducted using log transformed hormone values 
while changes from baseline were analyzed on the original scale. Linear models were 
calculated using SAS software, version 9.2 (SAS institute Inc., 2008, Cary, NC). P < 0.05 
was considered statistically significant. 
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IV. RESULTS 
Study participants 
As shown in Figure 1, of the 212 and 179 women randomized into the exercise and 
control groups, 166 (78.3%) and 153 (85.5%), respectively, completed the WISER study 
(P = 0.68). With the exception of education level (P = 0.10), women who dropped out of 
the study were no different than women who completed the study in terms of age, height, 
weight, BMI, race, ethnicity, marital status, previous contraceptive use, and parity (data 
not shown). Both baseline and follow-up midfollicular and midluteal phase samples were 
obtained from 319 and 311 women, respectively. Most of the women who completed the 
study were single (82%), Caucasian (72%), educated (67% were at college level or 
higher), and had a normal BMI (63.5%). There were no significant differences in baseline 
demographic characteristics between the study groups (Table 2.1). 
Baseline associations 
At baseline, estradiol was significantly associated with assessed fitness (r = -0.14, P = 
0.01). Testosterone was significantly correlated with age (r = -0.15, P = 0.008), BMI (r = 
0.13, P = 0.02), and percent body fat (r = 0.16, P = 0.005). Progesterone was significantly 
associated with age (r = 0.12, P = 0.03). SHBG was positively associated with age (r = 
0.11, P = 0.05) and negatively associated with BMI (r = -0.22, P < 0.001) and percent 
body fat (r = -0.21, P = 0.001). There were no significant associations between any of the 
sex hormones and self-reported physical activity, energy or alcohol intake, or 
reproductive factors such as age at menarche. 
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Treatment adherence 
Adherence to the exercise intervention in the WISER study was excellent; on 
average, exercise participants completed 134 minutes per week of the assigned 150 
minutes exercise intervention. Exercise adherence in stage 1 was 97.6% and 85.3% in 
stage 4. More details about the exercise adherence can be found somewhere else [294] . 
Treatment effects 
The exercise intervention resulted in a significant increase in aerobic fitness (increase 
of 0.90 METs reached at 85% of max HR for exercisers vs. 0.12 METs for controls) and 
improvements in body composition measures. Exercisers gained more lean mass (0.55 kg 
vs. 0.07 kg) and lost significantly more fat mass (0.57 kg vs. 0.04 kg) and body fat 
(0.95% vs. 0.09%) than controls. No changes in body weight were observed in either 
group (Table 2.2). 
There were no differences between exercise and control groups in both baseline and 
follow-up sex hormone or SHBG levels, except that exercisers had significantly lower 
estrone sulfate, with and without adjustment for baseline levels (Table 2.3). Similarly, 
adjustment for baseline levels to changes from baseline comparisons in estrone sulfate 
resulted in similar means and P values as those obtained without the adjustment. 
Therefore, the results reported in Table 2.3 for follow-up and changes from baseline in 
estrone sulfate are age- and BMI-adjusted only. 
With the exception of progesterone, there were no differences within-group in sex 
hormone or SHBG levels. Progesterone levels decreased modestly but significantly (P = 
0.02) in exercisers; however, this reduction was statistically similar to that experienced 
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by control participants. No differences were found between groups in change from 
baseline in any of the sex hormones or SHBG. Results were consistent when comparisons 
were restricted to normal weight, overweight, and obese subgroups. There were no 
significant changes from baseline in menstrual cycle length between or within groups 
(data not shown). 
 
V. DISCUSSION 
According to the American College of Sports Medicine and the American Heart 
Association, 30 minutes of moderate-intensity aerobic exercise performed five times a 
week is consistent with the promotion and maintenance of health [295]. The WISER 
study was the first randomized, controlled study designed to test whether a moderate-to-
vigorous exercise regimen resulting in no weight loss would result in changes in 
circulating levels of blood sex hormones and SHBG associated with reduction of breast 
cancer risk in premenopausal women. 
The exercise intervention in the WISER study resulted in favorable changes in 
aerobic fitness and body composition measures; however, no significant differences were 
observed between exercisers and control participants in the changes of serum estradiol, 
estrone sulfate, testosterone, progesterone, or SHBG. Although the study was not 
specifically powered to assess for hormonal differences between the two groups, the 
virtually identical results for these parameters make it unlikely that physiologically 
important differences were present. Most cross-sectional data are consistent with these 
null results. For example, previous studies have found no significant associations 
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between physical activity and premenopausal levels of estrone sulfate [248], testosterone 
[246, 250], progesterone [246, 247], and SHBG [245-247]. As for total and free estradiol, 
only two [247, 249] of six [245-250] and one [246] of two [246, 248] studies, 
respectively, have found a significant negative association. In contrast to our results, the 
one study that evaluated the association between physical activity and both estrone and 
free testosterone did find significant negative associations [246]. 
More importantly, our results are consistent with three small clinical studies in 
premenopausal women. In a study by Rogol et al. [296], there were no differences in 
integrated estradiol and progesterone levels in seventeen subjects who completed one 
year of endurance training compared to six (nonrandomized) controls. In the WISER 
pilot study, 15 weeks of moderate-to-vigorous intensity aerobic exercise in fifteen 
sedentary premenopausal women resulted in no significant changes in urinary estradiol or 
estrone levels despite a significant, albeit small (1.2 kg) loss in weight [268]. In the study 
of Williams et al., sedentary premenopausal women allocated to 120-240 minutes per 
week of moderate exercise in combination with a caloric restrictive diet (20-35% of 
baseline energy requirements) experienced significant reductions in body weight (3.7 kg), 
serum estradiol, and urinary EIG and PdG levels [287]. However, the control participants, 
who followed an intervention comparable to that of the WISER exercisers (36 minutes of 
moderate exercise twice a week in addition to unrestrictive, eucaloric diet), did not 
experience significant changes in body weight or sex steroid levels. 
There are different reasons why the exercise intervention of the WISER study may 
have failed to have resulted in detectable changes in sex hormone and SHBG levels. It 
  71
has been hypothesized that the effects of exercise on reproductive hormones are mediated 
by changes in body composition [285, 297]. While such changes are less important for 
cycling premenopausal women as compared to postmenopausal women, in whom the 
primary source of estrogens is peripheral aromatization of androgens in adipose tissue 
[298, 299], in our study the lack of any such effects may have been because body 
composition changes were modest. Thus perhaps a longer exercise intervention would 
have yielded different results. It is also possible that a more intensive sampling and/or 
sampling closer to the time of ovulation (when estradiol levels are higher) would have 
improved our ability to detect changes in hormone concentrations. 
Alternatively, it is possible exercise exerts an independent effect on hormone 
exposure by disrupting hypothalamic function resulting in changes in menstrual cycle 
characteristics such as delayed onset of menarche, irregular or absent menstrual periods, 
abnormal or loss of luteal function, and longer menstrual cycle length [285, 297]. In our 
study, although we observed no significant within- or between-group changes in 
menstrual cycle length, it is possible follicular and luteal phase lengths may have changed 
significantly even when no changes in menstrual cycle length were detected. We are 
currently investigating whether the WISER exercise intervention resulted in changes in 
follicular and luteal phase lengths as well as changes in estrogen metabolism. 
Finally, it is possible exercise may decrease breast cancer risk in premenopausal 
women through non-hormonal mechanisms such as changes in endogenous oxidative 
stress, insulin and glucose metabolism, inflammatory marker levels, and immune 
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function [285, 297]. We plan to separately report the effects of the exercise intervention 
on biomarkers for these mechanisms. 
The WISER study is the first clinical trial with randomized controls to study the 
effects of aerobic exercise on serum reproductive hormone levels in premenopausal 
women. Strengths include a large sample size, carefully timed follicular and luteal blood 
samples, and excellent protocol adherence. Findings from this study do not support the 
hypothesis that, at least in the absence of weight change or obvious menstrual cycle 
disruption, 150 minutes per week of moderate aerobic exercise leads to reductions in sex 
hormone concentrations and increases in SHBG concentrations in premenopausal 
women. 
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Table 2.1: Baseline Characteristics of Randomized Participants (n = 319) by 
Treatment Group 
 
Exercisers 
n = 166 
Controls 
n = 153 
P 
Age (years) 25.4 ± 3.4 25.2 ± 3.5 0.73 
Height (cm) 164.9 ± 6.9 165.4 ± 7.5 0.54 
Weight (kg) 67.4 ± 14.6 67.6 ± 14.6 0.94 
BMI (kg/m2) 24.7 ± 4.7 24.7 ± 4.8 0.88 
Fat Mass (kg) 24.2 ± 11.2 24.1 ± 10.6 0.90 
Percent body fat  36.4 ± 8.8 36.1 ± 8.3 0.77 
Lean Mass (kg) 39.7 ± 5.0 40.0 ± 5.2 0.63 
Weight Categories 
   Underweight (BMI < 18.5) 
   Normal (18.5 ≤ BMI < 25) 
   Overweight (25 ≤ BMI < 30) 
   Obese (BMI > 30) 
 
1 (1%) 
100 (60%) 
46 (28%) 
19 (11%) 
 
1 (1%) 
100 (65%) 
30 (20%) 
22 (14%) 
0.38 
Race 
   White 
   Black 
   Asian 
   Other 
 
124 (75%) 
13 (8%) 
20 (12%) 
9 (5%) 
 
107 (70%) 
12 (8%) 
26 (17%) 
8 (5%) 
0.66 
Hispanic 8 (5%) 6 (4%) 0.70 
Education 
High school or less  
Some college 
   College graduate or more 
 
11 (7%) 
43 (26%) 
112 (67%) 
 
7 (4%) 
44 (29%) 
102 (67%) 
0.66 
Marital Status 
Never married or Partnered 
Married or Partnered 
Separated or Divorced 
 
138 (83%) 
25 (15%) 
3 (2%) 
 
124 (81%) 
26 (17%) 
3 (2%) 
0.89 
Age at menarche (years)a 12.8 ± 1.5 12.7 ± 1.3 0.53 
Nulliparous 154 (93%) 144 (94%) 0.63 
Previously using Contraceptives  84 (51%) 82 (54%) 0.49 
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Family History of Breast Cancer b 
No 
Yes 
 
129 (96%) 
5 (4%) 
 
114 (97%) 
3 (3%) 
0.60 
Self-reported Diet (kcal/day)c 1901 ± 420 1933 ± 525 0.56 
Self-reported Physical Activity (MET-hrs/wk) 21.9 ± 16.6 21.8 ± 17.5 0.97 
Assessed Fitness (METs at 85% max HR)  6.9 ± 1.5 7.1 ± 1.5 0.45 
Note: For continuous variables, values are mean ± SD, and P-values are based on Student’s t-
tests. For categorical variables, P-values are based on chi-square tests.  
a n = 310, b n = 251, c n = 312 
  
  75
Table 2.2: Changes in Fitness, Body Weight, Body Composition, and Energy Intake 
 
 
Baseline 
 
Follow-up 
 
Change  
from Baseline  
METs reached at 85% of 
max HR 
   Exercise 
   Control 
   P-value 
 
n = 319 
7.0 ± 0.1 
7.0 ± 0.1 
0.59 
 
n = 309 
7.8 ± 0.1 
7.1 ± 0.1 
< 0.0001 
 
n = 309 
        0.90 a ± 0.07 
 0.12 ± 0.08 
< 0.0001 
Weight (kg)  
   Exercise 
   Control 
    P-value 
n = 319 
        68.0 ± 0.7 
        68.8 ± 0.8 
0.41 
n = 312 
       68.0 ± 0.7 
       69.0 ± 0.8 
0.37 
n = 312 
        -0.03 ± 0.2 
         0.03 ± 0.2 
0.83 
BMI (kg/m2) 
   Exercise 
   Control 
    P-value 
n = 319 
        25.0 ± 0.2 
        25.2 ± 0.2 
0.45 
n = 312 
       25.0 ± 0.2 
       25.2 ± 0.2 
0.50 
n = 312 
        -0.01 ± 0.06 
 0.01 ± 0.06 
0.85 
Fat Mass (kg) 
   Exercise 
   Control 
    P-value 
n = 319 
        24.6 ± 0.5 
        25.0 ± 0.5 
0.56 
n = 317 
       24.1 ± 0.5 
       25.0 ± 0.5 
0.17 
n = 317 
      -0.57 a ± 0.1 
        -0.04 ± 0.2 
0.013 
Percent Body Fat 
   Exercise 
   Control 
    P-value 
n = 319 
        36.9 ± 0.4 
        37.1 ± 0.4 
0.70 
n = 317 
       35.9 ± 0.4 
       37.0 ± 0.4 
0.06 
n = 317 
      -0.95 a ± 0.2 
        -0.09 ± 0.2 
0.0003 
Lean Mass (kg) 
   Exercise 
   Control 
    P-value 
n = 319 
        39.9 ± 0.4 
        40.3 ± 0.4 
0.41 
n = 317 
       40.4 ± 0.4 
       40.4 ± 0.4 
0.93 
n = 317 
       0.55 a ± 0.1 
         0.07 ± 0.1 
0.003 
Self-reported Diet (kcal/day) 
   Exercise 
   Control 
    P-value 
n = 312 
       1898 ± 38 
       1932 ± 40 
0.53 
n = 303 
      1895 ± 51 
      1711 ± 54 
0.011 
n = 298 
           -18 ± 51 
         -224a ± 53 
0.004 
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Note: Values are means ± SE. Positive values represent increases from baseline while negative 
values represent decreases from baseline. 
a Significant within-group change from baseline (P < 0.05). 
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Table 2.3: Baseline, Follow-up, and Changes from Baseline in Sex Hormone and 
SHBG Levels 
Sex Hormone   
n = 319 
Baseline Follow-up Change 
from Baseline 
Estradiol (E2) (pg/mL) 
Exercisers 
Controls  
P-value 
 
56 (50-63) 
58 (51-65) 
0.66 
 
60 (56-64) 
62 (58-66) 
0.44 
 
2.3 ± 2.8 
1.4 ± 3.0 
0.83 
Bioavailable E2 (pg/mL) 
Exercisers 
Controls  
P-value 
 
39 (36-41) 
41 (39-44) 
0.14 
 
40 (37-43) 
43 (40-46) 
0.13 
 
1.4 ± 1.9 
1.1 ± 2.0 
0.89 
Free E2 (pg/mL) 
Exercisers 
Controls  
P-value 
 
1.3 (1.2-1.4) 
1.4 (1.3-1.5) 
0.14 
 
1.4 (1.3-1.4) 
1.5 (1.4-1.6) 
0.13 
 
0.05 ± 0.06 
0.04 ± 0.07 
0.89 
Estrone sulfate (ng/mL)  
Exercisers 
Controls 
P-value 
 
2.0 (1.8-2.2) 
2.2 (2.0-2.4) 
0.040 
 
2.0 (1.9-2.2) 
2.3 (2.1-2.4) 
0.017 
 
-0.04 ± 0.06 
-0.01 ± 0.06 
0.74 
Testosterone (T) (pg/mL) 
     Exercisers 
     Controls  
P-value 
 
451 (423-482) 
473 (442-506) 
0.32 
 
446 (419-475) 
464 (435-495) 
0.38 
 
-8.8 ± 9.0 
-13.6 ± 9.5 
0.71 
Bioavailable T (pg/mL) 
Exercisers 
Controls  
P-value 
 
204 (187-222) 
224 (205-245) 
0.13 
 
204 (188-222) 
225 (206-246) 
0.11 
 
-2.7 ± 5.6 
-3.0 ± 5.8 
0.97 
Free T (pg/mL) 
Exercisers 
Controls  
P-value 
 
8.8 (7.9-9.7) 
9.2 (8.3-10.2) 
0.50 
 
8.7 (8.0-9.5) 
9.6 (8.8-10.5) 
0.11 
 
-0.13 ± 0.25 
-0.04 ± 0.30 
0.80 
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NOTE: Values are age- and BMI-adjusted geometric means (95% CI) for baseline and 
follow-up, and mean ± SE for changes in hormone levels. Positive values represent 
increases from baseline while negative values represent decreases from baseline. 
a n = 311, b Significant within-group change from baseline (P < 0.05) 
  
Progesterone (ng/mL)a 
     Exercisers 
     Controls  
P-value 
 
12 (10-14) 
13 (11-15) 
0.61 
 
10 (8-11) 
12 (10-14) 
0.12 
 
-2.2b ± 0.9 
-1.1 ± 1.0 
0.42 
SHBG (nmol/L) 
Exercisers 
Controls  
P-value 
 
27 (25-30) 
25 (23-27) 
0.15 
 
26 (24-29) 
24 (22-26) 
0.08 
 
-1.3 ± 1.0 
-1.8 ± 1.1 
0.74 
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Figure 2.1. CONSORT Diagram Showing Participant Recruitment, Screening, 
Randomization, and Retention
 
Invitation emailed to 
women aged 18-30 
n > 100,000 
Excluded n = 575 
Ineligible                                  n = 174 
Did not consent                        n = 109 
Dropped out before  
Randomization……………… n = 292 
 
Control group n = 179 
Completed all collections          n = 150 
Missing final luteal collection   n = 3 
Dropped out of the study           n = 26 
Included in follicular analysis   n = 166 
Included in luteal analysis         n = 161 
 
Included in follicular analysis   n = 153 
Included in luteal analysis         n = 150 
 
Telephone screened 
n = 1684 
Excluded n = 718 
Ineligible                                  n = 413 
Refused to participate              n = 294 
Other reasons                           n = 11 
 Attended orientation 
n = 966 
Randomized 
n = 391 
Exercise group n = 212 
Completed all collections            n = 161 
Missing final luteal collection     n = 5 
Dropped out of the study             n = 46 
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CHAPTER 3: 
 
URINARY ESTROGEN METABOLITES 
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I. SUMMARY 
Background: It is well accepted that exercise can decrease breast cancer risk. Limited 
clinical evidence suggests that this risk could be mediated through changes in estrogen 
metabolism in premenopausal women. Our objective was to investigate the effects of 
exercise on premenopausal estrogen metabolism pertinent to breast cancer risk. 
Methods: Sedentary, healthy, young eumenorrheic women were randomized into an 
intervention of 30 minutes of moderate-to-vigorous aerobic exercise 5 times a week for 
approximately 16 weeks (n = 212), or into a usual-lifestyle sedentary control group (n = 
179). Urinary levels of estrogens (estrone [E1], estradiol [E2], and estriol) and nine 
estrogen metabolites were measured at baseline and at study end by liquid 
chromatography/tandem mass spectrometry. The ratios of 2-hydroxyestrone to 16α-
hydroxyestrone (2-OHE1/16α-OHE1) and 2-OHE1 to 4-hydroxyestrone (2-OHE1/4-
OHE1) were also calculated. 
Results: The exercise intervention resulted in significant increases in aerobic fitness and 
lean body mass, and a significant decrease in percent body fat. For exercisers who 
completed the study (n = 165), 2-OHE1 /16α-OHE1 increased significantly (P = 0.043), 
while E1 decreased significantly (P = 0.030) in control participants (n = 153). The change 
from baseline in 2-OHE1/16α-OHE1 was significantly different between groups (P = 
0.045), even after adjustment for baseline values. 
Conclusions: The exercise intervention resulted in a significant increase in the 2-OHE1 
/16α-OHE1 ratio, but no differences in other estrogen metabolites or ratios. 
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Impact: Our results suggest that changes in premenopausal estrogen metabolism may be 
a mechanism by which increased physical activity lowers breast cancer risk. 
 
II. INTRODUCTION  
It is well accepted that lifetime estrogen exposure increases the risk for breast cancer 
as a result of cumulative stimulation of epithelial cell division by estrogen[297]. It has 
also been suggested that some metabolites resulting from the biotransformation and 
inactivation of estrogen can play a significant role in breast carcinogenesis [300]. 
Specifically, the products resulting from the oxidation of estradiol (E2) and estrone 
(E1) known as hydroxyestrogens have been shown to display varying degrees of 
carcinogenicity. For example, 2-hydroxyestrone (2-OHE1) partially antagonizes the 
growth-stimulatory effect of E2 in cultured human MCF-7 breast cancer cells [89] while 
2-hydroxyestradiol (2-OHE2) has little or no carcinogenic activity in Syrian hamsters 
[301, 302]. In cultured mouse mammary epithelial cells, 16α-hydroxyestrone (16α-OHE1) 
increases unscheduled DNA synthesis and promoted anchorage-independent growth 
[275, 303]. The metabolite 4-hydroxyestrone (4-OHE1) is considered genotoxic due to its 
redox cycling process, which generates reactive oxygen species (ROS) and highly 
cytotoxic semiquinone/quinone intermediates that react with DNA [300]. The 2-
hydroxyestrogens also undergo redox cycling, but appear to lack carcinogenic activity 
due to a more rapid clearance in vivo [304] associated with a faster rate of inactivation 
through O-methylation [94, 305]. Finally, one product resulting from O-methylation, 
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namely 2-methoxyestradiol (2-MeOE2), has been shown to be a potent inhibitor of cell 
proliferation and angiogenesis [96, 306]. 
Despite evidence suggesting the possible importance of other aspects of estrogen 
metabolism on breast cancer, human studies have largely focused on the ratio of 2-OHE1 
to 16α-OHE1 (2-OHE1/16α-OHE1). Given the different genotoxic capacity of these 
metabolites, it has been hypothesized that metabolism favoring the production of 2-OHE1 
over 16α-OHE1 may be inversely associated with breast cancer risk [307]. 
In premenopausal women, the strongest evidence in favor of this hypothesis comes 
from two early prospective studies in which urine specimens were collected several years 
prior to diagnosis. In the Guernsey III cohort study, women in the highest tertile of 
urinary 2-OHE1/16α-OHE1 ratio had a non-significantly lower odds ratio (0.75) for breast 
cancer than women in the lowest two tertiles [104]. Similarly, in a study reported by Muti 
et al., women in the highest quintile of the urinary 2-OHE1/16α-OHE1 ratio had an 
adjusted odds ratio for breast cancer of 0.58, although again this was not statistically 
significant [105]. In contrast, in a more recent prospective study, a higher 2-OHE1/16α-
OHE1 ratio was associated with an increase in premenopausal ER-positive breast cancer 
[102]. However, the association was not statistically significant and estrogen metabolites 
were measured in serum and not in urine as in the two previous studies. 
Significant relationships between premenopausal breast cancer risk and urinary levels 
of estrogen metabolites and their ratios have been observed in some case-control studies, 
but findings have been inconsistent. The case-control studies of both Coker et al. [308] 
and Kabat et al. [309] found an increased risk in women with an increased 2-OHE1/16α-
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OHE1 ratio, but other studies did not [310-312]. As for other measures, in two other 
studies, control women had significantly higher levels of 2-hydroxyestrogens, 4-
hydroxyestrogens, 16α-OHE1 [313], and 2-OHE1/4-OHE1 ratio [314] than women with 
breast cancer. 
While the association between estrogen metabolism and breast cancer risk needs 
further investigation, epidemiological evidence strongly supports the association between 
higher levels of aerobic exercise and reduced risk for breast cancer [285]. However, 
whether exercise in premenopausal women results in what may be favorable effects on 
estrogen metabolism is not clear. For example, in one small study highly fit women 
exercising strenuously for 368 minutes a week had similar values of 2-OHE1, 16α-OHE1, 
and 2-OHE1/16α-OHE1 ratio than those of women exercising recreationally for only 60 
minutes a week [258]. In contrast, in another small study higher levels of self-reported 
physical activity were associated with higher urinary concentrations of 2-OHE1 and a 
higher 2-OHE1/16α-OHE1 ratio [256]. Recently, a large study of 603 women from the 
NHS-II found high levels of physical activity not only to be correlated with a higher 2-
OHE1/16α-OHE1 ratio, but also significantly lower levels of E2 and 16α-OHE1 [315]. 
In comparison, data from exercise intervention studies has been conflicting. For 
instance, in interventions lasting 12 weeks [265], 16 weeks [268], or even 6 months 
[316], moderate-to-vigorous intensity aerobic exercise in premenopausal women did not 
result in any significant changes in urinary concentrations of E1, E2, estriol (E3), 2-
hydroxyestrogens, 4-hydroxyestrogens, or 16α-OHE1, or either 2-OHE1/16α-OHE1 or 2-
OHE1/4-OHE1 ratios. In two small exercise interventions coupled with calorie restriction 
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lasting 4 and 6 months, there were significant increases in urinary levels of luteal phase 
16α-OHE1 and 2-OHE1/16α-OHE1, respectively [266, 269]. 
Overall, the data on the effects of aerobic exercise on premenopausal estrogen 
metabolism are not only conflicting but also narrow in scope. With the exception of two 
studies [268, 315], all published studies to date have focused on a limited number of 
estrogen metabolites, namely 2-OHE1 and 16α-OHE1, and their ratio. Furthermore, no 
study has yet investigated the levels of the 2- and 4- methylated catecholestrogens despite 
their purported role in breast carcinogenesis as suggested by culture and animal studies. 
The WISER (Women In Steady Exercise Research) study was a large, randomized, 
exercise-controlled, parallel-arm, clinical study investigating the effects of 16-weeks of 
moderate-to-vigorous intensity aerobic exercise on several parameters pertinent to breast 
cancer risk in sedentary, healthy, young eumenorrheic women. Here we report changes 
from baseline in urinary levels of estrogens (E1, E2, and E3), nine estrogen metabolites (2-
OHE1, 2-OHE2, 16α-OHE1, 4-OHE1, 4-hydroxyestradiol [4-OHE2,], 2-methoxyestrone, 
[2-MeOE1], 2-MeOE2, 4-methoxyestrone [4-MeOE1], and 4-methoxyestradiol [4-
MeOE2]), and two estrogen metabolite ratios (2-OHE1/16α-OHE1, and 2-OHE1/4-OHE1). 
 
III. SUBJECTS AND METHODS  
Study design 
The WISER study was a randomized clinical trial investigating the effects of a 16-
week aerobic exercise intervention on breast cancer biomarkers of healthy, 
premenopausal women. All procedures were approved by the Human Subjects Review 
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Committee at the University of Minnesota (Institutional Review Board; IRB 
ID#0505M69867). Written informed consent was obtained from each participant prior to 
participation. A complete description of the study design, including participant 
recruitment, screening, randomization, and retention has been published [288].  
Briefly, WISER study investigators emailed more than 100,000 female residents of 
the Minneapolis-St. Paul metropolitan area regarding participation. Women who were 
interested were screened online based on age (18-30 years old), physical activity (two or 
less weekly sessions of moderate intensity exercise), smoking status (non-smoking), body 
mass index (BMI) (18-40 kg/m2 inclusive), and self-reported menstrual cycle length (24 
to 35 days). Women who met these criteria were further screened via telephone (n = 
1,684) and excluded based on previous hormonal contraception use (past three months or 
12 months if depot-medroxyprogesterone acetate), gynecological problems, metabolic or 
endocrine-related diseases, current or recent (past 6 months) pregnancy, non-melanoma 
cancer in the past 5 years, alcohol consumption (more than 7 servings per week), and 
body weight changes (more than 10% over the past year). 
Of the 966 women who attended a 2-hour orientation, 391 provided written consent 
and were enrolled in the study. After baseline measurements, women were randomized 
into either an exercise intervention (n = 212) or a no-exercise, usual-lifestyle control 
group (n = 179) for approximately 16 weeks. Randomization was stratified on baseline 
BMI tertiles (≤ 22.8, 22.8-26.3, ≥ 26.3) based on the 50th and 75th percentiles from 
NHANES I data and age (18-24 vs. 25-30). Participants who failed to return for follow-
up measures were dropped from of the study. Additionally, exercisers were subject to 
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study exclusion if they missed 15 or more exercise sessions. Figure 3.1 shows the 
recruitment, screening, randomization, retention, and completion of WISER participants. 
Exercise intervention 
Women randomized to the exercise intervention trained aerobically five times a week 
for 30 minutes on a treadmill, stair-stepper, or elliptical machine, at a specified intensity 
based on age-predicted maximal heart rate (max HR) for 16 weeks (± 2 weeks). The 
exercise intensity was initially set at 65%-70% of the age-predicted max HR and was 
gradually increased by 5% every four weeks until 80%-85% of age-predicted max HR 
was reached (stage 1 = 65%-70%; stage 2 = 70%-75%; stage 3 = 75%-80%; stage 4 = 
80%-85%). 
All training sessions took place at the University of Minnesota’s Recreation Center. 
At the first training session, a certified personal trainer provided instruction on the proper 
use of the exercise machines, heart rate monitor and watch, and completion of an exercise 
log after each workout. Trainers supervised exercise sessions and reviewed the exercise 
logs at least once weekly to monitor adherence and safety. When not meeting with a 
trainer, participants were expected to complete the remaining of the workout sessions 
unsupervised. Exercise adherence was assessed using the data from the heart rate monitor 
(Polar Electro Inc., Lake Success, NY) and exercise logs. 
Any physical activity performed after randomization and outside the prescribed 
exercise intervention was assessed at the end of the study with a physical activity 
questionnaire administered by a research staff member. All participants, regardless of 
randomization outcome, were asked to maintain their baseline body weight. Control 
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participants were asked to not only to maintain their usual level of physical activity but 
also to not change their eating habits. 
Anthropometrics 
Body mass was measured to the nearest 0.1 kg using an electronic scale (Scale 
Tronix, White Plains, NY) 4 times throughout the study (baseline, intervention weeks 4 
and 8, and follow-up). Height was measured without shoes to the nearest 0.1 cm (Scale 
Tronix, White Plains, NY) by a stadiometer at baseline. Body mass index was calculated 
by dividing body mass in kg by height in meters squared (kg/m2). Body composition was 
assessed at baseline and follow-up by dual energy x-ray absorptiometry (DXA) using a 
Lunar Prodigy DXA apparatus (Lunar Radiation Corp., Madison, WI). 
Aerobic fitness and physical activity 
Aerobic fitness was assessed at baseline and immediately after the intervention with a 
sub-maximal treadmill test described previously [288]. This workload was then converted 
to metabolic equivalents (METs) by using a standard conversion formula [289]. Self-
reported physical activity performed a year prior to the study and during the 4-month 
follow-up period was assessed by a research staff using a modified version of the 
Modifiable Activity Questionnaire [290]. This information was transformed into MET-
hours per week (MET-hrs/wk) using commonly accepted MET values [291]. 
Dietary intake 
Usual dietary intake was assessed through self-reported, 3-day food records 
completed concomitantly with the urine collections at baseline and follow-up. Nutrient 
intake was determined using The Food Processor SQL® by ESHA Research (Salem, OR). 
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Urine collection 
Forty-eight hours prior to the urine collection, participants were asked to avoid 
moderate or vigorous exercise and abstain from alcohol. Urine was collected for three 
consecutive 24-hour periods in the mid-follicular phase (follicular days 7 - 9 of baseline 
menstrual cycle 2 and follow-up menstrual cycle 6). Throughout each day, urine was 
collected in a 1-liter bottle and kept cold with ice packs inside an insulated bag.  At the 
end of each collection day, urine was transferred into a 3-liter bottle containing ascorbic 
acid (1 mg/mL) to prevent oxidation, and stored in a home refrigerator or cooler provided 
by the study. Once the urine collection was completed, collection bottles were retrieved 
by a research staff member and brought to the General Clinical Research Center at the 
University of Minnesota for processing. Urine was refrigerated and 0.1% sodium azide 
was added before the three 24-hour collections were pooled. Aliquots were taken and 
stored at -20 oC until analysis. 
Estrogen metabolites 
Urinary estrogens (E1, E2, and E3) and their metabolites (2-OHE1, 2-OHE2, 16α-
OHE1, 4-OHE1, 4-OHE2, 2-MeOE1, 2-MeOE2, 4-MeOE1, and 4-MeOE2) were analyzed 
in the mid-follicular phase of baseline and follow-up cycles by liquid 
chromatography/tandem mass spectrometry (LC/MS-MS) performed using a Thermo 
Electron Quantum Discovery Max Triple Quadrupole LC-MS/MS instrument [106]. 
Quantitative analysis was performed using Thermo Electron Xcalibur proprietary 
software. 
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Samples with non-detectable levels were assigned values of the lowest detectable 
standard (0.014 ng/mL urine). Concentrations were expressed both as nanomol per day 
(nmol/day) and nanograms per milligram of creatinine (ng/mg Cr). Urinary creatinine 
was analyzed at the Fairview University Diagnostic Laboratories. 
Samples were run in duplicate and in batches such that each batch contained both 
baseline and follow-up samples from each participant and an equal number of exercise 
and control participants. One quality control sample was included in each batch. The 
mean intra-assay and inter-assay CVs were 5.1% and 13.4% for E1; 5.2% and 16.0% for 
E2; 5.6% and 11.4% for E3; 4.2% and 12.3% for 2-OHE1; 7.7% and 10.8% for 2-OHE2; 
6.2% and 18.7% for 16α-OHE1; 4.3% and 12.2% for 4-OHE1; 14.0% and 51.2% for 4-
OHE2; 7.0% and 11.3% for 2-MeOE1; 5.8% and 10.0% for 2-MeOE2; 7.4% and 10.3% 
for 4-MeOE1; and 6.9% and 7.9% for 4-MeOE2. 
Statistical analyses 
Unadjusted comparisons of baseline characteristics were performed using Student’s t-
tests for continuous variables and chi-square tests for categorical variables. 
Two estrogen metabolite ratios of interest, namely the 2-OHE1/16α-OHE1 ratio and 2-
OHE1/4-OHE1 ratio, were calculated by dividing the concentration of 2-OHE1 by either 
16α-OHE1 or 4-OHE1, respectively. 
Baseline associations between urinary estrogens, their metabolites, and metabolite 
ratios and measures of body composition, adiposity, fitness, reproductive characteristics, 
and diet were determined using Spearman correlation coefficients.  
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The main study analysis assessed the intervention effects using only data from 
participants who completed the baseline and follow-up urine collection regardless of 
compliance level. Baseline and follow-up comparisons were conducted using log-
transformed values and results are presented as geometric means with 95% confidence 
intervals. Changes from baseline comparisons were compared on the original scale.  All 
comparisons were adjusted for study-design age and BMI strata with a general linear 
model. When there were significant differences at baseline in an outcome, follow-up and 
change from baseline comparisons were additionally adjusted for baseline values. Linear 
models were calculated using SAS software, version 9.2 (SAS institute Inc., 2008, Cary, 
NC). P < 0.05 was considered statistically significant. Estrogen metabolite data were 
analyzed as both nmol/day and ng/mg Cr. Results from the two analyses did not differ 
significantly, and we report results as nmol/day. 
 
IV. RESULTS 
Study participants 
Of the 212 and 179 women randomized into the exercise and control groups, 165 
(77.8%) and 153 (85.5%), respectively, completed the WISER study. With the exception 
of education (47% of drop-outs had some college education vs. 27% of study completers 
P = 0.002), drop-outs were no different from women who completed the study in any of 
the baseline demographic characteristics measured (data not shown). Also, there were no 
significant differences between exercisers and controls in baseline demographic 
characteristics (Table 3.1). In general, women who completed the study were mostly 
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Caucasian (72%), single (82%), nulliparous (93%), had education beyond high school 
(96%), and had no first-degree relatives with breast cancer (97%). 
Baseline estrogen metabolism 
With the exception of 2-OHE1 (P = 0.084) and 2-OHE1/16α-OHE1 ratio (P = 0.044), 
exercisers had similar levels of urinary estrogens, estrogen metabolites, and 2-OHE1/4-
OHE1 ratio than control participants at baseline (Table 3.2). No significant baseline 
associations between any of the urinary endpoints and measures of body composition, 
adiposity, fitness, reproductive characteristics, and diet were found. 
Overall, the concentration of estrone and its metabolites were higher than their 
estradiol counterparts, especially for E1, 2-OHE1, 4-OHE1, and 4-MeOE1 as compared to 
E2, 2-OHE2, 4-OHE2, and 4-MeOE2, respectively. Estrogen hydroxylation showed an 
isomeric preference for the C-2 position. Specifically, concentrations of 2-OHE1 were 
about 14- and 20-fold higher than those of 16α-OHE1 and 4-OHE1, respectively, and 
concentration of 2-OHE2 about 40-fold those of 4-OHE2. 
Exercise adherence 
On average, exercise participants completed 127 minutes per week of the assigned 
150 minutes of exercise intervention. Details about exercise adherence and compliance 
can be found elsewhere [317]. 
Intervention effects 
The exercise intervention resulted in significant improvements in body composition 
and aerobic fitness without changes in body weight. As previously reported, exercisers 
experienced significant increases in aerobic fitness (0.90 METs reached at 85% of max 
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HR vs. 0.12 METs in controls) and lean body mass (0.55kg vs. 0.07 kg), as well as 
significant decreases in fat mass (0.57 kg vs. 0.04 kg) and percent body fat (0.95% vs. 
0.09%). In contrast, control participants experienced no changes in body composition, 
aerobic fitness, and body weight despite a significant reduction in daily caloric intake (-
224 kcal/day). Exercisers also reduced their food consumption, but only by 18 kcal/day 
(P > 0.05). Details on the effects of this intervention on body composition, body weight, 
aerobic fitness, and energy intake have been published previously [318]. 
As previously reported, the exercise intervention resulted in no significant changes in 
endogenous levels of E2, estrone sulfate, progesterone, T, or SHBG (38).  Exercisers, 
however, did experience a significant increase in urinary 2-OHE1/16α-OHE1 ratio (P = 
0.043) while controls had a non-significant decrease in 2-OHE1/16α-OHE1 ratio. The 
difference in the change from baseline in 2-OHE1/16α-OHE1 ratio between groups was 
significant (P = 0.045), even after adjustment for baseline values. Figure 3.2 shows that 
many, but not all, of the participants who experienced an absolute change in 2-
OHE1/16α-OHE1 ratio greater than 100 had a high baseline 2-OHE1/16α-OHE1 ratio. 
Levels of E1 remained unchanged in exercisers but decreased in controls resulting in a 
statistically significant change from baseline between the groups (P = 0.042). No 
significant within-group changes or between-group differences at follow-up were 
observed for other estrogens, estrogen metabolites, or ratios. 
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V. DISCUSSION 
We found that in healthy premenopausal women, an exercise regimen of 150 minutes 
of moderate-to-vigorous aerobic exercise per week for 16 weeks resulted in significant 
changes in estrogen metabolism in a direction consistent with reduction of breast cancer 
risk. Specifically, exercise participants experienced a significant increase in urinary levels 
of 2-OHE1 and a small non-significant decrease in 16α-OHE1 levels. These changes 
resulted in a significant increase in the 2-OHE1/16α-OHE1 ratio. In contrast, women in 
the control group had a non-significant decrease in 2-OHE1/16α-OHE1 ratio largely 
attributable to those few controls with large baseline ratio having large decreases in the 
ratio. Controls also had an unexplained significant decrease in E1. We did not find 
evidence for exercise resulting in changes in the 4-hydroxylation pathway or other 
differences that conceivably could have been found. 
Overall, our results differ from those of other exercise intervention studies 
investigating the effects of aerobic exercise on premenopausal estrogen metabolism. For 
instance, in a small 5-month weight-loss clinical trial involving moderate-intensity 
exercise, both controls and exercisers had significant increases in the urinary 2-
OHE1/16α-OHE1 ratio, but in contrast to our results, the change in ratio between the 
groups was not statistically significant [266]. In a small pre-post design study, 4 months 
of moderate exercise coupled with calorie restriction resulted in non-significantly higher 
urinary levels of 2-OHE1 and 16α-OHE1 and the ratio [269]. In our study, both 2-OHE1 
and the 2-OHE1/16α-OHE1 ratio increased significantly, whereas 16α-OHE1 decreased 
non-significantly. Both of these studies differed from our study in that aerobic exercise 
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was coupled with significant calorie restriction making it impossible to discern whether 
the changes reported were the result of the exercise or diet. 
When compared to exercise-only interventions, our study remains the only one to 
report significant changes in estrogen metabolism. For example, in a moderate-to-
vigorous aerobic exercise intervention lasting 12 weeks (30-45 minutes, 4 days per 
week), Campbell and colleagues reported no significant changes in urinary 
premenopausal levels of 2-OHE1, 16α-OHE1, or 2-OHE1/16α-OHE1 ratio [265]. 
Similarly, in a pilot study carried out by our research group, total levels of 2-OHE (2-
OHE1 + 2-OHE2), 4-OHE (4-OHE1 + 4-OHE2), and the 2-OHE1/16α-OHE1 ratio 
remained unchanged in 15 young women exercising aerobically for 30 minutes a day, 5 
times a week for 16 weeks [268]. Similarly, Robles-Gil et al. did not find significant 
changes in E1, E2, or E3 in 20 premenopausal women after 6 months of 60 minutes of 
moderate-intensity exercise 3 days/week [316]. 
A possible explanation for the disparity between the results reported by these exercise 
intervention studies and our study may be found in the choice of study design and 
methodology. The WISER study had many methodological advantages over previously 
published research. First, the sample size in our study (n = 318) was an order of 
magnitude or more larger than those of the other three studies. Second, our study design 
utilized randomized controls (only Campbell et al. study was randomized). Third, unlike 
the studies of Campbell et al. and Robles-Gil et al., in which first morning urine samples 
were used, WISER participants collected three 24-hour urine collections allowing for a 
more robust and representative analysis of the chronic effect of aerobic exercise on 
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estrogen metabolism. Finally, our study provides the most comprehensive analysis on the 
effects of exercise on estrogen metabolism to date. We have analyzed urinary levels of 
the major parent estrogens (E1, E2 and E3) and nine of their estrogen metabolites by 
LC/MS-MS. This newer methodology is considered to be superior not only to the ELISA 
methods employed by these studies but also to the current gold standard GC-MS due to 
its increased sensitivity and sample throughput [106, 319]. Unlike Xu and colleagues, we 
were able to quantify and report 4-OHE2, concentrations, although its lack of detection in 
53.4% of our samples resulted in a higher-than-expected inter-assay CV. 
Altogether, the findings of the WISER study are significant because they provide the 
first clinical evidence that aerobic exercise can significantly change estrogen metabolism 
in premenopausal women. Specifically, our results show that such an exercise 
intervention can lead to increases in 2-OHE1 while having little effect in16α-OHE1, 
which ultimately result in significant increases in the 2-OHE1/16α-OHE1 ratio. 
Importantly, increases in this ratio have been associated with a significant reduction in 
breast cancer risk. 
From a clinical point of view, the assessment of urinary 2-OHE1/16α-OHE1 ratio is 
also relevant as it has been found to be a good approximation to the 2-OHE1/16α-OHE1 
ratio of breast tissue [320]. Perhaps one mechanism by which exercise mediates estrogen 
metabolism is through the regulation of P-450 cytochrome enzymes responsible for 
controlling estrogen hydroxylation and catecholestrogen methylation. Given the 
implication these results have for breast cancer prevention efforts, future studies should 
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not only attempt to corroborate our results, but also investigate the exact mechanisms by 
which exercise leads to these favorable estrogen metabolism changes. 
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Table 3.1: Baseline Characteristics of Randomized WISER Participants  
(n = 318)  
 
Note: There were no significant differences at baseline between study groups for any  
of these variables 
a n = 310, b n = 251, c n = 312 
  
 Exercisers 
n = 165 
Controls 
n = 153 
Demographics 
Age, years (mean ± SE) 
Not Married or Partnered (n, %) 
Education beyond High School (n, %) 
Caucasian (n, %) 
 
25.4 ± 0.3 
137 (83%) 
157 (95.2%) 
123 (75%) 
 
25.2 ± 0.3 
124 (81%) 
148 (96.7%) 
107 (70%) 
Body Composition (mean ± SE) 
Weight (kg) 
BMI (kg/m2) 
% Body Fat 
Fat Mass (kg) 
Lean Mass (kg) 
 
67.5 ± 1.1 
24.8 ± 0.4 
36.4 ± 0.7 
24.3 ± 0.9 
39.8 ± 0.4 
 
67.6 ± 1.2 
24.7 ± 0.4 
36.1 ± 0.7 
24.1 ± 0.9 
40.1 ± 0.4 
Reproductive Characteristics 
Age at Menarche, years (mean ± SE) a 
Nulliparous (n, %) 
Previous Contraceptive Use (n, %) 
 
12.7 ± 0.12 
153 (93%) 
84 (51%) 
 
12.7 ± 0.11 
144 (94%) 
82 (54%) 
Family History of Breast Cancer b   
No (n, %) 
 
129 (96%) 
 
114 (97%) 
Physical Activity, Fitness & Diet (mean ± SE) 
Moderate Exercise (MET-hrs/wk) 
Aerobic Fitness (METs at 85% max HR) 
Total calorie intake  (kcal/day) c 
 
1902 ± 421 
21.9 ± 1.3 
6.9 ± 0.1 
 
1933 ± 525 
21.8 ± 1.4 
7.1 ± 0.1 
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Table 3.2: Effects of 16 Weeks of Aerobic Exercise on Estrogen Metabolism of 
WISER participants 
 Baseline 
Geometric 
Mean  
(95% CI) 
P-value for 
Baseline 
Differences 
      Follow Up 
      Geometric 
      Mean  
      (95% CI) 
P-value for 
Differences  
in Mean  
Change 
Estrone, E1  
Exercisers 
Controls 
 
23.1 (19.0 – 28.2) 
25.0 (20.3 – 30.8) 
 
 
0.586 
 
23.0 (18.9 – 28.0) 
23.0 (18.8 – 28.2)a 
 
 
0.042 
Estradiol, E2  
Exercisers 
Controls 
 
7.8 (6.8 – 8.8) 
8.0 (7.0 – 9.1) 
 
0.786 
 
8.3 (7.2 – 9.5) 
8.0 (7.2 – 9.2) 
 
0.725 
Estriol, E3  
Exercisers 
Controls 
 
21.3 (16.5 – 27.4) 
21.1 (16.2 – 27.5) 
 
0.963 
 
18.6 (14.4 – 24.2) 
21.0 (16.0 – 27.5) 
 
0.715 
16α-OHE1  
Exercisers 
Controls 
 
2.9 (2.3 – 3.7) 
2.5 (1.9 – 3.1) 
 
0.303 
 
2.6 (2.1 – 3.4) 
2.5 (1.9 – 3.2) 
 
0.971 
2- OHE1  
Exercisers 
Control 
 
39.3 (33.7 – 45.8) 
47.6 (40.5 – 55.8) 
 
0.084 
 
44.2 (38.4 – 50.8) 
45.5 (39.3 – 52.6) 
 
0.098 
 
4- OHE1  
Exercisers 
Controls 
 
2.3 (2.1 – 2.7) 
2.4 (2.1 – 2.8) 
 
0.647 
 
2.4 (2.1 – 2.7) 
2.4 (2.1 – 2.7) 
 
0.362 
2-OHE2  
Exercisers 
Controls 
 
3.4 (2.4 – 5.0) 
2.5 (1.7 – 3.6) 
 
0.209 
 
3.5 (2.4 – 5.1) 
2.9 (1.9 – 4.2) 
 
0.194 
4-OHE2  
Exercisers 
Controls 
 
0.7 (0.4 – 1.0) 
0.7 (0.5 – 1.2) 
 
0.767 
 
0.8 (0.5 – 1.3) 
0.5 (0.3 – 0.8) 
 
0.898 
2-MeOE1  
Exercisers 
Controls 
 
8.2 (6.5 – 10.4) 
6.9 (5.4 – 8.8) 
 
0.312 
 
9.3 (7.4 – 11.8) 
8.6 (6.8 – 10.9) 
 
0.406 
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4-MeOE1  
Exercisers 
Controls 
 
1.9 (1.4 – 2.6) 
2.2 (1.6 – 3.0) 
 
0.562 
 
1.7 (1.2 – 2.4) 
1.5 (1.1 – 2.1) 
 
0.488 
2-MeOE2  
Exercisers 
Controls 
 
7.1 (5.4 – 9.3) 
5.8 (4.3 – 7.6) 
 
0.269 
 
7.0 (5.4 – 9.1) 
6.6 (5.1 – 8.7) 
 
0.556 
4-MeOE2 
Exercisers 
Controls 
 
1.6 (1.2 – 2.3) 
1.2 (0.9 – 1.8) 
 
0.254 
 
1.5 (1.0 – 2.1) 
0.9 (0.7 – 1.4) 
 
0.552 
2-OHE1/16α-
OHE1 
Exercisers 
Controls 
 
 
13.4 (10.4 – 17.2) 
19.3 (14.8 – 25.1) 
 
 
0.044 
 
 
16.8 (13.1 – 21.4) b 
18.5 (14.3 – 24.0) 
 
 
0.045 
2-OHE1/4-
OHE1 
Exercisers 
Controls 
 
 
16.8 (14.8 – 19.0) 
19.5 (17.1 – 22.2) 
 
 
0.104 
 
 
18.7 (16.8 – 20.9) 
18.9 (16.9 – 21.2) 
 
 
0.123 
NOTE: Values are age- and BMI-adjusted geometric means (95% CI). Follow-up and mean 
change from baseline comparisons in 2-OHE1 and 2-OHE1/16α-OHE1 were additionally adjusted 
for baseline values.  
Within-group differences:  aP-value = 0.030, bP-value = 0.043 
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Figure 3.1 CONSORT Diagram Showing Participant Recruitment, Screening, 
Randomization, and Retention. 
  
Invitation emailed to 
women aged 18-30 
n > 100,000 
Telephone screened 
n = 1684 
Excluded n = 718 
Ineligible                                   n = 413 
Refused to participate               n = 294 
Other reasons                            n = 11 
 Attended orientation 
n = 966 
Excluded n = 575 
Ineligible                                    n = 174 
Did not consent                          n = 109 
Dropped out before  
randomization       …………….n = 292 
 
Randomized 
n = 391 
Exercise group n = 212 
Completed all urine collections   n = 165 
Missing final urine collection      n = 1 
Dropped out of the study             n = 46 
 
Control group n = 179 
Completed all urine collections    n = 153 
Missing final urine collection       n = 0 
Dropped out of the study              n = 26 
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Figure 3.2. Changes in Baseline vs. Baseline in 2-OHE1/16α-OHE1 Ratio 
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CHAPTER 4: 
 
DISSERTATION SUMMARY 
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The purpose of this dissertation was to investigate the effects of a 16-week aerobic 
exercise intervention on hormonal breast cancer biomarkers such as endogenous sex 
hormones and urinary estrogen metabolites in premenopausal women. Moderate-to-
vigorous aerobic exercise performed for 30 minutes, five times a week resulted in 
significant improvements in aerobic fitness and body composition measures. While no 
body weight changes were observed in either study group, women in the exercise group 
experienced significant increases in lean body mass and decreases in percent body fat. 
With the exception of progesterone, endogenous sex hormones and SHBG levels did 
not change in either group. In exercisers, progesterone levels decreased significantly, 
albeit this change was similar to that of the control group suggesting a null effect by the 
exercise intervention.  
Similarly, no changes in urinary estrogen and estrogen metabolite levels were 
observed with the exception of a borderline statistically significant increase of 12.5% in 
2-OHE1 levels and a significant increase of 25 % in the 2-OHE1/16α-OHE1 ratio. 
Specifically, in exercisers the 2-OHE1/16α-OHE1 ratio increased significantly when 
compared to baseline levels (P = 0.043) and also when compared to the control group (P 
= 0.045), even after the adjustment for baseline 2-OHE1/16α-OHE1 ratio.  
A closer look into this data revealed those participants with a higher baseline 2-
OHE1/16α-OHE1 ratio experienced the greatest changes in 2-OHE1/16α-OHE1 ratio due 
to the intervention. This observation can be of particular importance for future exercise 
intervention studies, which will seem to benefit the most by recruiting female participants 
based on baseline 2-OHE1/16α-OHE1 ratio. Similarly, prospective cohort and nested 
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case-control studies could benefit by recruiting disease-free women with higher 2-
OHE1/16α-OHE1 ratio to assess the impact physical activity levels has on the incidence 
of breast cancer in this population. 
To date, only one other exercise intervention has determined whether a woman’s 
baseline 2-OHE1/16α-OHE1 ratio was predictive of her change in 2-OHE1/16α-OHE1 
ratio due to the intervention. The uncontrolled study of Westerlind and Williams, tested 
an exercise intervention targeted to increase caloric expenditure by 20% coupled with a 
daily caloric reduction of 20-35% for 4 menstrual cycles in 24 healthy, sedentary, 
eumenorrheic, premenopausal women [269]. Daily urine spot samples were collected 
everyday during the baseline cycle and the subsequent four intervention cycles. Urinary 
concentrations of 2-OHE1 and 16α-OHE1 were measured via ELISA methods and the 2-
OHE1/16α-OHE1 ratio was calculated manually.  
In this study, luteal levels of 2-OHE1 marginally decreased (P =0.06) while luteal 
levels of 16α-OHE1 decreased significantly (P =0.02). The luteal 2-OHE1/16α-OHE1 
ratio, however, did not significantly changed from baseline. Similarly, no significant 
changes were observed in the follicular levels of 2-OHE1, 16α-OHE1, or 2-OHE1/16α-
OHE1 ratio. As per the design of the study, women on average increased their VO2 max 
by 26% while reducing their daily caloric intake by 421 kcal. The increased energy 
deficit coupled with reduced caloric intake resulted significant losses in body weight (3.8 
kg) and body fat (4.6 %) but no significant changes in lean body mass. 
Interestingly, an inverse association was found between a woman’s baseline 2-
OHE1/16α-OHE1 ratio and her overall percent change in 2-OHE1/16α-OHE1 ratio due to 
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the intervention (r = -0.68, P < 0.001). Women divided into tertiles by baseline 2-
OHE1/16α-OHE1 ratio were found to be statistically similar in terms of baseline body 
composition measures, aerobic fitness, daily caloric intake, energy deficit, and menstrual 
cycle length. However, women in the lowest tertile experienced a significantly greater 
percent and absolute change in the 2-OHE1/16α-OHE1 ratio in both the follicular and 
luteal phase than women in the other two tertiles. Based on these results, the authors 
concluded women with higher 2-OHE1/16α-OHE1 ratio may not be responsive to 
exercise/caloric-restriction interventions and speculate these women would not benefit 
from such interventions as they are already at lower risk of developing breast cancer 
because of their preexisting high 2-OHE1/16α-OHE1 ratio. 
The results from this study are in direct contradiction to the findings of the WISER 
study in which women with the highest, not lowest, 2-OHE1/16α-OHE1 ratio experienced 
the greatest increases in 2-OHE1/16α-OHE1 ratio due to the intervention. It is important 
to note that Westerlind and Williams’s study had significant limitations including a small 
sample size (n =24) and a lack of a control group. In comparison, the WISER study 
randomized 212 women into the exercise group and 179 into a control group. 
Furthermore, the WISER study employed a more accurate, sensitive, and specific lab 
methodology (i.e., LC-MS/MS) than the ELISA method used in this study. Lastly, it is 
impossible to determine whether the changes reported in this study were a function of the 
exercise, calorie restriction, weight loss, or a combination of these factors whereas in the 
WISER study, the changes observed in 2-OHE1/16α-OHE1 ratio can only be attributed to 
the exercise intervention as diet and weight loss were carefully controlled. Clearly, the 
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possibility that baseline 2-OHE1/16α-OHE1 ratio can predict the extent of change in 2-
OHE1/16α-OHE1 ratio needs to be addressed by future exercise interventions.  
Collectively, these findings suggest the positive effects aerobic exercise allegedly has 
on premenopausal breast cancer risk may be mediated through hormonal mechanisms 
that involve changes in estrogen metabolism but not necessarily changes in endogenous 
sex hormone levels. Furthermore, these results support the current public health 
recommendations that promote at least 150 minutes of moderate-intensity aerobic 
exercise per week in adults not only to maintain health and prevent chronic disease, but 
also to help prevent breast cancer as well. 
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ESTRADIOL RIA 
DSL-4400 
Estradiol RIA 
Date of assay:     ____________ 
Time samples thawed:   __________ 
Time RIA kit to room temp:  _______ (label and leave precipitating reagent in 
refrigerator) 
 
Allow all reagents to reach room temperature and mix liquid reagents thoroughly by 
gentle inversion before use.   
 
Label and arrange 12x75mm plastic tubes in triplicate for Total Counts, Non-Specific 
Binding (NSB), Standards, Controls, and Unknowns (samples). 
 
Load assay tubes. Time: _________ 
 
Do not add anything to TC tubes 1, 2 
 
Pipette 200 L of Standard A (0 pg/mL) into NSB tubes 3, 4 
  
 Pipette 100 L of Standard A into tubes 5, 6 
 “ Standard B into tubes 7, 8 
 ” Standard C into tubes 9, 10 
 “ Standard D into tubes 11, 12 
 “ Standard E into tubes 13, 14 
 “ Standard F into tubes 15, 16 
 “ Standard G into tubes 17, 18 
 
 Pipette 100 L of Level I control to tubes 19, 20 
 “   Level II control to tubes 21, 22 
    WISER Control I to tubes 23, 24 
    WISER Control II to tubes 25, 26 
 
 Pipette 100 L Unknown samples (in duplicate) to tubes 27+ 
 
Mix two Estradiol [I-125] Reagent bottles. Time: _________ 
 
Immediately add 100 L of the Estradiol [I-125] Reagent to all tubes. Time: _________ 
Use 2.5mL pipette tip, position 2 with repeating pipette 
 
Add 100 L of the Estradiol Antiserum to all tubes except NSB and TC tubes (1-4).  
Time: _________ 
Use 2.5mL pipette tip, position 2 with repeating pipette 
 
Vortex tubes gently (level 4, ~30 sec):  Time: _________ 
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Cover with paraffin and incubate all test tubes at 37 °C for 30 minutes in the water bath.  
Time: _________ 
 
Allow Precipitating Reagent to reach room temp.  Time: _________Shake reagent 
thoroughly  
 
 
Add 1.0 mL of Precipitating Reagent (shake thoroughly) to all tubes except TC.  
Time: _________ 
Use 12.5 mL pipette tip, position 4 with repeating pipette 
 
Cover test tube rack with paraffin and immediately vortex all tubes. 
 
Incubate at room temperature for 15-20 minutes. Time: _________ 
 
Centrifuge all tubes except TC 15-20 minutes at 3000 rpm 
 
Decant all tubes except TC: 
 Placing all tubes into a sponge rack 
 Inverting sponge rack into radioactive waste container 
 Allowing tubes to drain on chux for 1-2 minutes 
 Gently blotting droplets on rims 
 Returning to upright position 
 Allowing to dry upright for 1-2 hours 
 
Return TC tubes back into the test tube rack. 
  
Count all tubes in the Gamma counter (1 min): 
• Call lab 4-5348 
• Take floppy diskette 
• Sign-in sheet date, your initials, Kurzer, # tubes 
• Insert diskette 
• Drawer under the gamma counter contains protocol clips 
• Place # 5 clip on left side of 1st tray (1st tray is furthest from you) 
• Load tubes in trays from right to left 
• Do not load any tubes in stop rack 
• Place the stop rack behind all of your trays 
• Make sure trays are perpendicular and notch is in the tray groove 
• Use function keys to run protocol 
• Remove clip from tray and place in numerical order in drawer 
• Eject diskette 
• Get disk, printout, and make sure area is left clean and organized 
• If anything goes awry contact Alma (lab) 5-8292 or (cell) 909-964-7283 and 
Wanda (o) 5-1249, (barn) 4-3062 
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ESTRONE SULFATE RIA 
DSL-5400 
Estrone RIA 
Date of assay:     ____________ 
Time samples thawed:   __________ 
Time RIA kit to room temp:  _______ (leave precipitating reagent in refrigerator) 
 
Allow all reagents to reach room temperature and mix liquid reagents thoroughly by 
gentle inversion before use.   
 
Label and arrange 12x75 mm plastic tubes in duplicate for Total Counts, Non-Specific 
Binding (NSB), Standards, Controls, and Unknowns (samples). 
 
Load assay tubes. Time: _________ 
 
Do not add anything to TC tubes 1, 2 
 
Pipette 200 L of Standard A (0 ng/mL) into NSB tubes 3, 4 
  
 Pipette 100 L of Standard A into tubes 5, 6 
 “ Standard B into tubes 7, 8 
 ” Standard C into tubes 9, 10 
 “ Standard D into tubes 11, 12 
 “ Standard E into tubes 13, 14 
 “ Standard F into tubes 15, 16 
 “ Standard G into tubes 17, 18 
 
 Pipette 100 L of Level I control to tubes 19, 20 
 “  Level II control to tubes 21, 22 
   WISER Control I to tubes 23, 24 
   WISER Control II to tubes 25, 26 
 
 Pipette 100 L Unknown samples (in duplicate) to tubes 27+ 
  
Add 500 L of the Estrone Sulfate [I-125] Reagent to all tubes. Time: _________ 
Use a repeating pipette in position 2 with a 12.5 mL pipette tip. 
 
Add 100 L of the Estrone Sulfate Antiserum to all tubes except NSB and TC tubes 
(1-4).  
Time:  ______ 
Use a repeating pipette in position 2 with a 2.5mL pipette tip. 
 
Vortex tubes gently for 1-2 seconds:  Time: _________ 
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Cover all test tubes with parafilm and incubate at room temperature for 3 hours on a 
shaker at 180 rpm. Time: _________ 
 
Allow Precipitating Reagent to reach room temp.  Time: _________Shake reagent 
thoroughly  
 
 
Add 1.0 mL of Precipitating Reagent (shake thoroughly) to all tubes except TC. Time: 
_________ 
Use a repeating pipette in position 4 with a 12.5 mL pipette tip. 
 
Cover test tube rack with paraffin and immediately vortex all tubes. 
 
Incubate all tubes at room temperature for 15 minutes. Time: _________ 
 
Centrifuge all tubes except TC for 15 minutes at 3000 rpm. 
 
Decant all tubes except TC by: 
 Placing all tubes into a sponge rack 
 Inverting sponge rack into radioactive waste container 
 Allowing tubes to drain on chux for 1-2 minutes 
 Gently blotting droplets on rims 
 Returning to upright position 
 Allowing to dry upright for 1-2 hours 
 
Return TC tubes back into the test tube rack. 
 
Count all tubes in the Gamma counter (1 min): 
• Call lab 4-5348 
• Take floppy diskette 
• Sign-in sheet date, your initials, Kurzer, # tubes 
• Insert diskette 
• Drawer under the gamma counter contains protocol clips 
• Place # 20 clip on left side of 1st tray (1st tray is furthest from you) 
• Load tubes in trays from right to left 
• Do not load any tubes in stop rack 
• Place the stop rack behind all of your trays 
• Make sure trays are perpendicular and notch is in the tray groove 
• Use function keys to run protocol 
• Remove clip from tray and place in numerical order in drawer 
• Eject diskette 
• Get disk, printout, and make sure area is left clean and organized 
• If anything goes awry contact Alma (lab) 5-8292 or (cell) 909-964-7283 and 
Wanda (o) 5-1249, (barn) 4-3062 
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PROGESTERONE 
DSL-3900 
 
Progesterone RIA 
Date of assay: ____________ 
Time samples thawed: __________________ 
Time IRMA kit to room temp: ______________  
 
Allow all reagents to reach room temperature and mix liquid reagents thoroughly by 
gentle inversion before use.   
 
Label and arrange tubes in duplicate for Total Counts (non-coated plastic test tubes), 
Standards (coated tube), Controls (coated tube) and Unknowns (coated tube). 
 
Reconstitute Standards and Controls using ddH20.  
Use same pipette tip to add ddH20 to all vials.  
Allow the solid to dissolve before inverting. 
*Add 1 mL ddH20 to Standard A 
  *Add 0.5 mL ddH20 to Standard B-F and Controls. 
 Mix thoroughly by inversion prior to use but avoid foam. 
 
Load assay tubes. Time: _________ 
 
 Do not add anything to TC tubes 1, 2 
 
 Pipette 25μL of Standard A into tubes 3, 4 
 “             Standard B into tubes 5, 6 
 ” Standard C into tubes 7, 8 
 “ Standard D into tubes 9, 10 
 “ Standard E into tubes 11, 12 
 “ Standard F into tubes 13, 14 
 
 Pipette 25μL of Level I control to tubes 15, 16 
 “  Level II control to tubes 17, 18 
 “           WISER Control I to tubes 19, 20 
 “  WISER Control II to tubes 21, 22 
 
 Pipette 25μL of Unknown samples (in duplicate) to tubes 23+ 
 
Immediately add 500 µL Progesterone [I-125] to all tubes. Time: _________ 
Use a repeating pipette in position 2 and a 12.5mL pipette tip. 
 
Mix by shaking the test tube rack gently by hand.  
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Incubate all tubes at 37 °C for 60-70 minutes on the water bath. Time: _________ 
 
Remove TC tubes and set aside. Place remaining tubes in a sponge rack and decant by 
simultaneous inversion into a radioactive waste receptacle. Strike the tubes sharply on 
absorbent material to facilitate complete drainage and then allow them to drain for 3 
minutes. Blot the tubes to remove any droplets adhering to the rim before returning them 
to the upright position. Time: _________ 
 
Return TC tubes back into the test tube rack. 
 
Count all tubes in the Gamma counter (1 min): 
• Call lab 4-5348 
• Take floppy diskette 
• Sign-in sheet date, your initials, Kurzer, # tubes 
• Insert diskette 
• Drawer under the gamma counter contains protocol clips 
• Place # 36 clip on left side of 1st tray (1st tray is furthest from you) 
• Load tubes in trays from right to left 
• Do not load any tubes in stop rack 
• Place the stop rack behind all of your trays 
• Make sure trays are perpendicular and notch is in the tray groove 
• Use function keys to run protocol 
• Remove clip from tray and place in numerical order in drawer 
• Eject diskette 
• Get disk, printout, and make sure area is left clean and organized 
• If anything goes awry contact Alma (lab) 5-8292 or (cell) 909-964-7283 and 
Wanda (o) 5-1249, (barn) 4-3062 
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TESTOSTERONE RIA 
DSL-4100 
Testosterone RIA 
Date of assay:     ____________ 
Time samples thawed:   __________ 
Time RIA kit to room temp:  _______ (leave precipitating reagent in refrigerator) 
 
Allow all reagents to reach room temperature.  
 
Label and arrange 12x75mm plastic tubes in duplicate for Total Counts, Non-Specific 
Binding (NSB), Standards, Controls, and Unknowns (samples). 
 
Reconstitute Standards and Controls using ddH20.  
 Use same pipette tip to add ddH20 to all vials. 
Allow the solid to dissolve before inverting. 
*Add 1 mL ddH20 to Standard A; invert to mix. 
  *Add 0.5 mL ddH20 to Standard B-F and Controls. 
 Mix thoroughly by inversion prior to use but avoid foam. 
 
Load assay tubes. Time: _________ 
 
Do not add anything to TC tubes 1, 2 
 
Pipette 150 L of Standard A (0 pg/mL) into NSB tubes 3, 4 
  
 Pipette 50 L of Standard A into tubes 5, 6 
 “ Standard B into tubes 7, 8 
 ” Standard C into tubes 9, 10 
 “ Standard D into tubes 11, 12 
 “ Standard E into tubes 13, 14 
 “ Standard F into tubes 15, 16 
 
 Pipette 50 L of Level I control to tubes 17, 18 
 “   Level II control to tubes 19, 20 
    WISER Control I to tubes 21, 22 
    WISER Control II to tubes 23, 24 
 
 Pipette 50 L Unknown samples (in duplicate) to tubes 25+ 
 
Add 500 L of the Testosterone [I-125] Reagent to all tubes. Time: _________ 
Use a repeating pipette in position 2 and a 12.5mL pipette tip. 
 
Add 100 L of the Testosterone Antiserum to all tubes except NSB and TC tubes (1-4). 
Time: _________ Use a repeating pipette in position 2 and a 2.5mL pipette tip. 
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Cover all the tubes with paraffin and gently vortex them (level 4, ~30 sec):  Time: 
_________ 
 
Incubate all test tubes at 37 °C for 60-70 minutes in the water bath. Time: _________ 
 
Allow Precipitating Reagent to reach room temp.  Time: _________Shake reagent 
thoroughly  
 
Add 1.0 mL of Precipitating Reagent (shake thoroughly) to all tubes except TC. Time: 
________ 
Use a repeating pipette in position 4 with a 12.5 mL pipette tip. 
 
Cover test tube rack with paraffin, vortex and incubate at room temperature for 10-15 
minutes. Time: _________ 
 
Centrifuge all tubes except TC 15-20 minutes at 3000 rpm 
 
Decant all tubes except TC: 
 Placing all tubes into a sponge rack 
 Inverting sponge rack into radioactive waste container 
 Allowing tubes to drain on chux for 1-2 minutes 
 Gently blotting droplets on rims 
 Returning to upright position 
 Allowing to dry upright for 1-2 hours 
 
Return TC tubes back into the test tube rack. 
  
Count all tubes in the Gamma counter (1 min): 
• Call lab 4-5348 
• Take floppy diskette 
• Sign-in sheet date, your initials, Kurzer, # tubes 
• Insert diskette 
• Drawer under the gamma counter contains protocol clips 
• Place # 12 clip on left side of 1st tray (1st tray is furthest from you) 
• Load tubes in trays from right to left 
• Do not load any tubes in stop rack 
• Place the stop rack behind all of your trays 
• Make sure trays are perpendicular and notch is in the tray groove 
• Use function keys to run protocol 
• Remove clip from tray and place in numerical order in drawer 
• Eject diskette 
• Get disk, printout, and make sure area is left clean and organized 
• If anything goes awry contact Alma (lab) 5-8292 or (cell) 909-964-7283 and 
Wanda (o) 5-1249, (barn) 4-3062 
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APPENDIX A-2 
 
ELISA METHOD 
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SHBG ELISA 
IBL-59106 
SHBG ELISA 
Date of assay: ____________ 
Time samples thawed: __________________ 
Time kit to room temp: ______________  
 
Allow all reagents to reach room temperature and mix liquid reagents thoroughly by 
gentle inversion before use.   
 
Plasma Sample Dilution: Plasma samples (Unknowns) must be diluted 1:10 with 
Calibrator A prior to assay (for example, 10 μL serum + 90 μL Calibrator A): Do not 
dilute Standards and Controls. 
 
Prepare Wash Solution:  Dilute Wash Buffer Concentrate1:10 with distilled water into a 
plate washer buffer bottle (for example:  one 50mL bottle of wash buffer concentrate with 
450mL of distilled water, per kit).  The Wash Solution is stable for one month at room 
temperature. 
 
Prepare Conjugate Working Solution:  Dilute anti-SHBG monoclonal antibody-HRP 
conjugate 1:50 in assay buffer (for example, one 300uL bottle of HRP in 15mL of assay 
buffer, per kit). 
 
Load microplate wells:         
 Pipette 20 L of Standard A into wells A1, A2 
 “ Standard B into wells B1, B2 
 ” Standard C into wells C1, C2 
 “ Standard D into wells D1, D2 
 “ Standard E into wells E1, E2 
 “ Standard F into wells F1, F2 
 Pipette 20 L  Kit Control into wells G1, G2 
 Pipette 20 L  Internal Control into wells H1, H2 
  
 Pipette 20 L diluted samples (in duplicate) to A3-A4 down to H3-H4 and then 
moving to the next set of wells to the right:  PLATE 1:____________________    
PLATE 2:____________________ 
 
Add 200 L of Assay Buffer to each well using a multi-channel pipettor:   
 
Incubate the plates on an orbital microplate shaker at 250 rpm for 30 minutes:  PLATE 
1:_________________ 
                                                                                                                     PLATE 
2:_________________ 
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While shaking, prepare the Conjugate Working Solution: one 300uL bottle of 
HRP in 15mL of assay buffer, per kit. 
 
Aspirate and Wash each well 3 times with the Wash Solution using an automatic 
microplate washer.   
 TO USE MICROPLATE WASHER ELx405:  Attach Wash Solution to intake hose.  
Make sure all other hoses are connected correctly to waste bottles and vacuum pump.  
Prime the washer by selecting RUN → PRIME → P_DAY PRIME → ENTER →START.  
Then place the plate with the samples in the washer, press RUN→ WASH → SHBG → 
ENTER → START. 
 
Add 150 L of the Conjugate Working Solution to each well using a multi-channel 
pipettor: 
  
 
Incubate the wells on an orbital microplate shaker at 250 rpm for 15 minutes:  PLATE 
1:_________________ 
                                                                                                                     PLATE 
2:_________________ 
  
Aspirate and Wash each well 3 times with the Wash Solution using the ELx405 SHBG 
wash program.  
 
Add 150 L of the TMB substrate to each well using a multi-channel pipettor:   
 
Incubate the wells on an orbital microplate shaker at 250 rpm for 10-15 minutes:  PLATE 
1:_____________ 
                                                                                                                         PLATE 
2:_____________ 
 
 
Add 50 L of the Stopping Solution to each well using a multi-channel pipettor:  PLATE 
1:_____________ 
                                                                                                                        PLATE 
2:_____________ 
  
Read the absorbance of the solution in the wells within 20 minutes, using a microplate reader set 
to 450 nm. 
 
Results are given in nmol/L. 
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APPENDIX A-3 
 
LC-MS/MS METHOD FOR ESTROGEN METABOLITE 
EXCRETION 
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KURZER LAB 
LC/MS METHOD- URINE PREP for Estrogen Metabolites (EM) 
 
URINE SAMPLE PREPARATION 
 
Day 1 
1. Thaw urine samples previously frozen and preserved in sodium azide and/or 
sodium ascorbate 
2. Mix thoroughly by vortex to ensure homogeneity 
3. Centrifuge samples for 5 minutes at 5oC 
4. Pipette 1.0 ml of urine into clean, SILANIZED glass, screw-top test tubes 
5. To each aliquot of urine, add 10 μl of deuterated-EM working internal standard 
solution (ISS) containing representative analytes of each compound 
6. Following the addition of ISS, add 1.0 ml of freshly prepared enzymatic 
Hydrolysis Buffer pH 4.1. This buffer contained 2.0 mg of L-ascorbic acid, 5 μl 
of α-Glucoronidase/Sulfatase from Helix Pomatia (Type H-2), and 1.0 ml of 
Sodium acetate. 
7. Vortex samples using batch shaker for about 1 minute 
8. Incubate samples overnight at 37 oC to ensure hydrolysis 
 
Day 2 
1. Remove hydrolyzed samples from the 37 oC incubator and allow to reach room 
temperature 
Do the following steps in the hood 
2. Extract the samples by adding 3 ml of ethyl ether to each tube 
3. Cap and vortex on batch shaker for 1 minute 
4. Centrifuge for 5 minutes at 5oC to allow phase separation 
5. Pipette upper ethyl ether layer into a clean silanized glass, screw-top test tube. Be 
careful not to transfer any aqueous or interfacial layer to the receiving tube as this 
may adversely impact later derivatization. 
6. Repeat this extraction steps 2-5 three times. 
7. Pool ethyl ether extracts in the same tube 
8. Evaporate to dryness at 40 oC with nitrogen 
9. If you plan to store and freeze at this point, bring back sample in 0.15 ml of 
methanol and transfer to sample vials with fused low volume SILANIZED 
inserts. 
10. If you plan to run on LC/MS the same day, take samples to the UMCC Mass Spec 
Lab. To the dried samples, add 25 μl of 0.1M sodium bicarbonate buffer (pH 9; 
0.1% ascorbic acid). 
11. Add 25 μl of dansyl chloride solution (1mg/ml acetone) which is the derivatizing 
solution 
12. Vortex samples 
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13. Heat samples for 6 minutes at 60 oC to fully derivatize (allow EM and d-EM 
dansyl derivatives to form). 
14. Analyze samples on Thermo Electron Quantum Discovery Max Triple 
Quadrupole LC-MS/MS Instrument. 
15. Use Thermo Electron Xcalibur proprietary software for quantitative analysis 
 
The chromatographic separation was performed on a 100 x 0.5mm (i.d) Zorbax SB-C18 
column 1.8μm particle size.  
 
The mobile phase consisted of two eluents; solvent A (50 ml/L acetonitrile-950ml/L H2O 
containing 1ml/L formic acid) and solvent B (950 ml/L acetonitrile-50 ml/L H2O 
containing 1 ml/L formic acid). 
 
Calibration standards and quality control samples were similarly hydrolyzed, extracted, 
and derivatized. 
 
 
STANDARD PREPARATION 
 
1. Prepare the working EM Standard Solution (EMSS) containing the 12 non-
deuterated EM to a concentration of 1 ng/μl (i.e., 1 ppm). 
2. Prepare the working Internal Standard Solution (ISS) containing the 7 
deuterated EM to get a concentration of 1 ng/μl (i.e., 1 ppm). 
3. Prepare serial standard dilution of the stock solutions: 
a. Dilution Tube 1 – Add 100μl of EMSS and 900μl of methanol and 
vortex. This tube contains 100ng/mL of standard and is labeled “Std 100” 
b. Dilution Tube 2 – Add 100μl of EMSS and 2.90ml of methanol and 
vortex. This tube contains 100ng in 2.9 ml of methanol to give a final 
concentration of 33.33 ng/ml 
c. Dilution Tube 3 –7 – Pipette 2 ml of methanol to each tube 
d. Pipette out 1ml of Dilution Tube 2 into a clean, silanized glass tube 
labeled “Std 33” and another 1 ml into Dilution Tube 3. Discard 
remaining 1 ml of Dilution Tube 2. 
e. Gently but thoroughly vortex the contents of Dilution Tube 3. This tube 
contains 11.11ng/ml of standard. Transfer 1 ml of Dilution Tube 3 into a 
clean silanized tube labeled “Std 11” and another 1 ml into Dilution Tube 
4. 
f. Gently but thoroughly vortex the contents of Dilution Tube 4. This tube 
contains 3.704ng/ml of standard. Transfer 1 ml of Dilution Tube 4 into a 
clean silanized tube labeled “Std 3.7” and another 1 ml into Dilution 
Tube 5. 
g. Gently but thoroughly vortex the contents of Dilution Tube 5. This tube 
contains 1.23ng/ml of standard. Transfer 1 ml of Dilution Tube 5 into a 
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clean silanized tube labeled “Std 1.23” and another 1 ml into Dilution 
Tube 6. 
h. Gently but thoroughly vortex the contents of Dilution Tube 6. This tube 
contains 0.412ng/ml of standard. Transfer 1 ml of Dilution Tube 6 into a 
clean silanized tube labeled “Std 0.41” and another 1 ml into Dilution 
Tube 7. 
i. Gently but thoroughly vortex the contents of Dilution Tube 7. This tube 
contains 0.137ng/ml of standard. Transfer 1 ml of Dilution Tube 7 into a 
clean silanized tube labeled “Std 0.14”  
4. Add 10μl of 1ppm ISS (equivalent to 10 ng) to each standard tube 
5. Blow dry in nitrogen 
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PLEASE NOTE: If at any time you have questions or problems arise, please contact 
any of the WISER staff immediately.  Contact information is in this handbook and on 
the website (www.wiserwomen.umn.edu). WISER staff is here to assist you through the 
study process. Do not hesitate to call for any reason 612-968-9589 
.
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WISER Overview—Timeline of Participation  
Menstrual Cycle 1 
 
Clinic Visit 1: will be scheduled 8 days after a positive Ovulation Predictor Kit test.  
• Contact WISER Staff—upon a positive Ovulation Predictor Kit test—at (w) 612.968.9589 (e) wiser@@umn.edu 
to assist in scheduling an appointment with GCRC for 8 days after positive ovulation predictor kit test (if day 8 falls on a 
Saturday Clinic Visit 1 will be Friday and if day 8 falls on Sunday Clinic Visit 1 will be Monday) 
If leaving a message, give: 
Date 
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• Your name and contact information, along with what early morning times you are available on day 8 for your clinic 
visit (try to give a range of times, and what would be best. For example, “I am free 8-10, but would prefer 8:30.”) ** 
Remember that every following clinic visit will have to be within one hour of this time. ** 
• Discontinue ovulation predictor testing after a positive result 
• DO NOT exercise 48 hours prior to visit 
• Do not eat anything or drink anything but water 10 hours before clinic visit—e.g. if clinic visit 1 is at 7:30 AM do not eat 
anything but water after 9:30 PM the night before  (Clinic Visit 1 should be scheduled during early morning hours) 
 
Menstrual Cycle 2 
Date 
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Clinic Visit 2: will be scheduled on day 8 of menstrual cycle 2. 
• Contact WISER Staff—on day 1 of menstrual cycle 2—at (w) 612.968.9589 or (e) wiser@umn.edu to assist in scheduling an 
appointment with GCRC for day 8 of menstrual cycle 2 (if day 8 falls on a Saturday Clinic Visit 2 will be Friday and if day 8 
falls on Sunday Clinic Visit 2 will be Monday) **Time of visit should be scheduled ± 1 hour of Clinic Visit 1. 
If leaving a message, give: 
• Your name and contact information, along with what early morning times you are available on day 8 for your clinic 
visit (try to give a range of times, and what would be best. For example, “I am free 8-10, but would prefer 8:30.”)  
• Do not put off calling after you get a positive --- feel free to leave a message with either of her phone or email! 
• DO NOT exercise 48 hours prior to visit 
• Start urine collection the morning of day 7 (the day before Clinic Visit 2) 
• Do not eat anything or drink anything but water 10 hours before clinic visit—e.g. if clinic visit 2 is at 7:30 AM do not eat 
anything but water after 9:30 PM the night before  (Clinic Visit 2 should be scheduled during early morning hours) 
• You will learn which group you have been randomized into at the fitness assessment 
 
Menstrual Cycle 2—continued  
 
Day 10 Urine Pick up: will be scheduled for day 10 of menstrual cycle 2. 
• WISER staff will contact you regarding the urine pick-up details. If you don’t hear from someone by your 2nd clinic visit 
please let WISER staff know. 
• Provide urine jugs and food diary for pick-up staff.  
 
Day 11 Fitness Assessment: will be on day 11 of menstrual cycle 2. 
• BETH KAUFMAN, AMANDA THIESCHAFER, HOLLY JAKITS- WISER Personal Trainers, will contact you to schedule a 
fitness assessment. 
• If randomized into exercise group, you will discuss exercise program with trainer at fitness assessment.
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Menstrual Cycle 3 
 
 
 
Clinic Visit 3: will be scheduled on day 10 of menstrual cycle 3. 
• Contact WISER Staff—on day 1 of menstrual cycle 3—at (w) 612.968.9589 or (e) wiser@umn.edu to assist in scheduling an 
appointment with GCRC for day 10 of menstrual cycle 3 **Time of visit should be scheduled ± 1 hour of Clinic Visit 1. 
• Clinic Visit 3 is for weight check only—in light clothing, no shoes—while we understand there are variations in body weight 
we are asking that you try to maintain your weight (± 5 pounds) throughout study participation. 
• Do not put off calling after you get a positive --- feel free to leave a message with either of her phones or email! 
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Menstrual Cycle 4 
 
Clinic Visit 4: will be scheduled on day 10 of menstrual cycle 4. 
• Contact WISER Staff—on day 1 of menstrual cycle 4—at 612.968.9589 or (e) wiser@umn.edu to assist in scheduling an 
appointment with GCRC for day 10 of menstrual cycle 4 **Time of visit should be scheduled ± 1 hour of Clinic Visit 1. 
• Clinic Visit 4 is for weight check only— in light clothing, no shoes—while we understand there are variations in body weight 
we are asking that you try to maintain your weight (± 5 pounds) throughout study participation 
• Remember to bring your menstrual logs to the clinic for staff to check off. 
• Do not put off calling after you get a positive --- feel free to leave a message with either of her phones or email! 
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Menstrual Cycle 5 
 
 
Clinic Visit 5:  will be scheduled 8 days after a positive Ovulation Predictor Kit test.  
• Call WISER Staff when you get your Day 1 for our records.   
• Next time to contact WISER Staff—upon a positive Ovulation Predictor Kit test—at (w) 612.968.9589 or (e) 
wiser@umn.edu to assist in scheduling an appointment with GCRC for 8 days after positive ovulation predictor kit test (if day 
8 falls on a Saturday Clinic Visit 5 will be Friday and if day 8 falls on Sunday Clinic Visit 5 will be Monday) **Time of visit 
should be scheduled ± 1 hour of Clinic Visit 1. 
If leaving a message, give: 
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Your name and contact information, along with what early morning times you are available on day 8 for your clinic 
visit (try to give a range of times, and what would be best. For example, “I am free 8-10, but would prefer 8:30.”) 
• Discontinue Ovulation Predictor Kit testing after a positive result 
• DO NOT exercise 48 hours prior to visit 
• Do not eat anything or drink anything but water 10 hours before clinic visit—e.g. if clinic visit 5 is at 7:30 AM do not eat 
anything but water after 9:30 PM the night before  (Clinic Visit 5 should be scheduled during early morning hours) 
 
Menstrual Cycle 6 
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Clinic Visit 6: will be scheduled on day 8 of menstrual cycle 6. 
 
• Contact WISER Staff—on day 1 of menstrual cycle 6—at (w) 612.968.9589 or (e) wiser@umn.edu to assist in scheduling an 
appointment with GCRC for day 8 of menstrual cycle 6 (if day 8 falls on a Saturday Clinic Visit 6 will be Friday and if day 8 
falls on Sunday Clinic Visit 6 will be Monday) **Time of visit should be scheduled ± 1 hour of Clinic Visit 1. 
If leaving a message, give: 
• Your name and contact information, along with what early morning times you are available on day 8 for your clinic visit (try to 
give a range of times, and what would be best. For example, “I am free 8-10, but would prefer 8:30.”) 
•  DO NOT exercise 48 hours prior to visit 
• Start urine collection the morning of day 7 (the day before Clinic Visit 6) 
• Do not eat anything or drink anything but water 10 hours before clinic visit—e.g. if clinic visit 6 is at 7:30 AM do not eat 
anything but water after 9:30 PM the night before  (Clinic Visit 6 should be scheduled during early morning hours) 
Menstrual Cycle 6—continued  
• Bring completed menstrual log to Clinic Visit 6 
 
Day 10 Urine Pick up: will be scheduled for day 10 of menstrual cycle 6. 
• WISER staff will contact you be contacted from WISER staff regarding the urine pick-up details. If you don’t hear from 
someone by your 2nd clinic visit please let WISER staff know. 
• Provide urine jugs and food diary for pick-up staff.  
 
Day 11 Fitness Assessment: will be on day 11 of menstrual cycle 6. 
• BETH KAUFMAN, HOLLY JAKITS or AMANDA THIESCHAFER, WISER Personal Trainers, will contact you to schedule 
a fitness assessment. 
If randomized into to exercise group, will discuss exercise program with trainer at fitness assessment.
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General Data collection information 
 
Fitness Assessments  
 
On or about day 11 of your 2nd and 6th cycles, you will walk on a treadmill with a heart 
rate monitor at 3.5 miles per hour with gradual increase in the incline of the treadmill 
until you reach a heart rate of 85% of your age predicted maximal heart rate (total time: 
15 minutes). Fitness assessments at baseline and follow-up allow us to evaluate 
participants’ cardiorespiratory endurance. This fitness assessment will take place at the 
University of Minnesota Recreational Center on the East Bank. 
 
There is the possibility of muscle soreness from exercise during the fitness assessments 
on day 11 of menstrual cycles 2 and 6 or during the exercise intervention. This soreness 
may last several days after each exercise training session, but it is not likely to be severe 
enough to limit any of your usual daily activities. There is also a small risk of muscle 
injury from exercise. Muscle injuries may require medical attention, may take several 
months to heal, and may limit your usual daily activities for a period of days or weeks. 
 
 
 
Blood Draws 
 
During 4 clinic visits you will have 2 tablespoons of blood drawn each time. Blood draws 
have to occur after 10+ hours of fasting and are therefore scheduled during the early 
morning hours. Blood is drawn to measure the following biomarkers at baseline and 
follow-up: estrogen and progesterone hormones, oxidative stress, inflammatory markers, 
and insulin and glucose. 
 
If you choose to participate in the optional DNA study, 2 additional tablespoons will be 
drawn at Clinic Visit 1 only.  
 
There is a small risk of infection when blood is taken, but the risk is minimal as all 
needles and equipment are sterilized and the procedures are performed by clinical staff at 
the General Clinical Research Center.  You may experience some mild to moderate pain 
lasting a few seconds upon insertion of the needle used to draw the blood.  You may also 
get a bruise from the blood draw. 
  
  166
 DEXA Scans 
 
During 2 clinic visits body composition will be assessed using the dual x-ray 
absorptiometry (DEXA) machine. DEXA scans are full-body x-rays done while lying 
down. You will need to remove all jewelry prior to having the DEXA scan.  
 
Note that pregnant women are excluded from this study, and that if you become pregnant, 
it will be important to inform the study investigators. To ensure no unborn fetus is 
exposed to radiation, we conduct the pregnancy test with each participant before 
proceeding with the DEXA scan.  The risks associated with exposing a fetus to ionizing 
radiation through this DEXA procedure are greater than those associated with exposing 
adults.   
 
Although it is possible to estimate body fat by taking a measure of a fold of your skin 
(with a skin caliper tool), the margin of error with that kind of measurement is much 
larger than for DEXA. It is so much larger that we would need to double our sample size 
in order to detect any significant changes in body fat percentage. The measure of body fat 
we obtain from DEXA, a low risk and reliable procedure, improves our ability to test the 
study hypothesis. 
 
 
 
 Health Surveys 
 
There are several health surveys being administered at baseline and again at follow-up. 
The surveys include a physical activity interview along with a survey asking questions 
regarding the following: exercise, life events, emotional state, body image, menstrual 
cycle characteristics, and demographics. 
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Data Collection for Participants 
 
Keeping a Menstrual Log 
You will be given a monthly calendar for the months you participate in the project. The 
calendar should be used for tracking your menstrual cycle—start of menstruation, 
menstrual flow, end of menstruation, signs and symptoms of menstruation, ovulation 
test results, + ovulation test date, and length of menstrual cycle—along with urine 
collection dates, food record dates, and scheduled clinic visits at the General Clinical 
Research Center. 
 
Remember to note the following: 
• Start of menstruation, time of day, cycle number, and flow perception 
(*P#/AM/Moderate/Anxiety, Cramps). Where period flow is categorized as: 
• Very heavy, heavy, moderate, somewhat light, or very light 
And symptoms include: 
• Acne, anxiety, backache, bloating, breast swelling, breast tenderness, 
cramps, fatigue, food craving, headache, irritability, joint pain, moody, 
muscle pain/aches, nausea, tension, water retention, or weight gain 
• Urine collection dates (urine) 
• Food record dates (fd rec) 
• Scheduled clinic visits with GCRC (CV1) 
• Urine pick-up (PU) 
• Ovulation test results (- OVU or + OVU) 
• Last day of menstrual flow/period (**P# End) 
• Number of days in menstrual cycle (+1, +2, … +28) 
 
Please see pages 15-20 for a sample of a completed menstrual log 
 
Using the Ovulation Predictor Kits 
 
The ovulation kits will be used during five menstrual cycles, starting with your first 
menstrual cycle. You will be given a nine-day ovulation kit to begin use on or about day 
10 of your menstrual cycle. The first day of Ovulation Predictor Kit testing should occur 
according to your shortest cycle length (e.g. Flo’s average cycle length is 29 days; her 
shortest cycle is 27 days. Flo will start Ovulation Predictor tests on day 10 of her cycle.). 
You may take the test at any time of the day you find convenient. However, you should 
take the test at approximately the same time each day and mid-afternoon is best. 
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You should avoid consuming excess amounts of liquid for at least 4 hours prior to 
performing the test.  
 
How to perform the test: 
1. Collect urine using the urine cup provided. If the test will be carried out after 
more than 1 hour from the time of urine collection, the urine should be 
refrigerated. If refrigerated, urine should be allowed to warm to room temperature 
before testing. 
2. When you are ready to begin the test, open one of the test pouches (open one at a 
time, immediately before testing). Remove the device from the foil. 
3. Draw urine up to the marked line on the pipette provided (approximately 5 drops). 
Disperse entire contents of the pipette into the sample well. Wait 3 minutes for the 
result to develop. 
4. Read the results between 3 – 5 minutes later. 
 
Interpretation of the results: 
1. If there is no line in the test region (T), or the line is lighter than the one in the 
control region (C), then you have not begun your LH surge, and you should 
continue to test daily. 
2. If the color of the line in the test region is equivalent to or more intense than the 
line in the control region, you have detected a positive Ovulation Predictor test. 
Ovulation should occur within 24-36 hours. 
3. During Menstrual Cycles 1 and 6: Contact WISER Staff at (w) 612.968.9589 or 
(e) wiser@umn.edu to assist in scheduling an appointment with the GCRC for 8 
days after a positive Ovulation Predictor test. 
 
Do not put off calling WISER Staff after you get a positive --- feel free to leave a 
message with either of her phones or email!  
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Completing the 3-day Urine Collections  
*** Please call if this is confusing at all: 612-624-3050 or 612-968-9589*** 
 
The urine collections will be two separate 72-hour collections, the first taken for three 
consecutive days near the beginning of your second menstrual cycle (days 7, 8, 9) and 
then once again for three days during your sixth menstrual cycle (days 7, 8, 9).   
 
The GCRC will provide you with four large 3-liter containers and four 1-liter containers, 
one set of large and small containers for each day you collect urine and one additional set 
(in case you fill one on any given day and need another). For each collection day the 
urine produced during the day will be put in the large 3-liter jug and the overnight urine 
starting at 11:00 pm will be put in the smaller 1-liter jug, including the first morning void 
of the following day. Note that the overnight urine should be kept separately from 
the urine produced during the previous day, this means that for each 24 hours there 
will be one 3-liter container with daytime urine and one 1-liter container with nighttime 
urine, including the first morning void. 
 
You will be provided with 4 baggies containing vitamin C and the contents of 1 baggie of 
powdered vitamin C must be put in each large 3-liter jug, which helps to preserve the 
urine. Note that the overnight urine stored in the 1-liter containers should not have 
vitamin C in it. The extra 1-liter collection container and accompanying cooler bag with 
the ice packs are meant to accommodate your active lifestyles of work, school and other 
commitments.   
 
You will also be provided with two collection hats. They are designed to make the 
collections easier. You can keep one at work and one at home if you like. Place the hat 
near the front of the toilet bowl before you urinate. After you urinate, pour the urine into 
the container.  
 
Each day, you will need to clean the 1-liter container and the collection hat. Wash them 
with hot water and dish soap. Make sure the liter container is dry before you use it again. 
 
Please follow the instructions below to complete the 3-day urine collections. 
 
1. On your first urine collection day, do not collect your first void in the morning. That 
urine was produced in your body overnight and therefore is representative of the 
previous night's urine.  At this point, with the 3-liter jugs still empty, add the 
vitamin C powder to each container.  
 
2. Record the time of that first void of the day as your starting time on the label 
and in your menstrual calendar. Urine is being produced in your body from that 
time on and will be collected in the first day's collection. So although you are not 
collecting this first void, it is the start time for the first 24 hours of the collection 
period.  
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NOTE: someone will contact you to schedule a time for pick up on day 10. WISER 
staff will verify that you have arranged a pick-up at the second clinic visit.  
 
3. Throughout the day, whenever you are away from home, carry the 1-liter container 
and collection hat with you in the cooler bag with ice packs to ensure a full day’s 
collection. 
 
4. When you arrive home for the evening, immediately transfer the urine to the large 3-
liter container labeled for that day. Each container may only contain urine from one 
day. Label your 3-liter urine container with the start and end times as well as the 
appropriate dates. You will be provided with labels to attach to all your containers. 
Keep all containers filled with urine in a refrigerator or cooler with ice. DO NOT 
STORE OUTSIDE during the winter.   
 
5. The ‘day collection’ for day 7 finishes at 11:00 pm if you got to bed after 11:00 pm. 
In this case, you need to remember to void at 11:00 pm and transfer the urine to the 
orange jug. If you go to bed before 11:00 pm, make sure you void then, and write 
down the time on the label. So, if you go to bed at 9:30 pm, you should urinate and 
write down 9:30 pm as the end time for the daytime collection and start time for the 
nighttime collection. 
 
6. When you wake up the next day (day 8), void and transfer that urine into the 1-liter 
container for day 7. This void constitutes the last void of the first day of urine 
collection. Note that your start and end time for the 24 hour urine collections will 
depend on what time you get up that first morning.  (The end time for the 
previous day is the start time for the next day.) You will need to get up at the same 
time for each of the three days of the 24-hour urine collections. You will need to 
urinate the following morning at this same time in order to finish each day's 
collection period. 
 
EXAMPLE: On day 7, you wake up and void at 8 a.m., but you do not 
collect since this urine was produced in the previous 24 hours. This is your 
START TIME of collection day 7—8 a.m., 02-06-06 (per Flo’s example). 
On day 8, you wake up again at 8 a.m., void and transfer the urine into the 
1-liter container labeled for the 1st day. Record the time of first voids in 
the menstrual log calendars. 
 
 
7.  Keep your 3-liter and 1-liter containers of the urine collections in the refrigerator.  
 
8. Repeat the steps as above, for the 2nd and 3rd days of urine collection – keeping in 
mind that the very last void you collect will actually be the morning of day 10 and it 
will be put in the smaller 1-liter container corresponding to day 9. 
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9. A research assistant will transfer the 3-liter and 1-liter containers with the three 24-hr 
urine collections to the GCRC. Someone will contact you to arrange for a urine pick-
up. If you do not hear from someone please tell WISER staff at your 2nd clinic visit. 
 
What if… 
 
 If you happen to urinate enough one day to more than fill the 3-liter container, 
simply use the extra container. Make sure to label both containers and indicate 
there are two containers for that day. Remember that the overnight urine starting 
at 11:01 pm until the first morning void is kept in the 1-liter container. 
 
 If you find while collecting urine that you produce more than 3 liters on the first 
day (and this was a normal day for you), please contact the study coordinator 
immediately and we can provide you with additional collection containers.   
 
 NOTE: Do not fill the container to the top, as it will increase the chance of 
leaking. Instead, once a container is ¾ full, move on to the second container.  
Always make sure you have one extra 3-liter container at home. 
 
 We do not need to know each time you use the restroom. We are concerned with 
the time frame for the day you collected, which should be 24 hours. 
 
 Make sure you place all labels on the 3-liter and 1-liter containers and check on 
the labels for dates, time and check the box that says “Vit C added”.  
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CORRECT URINE LABELS 
 
DAYTIME COLLECTION 
WISER Protocol # 1124 
Study ID 
VIT C ADDED     
Baseline                                      DAY 7 
Start DATE: 01.23.08 
End DATE: 01.23.08 
Start Time: 7:30 am   
End Time: 11:00 pm 
NIGHTTIME COLLECTION 
WISER Protocol # 1124 
Study ID 
Do not add VIT C  
Baseline                                          DAY 7 
Start DATE: 01.23.08 
End DATE: 01.24.08 
Start Time: 11:00pm       
End Time: 7:30 am 
DAYTIME COLLECTION 
WISER Protocol # 1124 
Study ID 
VIT C ADDED  
Baseline                                      DAY 8 
Start DATE: 01.24.08 
End DATE: 01.24.08 
Start Time: 7:30 am     
End Time: 11:00 pm 
NIGHTTIME COLLECTION 
WISER Protocol # 1124 
Study ID 
Do not add VIT C  
Baseline                                           DAY 8 
Start DATE: 01.24.08 
End DATE: 01.25.08 
Start Time: 11:00pm        
End Time: 8:00 am 
DAYTIME COLLECTION 
WISER Protocol # 1124 
Study ID 
VIT C ADDED  
Baseline                                       DAY 9 
Start DATE: 01.25.08 
End DATE: 01.25.08 
Start Time: 8:00 am      
End Time: 11:00 pm 
NIGHTTIME COLLECTION 
WISER Protocol # 1124 
Study ID 
Do not add VIT C  
Baseline                                           DAY 9 
Start DATE: 01.25.08 
End DATE: 01.26.08 
Start Time: 11:00 pm       
End Time: 7:30 am 
 
 
 
Completing the 3-Day Sleep Journals 
You will be completing a sleep journal during the two 3-day urine collections that you 
will do while participating in the WISER study. 
The sleep journal should be completed first thing in the morning of days 8, 9, and 10 of 
the urine collections. That means that there will be one sleep journal for each day of urine 
collection. Make sure you read the questions before hand so you are able to answer them 
accurately.  
Blank copies of the sleep journal can be found at the end of this handbook  
The sleep journals will be picked up by the WISER staff along with the food records and 
the urine jugs. 
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Sleep Journal (example)  
 
Person ID 1 0 0 0  
 
Menstrual cycle Day:  8  Date:  01 / 17 / 2008  
 
 
A. Complete these questions first thing in the morning. 
 
 
2. Did you wake up during the night? 
 No (0)    X  
Yes (1)      If yes, at what 
time(s)? 
2 : 30 X  am    pm 
  ___ : ___   am    pm 
  ___ : ___   am    pm 
 
\    
3. Did you sleep with any lights on?        No (0)    X Yes (1)       
 If yes, what kind of light?   small lamp, 60-watt bulb      
 For how long was the light on? 11:30pm-2:30am               
 
 
4. What time did you first wake up this morning? 6 : 40 x  am    pm 
 
5. Did you go back to sleep after 
first waking up? 
 No (0)   X  
     Yes (1) 
 
 
 
 
   If yes, what time did you get up and  
out of bed? 7 : 05 X  am    pm 
 
 
6. Did you take any naps yesterday? 
 
 No (0)    X Yes (1) 
  If yes, at what times?   
 
Nap Begin  Nap End   
5 : 30  am  X pm 6 : 00   am  X  pm 
 
 
___ : ___  am   pm ___ : ___   am    pm 
 
 
7. How would you rate your sleep quality last night? 
 
1  2  3  4  5 
 
Very             Below                  Average                  Above                  Excellent 
Poor                 Average                                              Average 
  
1. At what time did you go to bed and try to fall asleep last 
night? 11 :30   am  X  pm 
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Completing the 3-Day Food Records 
Instructions for Completing an Accurate Food Record 
You will be completing two 3-day food records at designated times during the study.  In 
order to calculate your nutrient intake, a complete and accurate record must be kept of 
your food and beverage consumption for the three days. Please be honest. If you have any 
questions on how to record an item, please call us. The following are instructions for 
recording food intake to help you to provide accurate data. 
 
1. Complete the food diaries for 3 consecutive days (days 7, 8 and 9) during menstrual 
cycles 2 and 6.  Include the day of the week and date on each form.  
 
2. Use a separate form for each day. If you need extra lines to complete one day of 
intake, use an additional sheet. Mark the sheets (page 1 of 1, page 1 of 2) if multiple 
sheets are included. 
 
3. Carry the food record sheets with you during the day and write down the foods as you 
consume them.   
• All meals, snacks, and “tastes” of food and beverages must be recorded, whether 
they are eaten at home or away.   
• If you forget to bring the record sheets, write down what you eat on a scrap of 
paper or napkin. 
 
4. Record the time you eat. 
 
5. Record the type of food, such as 2% milk, chicken noodle soup with vegetables, red 
delicious apple, cinnamon raisin bagel.   
• Be as specific as possible in recording food items.   
• If the item is a brand name product, please record it. 
• If you have the label of a food, keep it and turn it in with the food record. 
 
6. Record the amount you consume.   
• The amount you consume may be different than the amount you are served (i.e. 
you do not finish a portion of the meal) 
• Do not assume that you eat the portion size listed on the food label.   
• Measure food and beverage items whenever possible. List portion consumed 
either in weight (in grams or ounces) or in volume (in teaspoons, tablespoons or 
cups). You may use the following abbreviations for weight and measures: 
tsp. = teaspoon   oz = ounce 
Tbsp. = tablespoon   c = cup 
• List the cooked weight of foods. Most meat products lose approximately one-
quarter of their weight during cooking (evaporation of water, loss of fat). 
Therefore, 4 ounces of raw hamburger yields a 3 ounce cooked burger. Leaner 
varieties of meat lose slightly less weight during cooking. 
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• If you consume certain foods or beverages on a regular basis (such as a bowl of 
corn flakes, a glass of milk) measure the usual servings you consume for these 
common items.  
7. Record how the food is prepared, such as fried in 2 Tbsp. oil, steamed, peeled. If 
you know the type of oil used, please record it (e.g. olive oil, safflower, corn). 
 
8. If the food is a combination food, record all the ingredients. 
      For example, a cheeseburger might consist of: 
   3 oz cooked beef 
   ¾ oz slice American cheese 
   1, 2-oz onion bun  
   2 Tbsp. ketchup 
   1 tsp. yellow mustard 
 
9. Include all condiments and amounts, such as 2 tsp. sugar added to coffee, or 1 Tbsp. 
mayonnaise spread on a sandwich. 
 
10. Record all beverages you consume during the day and night, including water, milk, 
juice, pop, diet pop, tea, coffee, etc. and the amounts in fluid ounces. (Remember that 
8 fluid ounces is one cup.)  
 
11. Include all vitamins and supplements. Record the brand and type taken. If possible, 
please include any label information. 
 
12. Indicate at the bottom of each daily food record if this was a typical day in terms of 
food intake. If it was not a typical day, briefly explain why. 
 
13. Be sure to give a completed copy of your food record to the research assistant when 
your food record and urine are collected on day 10 of menstrual cycles 2 and 6. 
 
Portion Sizes 
When eating away from home, use the following guide to help estimate serving sizes: 
• 3 ounces of cooked meat is the size of a deck of cards or the palm of your hand 
• 1 chicken thigh or ½ small breast equals 2 ounces 
• 1 medium chicken leg equals 2 ounces 
• 1 chicken wing equals 1 ounce 
• ½ cup canned fish equals 3 ounces 
• ¼ cup cooked, chopped meat equals 1 ounce 
• Your thumb is the size of one ounce of cheese 
• The tip of your thumb is about one teaspoon of margarine or butter 
• Your closed fist is about one cup of rice, noodles, vegetables, etc. 
• One closed handful (the amount you can grab in your hand with fingers almost 
touching your palm) is about one ounce of nuts 
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• One large all-you-can-grab handful is about one ounce of chips or pretzels 
• If you are uncertain, estimate using familiar objects. For example, you can use a 
“baseball” to estimate an ice cream serving.   
 
Measurement conversions may be useful for understanding food labels: 
          3 tsp. = 1 Tbsp.                       8 fluid oz. = 1 cup 
                4 Tbsp. = ¼ cup                       5 1/3 Tbsp. = 1/3 cup 
          ½ pint = 1 cup                         4 cups = 2 pints = 1 quart 
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Daily Food Record (example) 
Name: __Flo Example____    Date: _02.05.06_  Day:  Su   M   T   W  Th   F Sa 
Diet Period:   Baseline Follow-up  Cycle Day:     7 8 9 
 
Time Food or Beverage Consumed Amount Description/Preparation Method 
6:00 am Coffee with 10 oz  
    Granulated sugar 2 tsp.  
7:00 am Powder shake   
    Cranberry juice ¾ c Archer farms 
    Sugar-free cocoa mix 2 T Carnation rich chocolate 
    Banana 1 large  
10:00 am Water 12 oz  
12:00 pm Turkey sandwich   
    Turkey lunchmeat 3 oz Louis Rich oven roasted 
    Whole wheat bread 2 slices Roman Meal, 1 oz per slice 
    Margarine 1 tsp. Promise low fat 
    Lettuce 1 leaf romaine lettuce 
 Bag of Doritos 1 ¾ oz “nacho cheesier” 
 Skim milk 1 c  
 Orange 1 medium fresh 
3:00 pm Diet coke 10 oz Drank most of 12 oz can. 
    Frosted cake donut 1 Fried, with 2 Tbsp frosting 
8 – 5 pm Water 20 oz Water consumed at desk 
7:00 pm Pasta with meat sauce   
    Spaghetti noodles 1 c  
    Ground beef 3 oz  Cooked, drained, rinsed 
    Pasta sauce ½ c Healthy Choice mushroom 
 Parmesan cheese 1 T Kraft 
 Tossed salad   
    Iceberg lettuce 2 c  
    Cherry tomatoes 4  
    Shredded carrot ¼ c  
    Italian dressing 2 T Wine vinegar, olive oil, pinch salt 
 Mineral water with 12 oz Mendota Springs 
    Lime slice ½” slice  
8:00 pm Water 8 oz  
 
_____ Typical day    
__X___  Not a typical day (please explain why): Was a weekend day and I was out of 
town. 
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Completing the Food Frequency Questionnaire 
Instructions for Completing the Food Frequency Questionnaire 
You will be completing a web-based diet history questionnaire at the beginning of the 
study. This questionnaire consists of questions about consumption of 120 food items and 
it takes approximately 50-60 minutes to complete it. 
 
1. Open your internet browser and type in the following address: 
https://riskfactor.cancer.gov/respondent.html 
You will see a login screen that asks for the study code, respondent id, and 
password. This information will be given to you in an email reminder prior to 
your first clinic visit. 
 
2. Type in the study code, respondent id, and password provided. This will take you 
to a welcome screen, where you will click on the green button that says “Start 
Questionnaire”.  
 
3. A new screen will pop up with instructions. Please read them carefully before 
clicking on “Start Questionnaire”. 
 
4. Read each question carefully and follow the instructions until you are finished. 
 
5. You may interrupt the questionnaire at any time by clicking on the log out link on 
the top left corner of your screen. When you log back in, you will be able to 
continue answering the remaining questions without having to go back to the 
beginning of the questionnaire. 
 
*Please let us know if you do not have access to a computer! 
 
Questions? Any questions about completing the food record can be directed to 
ANDREA at (w) 612.624.3050 or (e) plat0072@umn.edu.  
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Using a Heart Rate Monitor 
How to use a Polar FS1 Heart Rate Monitor 
To measure your heart rate you need to wear the transmitter. 
Check that you are not near other people with heart rate monitors or any source of 
electromagnetic disturbances. 
 
1. Attach one end of the transmitter to the elastic strap. 
 
2. Adjust the transmitter’s strap length to fit snugly and comfortably. Secure the 
strap around your chest. 
 
3. Lift the transmitter off your chest and moisten the two grooved electrode areas 
on the back. Check that the wet electrode areas are firmly against your skin and 
that the Polar logo is in a central, upright position. 
 
4. Wear the wrist unit as a watch. 
 
5. In the Time of Day display press the front button to enter the menu. EXE 
(Exercise) is displayed. (NOTE: This will be done after completing your warm-up. 
You will be collecting data during your 30 minutes of aerobic exercise only.) 
 
6. After three seconds the wrist unit goes into Exercise mode and the stopwatch 
starts. The stopwatch is displayed and the outline of the heart symbol will flash 
until your heart rate is detected. 
 
7. Your heart rate and the symbol will appear within 15 seconds. 
 
8. Begin exercising immediately after seeing the heart rate symbol appear on the 
watch. 
 
A flashing heart symbol indicates an ongoing heart rate measurement. The heart symbol 
flashes at the pace of your heart. 
 
Note: 
• Please allow sufficient time for signal pick up. 
• If the wrist unit does not receive your heart rate, the stopwatch keeps running and 
the flashing heart frame symbol disappears, check that the transmitter electrodes 
are wet and that the strap is snug enough. 
• Keep in mind that your watch saves limited amount of workouts; you will be 
exchanging it weekly with your trainer. 
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Completing the Exercise Training Workout Logs  
Upon completing an exercise session the Workout Log will have to be completed. 
Each session requires you to: 
 
1. Enter the number of minutes exercising and average heart rate recorded from the 
Polar FS1 Heart Rate Monitor 
• Information needs to be recorded immediately following your exercise 
session. Your exercise information is in the memory of the wrist, but will 
not be stored long-term. Exercise information is removed upon beginning 
a new session. FILE is protected for accidental start and information is 
saved only if the exercise recording has been on for more than one minute. 
 
1. After you finish your 30 minutes of exercising, press the front button 
on the watch. “STOP” will appear 
2. In the Time of Day display, press the front button until FILE is 
displayed. 
3. Wait for three seconds to enter the File. Your total exercise duration is 
displayed.  Record this total exercise duration. 
4. Press the front button. Your average heart rate of the exercise session 
is displayed.  Record this average heart rate. 
 
2. Enter the date and the number of the exercise week (i.e. first week is Week 1, 
second week of exercise is Week 2 etc.) 
 
3. Check that all stretches have been completed according to the stretches 
prescribed. 
 
4. Enter the number of minutes warming-up 
 
5. Circle the appropriate equipment used during session 
 
6. Enter the number of minutes cooling-down 
 
7. Add any additional comments regarding the exercise session, including muscle 
soreness, related injuries, and any barriers to completing a session. 
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NAME: _Flo Example  STUDY ID:  0000    
 
SEPT 2007 
Day 
 
Date 
Monday  
 
09/03/07_ 
Tuesday  
 
09/04/07_ 
Wednesday  
 
_09/05/07_ 
Thursday 
 
_09/06/07 
Friday 
 
09/07/07 
Saturday 
 
09/08/07 
Sunday  
 
09/09/07 
WEEK 
NUMBER  
1 1 1 1 1 1 1 
Warm-up 
 
Minutes: 
___5___ 
Minutes: 
___5___ 
Minutes: 
___5___ 
Minutes: 
___5___ 
Minutes: 
___5___ 
Minutes: 
___5___ 
Minutes: 
___5___ 
Exercise 
 
 
Minutes: 
 
__30___ 
 
Avg HR:  
 
__135___ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
Minutes: 
 
__30___ 
 
Avg HR:  
 
__135___ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
Minutes: 
 
__30___ 
 
Avg HR:  
 
__134___ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
Minutes: 
 
__30___ 
 
Avg HR:  
 
__135___ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
Minutes: 
 
__30____ 
 
Avg HR:  
 
__133___ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
Minutes: 
 
__30___ 
 
Avg HR:  
 
__133___ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
Minutes: 
 
__30___ 
 
Avg HR:  
 
__134___ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
 
Cool-down 
Minutes:  
___5___ 
Minutes: 
__5____ 
Minutes: 
__5____ 
Minutes: 
__5____ 
Minutes: 
__5____ 
Minutes:  
__5____ 
Minutes: 
__5____ 
Stretching        
Comments: 
Workout week starts on Thursday,  February 9 (day 11 of cycle 2) 
Had muscle soreness on Friday, took Saturday off  
Had Wednesday off because completed five workouts in week 1 
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WISER Contact Information 
  
 
 
Scheduling Appointments and Questions 
• Contact study coordinator, ALMA at (w) 612.968.9589 or (e) wiser@umn.edu to 
schedule Clinic Visits 1-6 and urine and food record pick-ups during menstrual 
cycles 2 and 6. 
 
• Contact ANDREA at (w) 612.624.3050 or (e) plat0072@umn.edu with questions 
regarding food records and food frequency questionnaire. 
 
• Contact BETH at (w) 612.626.8044, (c) 612.670.2702 or (e) moen0177@umn.edu 
with questions regarding the fitness assessments and exercise sessions. 
 
• Contact AMANDA (w) 612.626.8044, (c) 320.333.5460 or (e)thie0170@umn.edu 
with questions regarding the fitness assessments and exercise sessions. 
 
• Contact LAURA at (w) 612.625.8693 or (e) rich0649@umn.edu if unable to 
reach other contacts. 
 
 
For all contacts if leaving a message, give: 
Your name and contact information, along with what early morning times you are 
available for clinic visit, exercise session, or urine collection (try to give a range of times, 
and what would be best. For example, “I am free 8-10, but would prefer 8:30.”) 
 
PLEASE NOTE: If at any time you have questions or problems arise, please contact any 
of the WISER staff immediately. The WISER staff members are here to assist you through 
the study process, do not hesitate to call for any reason. The website may also provide 
you with study information and details: www.wiserwomen.umn.edu. 
 
If we do not hear from you: 
PLEASE NOTE: If a participant does not set up clinic appointments and/or attend 
exercise sessions when they would be expected to occur, a WISER staff member will make 
three (3) attempts to contact each participant, at various times, via phone and email, over 
10 business days, advising the participant inquiring of her interest in continuing 
participation and advising of the possibility of termination of her study participation. The 
third message will state that the participant has 72 hours to contact WISER staff to set up 
rescheduling or to communicate that the participant has chosen to end her participation.  
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WISER Staff 
 
 
Mindy S. Kurzer, Ph.D. 
WISER Principal Investigator 
Dept. of Food Science and Nutrition 
University of Minnesota 
1334 Eckles Ave. 
St. Paul, MN 55108 
Tel: (612) 624-9789     
Fax: (612) 625-5272 
mkurzer@umn.edu 
 
Maureen O’Dougherty, Ph.D. 
WISER Research Coordinator 
Dept. of Food Science and Nutrition 
University of Minnesota 
1334 Eckles Ave. 
St. Paul, MN 55108 
Tel: (612) 624-4959 
Fax: (612) 625-5272 
modoughe@umn.edu 
  
Andrea Arikawa, Ph.D. 
WISER Postdoctoral Fellow 
Dept. of Food Science and Nutrition 
University of Minnesota 
1334 Eckles Ave. 
St. Paul, MN 55108 
Tel: (612) 624-3050 
Fax: (612) 625-5272 
plat0072@umn.edu 
 
Laura Richardson, MPH 
WISER Recruiter 
Dept. of Food Science and Nutrition 
University of Minnesota 
1334 Eckles Ave. 
St. Paul, MN 55108 
Tel: (612) 625-8693 
Fax: (612) 625-5272 
rich0649@umn.edu 
 
 
Alma Smith 
Ph.D. Nutrition Student 
Clinic Coordinator 
Dept. of Food Science and Nutrition 
University of Minnesota 
1334 Eckles Ave. 
St. Paul, MN 55108 
Tel: (612) 612-968-9589 
Fax: (612) 624-3412x4 
smit4113@umn.edu  
 
Amanda Thieschafer 
WISER Trainer 
Dept of Kinesiology 
University of Minnesota 
1900 University Ave SE 
Minneapolis, MN 55455 
Tel: (612) 626-8044 
Cell: (320)333-5460 
thie0170@umn.edu  
 
 
 
Beth Kaufman, MS 
WISER Trainer 
Dept of Kinesiology 
University of Minnesota 
1900 University Ave SE 
27 University Recreation Center 
Minneapolis, MN 55455 
Tel: (612) 626-8044  
moen0177@umn.edu 
 
Holly Jakits 
WISER Trainer 
Dept. of Food Science and Nutrition 
University of Minnesota 
1334 Eckles Ave. 
St. Paul, MN 55108 
Jaki0003@umn.edu  
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General Clinical Research Center (GCRC) 
 
Map to GCRC (http://www.gGCRC.umn.edu/print/gGCRC/location/home.html): 
includes location, transportation, and parking information 
 
 
     
 
 
Location  
The GCRC is located on the 2nd floor of the Masonic and Veterans of Foreign Wars 
Building. This building is located on the East Bank of the University of Minnesota 
campus, adjacent to Fairview-University Medical Center. (It is shown as the Masonic 
Memorial Hospital on the map above, but the sign upon entering the building reads, 
“Masonic Cancer Center.”) 
 
Phone:   612.626.0476 
Fax:    612.626.2456 
Mailing Address:  MMC 504  
   420 Delaware St SE 
   Minneapolis, MN 55455 
Shipping Address: 424 Harvard St SE 
   Masonic 211B – GCRC 
   Minneapolis, MN 55455 
Public Transportation 
Numerous city buses go to the Minneapolis campus via Washington Avenue, including 2, 
16, 35A, 47D, 50, 52A, 52B, 52C, 52E, 52F, 52H, 52K, 52L, 52M, 52P, 52U, 95E, and 
95U.  Information on specific routes, times, and fares may be obtained by calling the 
Metro transit office at 612-373-3333 or going to their website at www.metrotransit.org.  
  185
Directions to GCRC from I-35W 
These directions will take you to the Hospital Parking Ramp.   
Exit University Avenue and go east.  Make a right (south) on Oak Street.  Go past 
Washington Avenue (stop light) and make a right (west) on Delaware.  Go 1½ blocks and 
enter parking ramp on right. 
Directions to GCRC from I-94 
These directions will take you to the Hospital Parking Ramp. 
Exit Huron Blvd go north.  Go 2 blocks north to Washington Ave SE.  Make a left (west).  
Go 2 blocks to Oak Street.  Make a left (south) onto Oak Street.  At the next intersection 
(Delaware Street) make a right (west) and go 1½ blocks until you get to the ramp.  
Parking near GCRC 
If you choose to drive to the GCRC, you have several choices for parking near the 
Clinical Research Center (GCRC) depending on the time of your appointment. 
 
(1) The Hospital Parking Ramp is the closest to the GCRC. It is located on Delaware 
Avenue between Harvard and Walnut Streets.  The ramp charges an hourly rate; you 
receive a ticket on the way into the ramp and pay on the way out.  You will be charged a 
reduced rate ($2.50 for the first 30-60 minutes, $3.75 for 1-1.5 hours, $4.50 for 1.5-2.5 
hours, and 2.5-3.5 hours) if you take your ticket to the GCRC and have it stamped.   
 
(2) The Oak Street Ramp is a bit farther away, located off Oak Street.  This is a good 
ramp to use if you have a 6:00, 6:30, or 7:00 a.m. appointment.  Enter off Oak or Ontario 
streets and take a ticket as you enter.  You will be charged $2.25 per hour based on the 
total time stamped on your ticket. 
 
(3) The Washington Avenue ramp is located on Washington Avenue, next to the 
Radisson Hotel.  This is also a good ramp to use for early morning appointments.  To 
enter the ramp, turn right on Harvard St from Washington Avenue, then circle behind the 
ramp and enter on Union Street (this route is necessary due to one-way streets).  You will 
be charged $2.25 per hour based on the total time stamped on your ticket. 
 
(4) There is also metered parking available along Washington Avenue in front of the 
Radisson Hotel, off Delaware Street at Walnut, and off Harvard Street south of the 
GCRC.  Meters are usually $1.25 per hour; please check individual metered areas for 
rates and times the meters are enforced.  
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YWCA  
 
Minneapolis YWCA Locations (http://www.ywcampls.org/locations/index.asp) 
Downtown YWCA 
Address 
1130 Nicollet Mall 
Minneapolis, MN 5540. 
612.332.0501 
 
Hours 
Day   Time 
Monday-Friday 6:00 am – 9:00 pm 
Saturday  7:30 am – 5:00 pm 
Sunday  9:00 am – 3:00 pm 
 
Pay parking is available in the lot behind the building. The rate is $1 for 2 hours while 
you are in the facility. Enter from 12th Street between LaSalle Ave and Nicollet Mall.  
 
Midtown YWCA 
Address 
2121 East Lake Street 
Minneapolis, MN 55407 
612.215.4333 
 
Hours 
Day   Time 
Monday-Friday 5:30 am – 11:00 pm 
Saturday & Sunday 7:30 am – 9:00 pm 
 
The Midtown YWCA is steps from the Hiawatha Light Rail Station, is on several bus 
lines, and offers free parking in the adjacent lot. 
 
Uptown YWCA 
Address 
2808 Hennepin Avenue South 
Minneapolis, MN 55408 
612.874.7131 
 
Hours 
Day   Time 
Monday-Friday  5:30 am – 11:00 pm 
Saturday & Sunday 7:30 am – 9:00 pm 
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Pay parking is available in the adjacent ramp. The rate is $1 for 2 hours while you are in 
our facility. Enter from Hennepin Avenue. 
 
 
University of Minnesota Recreation Centers 
University Recreation Complex  
1906 University Avenue SE 
Minneapolis, MN 55455 
Map to University Recreation Complex 
 
Public Transportation 
Numerous city buses go to the Minneapolis campus via Washington Avenue, including 2, 
16, 35A, 47D, 50, 52A, 52B, 52C, 52E, 52F, 52H, 52K, 52L, 52M, 52P, 52U, 95E, and 
95U.  Information on specific routes, times, and fares may be obtained by calling the 
Metro transit office at 612-373-3333 or going to their website at www.metrotransit.org.  
 
Parking 
(1) The 4th Street Ramp is located on the northeast corner of 4th Street SE and 17th 
Avenue SE. To enter the ramp turn right (north) off of 4th Street SE onto 17th Avenue SE 
and turn left to enter ramp. You will be charge $2.50 per hour for the first two hours and 
slightly less per hour for greater than two hours up to $12.00 maximum.  
 
(2) The Washington Ave Ramp is located on Washington Avenue, next to the Radisson 
Hotel.  To enter the ramp, turn right on Harvard St from Washington Avenue, then circle 
behind the ramp and enter on Union Street (this route is necessary due to one-way 
streets).  However, if you exit after 8:00, you will be charged $1.75 per hour based on the 
total time stamped on your ticket. 
 
(3) The Huron Blvd Parking Complex is located northeast of 4th Street SE and Oak Street 
SE. To enter the Huron Parking Complex travel east on University to Huron Blvd. North 
on Huron Blvd, or follow Huron Blvd North, or enter from south side (Huron Blvd/4th 
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St) or from north side (5th St). You will be charged $3.50 to park in the Huron Blvd 
Parking Complex. 
 
Hours 
Day    Time    
Monday-Friday  5:45am-8:00pm   
Saturday   10:00am-4:00pm   
Sunday   12:00pm-5:00pm 
 
St. Paul Gymnasium 
1536 N Cleveland Avenue 
St. Paul, MN 55108 Gym 
 
Map to St. Paul Gymnasium 
nasium 
Public Transportation 
City buses going to the St. Paul campus include the 3 and 87.  Information on specific 
routes, times, and fares may be obtained by calling the Metro transit office at 612-373-
3333 or going to their website at www.metrotransit.org.  
 
Additionally, the Campus Connector provides direct bus service between the St. Paul, 
East Bank, and West Bank campuses approximately every five to 30 minutes from 7 a.m. 
through midnight, depending on the time of day and academic year. 
 
Parking 
(1) There are Lot 171 Meters directly in front of the St. Paul Gym off of Cleveland 
Avenue N. Meters are $1.25 per hour. 
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(2) The Gortner Avenue Ramp is in between (south of) Buford Avenue and (north of) 
Commonwealth Avenue off of Gortner Avenue. The ramp can be entered off Gortner 
Avenue. You will be charged $2.50 per hour for the first two hours and slightly less per 
hour for greater than two hours up to $12.00 maximum. 
 
(3) There is a limited amount of free one-hour street parking west of Cleveland Avenue 
near the St. Paul Gym. 
 
Date   Time 
Monday-Thursday  5:45am-8:00pm    
Saturday   10:00am-4:00pm  
Sunday   12:00pm-5:00pm  
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Data Collection Forms 
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WISER (Women In Steady Exercise Research) 
Daily Food Record 
 
Name: _________________ Date: ________ Day:  Su   M   T   W   Th   F  Sa 
Diet Period:   Baseline Follow-up  Cycle Day:     7 8 9 
 
_____ Typical day    
_____  Not a typical day (please explain why): 
Time Food or Beverage Consumed Amount Description/Preparation Method 
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WISER (Women In Steady Exercise Research) 
Daily Food Record 
 
Name: _____________________ Date: ________ Day:  Su   M   T   W   Th   F  Sa 
Diet Period:   Baseline Follow-up  Cycle Day:     7 8 9 
 
_____ Typical day    
_____  Not a typical day (please explain why):   
Time Food or Beverage Consumed Amount Description/Preparation Method 
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WISER (Women In Steady Exercise Research) 
Daily Food Record 
 
Name: _____________________ Date: ________ Day:  Su   M   T   W   Th   F  Sa 
Diet Period:   Baseline Follow-up  Cycle Day:     7 8 9 
 
_____ Typical day    
_____  Not a typical day (please explain why):   
Time Food or Beverage Consumed Amount Description/Preparation Method 
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Sleep Journal  
 
Person ID      
 
Menstrual cycle Day:  8  Date:  ____ / ____ / ___    
 
 
A. Complete these questions first thing in the morning. 
 
1. At what time did you go to bed and try to fall asleep last night? ___ : ___   am    pm 
 
 
  3. Did you sleep with any lights on?       
  No (0)     Yes (1)       If yes, what kind of light? _________ 
                      
For how long was the light on? _________ 
                              
 
 
 
 
 
5. Did you go back to sleep after first 
waking up? 
 No (0)    
  
 Yes (1)  
 
   If yes, what time 
did you get up 
and out of bed? ___ : __ 
  am    
pm 
 
6. Did you take any naps yesterday?  No (0)     Yes (1) 
  If yes, at what times?  
 
 
Nap Begin  Nap End   
___ : ___ 
 am   
pm 
___ : ___ 
  am    
pm 
 
 
___ : ___ 
 am   
pm 
___ : ___ 
  am    
pm 
 
 
 
 
7. How would you rate your sleep quality last night? 
 
1  2  3  4  5 
 
Very             Below                  Average                  Above                  Excellent 
Poor                 Average                                              Average
2. Did you wake up during the night?
 
 No (0)    
  Yes (1)     
   If yes, at what time(s)? 
___ : __ 
  am    
pm 
  
___ : __ 
  am    
pm 
  
___ : __ 
  am    
pm 
4. W4. What time did you first wake up this morning? ___ : ___   am    pm 
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Sleep Journal  
 
Person ID      
 
Menstrual cycle Day:  8  Date:  ____ / ____ / ___    
 
 
A. Complete these questions first thing in the morning. 
 
1. At what time did you go to bed and try to fall asleep last night? ___ : ___   am    pm 
 
 
  3. Did you sleep with any lights on?       
  No (0)     Yes (1)       If yes, what kind of light? _________ 
                      
For how long was the light on? _________ 
                              
 
 
 
 
 
5. Did you go back to sleep after first 
waking up? 
 No (0)    
  
 Yes (1)  
 
   If yes, what time 
did you get up 
and out of bed? ___ : __ 
  am    
pm 
 
6. Did you take any naps yesterday?  No (0)     Yes (1) 
  If yes, at what times?  
 
 
Nap Begin  Nap End   
___ : ___ 
 am   
pm 
___ : ___ 
  am    
pm 
 
 
___ : ___ 
 am   
pm 
___ : ___ 
  am    
pm 
 
 
 
 
7. How would you rate your sleep quality last night? 
 
1  2  3  4  5 
 
Very             Below                  Average                  Above                  Excellent 
Poor                 Average                                              Average
2. Did you wake up during the night?
 
 No (0)    
  Yes (1)     
   If yes, at what time(s)? 
___ : __ 
  am    
pm 
  
___ : __ 
  am    
pm 
  
___ : __ 
  am    
pm 
4. W4. What time did you first wake up this morning? ___ : ___   am    pm 
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Sleep Journal  
 
Person ID      
 
Menstrual cycle Day:  8  Date:  ____ / ____ / ___    
 
 
A. Complete these questions first thing in the morning. 
 
1. At what time did you go to bed and try to fall asleep last night? ___ : ___   am    pm 
 
 
  3. Did you sleep with any lights on?       
  No (0)     Yes (1)       If yes, what kind of light? _________ 
                      
For how long was the light on? _________ 
                              
 
 
 
 
 
5. Did you go back to sleep after first 
waking up? 
 No (0)    
  
 Yes (1)  
 
   If yes, what time 
did you get up 
and out of bed? ___ : __ 
  am    
pm 
 
6. Did you take any naps yesterday?  No (0)     Yes (1) 
  If yes, at what times?  
 
 
Nap Begin  Nap End   
___ : ___ 
 am   
pm 
___ : ___ 
  am    
pm 
 
 
___ : ___ 
 am   
pm 
___ : ___ 
  am    
pm 
 
 
 
 
7. How would you rate your sleep quality last night? 
 
1  2  3  4  5 
 
Very             Below                  Average                  Above                  Excellent 
Poor                 Average                                              Avera
2. Did you wake up during the night?
 
 No (0)    
  Yes (1)     
   If yes, at what time(s)? 
___ : __ 
  am    
pm 
  
___ : __ 
  am    
pm 
  
___ : __ 
  am    
pm 
4. W4. What time did you first wake up this morning? ___ : ___   am    pm 
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WORKOUT LOG 
NAME:           STUDY ID:      
 
  
              2 0 0 8  
  
Day 
Date 
Time of day:  
Monday 
 
 
Tuesday 
 
 
Wednesday 
 
 
Thursday 
 
 
Friday 
 
 
Saturday 
 
 
Sunday 
 
 
Week Number        
Target Heart 
Rate 
       
Warm Up  
 
Minutes: 
______ 
Minutes: 
______ 
Minutes: 
______ 
Minutes: 
______ 
Minutes: 
______ 
Minutes: 
______ 
Minutes: 
______ 
Exercise 
 
 
Minutes: 
 
______ 
 
Avg HR:  
 
______ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
Minutes: 
 
______ 
 
Avg HR:  
 
______ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
Minutes: 
 
______ 
 
Avg HR: 
 
______ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
Minutes: 
 
______ 
 
Avg HR:  
 
______ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
Minutes: 
 
______ 
 
Avg HR:  
 
______ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
Minutes: 
 
______ 
 
Avg HR:  
 
______ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
Minutes: 
 
______ 
 
Avg HR: 
 
______ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
 
Cool-down 
Minutes:  
______ 
Minutes: 
______ 
Minutes: 
_______ 
Minutes: 
______ 
Minutes: 
______ 
Minutes: 
______ 
Minutes: 
______ 
 
Stretching 
   
Comments 
 
 
 
  
  198
WORKOUT LOG 
NAME:           STUDY ID:      
 
  
                2 0 0 8  
  
Day 
Date 
Time 
Monday 
 
 
Tuesday 
 
 
Wednesday 
 
 
Thursday 
 
 
Friday 
 
 
Saturday 
 
 
Sunday 
 
 
Week Number        
Target Heart 
Rate 
       
Warm Up  
 
Minutes: 
______ 
Minutes: 
______ 
Minutes: 
______ 
Minutes: 
______ 
Minutes: 
______ 
Minutes: 
______ 
Minutes: 
______ 
Exercise 
 
 
Minutes: 
 
______ 
 
Avg HR:  
 
______ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
Minutes: 
 
______ 
 
Avg HR:  
 
______ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
Minutes: 
 
______ 
 
Avg HR: 
 
______ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
Minutes: 
 
______ 
 
Avg HR:  
 
______ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
Minutes: 
 
______ 
 
Avg HR:  
 
______ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
Minutes: 
 
______ 
 
Avg HR:  
 
______ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
Minutes: 
 
______ 
 
Avg HR: 
 
______ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
 
Cool-down 
Minutes:  
______ 
Minutes: 
______ 
Minutes: 
_______ 
Minutes: 
______ 
Minutes: 
______ 
Minutes: 
______ 
Minutes: 
______ 
 
Stretching 
   
Comments 
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WORKOUT LOG 
NAME:           STUDY ID:      
 
  
                2 0 0 8  
  
Day 
Date 
Time 
Monday 
 
 
Tuesday 
 
 
Wednesday 
 
 
Thursday 
 
 
Friday 
 
 
Saturday 
 
 
Sunday 
 
 
Week Number        
Target Heart 
Rate 
       
Warm Up  
 
Minutes: 
______ 
Minutes: 
______ 
Minutes: 
______ 
Minutes: 
______ 
Minutes: 
______ 
Minutes: 
______ 
Minutes: 
______ 
Exercise 
 
 
Minutes: 
 
______ 
 
Avg HR:  
 
______ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
Minutes: 
 
______ 
 
Avg HR:  
 
______ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
Minutes: 
 
______ 
 
Avg HR: 
 
______ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
Minutes: 
 
______ 
 
Avg HR:  
 
______ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
Minutes: 
 
______ 
 
Avg HR:  
 
______ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
Minutes: 
 
______ 
 
Avg HR:  
 
______ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
Minutes: 
 
______ 
 
Avg HR: 
 
______ 
 
Equipment 
 (circle one): 
Treadmill 
Elliptical  
Stepper 
 
Cool-down 
Minutes:  
______ 
Minutes: 
______ 
Minutes: 
_______ 
Minutes: 
______ 
Minutes: 
______ 
Minutes: 
______ 
Minutes: 
______ 
 
Stretching 
   
Comments 
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APPENDIX C-1 
 
SAS CODE: ENDOGENOUS SEX HORMONES AND SHBG 
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/*Purpose of this code: create demographic variables*/ 
Data WISER.Demographics_319; 
INFILE 'D:\Users\Alma\Desktop\School\SexHormones\Datasets 
\319\Demographics_319.csv'  
firstobs=2 DLM ="," DSD missover; 
INPUT  ID         :$4. 
       Group      :$1. 
       Entry_date :MMDDYY10. 
       DOB        :MMDDYY10. 
   Ht_CV1     :6.2 
       Wt_CV1     :6.2 
   AmInALN    :$1. 
       Asian      :$1. 
   Black      :$1. 
       Hawaiian   :$1. 
   White      :$1.       
   OthRH      :$1. 
   Hispanic   :$3. 
       EDU        :$40. 
   MarStat    :$18. 
       BCuse      :$1. 
       Parity     :1.  
    ; 
 
FORMAT ID         $4. 
       Group      $1. 
       Entry_date MMDDYY10. 
       DOB        MMDDYY10. 
   Ht_CV1     6.2 
       Wt_CV1     6.2 
   AmInALN    $1. 
       Asian      $1. 
   Black      $1. 
       Hawaiian   $1. 
   White      $1.       
   OthRH      $1. 
   Hispanic   $3. 
       EDU        $40. 
   MarStat    $18. 
       BCuse      $1. 
       Parity     1.  
    ; 
RUN; 
 
Data WISER.Demographics_319; 
SET WISER.Demographics_319; 
 
length trt $8.; 
if group=1 then trt='exercise'; 
if group=2 then trt='control'; 
 
Age=((Entry_Date-DOB)/365.25); 
length Age_strata $9.; 
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If Age LT 25 then Age_Strata ='1_under25'; 
If Age GE 25 then Age_Strata='2_over25'; 
 
BMI= (Wt_CV1)/((Ht_CV1/100)**2);  
/*BMI=body weight in kg/ height in m squared*/ 
 
length BMI_strata $9.; 
If BMI LT 22.8 then BMI_Strata= '1_lowBMI'; 
If BMI GE 22.8 and BMI LT 26.3 then BMI_Strata= '2_midBMI'; 
If BMI GE 26.3 then BMI_Strata='3_highBMI'; 
 
length BMI_class $8.; 
If BMI GE 0 and BMI LT 25.0 then BMI_Class= '1_Normal'; 
If BMI GE 25.0 and BMI LT 30.0 then BMI_Class= '2_Overwt'; 
If BMI GE 30.0 then BMI_Class='3_Obese'; 
 
length BMI_class4 $9.; 
BMI_class4= BMI_class; 
If BMI GE 0 and BMI LT 18.5 then BMI_Class4= '0_Underwt'; 
 
length BMI_over25 $8.; 
if BMI GE 18.5 and BMI LT 25.0 then BMI_over25='1_Normal'; 
if BMI GE 25.0 then BMI_over25='2_over25'; 
 
If EDU = 'College/University degree' then  
Education_cat = 'College or more'; 
If EDU = 'Graduate or Professional degree' then Education_cat = 'College or more'; 
If EDU = 'Some college (less than 4 years)' then Education_cat = 'Some college'; 
If EDU = 'Vocational training (beyond high school)' then Education_cat = 'HS or less'; 
If EDU = 'Completed high school diploma (or GED)' then Education_cat ='HS or less'; 
IF EDU = 'Less than high school diploma' then  
Education_cat ='HS or less'; 
 
If White = '1' then race = 'White';  
else if Black = '1' then race = 'Black'; 
else if Asian = '1' then race = 'Asian'; 
else race = 'Other'; 
 
If marstat = 'Divorced' then status = 'not together'; 
if marstat = 'Separated' then status = 'not together'; 
if marstat = 'Married' then status ='together'; 
if marstat = 'Domestic partnered' then status ='together'; 
if marstat = 'Never married' then status = 'never'; 
 
FORMAT Age 5.1 
       BMI 5.1; 
RUN; 
 
/********************************************************** 
Purpose of this code: to create body composition variables  
ID 1960 and 2663 did not complete follow up DEXA  
0 baseline, 1 follow up 
**********************************************************/ 
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Data WISER.Bodycomp_319; 
INFILE 'D:\Users\Alma\Desktop\School\SexHormones\Datasets\319\ 
Bodycomp_319.csv' firstobs=2 DLM ="," DSD missover; 
INPUT  ID :$4. ToTissuepre :6.0  ToFatpre :5.0  
  ToLeanpre :5.0 ToTissuefu :6.0 ToFatfu :5.0  
  ToLeanfu :5.0; 
    
FORMAT   ID           $4. 
          ToTissuepre  6.0 
      ToFatpre     5.0    
      ToLeanpre    5.0   
      ToTissuefu   6.0    
      ToFatfu      5.0    
      ToLeanfu     5.0 
   ; 
RUN; 
 
DATA WISER.Bodycomp_319; 
set WISER.Bodycomp_319; 
 
Fat_mass_0= ToFatpre/1000.0; 
Fat_mass_1= ToFatfu/1000.0; 
Percent_bodyfat_0=(ToFatpre/ToTissuepre)*100; 
Percent_bodyfat_1=(ToFatfu/ToTissuefu)*100; 
Lean_mass_0= ToLeanpre/1000.0; 
Lean_mass_1= ToLeanfu/1000.0; 
Percent_leanmass_0=(ToLeanpre/ToTissuepre)*100; 
Percent_leanmass_1=(ToLeanfu/ToTissuefu)*100; 
 
array a[4] fat_mass_0 lean_mass_0 percent_bodyfat_0 percent_leanmass_0; 
array b[4] fat_mass_1 lean_mass_1 percent_bodyfat_1 percent_leanmass_1; 
array c[4] D_fat_mass D_lean_mass D_percent_bodyfat D_percent_leanmass; 
array d[4] PD_fat_mass PD_lean_mass PD_percent_bodyfat PD_percent_leanmass; 
 
do j=1 to 4; 
c[j]= b[j] - a[j]; 
d[j]= (100.0* c[j])/a[j]; 
end; 
 
FORMAT     Fat_mass_0      5.3 
           Fat_mass_1      5.3 
   D_fat_mass      5.2 
   PD_fat_mass     5.2 
           Percent_bodyfat_0     5.2 
   Percent_bodyfat_1     5.2 
   D_percent_bodyfat     5.2 
   PD_percent_bodyfat    5.2 
   Lean_mass_0     5.2 
   Lean_mass_1     5.2 
   D_lean_mass     5.2 
   PD_lean_mass    5.2 
   Percent_leanmass_0    5.2 
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       Percent_leanmass_1    5.2 
   D_percent_leanmass    5.2 
   PD_percent_leanmass   5.2 
    ; 
 
KEEP  ID fat_mass_0 lean_mass_0  
 percent_bodyfat_0 percent_leanmass_0 
fat_mass_1 lean_mass_1  
percent_bodyfat_1 percent_leanmass_1 
   D_fat_mass D_lean_mass  
 D_percent_bodyfat D_percent_leanmass 
   PD_fat_mass PD_lean_mass  
 PD_percent_bodyfat PD_percent_leanmass; 
RUN;  
 
PROC PRINT data=WISER.Bodycomp_319 (OBS=5); 
RUN; 
Data WISER.Menarche_310; 
INFILE 'D:\Users\Alma\Desktop\School\SexHormones 
\Datasets\319\Menarche_310.csv'  
firstobs=2 DLM ="," DSD missover; 
 
INPUT  ID         :$4. 
       F25q1      :4.1 
    ; 
 
FORMAT ID         $4. 
       F25q1      4.1 
    ; 
RUN; 
 
Data WISER.Menarche_310 (rename=(F25q1=Menarche_age)); 
SET WISER.Menarche_310; 
RUN; 
 
Data WISER.FamilyHistory_251; 
INFILE 'D:\Users\Alma\Desktop\School\Sex Hormones\ 
Datasets\319\BC_251.csv'  
firstobs=2 DLM ="," DSD missover; 
 
INPUT  ID :$4. Group :$1.  
       First_degree_relatives :1.  
       Second_degree_relatives :1.; 
    
FORMAT   ID                        $4. 
         Group                     $1. 
         First_degree_relatives    1.    
     Second_degree_relatives   1.; 
RUN; 
 
Data WISER.FamilyHistory_251; 
Set wiser.FamilyHistory_251; 
length BC_history $3; 
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if First_degree_relatives =0 then BC_history = 'NO'; 
else BC_history ='YES'; 
drop group; 
run; 
 
Data WISER.Foodrecords_312_0; 
INFILE 'D:\Users\Alma\Desktop\School\Sex Hormones\ 
Datasets\319\Foodrecords_312_0.csv' 
firstobs=2 DLM ="," DSD missover LRECL=386; 
 
INPUT  ID:$4. timepoint :$1. Kcal:7.2 FatCals:7.2 SatCals:6.2 Prot_g:6.2 Carb_g:7.2 Fib_g:6.2 
SolFib_g:5.2 Sugar_g:7.2 MonSac_g:6.2 Disacc_g:6.2 Ocarb_g:7.2 Fat_g:6.2 
SatFat_g:6.2 MonoFat_g:5.2 PolyFat_g:5.2  
TransFat_g:5.2 Chol_mg:7.2 Water_g:8.2 vitA_IU:8.2 vitA_RAE:7.2    Carotene_RE:7.2 
etinol_RE:7.2 
Bcarot_mcg:7.2 B1_mg:5.2 B2_mg:5.2 B3_mg:6.2 B3_NE_mg:6.2 B6_mg:5.2 
B12_mcg:5.2 Biot_mcg:5.2  
VitC_mg:6.2 VitD_IU:7.2 vitD_mcg:5.2 tocopherol_mg:6.2 Folate_mcg:7.2 
Fol_DFE_mcg:7.2 VitK_mcg:6.2 Panto_mg:6.2 Calcium_mg:7.2 Chrom_mcg:5.2
 Copp_mg:5.2 Fluor_mg:5.2 Iodine_mcg:6.2 Iron_mg:6.2  
Magn_mg:7.2 Mang_mg:5.2 Moly_mcg:5.2 Phos_mg:7.2 Pot_mg:8.2 Sel_mcg:6.2 
Sod_mg:8.2 Zinc_mg:5.2  
Omeg3_g:5.2 Omeg6_g:6.2 Wgt_g:8.2 Alc_g:7.2 Caff_mg:7.2 Chln_mg:7.2; 
RUN; 
 
Data wiser.Foodrecords_312_0; 
Set wiser.Foodrecords_312_0(rename=(Kcal=kcal_0 FatCals=Fatcals_0 SatCals=satcals_0 Prot_g= 
Prot_g_0 Carb_g=Carb_g_0 Fib_g=Fib_g_0 SolFib_g=SolFib_g_0 
Sugar_g=Sugar_g_0 MonSac_g=MonSac_g_0 Disacc_g=Disacc_g_0  
Ocarb_g=Ocarb_g_0 Fat_g=Fat_g_0 SatFat_g=SatFat_g_0  
MonoFat_g=MonoFat_g_0 PolyFat_g=PolyFat_g_0 TransFat_g=TransFat_g_0 Chol_mg=Chol_mg_0 
Water_g=Water_g_0 B1_mg=B1_mg_0 B2_mg=B2_mg_0 
B3_mg=B3_mg_0B3_NE_mg=B3_NE_mg_0 B6_mg=B6_mg_0 B12_mcg=B12_mcg_0 
Biot_mcg=Biot_mcg_0 VitC_mg=VitC_mg_0  
vitD_IU=vitD_IU_0 vitD_mcg=vitD_mcg_0 tocopherol_mg=tocopherol_mg_0 
Folate_mcg=Folate_mcg_0 Fol_DFE_mcg=Fol_DFE_mcg_0 VitK_mcg=VitK_mcg_0 Panto_mg 
=Panto_mg_0 Calcium_mg=Calcium_mg_0 Chrom_mcg=Chrom_mcg_0 Copp_mg=Copp_mg_0 
Fluor_mg=Fluor_mg_0  
Iodine_mcg=Iodine_mcg_0 Iron_mg=Iron_mg_0 Magn_mg=Magn_mg_0 Mang_mg=Mang_mg_0 
Moly_mcg=Moly_mcg_0 Phos_mg=Phos_mg_0  
Pot_mg=Pot_mg_0 Sel_mcg=Sel_mcg_0 Sod_mg=Sod_mg_0 Zinc_mg=Zinc_mg_0 
Omeg3_g=Omeg3_g_0 Omeg6_g=Omeg6_g_0 Wgt_g=Wgt_g_0 Alc_g=Alc_g_0 Caff_mg=Caff_mg_0 
Chln_mg=Chln_mg_0)); 
RUN; 
 
Data WISER.Foodrecords_312_1; 
INFILE 'D:\Users\Alma\Desktop\School\Sex Hormones\ 
Datasets\319\Foodrecords_312_1.csv'  
firstobs=2 DLM =","  
DSD missover LRECL=386; 
 
INPUT ID:$4. timepoint :$1. Kcal:7.2 FatCals:7.2 
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  SatCals:6.2 Prot_g:6.2 Carb_g:7.2 Fib_g:6.2 SolFib_g:5.2 Sugar_g:7.2 MonSac_g:6.2 
Disacc_g:6.2Ocarb_g:7.2 Fat_g:6.2 SatFat_g:6.2 MonoFat_g:5.2 PolyFat_g:5.2
 TransFat_g:5.2 Chol_mg:7.2 Water_g:8.2 vitA_IU:8.2 vitA_RAE:7.2 Carotene_RE:7.2 
etinol_RE:7.2 
Bcarot_mcg:7.2 B1_mg:5.2 B2_mg:5.2 B3_mg:6.2 B3_NE_mg:6.2 B6_mg:5.2 B12_mcg:5.2 
Biot_mcg:5.2  
VitC_mg:6.2 VitD_IU:7.2 vitD_mcg:5.2 tocopherol_mg:6.2 Folate_mcg:7.2 Fol_DFE_mcg:7.2 
VitK_mcg:6.2 Panto_mg:6.2 Calcium_mg:7.2 Chrom_mcg:5.2 Copp_mg:5.2
 Fluor_mg:5.2 Iodine_mcg:6.2 Iron_mg:6.2  
Magn_mg:7.2 Mang_mg:5.2 Moly_mcg:5.2 Phos_mg:7.2 Pot_mg:8.2 Sel_mcg:6.2 Sod_mg:8.2 
Zinc_mg:5.2  
Omeg3_g:5.2 Omeg6_g:6.2 Wgt_g:8.2 Alc_g:7.2 Caff_mg:7.2 Chln_mg:7.2; 
RUN; 
 
Data wiser.Foodrecords_312_1; 
Set wiser.Foodrecords_312_1(rename=(Kcal=kcal_1 FatCals=Fatcals_1  
SatCals=satcals_1 Prot_g= Prot_g_1 Carb_g=Carb_g_1 Fib_g=Fib_g_1 SolFib_g=SolFib_g_1 
Sugar_g=Sugar_g_1 MonSac_g=MonSac_g_1 Disacc_g=Disacc_g_1 Ocarb_g=Ocarb_g_1
 Fat_g=Fat_g_1 SatFat_g=SatFat_g_1  
MonoFat_g=MonoFat_g_1 PolyFat_g=PolyFat_g_1 TransFat_g=TransFat_g_1 
Chol_mg=Chol_mg_1 Water_g=Water_g_1 B1_mg=B1_mg_1  
B2_mg=B2_mg_1 B3_mg=B3_mg_1 B3_NE_mg=B3_NE_mg_1 B6_mg=B6_mg_1 
B12_mcg=B12_mcg_1 Biot_mcg=Biot_mcg_1 VitC_mg=VitC_mg_1  
vitD_IU=vitD_IU_1 vitD_mcg=vitD_mcg_1 tocopherol_mg=tocopherol_mg_1 
Folate_mcg=Folate_mcg_1 Fol_DFE_mcg=Fol_DFE_mcg_1 
VitK_mcg=VitK_mcg_1 Panto_mg =Panto_mg_1 Calcium_mg=Calcium_mg_1 
Chrom_mcg=Chrom_mcg_1 Copp_mg=Copp_mg_1 Fluor_mg=Fluor_mg_1  
Iodine_mcg=Iodine_mcg_1 Iron_mg=Iron_mg_1 Magn_mg=Magn_mg_1 
Mang_mg=Mang_mg_1 Moly_mcg=Moly_mcg_1 Phos_mg=Phos_mg_1  
Pot_mg=Pot_mg_1 Sel_mcg=Sel_mcg_1 Sod_mg=Sod_mg_1 Zinc_mg=Zinc_mg_1 
Omeg3_g=Omeg3_g_1 Omeg6_g=Omeg6_g_1 Wgt_g=Wgt_g_1  
Alc_g=Alc_g_1 Caff_mg=Caff_mg_1 Chln_mg=Chln_mg_1)); 
run; 
 
Data wiser.Foodrecords_312; 
Merge wiser.Foodrecords_312_0 wiser.Foodrecords_312_1; 
by ID; 
drop timepoint; 
run; 
 
Data wiser.Foodrecords_312; 
set wiser.Foodrecords_312; 
D_kcal= kcal_1 - kcal_0; 
PD_kcal = 100.0*D_kcal/kcal_0; 
run; 
 
options ls=100 nodate pageno=1 NOFMTERR;   
options mprint; 
 
* wiser01.sas      26 Feb 2010  ; 
 
* analysis data sets: 
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wiser.exercise_compliance  (n = 188) from  exercise logs 
 
wiser.adherence (exercise adherence, merged back into strata in wiser00)  
 
self-reported physical activity: 
 NOTE: There were 402 observations read from the data set WORK.SRPA_0. (baseline) 
 NOTE: There were 319 observations read from the data set WORK.SRPA_1. (final) 
 NOTE: There were 128 observations read from the data set WORK.SRPA_2. (final+ 6 months) 
 NOTE: The data set WISER.SRPA has 403 observations and 10 variables; 
 
  *******************************************************************; 
  *  macro to read job and leisure datasets, match leisure to activity code, and calculate METS per week; 
  *******************************************************************; 
 
  %macro activity (job=,leisure=,out=,ext=); 
  proc sort data = &leisure; * mult obs per id; 
  by activity_code; 
  proc sort data = wiser.paicomptable; 
  by activity_code; 
  proc sort data=&job ; 
  by id; 
 
  Occupational categories:  
  if category = 0  then job_mets = 0 
  if category = 1  then job_mets = 2 
  if category = 1.5 then job_mets = 3 
  if category = 2  then job_mets = 4 
  if category = 2.5 then job_mets = 5 
  if category = 3  then job_mets = 6; 
 
  proc contents data= &leisure; 
  proc contents data= wiser.paicomptable; 
  proc contents data= &job; 
 
  data leisure1; 
  merge &leisure wiser.paicomptable; 
  by activity_code; 
  if id=. then delete; 
  if (activity_name="treading water") then mets=6; 
  sum_months=sum(jan,feb,mar,apr,may,jun,jul,aug,sep,oct,nov,dec); 
leisure_mets = mets*(sum_months * Avg___times * Avg___min)/(60.0 * 52.0); 
keep id activity_code leisure_mets; 
 
data job1; 
set &job ; 
if id NE . ; 
if (__hrs_day < __hrs_sitting) then do; 
      if (id=1068) then __hrs_sitting = __hrs_sitting/__Days_week; 
   else delete; 
   end; 
job_act_hrs = __hrs_day - __hrs_sitting + ( Walk_bike_min/60.0); 
job_mets = 2.0*category* __Months * __Days_week * job_act_hrs /52.0; 
keep id job_name job_mets; 
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 proc sort data=leisure1; by id; 
 proc sort data=job1; by id; 
 proc print data=leisure1 (obs=20); 
 proc print data=job1 (obs=20); 
 
 data mets0; 
 set leisure1 job1; 
 proc sort data=mets0; 
 by id; 
 
 data &out; 
 set mets0; 
 by id; 
 if (first.id=1) then do;  
      
total_mets_week&ext=0; leisure_mets_week&ext=0; job_mets_week&ext=0;  
     end; 
retain total_mets_week&ext leisure_mets_week&ext job_mets_week&ext; 
leisure_mets_week&ext = sum(leisure_mets, leisure_mets_week&ext); 
job_mets_week&ext = sum(job_mets, job_mets_week&ext); 
total_mets_week&ext = sum(leisure_mets,job_mets, total_mets_week&ext); 
   if (last.id=1) then output; 
   keep id total_mets_week&ext leisure_mets_week&ext job_mets_week&ext; 
   FORMAT ID$4.; 
 
 proc print data=&out(obs=20); 
 %mend activity; 
  *******************************************************************; 
  *******************************************************************; 
 
 %activity(job=wiser.paiocctable_pre, leisure=wiser.paiacctable_pre,out=srpa_0,ext=_0); 
 %activity(job=wiser.PAIOcctable_POST, leisure=wiser.PAIAcctable_POST,out=srpa_1,ext=_1); 
/* %activity(job=wiser.PAIOcctble_6mo_post, leisure=wiser.PAIActtbl_6mo_post,out=srpa_2,ext=_2); */ 
 
 data wiser.srpa; 
   merge srpa_0 srpa_1 /*srpa_2*/; 
   by id; 
 
  proc export data=wiser.srpa 
   outfile="D:\Users\Alma\Desktop\School\Sex Hormones\Datasets\Original datasets\SRPA.xls" 
   dbms=excel replace; 
 
 run; quit; 
 
 /* 
 data check1; 
   set leisure; 
   if  srmets < 0; 
 proc print; 
 data check2; 
   set job; 
   if  srmets < 0; 
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 proc print; 
 
 proc print data=wiser.srpa; 
  where  mets_week > 100.0; 
 proc print data=leisure; 
   where (id=1841 or id=2316); 
 proc print data=job (obs=20); 
   where (id=1841 or id=2316); 
*/ 
 
 Data wiser.SRPA; 
 Merge WISER.SRPA; 
 BY id; 
 D_SRPA= total_mets_week_1 - total_mets_week_0; 
 if (total_mets_week_0 >0) then D_percent_srpa = 100.0*D_srpa/total_mets_week_0; 
 else D_percent_srpa= .;  
 run; 
 
 
Data WISER.SRPA_319; 
INFILE 'D:\Users\Alma\Desktop\School\Sex Hormones\ 
Datasets\319\SRPA_319.csv'  
firstobs=2 DLM ="," DSD missover; 
 
INPUT   ID           :$4. 
        Total_mets_week_0  :5.2 
     Leisure_mets_week_0 :5.2 
     Job_mets_week_0  :5.2 
     Total_mets_week_1  :5.2 
     Leisure_mets_week_1 :5.2 
     Job_mets_week_1  :5.2 
  ; 
 
FORMAT   ID           :$4. 
        Total_mets_week_0  :5.2 
     Leisure_mets_week_0 :5.2 
     Job_mets_week_0  :5.2 
     Total_mets_week_1  :5.2 
     Leisure_mets_week_1 :5.2 
     Job_mets_week_1  :5.2 
  ; 
  run; 
 
Data wiser.SRPA_319; 
Set WISER.SRPA_319; 
D_SRPA= total_mets_week_1 - total_mets_week_0; 
if (total_mets_week_0 >0) then D_percent_srpa = 100.0*D_srpa/total_mets_week_0; 
else D_percent_srpa= .;  
 
 FORMAT  D_SRPA     :6.2 
         D_percent_srpa :7.2; 
run; 
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PROC PRINT; 
RUN; 
 
/*Purpose of this code: Create fitness variables*/ 
 
Data WISER.Fitness_319; 
INFILE 'D:\Users\Alma\Desktop\School\Sex Hormones\ 
Datasets\319\Fitness_319.csv'  
firstobs=2 DLM ="," DSD missover; 
 
INPUT ID :$4. Group :$1. MET_BL :5.2 MET_FU :5.2; 
 
FORMAT  ID          $4. 
        Group       $1. 
   MET_BL      5.2 
   MET_FU      5.2 
   ; 
RUN; 
 
DATA WISER.Fitness_319 (rename=(MET_BL=Mets_0 MET_FU= Mets_1)); 
Set WISER.Fitness_319; 
run; 
 
DATA WISER.Fitness_319; 
Set WISER.Fitness_319;  
D_Mets= Mets_1-Mets_0; 
PD_Mets= 100.0*D_Mets/Mets_0; 
 
Format D_Mets 5.2 
      PD_Mets 5.2; 
RUN; 
 
Data b; 
Set WISER.Demographics_319; 
keep id; 
run; 
 
Data a1; 
Merge WISER.exercise_adherence (in=in_a) b(in=in_b); 
by id; 
from_a = in_a; 
from_b = in_b; 
run; 
 
Data a2; 
Set a1; 
if (from_a NE from_b); 
run; 
proc print data=a2; 
run; 
 
Data a3; 
set a1; 
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if from_a =1 and from_b =1; 
run; 
proc print data=a3; 
run; 
 
Data a4; 
set a3; 
keep id Exercise_complier; 
run;  
 
Data a5; 
Set wiser.bodyweights_319; 
keep id weight_complier; 
run; 
proc print; 
run; 
Data a6; 
Merge a3 a5; 
drop from_a from_b; 
run; 
 
Data wiser.compliance; 
Set a6; 
complier= (weight_complier=1 and exercise_complier=1); 
run; 
 
proc print data=wiser.compliance; 
run; 
 
/*PURPOSE OF THIS CODE: properly format WISER.Hormones_319.csv 
 Units for E2, BE2, FE2,FT = pg/ml 
       for TT, BT, and P=ng/ml 
       for SHBG = nmol/L*/ 
 
Data WISER.Hormones; 
INFILE 'D:\Users\Alma\Desktop\School\Sex Hormones\ 
Datasets\319\Hormones_319.csv'  
firstobs=2 DLM ="," DSD missover; 
 
INPUT  ID       :$4. 
       Group    :$1. 
       E2_0     :7.3 
       E2_1     :7.3 
   BE2_0    :7.3 
       BE2_1    :7.3 
   FE2_0    :6.3 
       FE2_1    :6.3 
   E1SO4_0  :6.3 
       E1SO4_1  :6.3 
   TT_0     :6.3       
   TT_1     :6.3 
   BT_0     :6.3 
       BT_1     :6.3 
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   FT_0     :6.3 
       FT_1     :6.3 
   SHBG_0   :7.3 
       SHBG_1   :7.3 
   P_0      :6.3 
       P_1      :6.3   
    ; 
 
FORMAT ID        $4. 
       Group     $1.  
       E2_0    7.3 
       E2_1     7.3 
   BE2_0    7.3 
       BE2_1    7.3 
   FE2_0    6.3 
       FE2_1    6.3 
   E1SO4_0  6.3 
       E1SO4_1  6.3 
   TT_0     6.3 
       TT_1     6.3 
   BT_0     6.3 
       BT_1     6.3 
   FT_0     6.3 
       FT_1     6.3 
   SHBG_0   7.3 
       SHBG_1   7.3 
   P_0      6.3 
       P_1      6.3 
; 
 
if (ID=1045) then P_1= .; /*CV6 blood drawn on day 8 instead of 8 days after ovulation*/ 
drop group; 
run; 
 
Data wiser.change_hormones_319; 
Set WISER.hormones; 
 
Format 
       D_E2       7.2 
       D_BE2      6.2 
       D_FE2      6.2 
       D_E1SO4    6.2 
       D_TT       6.2 
       D_BT       6.2 
       D_FT      6.2 
       D_SHBG    6.2 
       D_P       6.2 
   PD_E2     6.2 
       PD_BE2    7.2 
       PD_FE2    7.2 
       PD_E1SO4  7.2 
       PD_TT     7.2 
       PD_BT     7.2 
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       PD_FT     7.2 
       PD_SHBG   7.2 
       PD_P      7.2; 
 
array a[9] E2_0 BE2_0 FE2_0 E1SO4_0 TT_0 BT_0 FT_0 SHBG_0 P_0; 
array b[9] E2_1 BE2_1 FE2_1 E1SO4_1 TT_1 BT_1 FT_1 SHBG_1 P_1; 
array c[9] D_E2 D_BE2 D_FE2 D_E1SO4 D_TT D_BT D_FT D_SHBG D_P; 
array d[9] PD_E2 PD_BE2 PD_FE2 PD_E1SO4 PD_TT PD_BT PD_FT PD_SHBG PD_P; 
 
do j=1 to 9; 
 c[j]= b[j]-a[j]; 
 d[j]= 100.0*c[j]/a[j]; 
 end;  
Drop j; 
RUN; 
 
Proc Means Data=wiser.change_hormones_319  
nmiss max min mean stddev; 
var E2_0 BE2_0 FE2_0 E1SO4_0 TT_0 BT_0 FT_0 SHBG_0 P_0; 
run; 
 
Proc Univariate plot Data=wiser.change_hormones_319; 
var E2_0 BE2_0 FE2_0 E1SO4_0 TT_0 BT_0 FT_0 SHBG_0 P_0; 
run; 
 
Proc Means Data=wiser.change_hormones_319  
nmiss max min mean median stddev; 
var D_E2 D_BE2 D_FE2 D_E1SO4 D_TT D_BT D_FT D_SHBG D_P; 
run;  
 
Proc Univariate plot DATA= WISER.change_hormones_319; 
var D_E2 D_BE2 D_FE2 D_E1SO4 D_TT D_BT D_FT D_SHBG D_P; 
run;  
 
/*All hormones are right-skewed (max/min >10) so need to log transform*/ 
 
Data wiser.log_hormones_319; 
Set wiser.hormones; 
log_E2_0     = log(E2_0) ; 
log_E2_1     = log(E2_1) ;      
log_BE2_0    = log(BE2_0) ; 
log_BE2_1    = log(BE2_1) ; 
log_FE2_0    = log(FE2_0) ; 
log_FE2_1    = log(FE2_1) ; 
log_E1SO4_0  = log(E1SO4_0); 
log_E1SO4_1  = log(E1SO4_1); 
log_TT_0     = log(TT_0) ; 
log_TT_1     = log(TT_1) ;     
log_BT_0     = log(BT_0) ; 
log_BT_1     = log(BT_1) ; 
log_FT_0     = log(FT_0) ; 
log_FT_1     = log(FT_1) ; 
log_SHBG_0   = log(SHBG_0) ; 
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log_SHBG_1   = log(SHBG_1) ; 
log_P_0      = log(P_0) ; 
log_P_1      = log(P_1) ; 
 
Format 
log_E2_0     7.2 
log_E2_1     7.2      
log_BE2_0    7.2 
log_BE2_1    7.2 
log_FE2_0    7.2 
log_FE2_1    7.2 
log_E1SO4_0  7.2 
log_E1SO4_1  7.2 
log_TT_0     7.2 
log_TT_1     7.2     
log_BT_0     7.2 
log_BT_1     7.2 
log_FT_0     7.2 
log_FT_1     7.2 
log_SHBG_0   7.2 
log_SHBG_1   7.2 
log_P_0      7.2 
log_P_1      7.2 
; 
 
keep ID log_E2_0 log_BE2_0 log_FE2_0 log_E1SO4_0 log_TT_0 log_BT_0 log_FT_0 log_SHBG_0 
log_P_0 log_E2_1 log_BE2_1 log_FE2_1 log_E1SO4_1 log_TT_1 log_BT_1 log_FT_1 log_SHBG_1 
log_P_1 ; 
run; 
 
Data WISER.Hormones_319; 
Merge wiser.log_hormones_319 wiser.change_hormones_319; 
drop E2_0 BE2_0 FE2_0 E1SO4_0 TT_0 BT_0 FT_0 SHBG_0 P_0 E2_1 BE2_1 FE2_1 E1SO4_1 
TT_1 BT_1 FT_1 SHBG_1 P_1 ; 
run; 
 
/********************************************************** 
IDs 1960, 1996, 2021, 2030, 2062, and 2638 didn't do follow-up weight so use CV5 wt instead 
ID 2663 didn't do CV6, CV5 or CV4 so use CV1 wt instead 
********************************************************/ 
 
Data ht; 
Set WISER.demographics_319; 
keep id ht_cv1; 
run; 
 
Data wiser.bodyweights_319;; 
INFILE 'D:\Users\Alma\Desktop\School\Sex Hormones\ 
Datasets\319\Bodyweights_319.csv'  
firstobs=2 DLM ="," DSD missover; 
 
INPUT ID :$4. WeightCV1 :5.1  WeightCV4 :5.1  
 WeightCV5 :5.1 WeightCV6 :5.1 ; 
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FORMAT    ID            $4. 
          WeightCV1   5.1 
      WeightCV4      5.1    
      WeightCV5     5.1   
      WeightCV6    5.1    
   ; 
RUN; 
Data wiser.bodyweights_319; 
merge ht wiser.bodyweights_319  
(Rename=(WeightCV1= weight_0 WeightCV4= weight_2months WeightCV5= weight_3months 
WeightCV6= weight_1)); 
D_weight= weight_1 - weight_0; 
PD_weight=100.0*D_weight/weight_0; 
weight_complier = (-4.0 LE PD_weight LE 4.0); 
BMI_0= (Weight_0)/((Ht_CV1/100.0)**2);  
BMI_1= (Weight_1)/((Ht_CV1/100.0)**2); 
D_BMI= BMI_1 - BMI_0; 
PD_BMI = 100.0*D_BMI/BMI_0; 
 
Format  BMI_0  4.1 
        BMI_1  4.1 
     D_BMI   5.2 
     PD_BMI  5.2; 
run; 
 
PROC Freq data=WISER.Bodyweights_319; 
tables weight_complier; 
run; 
 
options ls=100 nodate pageno=1 NOFMTERR;   
options mprint; 
 
* wiser01.sas      26 Feb 2010  ; 
 
* analysis data sets: 
 
       wiser.exercise_compliance  (n = 188) from  exercise logs 
 
       wiser.adherence (exercise adherence, merged back into strata in wiser00)  
 
    self-reported physical activity: 
 NOTE: There were 402 observations read from the data set WORK.SRPA_0. (baseline) 
 NOTE: There were 319 observations read from the data set WORK.SRPA_1. (final) 
 NOTE: There were 128 observations read from the data set WORK.SRPA_2. (final+ 6 months) 
 NOTE: The data set WISER.SRPA has 403 observations and 10 variables; 
 
data a; 
    set wiser.exercise_logs;   
  if (id NE .); 
  if (week NE .); 
  if (0 <stage_of_exercise LE 4); 
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  proc sort data = a; 
    by id stage_of_exercise week day; 
 
 
  data wiser.exercise_compliance; 
    set a;   
    by id stage_of_exercise week day; 
  if (id = 1504 and week > 12) then  stage_of_exercise=4; * missing; 
  if (id = 1641 and (5 LE week LE 9))   then  stage_of_exercise=2; * missing; 
  if (id = 1641 and (10 LE week LE 12)) then  stage_of_exercise=3; * missing; 
  if (id = 1641 and (13 LE week LE 14)) then  stage_of_exercise=4; * missing; 
  if (id = 1768 and (11 LE week LE 12)) then  stage_of_exercise=3; * missing; 
  if (id = 1768 and (13 LE week LE 15)) then  stage_of_exercise=4; * missing; 
  if (id = 1874 and (0 < week LE 5))    then  stage_of_exercise=1; * missing; 
  if (id = 1985 and (17 LE week LE 18)) then  stage_of_exercise=4; * missing; 
  if (id = 2120 and (10 LE week LE 12)) then  stage_of_exercise=3; * missing; 
  if (id = 2120 and (13 LE week LE 17)) then  stage_of_exercise=4; * missing; 
  if (id = 2128 and THRlow=.) then delete; * missing; 
  if (id = 2128 and ( week = 6)) then  stage_of_exercise=2; * missing; 
  if (id = 2156 and (0 LE week LE 3)) then  stage_of_exercise=1; * missing; 
  if (id = 2156 and (4 LE week LE 8)) then  stage_of_exercise=2; * missing; 
  if (id = 2156 and (9 LE week LE 10)) then  stage_of_exercise=3; * missing; 
  if (id = 2156 and (11 LE week LE 15)) then  stage_of_exercise=4; * missing; 
  if (id = 2218 and ( week = 4)) then  stage_of_exercise=1; * missing; 
  if (id = 2218 and (5 LE week LE 6)) then  stage_of_exercise=2; * missing; 
  if (id = 2510) then delete;  * missing target HR, stage of exercise; 
  if (id = 2555 and ( week = 12)) then  stage_of_exercise=3; * missing; 
  if (id = 2559 and ( week = 16)) then  stage_of_exercise=4; * missing; 
  if (id = 2563 and ( week = 1)) then  stage_of_exercise=1; * missing; 
  if (id = 2564 and ( week = 10)) then  stage_of_exercise=3; * missing; 
  if (id = 2564 and ( week = 13)) then  stage_of_exercise=4; * missing; 
  if (id = 2579 and (6 LE week LE 8))   then  stage_of_exercise=2; * missing; 
  if (id = 2579 and (9 LE week LE 12))  then  stage_of_exercise=3; * missing; 
  if (id = 2579 and (13 LE week LE 15)) then  stage_of_exercise=4; * missing; 
  if (id = 2656 and (9 LE week LE 11)) then  stage_of_exercise=3; * missing; 
  if (id = 2679 and (6 LE week LE 7)) then  stage_of_exercise=2; * missing; 
  if (id = 2689 and (5 LE week LE 6)) then  stage_of_exercise=2; * missing; 
  if (id = 2689 and (9 LE week LE 10)) then  stage_of_exercise=3; * missing; 
  if (id = 2691 and ( week = 8)) then  stage_of_exercise=2; * missing; 
  if (id = 2691 and ( week = 9)) then  stage_of_exercise=3; * missing; 
  
  array obs[4] obs1 - obs4; * minutes exercised at each exercise  stage; 
  array exp[4] exp1 - exp4; * assigned days of exercise at each exercise stage; 
  array c[4] compl1-compl4; * percent minutes exercised/minutes assigned 
                               compliance at each exercise stage; 
  retain obs1 - obs4 exp1 - exp4 compl1-compl4 total_obs total_exp total_compl; 
  if (first.id=1) then do j = 1 to 4; obs[j] = 0; exp[j]=0; c[j]=0;  
        total_obs=0; total_exp=0; total_compl=0;   
        end; 
  total_obs = SUM(ExM, total_obs); 
  obs[stage_of_exercise] = SUM(ExM, obs[stage_of_exercise]); 
  if (last.week = 1) then do; 
    exp[stage_of_exercise] = SUM(exp[stage_of_exercise], Work_out_days_per_week); 
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    total_exp = SUM(total_exp, Work_out_days_per_week); 
 end; 
  if (last.id=1) then do; 
    total_weeks_exercise = week; 
    final_stage_exercise = stage_of_exercise; 
    do j = 1 to 4; 
   if (exp[j]>0) then  c[j] = 100.0*obs[j]/(30.0*exp[j]);  
     * percent minutes exercised/prescribed; 
   else c[j]= . ;    
   end; 
   if (total_exp > 0) then total_compl=100.0* total_obs/(30.0*total_exp); 
   else total_compl=. ; 
 output; 
 end; 
  keep id compl1-compl4 obs1 - obs4 exp1 - exp4 total_weeks_exercise final_stage_exercise 
       total_obs total_exp total_compl; 
 
  proc sort  data=wiser.exercise_compliance; 
   by id; 
 
  proc print data=wiser.exercise_compliance(obs=20); 
 
  data wiser.adherence; 
    merge  wiser.exercise_compliance wiser.srpa wiser.strata; 
 by id; 
 exercise_complier = 0; 
 if (trt="exercise" and final_stage_exercise=4) then  exercise_complier = 1; 
    D_srpa = total_mets_week_1 - total_mets_week_0; 
    if (trt="control" and D_srpa < 5.0) then  exercise_complier = 1; 
 keep id exercise_complier; 
 
  run; quit; 
 
/* Other problems in exercise logs: 
  2326 - missing 
  2367 - no logs 
  2508 - no logs 
  2510 - missing stage of exercise 
 
 
  /* proc contents data=wiser.exercise_logs;   
 
 AHR           Num      8    average heart rate 
 CDM           Num      8    cool down minutes 
 Date          Num      8    workout date 
 Day           Num      8    workout day on a given week 
 ExM           Num      8    exercise minutes 
 ID            Num      8    ID 
 Stage_of_exercise        Num      8    Stage of exercise 
 THRhigh                  Num      8    higher target heart rate in the range 
 THRlow                   Num      8    lower target heart rate in the range 
 WUM                      Num      8    warm-up minutes 
 Week                     Num      8    week of exercise, ranges from 1 to 20 
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 Work_out_days_per_week   Num      8    expected workout days per week 
 */ 
 
/*DATE:07/13/10 
PURPOSE OF THIS CODE IS TO CALCULATE CHANGE IN MC BETWEEN CV7 AND CV2 
CODE CATEGORIES: 
A=4 MC between CV2 and CV7 
B=3 MC between CV2 and CV7 
C=5 MC between CV2 and CV7 
D=6 MC between CV2 and CV7 
E=2 MC between CV2 and CV7 
F=Unknown 
  
P3-P1 =1  E 
P4-P1= 23  B 
P5-P1= 261 A 
P5-P1 =1  B 
P5-P1=1      C 
P6-P1= 19  C 
P6-P1=4      A 
P7-P1=3      D 
P7-P1=1      C 
*/ 
 
Data WISER.MC1; 
INFILE 'D:\Users\Alma\Desktop\School\Menstrual logs\ 
MClogs_data1.csv'  
firstobs=2 DLM ="," DSD missover; 
 
INPUT  ID                    :$4. 
       CODE                :$1. 
       CODE_EXPLANATION      :$56. 
   CYCLES                :$6. 
    ; 
 
FORMAT ID         $4. 
       CODE       $1. 
   CODE_EXPLANATION $56. 
    CYCLES     $6. 
    ; 
RUN; 
 
Data WISER.MC2; 
INFILE 'D:\Users\Alma\Desktop\School\Menstrual logs\ 
MClogs_data.csv'  
firstobs=2 DLM ="," DSD missover; 
 
INPUT  ID         :$4. 
       Start_P0   :MMDDYY10. 
       LH_P0      :MMDDYY10. 
   Start_P1   :MMDDYY10. 
       LH_P1      :MMDDYY10. 
       Start_P2   :MMDDYY10. 
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       LH_P2      :MMDDYY10. 
       Start_P3   :MMDDYY10. 
       LH_P3      :MMDDYY10. 
       Start_P4   :MMDDYY10. 
       LH_P4      :MMDDYY10. 
       Start_P5   :MMDDYY10. 
       LH_P5      :MMDDYY10. 
       Start_P6   :MMDDYY10. 
       LH_P6      :MMDDYY10. 
       Start_P7   :MMDDYY10. 
       LH_P7      :MMDDYY10. 
       Start_P8   :MMDDYY10. 
       LH_P8      :MMDDYY10.  
    ; 
 
FORMAT ID       $4. 
       Start_P0 MMDDYY10. 
       LH_P0    MMDDYY10. 
   Start_P1 MMDDYY10. 
       LH_P1    MMDDYY10. 
       Start_P2 MMDDYY10. 
       LH_P2    MMDDYY10. 
       Start_P3 MMDDYY10. 
       LH_P3    MMDDYY10. 
       Start_P4 MMDDYY10. 
       LH_P4    MMDDYY10. 
       Start_P5 MMDDYY10. 
       LH_P5    MMDDYY10. 
       Start_P6 MMDDYY10. 
       LH_P6    MMDDYY10. 
       Start_P7 MMDDYY10. 
       LH_P7    MMDDYY10. 
       Start_P8 MMDDYY10. 
       LH_P8    MMDDYY10.  
    ; 
run; 
 
Data WISER.MC2; /*Calculates MC length*/ 
set WISER.MC2; 
MClength_P0= Start_P1- Start_P0; 
MClength_P1= Start_P2- Start_P1; 
MClength_P2= Start_P3- Start_P2; 
MClength_P3= Start_P4- Start_P3; 
MClength_P4= Start_P5- Start_P4; 
MClength_P5= Start_P6- Start_P5; 
MClength_P6= Start_P7- Start_P6; 
MClength_P7= Start_P8- Start_P7; 
run; 
 
Proc Sort Data= WISER.MC1; 
BY ID; 
proc freq data=wiser.mc1; 
table code; 
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run; 
Proc Sort Data =WISER.MC2; 
BY ID; 
quit; 
 
DATA WISER.MergedMC; /*Calculates change in MC length according to the above note*/ 
Merge WISER.MC1 WISER.MC2; 
BY ID; 
run; 
 
DATA a; 
Set WISER.MergedMC; 
Where CODE = 'A'; 
MClength_0 = MClength_P1; 
If Cycles = 'P5-P1' then MClength_1 = MClength_P5; 
else If Cycles = 'P6-P1' then MClength_1 = MClength_P6; 
D_MC = MClength_1 - MClength_0; 
RUN; 
proc print data=a; 
var id MClength_P1 MClength_0 MClength_P5 MClength_P6 CYCLES MCLength_1 D_MC; 
run; 
  
 
DATA b; 
Set WISER.MergedMC; 
Where CODE = 'B'; 
MClength_0 = MClength_P1; 
If Cycles = 'P4-P1' then MClength_1 = MClength_P4; 
Else if cycles = 'P5-P1' then MClength_1 = MClength_P5; 
D_MC = MClength_1 - MClength_0; 
RUN;  
proc print data=b; 
var id MClength_P1 MClength_0 MClength_P4 MClength_P5 CYCLES MCLength_1 D_MC; 
run; 
 
DATA C; 
Set WISER.MergedMC; 
Where CODE = 'C'; 
MClength_0 = MClength_P1; 
If Cycles = 'P6-P1' then MClength_1 = MClength_P6; 
If Cycles = 'P7-P1' then MClength_1 = MClength_P7; 
Else if cycles = 'P5-P1' then MClength_1 = MClength_P5; 
D_MC = MClength_1 - MClength_0; 
RUN; 
proc print data=c; 
var id MClength_P1 MClength_0 MClength_P5 MClength_P6 MClength_P7 CYCLES MCLength_1 
D_MC; 
run; 
 
DATA DD; 
Set WISER.MergedMC; 
Where CODE = 'D'; 
MClength_0 = MClength_P1; 
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If Cycles = 'P7-P1' then MClength_1 = MClength_P7; 
D_MC = MClength_1 - MClength_0; 
RUN;  
proc print data =DD; 
var id MClength_P1 MClength_0 MClength_P7 CYCLES MCLength_1 D_MC; 
run; 
 
DATA E; 
Set WISER.MergedMC; 
Where CODE = 'E'; 
MClength_0 = MClength_P1; 
If Cycles = 'P3-P1' then MClength_1 = MClength_P3; 
D_MC = MClength_1 - MClength_0; 
RUN; 
 
proc print data=E; 
var id MClength_P1 MClength_0 MClength_P3 CYCLES MCLength_1 D_MC; 
run; 
 
Data H; 
Set WISER.Demographics_319; 
keep ID trt; 
run; 
 
Data WISER.ChangeMC; 
Merge A B C DD E H; 
By id; 
keep ID TRT MCLength_P1 MCLength_P2 MCLength_P3 MCLength_P4 MCLength_P5 
MCLength_P6 MCLength_P7  
CODE Cycles MCLength_0 MCLength_1 D_MC; 
run; 
proc print DATA=WISER.ChangeMC; 
run; 
pROC SORT DATA=WISER.CHANGEMC; 
BY TRT; 
RUN; 
 
PROC MEANS DATA =WISER.CHANGEMC; 
VAR MClength_0 MClength_1 D_MC; 
BY trt; 
RUN; 
 
Proc GLM Data=wiser.changemc; 
class trt; 
model MClength_0 MCLength_1 D_MC = trt ; 
lsmeans trt /stderr pdiff; 
run; 
 
Data WISER.Merged_Data_319; 
Merge WISER.Demographics_319 WISER.Bodycomp_319 Wiser.Bodyweights_319 
WISER.Menarche_310 WISER.Familyhistory_251  
      WISER.FoodRecords_312 WISER.Fitness_319 wiser.log_hormones_319 WISER.SRPA_319; 
run; 
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Data WISER.Baseline_Associations; 
Set WISER.Merged_Data_319 ; 
KEEP  trt  
   age Ht_CV1 Weight_0 BMI_0 
      Percent_bodyfat_0 lean_mass_0   
      Menarche_age  
Kcal_0 Fat_g_0 Carb_g_0 Prot_g_0 Fib_g_0 Caff_mg_0 Alc_g_0 
   Mets_0 total_mets_week_0 
log_E2_0 log_BE2_0 log_FE2_0 log_E1SO4_0 log_TT_0 log_BT_0 log_FT_0 
log_SHBG_0 log_P_0; 
 run; 
  
/*Associations between hormones*/ 
Proc Corr Data=WISER.Baseline_Associations; 
var log_E2_0 log_BE2_0 log_FE2_0 log_E1SO4_0 LOG_TT_0 LOG_BT_0 LOG_FT_0 LOG_SHBG_0 
LOG_P_0; 
run; 
 
/*Associations with baseline demographic factors*/ 
Proc Corr Data= WISER.Baseline_Associations;  
var log_E2_0 log_BE2_0 log_FE2_0 log_E1SO4_0 LOG_TT_0 LOG_BT_0 LOG_FT_0 LOG_SHBG_0 
LOG_P_0; 
with age Ht_CV1 weight_0 Percent_bodyfat_0 BMI_0 Menarche_age Kcal_0  Caff_mg_0 Alc_g_0 
   Mets_0 total_mets_week_0; 
  run; quit; 
 
/*Table 1. Baseline characteristics of Randomized participants (n=319)*/ 
 
Data WISER.Table1; 
Merge WISER.Demographics_319 WISER.Bodycomp_319 WISER.Menarche_310 
WISER.Familyhistory_251 WISER.FoodRecords_312 
WISER.Fitness_319 wiser.srpa_319; 
By id; 
 
KEEP ID trt age age_strata Ht_CV1 Wt_CV1 fat_mass_0 Percent_bodyfat_0 lean_mass_0  
     BMI BMI_strata BMI_class BMI_class4 BMI_over25 
     race Hispanic Education_cat MarStat status 
     Menarche_age BC_history BCuse Parity 
Kcal_0 FatCals_0 Fib_g_0 Caff_mg_0 Alc_g_0 total_mets_week_0 Mets_0 
; 
run; 
 
Proc Ttest Data=wiser.Table1 ci=none; 
class trt; 
var  age Ht_CV1 Wt_CV1 BMI fat_mass_0 Percent_bodyfat_0 lean_mass_0 Menarche_age Kcal_0 
Alc_g_0 Mets_0 total_mets_week_0; 
run; 
 
Proc Freq Data=wiser.Table1; 
tables  trt*(BMI_strata BMI_class4 race Hispanic Education_cat MarStat status BC_history 
BCuse Parity BMI_class age_strata) 
/ nocol chisq; 
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run; 
 
/*Table 3. Changes in body weight, anthropometry, fitness, PA*/ 
Data WISER.Merged_Data_319; 
Merge WISER.Demographics_319 WISER.Bodycomp_319 Wiser.Bodyweights_319 
WISER.Menarche_310 WISER.Familyhistory_251  
WISER.FoodRecords_312 WISER.Fitness_319 wiser.log_hormones_319 WISER.SRPA_319; 
by id; 
run; 
 
/* trt* age_strata, trt*bmi_strata and trt*age_strata*bmi_strata interactions were not significant 
so will be removed from model*/ 
 
Proc GLM Data=wiser.merged_data_319; 
class trt bmi_strata age_strata; 
model Mets_0 Mets_1 D_mets = trt bmi_strata | age_strata; 
lsmeans trt /stderr pdiff; 
run; 
 
Proc GLM Data=wiser.merged_data_319; 
class trt bmi_strata age_strata; 
*model weight_0 weight_1 D_weight = trt | bmi_strata | age_strata; 
model weight_0 weight_1 D_weight= trt bmi_strata | age_strata; 
lsmeans trt /stderr pdiff; 
run; 
 
Proc GLM Data=wiser.merged_data_319; 
class trt bmi_strata age_strata; 
*model bmi_0 bmi_1 D_bmi PD_bmi = trt | bmi_strata | age_strata; 
model bmi_0 bmi_1 D_bmi = trt bmi_strata | age_strata; 
lsmeans trt /stderr pdiff; 
run; 
 
Proc GLM Data=wiser.merged_data_319; 
class trt bmi_strata age_strata; 
*model fat_mass_0 fat_mass_1 D_fat_mass PD_fat_mass= trt|bmi_strata|age_strata; 
model fat_mass_0 fat_mass_1 D_fat_mass = trt bmi_strata | age_strata; 
lsmeans trt /stderr pdiff; 
run; 
 
Proc GLM Data=wiser.merged_data_319; 
class trt bmi_strata age_strata; 
*model percent_bodyfat_0 percent_bodyfat_1 D_percent_bodyfat PD_percent_bodyfat= 
trt|bmi_strata|age_strata; 
model percent_bodyfat_0 percent_bodyfat_1 D_percent_bodyfat= trt bmi_strata | age_strata; 
lsmeans trt /stderr pdiff; 
run; 
 
Proc GLM Data=wiser.merged_data_319; 
class trt bmi_strata age_strata; 
*model percent_leanmass_0 percent_leanmass_1 D_percent_leanmass PD_percent_leanmass= 
trt|bmi_strata|age_strata; 
model lean_mass_0 lean_mass_1 D_lean_mass = trt bmi_strata | age_strata; 
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lsmeans trt /stderr pdiff; 
run; 
 
Proc GLM Data=wiser.merged_data_319; 
class trt bmi_strata age_strata; 
model kcal_0 kcal_1 D_kcal = trt bmi_strata | age_strata; 
lsmeans trt /stderr pdiff; 
run; 
 
Proc GLM Data=wiser.merged_data_319; 
class trt bmi_strata age_strata; 
model total_mets_week_0 total_mets_week_1 D_srpa = trt bmi_strata | age_strata; 
lsmeans trt /stderr pdiff; 
run; 
 
Proc means data=wiser.merged_data_319 n min max mean; 
var D_percent_bodyfat; 
run; 
 
proc univariate data=wiser.merged_data_319; 
var D_percent_bodyfat; 
run; 
 
data x; 
set wiser.merged_data_319; 
if D_percent_bodyfat GE -2.0 and D_percent_bodyfat LE 2.0; 
run; 
proc print data=x; 
var D_percent_bodyfat; 
run;  
 
/********************************************************** 
All follicular completers n=319 (N=323 FOR BASELINE) 
Purpose of this code: to check if there are differences at baseline between groups in hormone levels 
Units for E2, BE2, FE2,FT = pg/ml 
      for TT, BT, and P=ng/ml 
      for SHBG = nmol/L 
**********************************************************/ 
Data a; 
set wiser.merged_data_319; 
keep ID trt age_strata bmi_strata bmi_class; 
run; 
 
Data b; 
set wiser.change_hormones_319; 
keep ID D_E2 D_BE2 D_FE2 D_E1SO4 D_TT D_BT D_FT D_SHBG D_P; 
RUN; 
 
Data Wiser.Table3; 
Merge a b wiser.log_hormones_319; 
BY ID; 
run; 
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/*Baseline comparisons strata adjusted: full model* 
E1SO4_0 : trt p=0.0017 BMI_strata p =0.0107 trt*BMI_strata p=0.0156 and trt*age_strata*bmi_strata 
p=0.005 
TT_0: age_strata p=0.002 bmi_strata p=0.001 
BT_0: trt p=0.0412 age_strata AND bmi_strata p< 0.001 
FT_0: age_strata p=0.003 bmi_strata p< 0.001 
SHBG_0: age_strata p=0.001 bmi_strata p<0.001 */ 
Proc GLM data=wiser.Table3;  
class  trt age_strata bmi_strata; 
model log_E2_0 log_BE2_0 log_FE2_0 log_E1SO4_0  
log_TT_0 log_BT_0 log_FT_0 log_SHBG_0 log_P_0= 
age_strata |bmi_strata | trt/ SS3; 
run; quit; 
 
/*Baseline comparisons strata adjusted: age and bmi interaction only log_E1SO4 includes trt*bmi 
interaction*/ 
 
Proc GLM data=wiser.Table3;  
class  trt age_strata bmi_strata; 
model log_E2_0 log_BE2_0 log_FE2_0 log_E1SO4_0 log_TT_0 log_BT_0 log_FT_0  
log_SHBG_0 log_P_0= trt age_strata |bmi_strata/ SS3; 
lsmeans trt / stderr pdiff CL; 
ODS output LSMeanCL=logCI_0; 
run;quit; 
 
Data b; 
Set logCI_0; 
geometric_mean= exp(lsmean); 
left_CI= exp(LowerCL); 
right_CI= exp(UpperCL); 
drop lsmean LowerCL UpperCL; 
run; 
proc print data=b; 
run; 
 
/*Follow up comparisons strata adjusted: age and bmi interactions 
E1SO4_1 : trt p=0.0026 trt*BMI_strata p=0.035  
TT_1*: age_strata p=0.0026, bmi_strata p=0.0007  
BT_1,FT_1*: age_strata p=0.0002, bmi_strata p<00001, trt p=0.0255 
SHBG_1*: age_strata p=0.0016, bmi_strata p<0.0001, age*bmi p=0.026 
P_1 age_strata p=0.0183*/  
 
Proc GLM data=wiser.Table3;  
class  trt age_strata bmi_strata; 
model log_E2_1 log_BE2_1 log_FE2_1 log_E1SO4_1  
      log_TT_1 log_BT_1 log_FT_1 log_SHBG_1 log_P_1= age_strata |bmi_strata | trt/ SS3; 
run; quit; 
 
/*Baseline comparisons strata adjusted: age and bmi interaction only log_E1SO4 includes trt*bmi 
interaction*/ 
 
Proc GLM data=wiser.Table3;  
class  trt age_strata bmi_strata; 
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model log_E2_1 log_BE2_1 log_FE2_1 log_E1SO4_1 log_TT_1       log_BT_1 log_FT_1 log_SHBG_1 
log_P_1= trt age_strata |bmi_strata/ SS3; 
lsmeans trt / stderr pdiff CL; 
ODS output LSMeanCL=logCI_2; 
run;quit; 
 
Data e; 
Set logCI_2; 
geometric_mean= exp(lsmean); 
left_CI= exp(LowerCL); 
right_CI= exp(UpperCL); 
drop lsmean LowerCL UpperCL; 
run; 
proc print data= e; 
run; 
 
Proc GLM data=wiser.Table3;  
class  trt age_strata bmi_strata; 
model log_E1SO4_1= trt age_strata |bmi_strata trt*bmi_strata/ SS3; 
lsmeans trt / stderr pdiff CL; 
ODS output LSMeanCL=logCI_3; 
run;quit; 
 
Data f; 
Set logCI_3; 
geometric_mean= exp(lsmean); 
left_CI= exp(LowerCL); 
right_CI= exp(UpperCL); 
drop lsmean LowerCL UpperCL; 
run; 
proc print data=f; 
run; 
 
/*Changes from baseline comparisons: age and bmi strata interaction*/ 
 
Proc GLM data=wiser.Table3; 
class trt age_strata bmi_strata; 
model D_E2 D_BE2 D_FE2 D_E1SO4 D_TT D_BT D_FT D_SHBG D_P = BMI_strata | age_strata trt/ 
SS3; 
lsmeans trt/ stderr pdiff; 
ods select LSMeans Diff; 
run; quit; 
 
Proc GLM data=Wiser.Table3; /*Reduced model*/ 
class trt age_strata bmi_strata; 
model D_E1SO4 = BMI_strata | age_strata trt log_E1SO4_0/ SS3; 
lsmeans trt/ stderr pdiff; 
ods select LSMeans Diff; 
run; quit; 
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APPENDIX C-2 
 
SAS CODE: URINARY ESTROGEN METABOLITES 
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/*PURPOSE: to import creatinine csv datasheet and format it*/ 
  
Data EM.Creatinine; 
INFILE 'D:\Users\Alma\Desktop\School\Estrogen Metabolites\ 
Data\Creatinine.csv'  
firstobs=2 DLM ="," DSD missover LRECL= 1000 ; 
 
INPUT ID      :$4. 
  Pre_Cr_mgperdL    :3. 
  Post_Cr_mgperdL   :3.  
  Pre_Cr_g     :4.2 
  Post_Cr_g     :4.2 
  Pre_Total_Vol    :5. 
  Post_Total_Vol    :5. 
  Pre_Total_Hrs    :5.2 
  Post_Total_Hrs    :5.2 
  ; 
 
FORMAT ID      $4. 
  Pre_Cr_mgperdL    3. 
  Post_Cr_mgperdL    3.  
  Pre_Cr_g     4.2 
  Post_Cr_g     4.2 
  Pre_Total_Vol    5. 
  Post_Total_Vol    5. 
  Pre_Total_Hrs    5.2 
  Post_Total_Hrs    5.2; 
RUN; 
 
  
/*PURPOSE: Import raw urine collection datasheet 
           Calculate total urine collection time and volume  
           Calculate total urine collection as ml of urine per day*/  
 
Data EM.Tot_UrineVol; 
INFILE 'D:\Users\Alma\Desktop\School\Estrogen Metabolites\ 
Data\Tot_UrineVol.csv' firstobs=2 DLM ="," DSD missover   
       LRECL= 1000 ; 
INPUT   ID          :$4. 
  SHrs1pre      :Datetime18. 
  EHrs1pre      :Datetime18. 
  Vol1pre   :5. 
  SHrs2pre      :Datetime18. 
  EHrs2pre      :Datetime18. 
  Vol2pre   :5. 
  SHrs3pre      :Datetime18. 
  EHrs3pre      :Datetime18. 
  Vol3pre   :5. 
  Comments_CV3  :$30. 
  SHrs1fu      :Datetime18. 
  EHrs1fu      :Datetime18. 
  Vol1fu   :5. 
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  SHrs2fu      :Datetime18. 
  EHrs2fu      :Datetime18. 
  Vol2fu   :5. 
  SHrs3fu      :Datetime18. 
  EHrs3fu      :Datetime18. 
  Vol3fu   :5. 
  ; 
/*Convert urine collection time from seconds to hours*/ 
Hrs1pre= (EHrs1pre -SHrs1pre)/3600; /*3600 = # seconds in an hr*/ 
Hrs2pre= (EHrs2pre -SHrs2pre)/3600; 
Hrs3pre= (EHrs3pre -SHrs3pre)/3600; 
Hrs1post= (EHrs1fu -SHrs1fu)/3600; 
Hrs2post= (EHrs2fu -SHrs2fu)/3600; 
Hrs3post= (EHrs3fu -SHrs3fu)/3600; 
 
/*Calculate total urine collection time by adding time of day 1, 2, and 3*/ 
Pre_Hrs= SUM(Hrs1pre,Hrs2pre,Hrs3pre);  
Post_Hrs= SUM(Hrs1post,Hrs2post,Hrs3post); 
 
/*Based on notes from CV3 and CV8 raw spreadsheets the # of collection hours had to be changed*/ 
If ID='1093' then Pre_Hrs = Hrs2pre + Hrs3pre; 
If ID='1517' then Pre_Hrs = Hrs2pre + Hrs3pre; 
If ID='2438' then Pre_Hrs = 72.0; 
If ID='2538' then Pre_Hrs = 72.0; 
 
/*Convert total urine collection time from hours to days*/ 
Pre_Days = Pre_Hrs/24.0; /*24 = # hours in a day*/ 
Post_Days = Post_Hrs/24.0; 
 
/*Calculate total urine collection volume by adding volumes of day 1, 2 and 3*/ 
Pre_Vol = SUM(Vol1pre, Vol2pre, Vol3pre); 
Post_Vol = SUM(Vol1fu, Vol2fu, Vol3fu); 
 
/*Calculate urine collection as ml per day*/ 
Pre_mLperday = Pre_Vol/Pre_Days; 
Post_mLperday = Post_Vol/Post_Days; 
 
FORMAT  ID          $4. 
  Hrs1pre   5.1  
  Hrs2pre   5.1  
  Hrs3pre   5.1 
  Vol1pre   5. 
  Vol2pre   5. 
  Vol3pre   5. 
  Hrs1post   5.1  
  Hrs2post   5.1  
  Hrs3post   5.1 
  Vol1fu   5. 
  Vol2fu   5. 
  Vol3fu   5. 
  Comments_CV3  $30. 
  Pre_Hrs   5.1 
  Post_Hrs   5.1 
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  Pre_Days   3.1 
  Post_Days   3.1 
  Pre_Vol   5.1 
  Post_Vol   5.1 
  Pre_mLperday  6.1 
  Post_mLperday  6.1 
    ; 
run; 
 
proc print ; 
run; 
 
/*PURPOSE: Import raw EM datasheet */ 
/*NOTE: Urine concentrations in EM_318.csv are in ng/ml urine and ND samples are read as missing 
ID 2622 finished CV7 but not CV8 and therefore excluded*/ 
 
 
Data EM.EM_ngpermL_original; 
INFILE 'D:\Users\Alma\Desktop\School\Estrogen Metabolites\ 
Data\EM_318.csv'  
firstobs=2 DLM ="," DSD missover; 
INPUT   ID         :$4. 
  E1_0    :8.3 
  E1_1    :8.3 
  E2_0    :8.3 
  E2_1    :8.3 
  E3_0    :8.3 
  E3_1    :8.3 
  _16_OH_E1_0 :8.3 
  _16_OH_E1_1 :8.3 
  OH_2_E1_0   :8.3 
  OH_2_E1_1   :8.3 
  OH_4_E1_0   :8.3 
  OH_4_E1_1   :8.3 
  OH_2_E2_0   :8.3 
  OH_2_E2_1   :8.3 
  OH_4_E2_0   :8.3 
  OH_4_E2_1   :8.3 
  MeO_2_E1_0  :8.3 
  MeO_2_E1_1  :8.3 
  MeO_4_E1_0  :8.3 
  MeO_4_E1_1  :8.3 
  MeO_2_E2_0  :8.3 
  MeO_2_E2_1  :8.3 
  MeO_4_E2_0  :8.3 
  MeO_4_E2_1  :8.3 
; 
 
FORMAT ID          $4. 
  E1_0    8.3 
  E1_1    8.3 
  E2_0    8.3 
  E2_1    8.3 
  231
  E3_0    8.3 
  E3_1    8.3 
  _16_OH_E1_0 8.3 
  _16_OH_E1_1 8.3 
  OH_2_E1_0   8.3 
  OH_2_E1_1   8.3 
  OH_4_E1_0   8.3 
  OH_4_E1_1   8.3 
  OH_2_E2_0   8.3 
  OH_2_E2_1   8.3 
  OH_4_E2_0   8.3 
  OH_4_E2_1   8.3 
  MeO_2_E1_0  8.3 
  MeO_2_E1_1  8.3 
  MeO_4_E1_0  8.3 
  MeO_4_E1_1  8.3 
  MeO_2_E2_0  8.3 
  MeO_2_E2_1  8.3 
  MeO_4_E2_0  8.3 
  MeO_4_E2_1  8.3; 
run; 
 
proc means n nmiss min max;  
/*There are missing values for all EM*/ 
run; 
 
/*PURPOSE: Per MK, WT, and WP, missing datapoints are to be assigned the lowest standard value 
(0.014ng/ml)*/ 
Data EM.EM_ngperml_LowSTD; 
Set EM.EM_ngperml_original; 
 
If E1_0 = . then E1_0=0.014; 
If E1_1 = . then E1_1=0.014; 
If E2_0 = . then E2_0=0.014; 
If E2_1 = . then E2_1=0.014; 
If E3_0 = . then E3_0=0.014; 
If E3_1 = . then E3_1=0.014; 
If _16_OH_E1_0 = . then _16_OH_E1_0=0.014; 
If _16_OH_E1_1 = . then _16_OH_E1_1=0.014; 
If OH_2_E1_0 = . then OH_2_E1_0=0.014; 
If OH_2_E1_1 = . then OH_2_E1_1=0.014; 
If OH_4_E1_0 = . then OH_4_E1_0=0.014; 
If OH_4_E1_1 = . then OH_4_E1_1=0.014; 
If OH_2_E2_0 = . then OH_2_E2_0=0.014; 
If OH_2_E2_1 = . then OH_2_E2_1=0.014; 
If OH_4_E2_0 = . then OH_4_E2_0=0.014; 
If OH_4_E2_1 = . then OH_4_E2_1=0.014; 
If MeO_2_E1_0 = . then MeO_2_E1_0 =0.014; 
If MeO_2_E1_1 = . then MeO_2_E1_1 =0.014; 
If MeO_4_E1_0 = . then MeO_4_E1_0 =0.014; 
If MeO_4_E1_1 = . then MeO_4_E1_1 =0.014; 
If MeO_2_E2_0 = . then MeO_2_E2_0 =0.014; 
If MeO_2_E2_1 = . then MeO_2_E2_1 =0.014; 
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If MeO_4_E2_0 = . then MeO_4_E2_0 =0.014; 
If MeO_4_E2_1 = . then MeO_4_E2_1 =0.014; 
run; 
 
proc means; 
run; /*All previously missing values have now been re-assigned 0.014ng/ml values*/ 
 
proc univariate plot Data=EM.EM_ngperml_LowSTD; 
/*all EM are right-skewed so will need to take logs*/ 
run; 
proc print; 
run; 
 
/*PURPOSE: Convert ng EM/ml urine into ng EM/mg Cr */ 
  
Data EM.EM_ngpermgCr_LowSTD; 
Merge EM.EM_ngperml_LowSTD EM.Creatinine EM.Tot_UrineVol; 
Drop  Pre_Cr_g Post_Cr_g Pre_Total_Vol Post_Total_Vol Pre_Total_Hrs Post_Total_Hrs 
SHrs1pre EHrs1pre Vol1pre SHrs2pre EHrs2pre Vol2pre SHrs3pre EHrs3pre Vol3pre 
Comments_CV3 
SHrs1fu EHrs1fu Vol1fu SHrs2fu EHrs2fu Vol2fu SHrs3fu EHrs3fu Vol3fu  
Hrs1pre Hrs2pre Hrs3pre Pre_hrs Pre_days Hrs1post Hrs2post Hrs3post Post_hrs Post_days; 
 
/*((ng EM/mL urine)*(100mL/1dL))/(mg Cr/dL urine)*/ 
E1_0_ngpermgCr = (E1_0*100)/Pre_Cr_mgperdL; 
E1_1_ngpermgCr = (E1_1*100)/Post_Cr_mgperdL; 
E2_0_ngpermgCr = (E2_0*100)/Pre_Cr_mgperdL; 
E2_1_ngpermgCr = (E2_1*100)/Post_Cr_mgperdL; 
E3_0_ngpermgCr = (E3_0*100)/Pre_Cr_mgperdL; 
E3_1_ngpermgCr = (E3_1*100)/Post_Cr_mgperdL; 
_16_OH_E1_0_ngpermgCr= (_16_OH_E1_0*100)/Pre_Cr_mgperdL; 
_16_OH_E1_1_ngpermgCr= (_16_OH_E1_1*100)/Post_Cr_mgperdL; 
OH_2_E1_0_ngpermgCr = (OH_2_E1_0*100)/Pre_Cr_mgperdL; 
OH_2_E1_1_ngpermgCr = (OH_2_E1_1*100)/Post_Cr_mgperdL; 
OH_4_E1_0_ngpermgCr = (OH_4_E1_0*100)/Pre_Cr_mgperdL; 
OH_4_E1_1_ngpermgCr = (OH_4_E1_1*100)/Post_Cr_mgperdL; 
OH_2_E2_0_ngpermgCr = (OH_2_E2_0*100)/Pre_Cr_mgperdL; 
OH_2_E2_1_ngpermgCr = (OH_2_E2_1*100)/Post_Cr_mgperdL; 
OH_4_E2_0_ngpermgCr = (OH_4_E2_0*100)/Pre_Cr_mgperdL; 
OH_4_E2_1_ngpermgCr = (OH_4_E2_1*100)/Post_Cr_mgperdL; 
MeO_2_E1_0_ngpermgCr= (MeO_2_E1_0*100)/Pre_Cr_mgperdL; 
MeO_2_E1_1_ngpermgCr= (MeO_2_E1_1*100)/Post_Cr_mgperdL; 
MeO_4_E1_0_ngpermgCr= (MeO_4_E1_0*100)/Pre_Cr_mgperdL; 
MeO_4_E1_1_ngpermgCr= (MeO_4_E1_1*100)/Post_Cr_mgperdL; 
MeO_2_E2_0_ngpermgCr= (MeO_2_E2_0*100)/Pre_Cr_mgperdL; 
MeO_2_E2_1_ngpermgCr= (MeO_2_E2_1*100)/Post_Cr_mgperdL; 
MeO_4_E2_0_ngpermgCr= (MeO_4_E2_0*100)/Pre_Cr_mgperdL; 
MeO_4_E2_1_ngpermgCr= (MeO_4_E2_1*100)/Post_Cr_mgperdL; 
   
FORMAT  ID           $4. 
  E1_0_ngpermgCr    6.3 
  E1_1_ngpermgCr    6.3 
  E2_0_ngpermgCr    6.3 
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  E2_1_ngpermgCr    6.3 
  E3_0_ngpermgCr    6.3 
  E3_1_ngpermgCr    6.3 
  _16_OH_E1_0_ngpermgCr 6.3 
  _16_OH_E1_1_ngpermgCr 6.3 
  OH_2_E1_0_ngpermgCr   6.3 
  OH_2_E1_1_ngpermgCr   6.3 
  OH_4_E1_0_ngpermgCr   6.3 
  OH_4_E1_1_ngpermgCr   6.3 
  OH_2_E2_0_ngpermgCr   6.3 
  OH_2_E2_1_ngpermgCr   6.3 
  OH_4_E2_0_ngpermgCr   6.3 
  OH_4_E2_1_ngpermgCr   6.3  
  MeO_2_E1_0_ngpermgCr  6.3 
  MeO_2_E1_1_ngpermgCr  6.3 
  MeO_4_E1_0_ngpermgCr  6.3 
  MeO_4_E1_1_ngpermgCr  6.3 
  MeO_2_E2_0_ngpermgCr  6.3 
  MeO_2_E2_1_ngpermgCr  6.3 
  MeO_4_E2_0_ngpermgCr  6.3 
  MeO_4_E2_1_ngpermgCr  6.3;  
run; 
 
proc means n min; 
var  E1_0_ngpermgCr E1_1_ngpermgCr  
E2_0_ngpermgCr E2_1_ngpermgCr  
E3_0_ngpermgCr E3_1_ngpermgCr  
_16_OH_E1_0_ngpermgCr _16_OH_E1_1_ngpermgCr  
OH_2_E1_0_ngpermgCr OH_2_E1_1_ngpermgCr OH_2_E2_0_ngpermgCr 
OH_2_E2_1_ngpermgCr 
OH_4_E1_0_ngpermgCr OH_4_E1_1_ngpermgCr OH_4_E2_0_ngpermgCr 
OH_4_E2_1_ngpermgCr 
MeO_2_E1_0_ngpermgCr MeO_2_E1_1_ngpermgCr MeO_2_E2_0_ngpermgCr 
MeO_2_E2_1_ngpermgCr 
MeO_4_E1_0_ngpermgCr MeO_4_E1_1_ngpermgCr MeO_4_E2_0_ngpermgCr 
MeO_4_E2_1_ngpermgCr;  
run; 
 
/*PURPOSE: To convert ng EM/ml urine into nmol/day*/ 
Data EM.EM_nmolperday_LowSTD; 
Merge EM.EM_ngpermL_LowSTD EM.Tot_UrineVol; 
Keep ID Pre_mLperday Post_mLperday 
  E1_0 E1_1 E2_0 E2_1 E3_0 E3_1  
  _16_OH_E1_0 _16_OH_E1_1  
  OH_2_E1_0 OH_2_E1_1 OH_2_E2_0 OH_2_E2_1    
  OH_4_E1_0 OH_4_E1_1 OH_4_E2_0 OH_4_E2_1 
  MeO_2_E1_0 MeO_2_E1_1 MeO_2_E2_0 MeO_2_E2_1  
  MeO_4_E1_0 MeO_4_E1_1 MeO_4_E2_0 MeO_4_E2_1;  
 run; 
 
/*PURPOSE: Convert concentration from mg/day to nmol/day*/ 
Data EM.EM_nmolperday_LowSTD; 
Set EM.EM_nmolperday_LowSTD; 
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E1_0_nmolperday = (E1_0/270.37)*Pre_mLperday; 
E1_1_nmolperday = (E1_1/270.37)*Post_mLperday; 
E2_0_nmolperday = (E2_0/272.38)*Pre_mLperday; 
E2_1_nmolperday = (E2_1/272.38)*Post_mLperday; 
E3_0_nmolperday = (E3_0/288.38)*Pre_mLperday; 
E3_1_nmolperday = (E3_1/288.38)*Post_mLperday; 
_16_OH_E1_0_nmolperday= (_16_OH_E1_0/286.37)*Pre_mLperday; 
_16_OH_E1_1_nmolperday= (_16_OH_E1_1/286.37)*Post_mLperday; 
OH_2_E1_0_nmolperday = (OH_2_E1_0/286.37)*Pre_mLperday; 
OH_2_E1_1_nmolperday = (OH_2_E1_1/286.37)*Post_mLperday; 
OH_4_E1_0_nmolperday = (OH_4_E1_0/286.37)*Pre_mLperday; 
OH_4_E1_1_nmolperday = (OH_4_E1_1/286.37)*Post_mLperday; 
OH_2_E2_0_nmolperday = (OH_2_E2_0/288.37)*Pre_mLperday; 
OH_2_E2_1_nmolperday = (OH_2_E2_1/288.37)*Post_mLperday; 
OH_4_E2_0_nmolperday = (OH_4_E2_0/288.37)*Pre_mLperday; 
OH_4_E2_1_nmolperday = (OH_4_E2_1/288.37)*Post_mLperday; 
MeO_2_E1_0_nmolperday= (MeO_2_E1_0/300.39)*Post_mLperday; 
MeO_2_E1_1_nmolperday= (MeO_2_E1_1/300.39)*Pre_mLperday; 
MeO_4_E1_0_nmolperday= (MeO_4_E1_0/300.39)*Pre_mLperday; 
MeO_4_E1_1_nmolperday= (MeO_4_E1_1/300.39)*Post_mLperday; 
MeO_2_E2_0_nmolperday= (MeO_2_E2_0/302.41)*Pre_mLperday; 
MeO_2_E2_1_nmolperday= (MeO_2_E2_1/302.41)*Post_mLperday; 
MeO_4_E2_0_nmolperday= (MeO_4_E2_0/302.41)*Pre_mLperday; 
MeO_4_E2_1_nmolperday= (MeO_4_E2_1/302.41)*Post_mLperday;  
   
FORMAT  ID           $4. 
  E1_0_nmolperday    6.2 
  E1_1_nmolperday    6.2 
  E2_0_nmolperday    6.2 
  E2_1_nmolperday    6.2 
  E3_0_nmolperday    6.2 
  E3_1_nmolperday    6.2 
  _16_OH_E1_0_nmolperday 6.2 
  _16_OH_E1_1_nmolperday 6.2 
  OH_2_E1_0_nmolperday   6.2 
  OH_2_E1_1_nmolperday   6.2 
  OH_4_E1_0_nmolperday   6.2 
  OH_4_E1_1_nmolperday   6.2 
  OH_2_E2_0_nmolperday   6.2 
  OH_2_E2_1_nmolperday   6.2 
  OH_4_E2_0_nmolperday   6.2 
  OH_4_E2_1_nmolperday   6.2  
  MeO_2_E1_0_nmolperday  6.2 
  MeO_2_E1_1_nmolperday  6.2 
  MeO_4_E1_0_nmolperday  6.2 
  MeO_4_E1_1_nmolperday  6.2 
  MeO_2_E2_0_nmolperday  6.2 
  MeO_2_E2_1_nmolperday  6.2 
  MeO_4_E2_0_nmolperday  6.2 
  MeO_4_E2_1_nmolperday  6.2; 
 
DROP  Pre_mLperday Post_mLperday 
  235
   E1_0 E2_0 E3_0 _16_OH_E1_0 
   OH_2_E1_0 OH_4_E1_0 OH_2_E2_0 OH_4_E2_0  
     MeO_2_E1_0 MeO_4_E1_0 MeO_2_E2_0 MeO_4_E2_0  
   E1_1 E2_1 E3_1 _16_OH_E1_1 
   OH_2_E1_1 OH_4_E1_1 OH_2_E2_1 OH_4_E2_1  
      MeO_2_E1_1 MeO_4_E1_1 MeO_2_E2_1 MeO_4_E2_1; 
run; 
 
proc means; 
run; 
 
/*PURPOSE: Calculate EM ratios (ng EM/ml urine)*/ 
Data EM.Ratios_EM_ngperml_LowSTD; 
Set EM.EM_ngperml_LowSTD; 
 
R_2to16E1_0    = OH_2_E1_0/_16_OH_E1_0; 
R_2to16E1_1    = OH_2_E1_1/_16_OH_E1_1; 
R_2to4E1_0    = OH_2_E1_0/OH_4_E1_0; 
R_2to4E1_1    = OH_2_E1_1/OH_4_E1_1; 
Total_2OHE_0   = (OH_2_E1_0 + OH_2_E2_0); 
Total_2OHE_1   = (OH_2_E1_1 + OH_2_E2_1);  
Total_4OHE_0   = (OH_4_E1_0 + OH_4_E2_0); 
Total_4OHE_1   = (OH_4_E1_1 + OH_4_E2_1);  
Total_2MeOE_0   = (MeO_2_E1_0 + MeO_2_E2_0); 
Total_2MeOE_1   = (MeO_2_E1_1 + MeO_2_E2_1);  
Total_4MeOE_0   = (MeO_4_E1_0 + MeO_4_E2_0); 
Total_4MeOE_1   = (MeO_4_E1_1 + MeO_4_E2_1);  
R_total_2to4OHE_0  = (Total_2OHE_0/Total_4OHE_0); 
R_total_2to4OHE_1  = (Total_2OHE_1/Total_4OHE_1); 
R_total_2to4MeOE_0  = (Total_2MeOE_0/Total_4MeOE_0); 
R_total_2to4MeOE_1  = (Total_2MeOE_1/Total_4MeOE_1);  
 
FORMAT   
R_2to16E1_0    8.3 
R_2to16E1_1    8.3 
R_2to4E1_0    8.3 
R_2to4E1_1    8.3 
Total_2OHE_0   8.3 
Total_2OHE_1   8.3  
Total_4OHE_0   8.3 
Total_4OHE_1   8.3  
Total_2MeOE_0   8.3 
Total_2MeOE_1   8.3  
Total_4MeOE_0   8.3 
Total_4MeOE_1   8.3  
R_total_2to4OHE_0  8.3 
R_total_2to4OHE_1  8.3 
R_total_2to4MeOE_0  8.3 
R_total_2to4MeOE_1  8.3  
; 
RUN; 
 
proc means data=em.Ratios_EM_ngperml_LowSTD; 
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run; 
 
/*RESULT: All hormones are right-skewed (max/min >10) so need to log transform*/ 
Data EM.Log_EM_ngperml_LowSTD; 
Set EM.Ratios_EM_ngperml_LowSTD; 
 
log_E1_0           = log(E1_0) ; 
log_E1_1           = log(E1_1) ;   
log_E2_0           = log(E2_0) ; 
log_E2_1           = log(E2_1) ;   
log_E3_0           = log(E3_0) ; 
log_E3_1           = log(E3_1) ;  
log__16_OH_E1_0    = log(_16_OH_E1_0); 
log__16_OH_E1_1    = log(_16_OH_E1_1); 
log_OH_2_E1_0      = log(OH_2_E1_0); 
log_OH_2_E1_1      = log(OH_2_E1_1); 
log_OH_4_E1_0      = log(OH_4_E1_0); 
log_OH_4_E1_1      = log(OH_4_E1_1); 
log_OH_2_E2_0      = log(OH_2_E2_0); 
log_OH_2_E2_1      = log(OH_2_E2_1); 
log_OH_4_E2_0      = log(OH_4_E2_0); 
log_OH_4_E2_1      = log(OH_4_E2_1); 
log_MeO_2_E1_0     = log(MeO_2_E1_0); 
log_MeO_2_E1_1     = log(MeO_2_E1_1); 
log_MeO_4_E1_0     = log(MeO_4_E1_0); 
log_MeO_4_E1_1     = log(MeO_4_E1_1); 
log_MeO_2_E2_0     = log(MeO_2_E2_0); 
log_MeO_2_E2_1     = log(MeO_2_E2_1); 
log_MeO_4_E2_0     = log(MeO_4_E2_0); 
log_MeO_4_E2_1     = log(MeO_4_E2_1); 
log_R_2to16E1_0   = log(R_2to16E1_0); 
log_R_2to16E1_1   = log(R_2to16E1_1); 
log_R_2to4E1_0    = log(R_2to4E1_0); 
log_R_2to4E1_1    = log(R_2to4E1_1); 
log_R_total_2to4OHE_0  = log(R_total_2to4OHE_0); 
log_R_total_2to4OHE_1  = log(R_total_2to4OHE_1); 
log_R_total_2to4MeOE_0  = log(R_total_2to4MeOE_0); 
log_R_total_2to4MeOE_1  = log(R_total_2to4MeOE_1); 
log_Total_2OHE_0   = log(Total_2OHE_0); 
log_Total_2OHE_1   = log(Total_2OHE_1); 
log_Total_4OHE_0   = log(Total_4OHE_0); 
log_Total_4OHE_1   = log(Total_4OHE_1); 
log_Total_2MeOE_0   = log(Total_2MeOE_0); 
log_Total_2MeOE_1   = log(Total_2MeOE_1); 
log_Total_4MeOE_0   = log(Total_4MeOE_0); 
log_Total_4MeOE_1   = log(Total_4MeOE_1); 
 
Format 
log_E1_0          8.3 
log_E1_1          8.3   
log_E2_0          8.3 
log_E2_1          8.3   
log_E3_0          8.3 
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log_E3_1          8.3  
log__16_OH_E1_0    8.3 
log__16_OH_E1_1    8.3 
log_OH_2_E1_0     8.3 
log_OH_2_E1_1     8.3 
log_OH_4_E1_0     8.3 
log_OH_4_E1_1     8.3 
log_OH_2_E2_0     8.3 
log_OH_2_E2_1     8.3 
log_OH_4_E2_0     8.3 
log_OH_4_E2_1     8.3 
log_MeO_2_E1_0    8.3 
log_MeO_2_E1_1    8.3 
log_MeO_4_E1_0    8.3 
log_MeO_4_E1_1    8.3  
log_MeO_2_E2_0    8.3 
log_MeO_2_E2_1    8.3 
log_MeO_4_E2_0    8.3 
log_MeO_4_E2_1    8.3 
log_R_2to16E1_0    8.3 
log_R_2to16E1_1    8.3 
log_R_2to4E1_0    8.3 
log_R_2to4E1_1    8.3 
log_R_total_2to4OHE_0   8.3 
log_R_total_2to4OHE_1   8.3 
log_R_total_2to4MeOE_0   8.3 
log_R_total_2to4MeOE_1   8.3 
log_Total_2OHE_0    8.3 
log_Total_2OHE_1    8.3 
log_Total_4OHE_0    8.3 
log_Total_4OHE_1    8.3 
log_Total_2MeOE_0    8.3 
log_Total_2MeOE_1    8.3 
log_Total_4MeOE_0    8.3 
log_Total_4MeOE_1    8.3; 
run; 
proc means; 
run; 
 
/*PURPOSE: Calculate change in concentration*/ 
Data EM.D_EM_ngperml_LowSTD; 
Set EM.Log_EM_ngperml_LowSTD; 
 
array a[20] E1_0 E2_0 E3_0 _16_OH_E1_0 
    OH_2_E1_0 OH_4_E1_0 OH_2_E2_0 OH_4_E2_0  
            MeO_2_E1_0 MeO_4_E1_0 MeO_2_E2_0 MeO_4_E2_0  
R_2to16E1_0 R_2to4E1_0 R_total_2to4OHE_0  R_total_2to4MeOE_0 
    Total_2OHE_0 Total_4OHE_0  
  Total_2MeOE_0 Total_4MeOE_0; 
 
array b[20]  E1_1 E2_1 E3_1 _16_OH_E1_1 
     OH_2_E1_1 OH_4_E1_1 OH_2_E2_1 OH_4_E2_1  
             MeO_2_E1_1 MeO_4_E1_1 MeO_2_E2_1 MeO_4_E2_1  
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     R_2to16E1_1 R_2to4E1_1  
   R_total_2to4OHE_1 R_total_2to4MeOE_1 
     Total_2OHE_1 Total_4OHE_1  
   Total_2MeOE_1 Total_4MeOE_1; 
 
array c[20] D_E1 D_E2 D_E3 D__16_OH_E1 
    D_OH_2_E1 D_OH_4_E1 D_OH_2_E2 D_OH_4_E2  
            D_MeO_2_E1 D_MeO_4_E1 D_MeO_2_E2 D_MeO_4_E2  
D_R_2to16E1 D_R_2to4E1  
D_R_total_2to4OHE   D_R_total_2to4MeOE 
    D_Total_2OHE D_Total_4OHE  
  D_Total_2MeOE D_Total_4MeOE; 
 
 
do j=1 to 20; 
 c[j]= b[j]-a[j]; 
 end;  
Drop j; 
 
Format   D_E1     8.3 
  D_E2     8.3 
  D_E3    8.3 
  D_MeO_2_E1   8.3 
  D_MeO_4_E1   8.3 
  D_MeO_2_E2   8.3  
  D_MeO_4_E2   8.3 
  D__16_OH_E1  8.3 
  D_OH_2_E1    8.3 
  D_OH_4_E1    8.3 
  D_OH_2_E2    8.3 
  D_OH_4_E2    8.3 
  D_R_2to16E1   8.3 
  D_R_2to4E1   8.3 
  D_Total_2OHE  8.3  
  D_Total_4OHE  8.3  
  D_Total_2MeOE  8.3 
  D_Total_4MeOE  8.3  
  D_R_total_2to4OHE 8.3 
  D_R_total_2to4MeOE 8.3; 
RUN; 
 
proc means DATA=EM.D_EM_ngperml_LowSTD; 
RUN; 
 
/*PURPOSE: Check the distribution of data, if skewed then need to log transform*/ 
proc univariate plot data=EM.D_EM_ngperml_LowSTD; 
var D_E1 D_E2 D_E3 D__16_OH_E1 
    D_OH_2_E1 D_OH_4_E1 D_OH_2_E2 D_OH_4_E2  
    D_MeO_2_E1 D_MeO_4_E1 D_MeO_2_E2 D_MeO_4_E2  
D_R_2to16E1 D_R_2to4E1 D_R_total_2to4OHE        D_R_total_2to4MeOE D_Total_2OHE 
D_Total_4OHE D_Total_2MeOE D_Total_4MeOE; 
/*Distributions are normally distributed so no need to log transform changes from baseline*/ 
run; 
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/*PURPOSE: Merge all datasets into one*/ 
Data Merged_A_LowSTD; 
Merge EM.Ratios_EM_ngperml_LowSTD EM.D_EM_ngperml_LowSTD 
EM.LOG_EM_ngperml_LowSTD; 
RUN; 
 
/*Create a dataset with ID, trt, age_strata and bmi_strata to merge to EM.EM_318*/ 
Data Merged_B_LowSTD; 
Set WISER.Table1; 
keep id trt age_strata bmi_strata bmi_class bmi_over25; 
run; 
 
Data Merged_B_LowSTD; 
Set Merged_B_LowSTD; 
If ID= '2622' then DELETE; 
if ID= '2601' then DELETE; 
RUN; 
 
/*PURPOSE: Add to merged data set id, trt and age & bmi strata*/ 
Data EM.EM_Merged_ngperml_LowSTD; 
Merge Merged_B_LowSTD Merged_A_LowSTD; 
RUN; 
 
proc freq data=EM.EM_Merged_ngperml_LowSTD;; 
tables trt; 
run; 
 
/*PURPOSE: Calculate EM ratios (ng EM/mg Cr)*/ 
Data EM.Ratios_EM_ngpermgCr_LowSTD; 
Set EM.EM_ngpermgCr_LowSTD; 
 
R_2to16E1_0_ngpermgCr = OH_2_E1_0_ngpermgCr/_16_OH_E1_0_ngpermgCr; 
R_2to16E1_1_ngpermgCr    = 
OH_2_E1_1_ngpermgCr/_16_OH_E1_1_ngpermgCr; 
R_2to4E1_0_ngpermgCr    = OH_2_E1_0_ngpermgCr/OH_4_E1_0_ngpermgCr; 
R_2to4E1_1_ngpermgCr    = OH_2_E1_1_ngpermgCr/OH_4_E1_1_ngpermgCr; 
Total_2OHE_0_ngpermgCr   = (OH_2_E1_0_ngpermgCr + 
OH_2_E2_0_ngpermgCr); 
Total_2OHE_1_ngpermgCr   = (OH_2_E1_1_ngpermgCr + 
OH_2_E2_1_ngpermgCr);  
Total_4OHE_0_ngpermgCr   = (OH_4_E1_0_ngpermgCr + 
OH_4_E2_0_ngpermgCr); 
Total_4OHE_1_ngpermgCr   = (OH_4_E1_1_ngpermgCr + 
OH_4_E2_1_ngpermgCr);  
Total_2MeOE_0_ngpermgCr   = (MeO_2_E1_0_ngpermgCr + 
MeO_2_E2_0_ngpermgCr); 
Total_2MeOE_1_ngpermgCr   = (MeO_2_E1_1_ngpermgCr + 
MeO_2_E2_1_ngpermgCr);  
Total_4MeOE_0_ngpermgCr   = (MeO_4_E1_0_ngpermgCr + 
MeO_4_E2_0_ngpermgCr); 
  240
Total_4MeOE_1_ngpermgCr   = (MeO_4_E1_1_ngpermgCr + 
MeO_4_E2_1_ngpermgCr);  
R_tot_2to4OHE_0_ngpermgCr  = (Total_2OHE_0_ngpermgCr/Total_4OHE_0_ngpermgCr); 
R_tot_2to4OHE_1_ngpermgCr  = (Total_2OHE_1_ngpermgCr/Total_4OHE_1_ngpermgCr); 
R_tot_2to4MeOE_0_ngpermgCr = (Total_2MeOE_0_ngpermgCr/Total_4MeOE_0_ngpermgCr); 
R_tot_2to4MeOE_1_ngpermgCr = (Total_2MeOE_1_ngpermgCr/Total_4MeOE_1_ngpermgCr);  
 
FORMAT   
R_2to16E1_0_ngpermgCr    8.3 
R_2to16E1_1_ngpermgCr    8.3 
R_2to4E1_0_ngpermgCr    8.3 
R_2to4E1_1_ngpermgCr    8.3 
Total_2OHE_0_ngpermgCr   8.3 
Total_2OHE_1_ngpermgCr   8.3  
Total_4OHE_0_ngpermgCr   8.3 
Total_4OHE_1_ngpermgCr   8.3  
Total_2MeOE_0_ngpermgCr   8.3 
Total_2MeOE_1_ngpermgCr   8.3  
Total_4MeOE_0_ngpermgCr   8.3 
Total_4MeOE_1_ngpermgCr   8.3  
R_tot_2to4OHE_0_ngpermgCr  8.3 
R_tot_2to4OHE_1_ngpermgCr  8.3 
R_tot_2to4MeOE_0_ngpermgCr  8.3 
R_tot_2to4MeOE_1_ngpermgCr  8.3  
; 
 
DROP E1_0 E1_1 E2_0 E2_1  
E3_0 E3_1 _16_OH_E1_0 _16_OH_E1_1  
OH_2_E1_0 OH_2_E1_1 OH_2_E2_0 OH_2_E2_1 
OH_4_E1_0 OH_4_E1_1 OH_4_E2_0 OH_4_E2_1 
MeO_2_E1_0 MeO_2_E1_1 MeO_2_E2_0 MeO_2_E2_1 
MeO_4_E1_0 MeO_4_E1_1 MeO_4_E2_0 MeO_4_E2_1; 
RUN; 
proc means data=em.Ratios_EM_ngpermgCr_LowSTD; 
run; 
 
/*RESULT: All hormones are right-skewed (max/min >10) so need to log transform*/ 
Data EM.Log_EM_ngpermgCr_LowSTD; 
Set EM.Ratios_EM_ngpermgCr_LowSTD; 
 
log_E1_0_ngpermgCr           = log(E1_0_ngpermgCr) ; 
log_E1_1_ngpermgCr           = log(E1_1_ngpermgCr) ;   
log_E2_0_ngpermgCr           = log(E2_0_ngpermgCr) ; 
log_E2_1_ngpermgCr           = log(E2_1_ngpermgCr) ;   
log_E3_0_ngpermgCr           = log(E3_0_ngpermgCr) ; 
log_E3_1_ngpermgCr           = log(E3_1_ngpermgCr) ;  
log__16_OH_E1_0_ngpermgCr    = log(_16_OH_E1_0_ngpermgCr); 
log__16_OH_E1_1_ngpermgCr    = log(_16_OH_E1_1_ngpermgCr); 
log_OH_2_E1_0_ngpermgCr      = log(OH_2_E1_0_ngpermgCr); 
log_OH_2_E1_1_ngpermgCr      = log(OH_2_E1_1_ngpermgCr); 
log_OH_4_E1_0_ngpermgCr      = log(OH_4_E1_0_ngpermgCr); 
log_OH_4_E1_1_ngpermgCr      = log(OH_4_E1_1_ngpermgCr); 
log_OH_2_E2_0_ngpermgCr      = log(OH_2_E2_0_ngpermgCr); 
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log_OH_2_E2_1_ngpermgCr      = log(OH_2_E2_1_ngpermgCr); 
log_OH_4_E2_0_ngpermgCr      = log(OH_4_E2_0_ngpermgCr); 
log_OH_4_E2_1_ngpermgCr      = log(OH_4_E2_1_ngpermgCr); 
log_MeO_2_E1_0_ngpermgCr     = log(MeO_2_E1_0_ngpermgCr); 
log_MeO_2_E1_1_ngpermgCr     = log(MeO_2_E1_1_ngpermgCr); 
log_MeO_4_E1_0_ngpermgCr     = log(MeO_4_E1_0_ngpermgCr); 
log_MeO_4_E1_1_ngpermgCr     = log(MeO_4_E1_1_ngpermgCr); 
log_MeO_2_E2_0_ngpermgCr     = log(MeO_2_E2_0_ngpermgCr); 
log_MeO_2_E2_1_ngpermgCr     = log(MeO_2_E2_1_ngpermgCr); 
log_MeO_4_E2_0_ngpermgCr     = log(MeO_4_E2_0_ngpermgCr); 
log_MeO_4_E2_1_ngpermgCr     = log(MeO_4_E2_1_ngpermgCr); 
log_R_2to16E1_0_ngpermgCr   = log(R_2to16E1_0_ngpermgCr); 
log_R_2to16E1_1_ngpermgCr   = log(R_2to16E1_1_ngpermgCr); 
log_R_2to4E1_0_ngpermgCr    = log(R_2to4E1_0_ngpermgCr); 
log_R_2to4E1_1_ngpermgCr    = log(R_2to4E1_1_ngpermgCr); 
log_R_tot_2to4OHE_0_ngpermgCr  = log(R_tot_2to4OHE_0_ngpermgCr); 
log_R_tot_2to4OHE_1_ngpermgCr  = log(R_tot_2to4OHE_1_ngpermgCr); 
log_R_tot_2to4MeOE_0_ngpermgCr  = log(R_tot_2to4MeOE_0_ngpermgCr); 
log_R_tot_2to4MeOE_1_ngpermgCr  = log(R_tot_2to4MeOE_1_ngpermgCr); 
log_Total_2OHE_0_ngpermgCr   = log(Total_2OHE_0_ngpermgCr); 
log_Total_2OHE_1_ngpermgCr   = log(Total_2OHE_1_ngpermgCr); 
log_Total_4OHE_0_ngpermgCr   = log(Total_4OHE_0_ngpermgCr); 
log_Total_4OHE_1_ngpermgCr   = log(Total_4OHE_1_ngpermgCr); 
log_Total_2MeOE_0_ngpermgCr   = log(Total_2MeOE_0_ngpermgCr); 
log_Total_2MeOE_1_ngpermgCr   = log(Total_2MeOE_1_ngpermgCr); 
log_Total_4MeOE_0_ngpermgCr   = log(Total_4MeOE_0_ngpermgCr); 
log_Total_4MeOE_1_ngpermgCr   = log(Total_4MeOE_1_ngpermgCr); 
 
Format 
log_E1_0_ngpermgCr          8.3 
log_E1_1_ngpermgCr          8.3   
log_E2_0_ngpermgCr          8.3 
log_E2_1_ngpermgCr          8.3   
log_E3_0_ngpermgCr          8.3 
log_E3_1_ngpermgCr          8.3  
log__16_OH_E1_0_ngpermgCr    8.3 
log__16_OH_E1_1_ngpermgCr    8.3 
log_OH_2_E1_0_ngpermgCr     8.3 
log_OH_2_E1_1_ngpermgCr     8.3 
log_OH_4_E1_0_ngpermgCr     8.3 
log_OH_4_E1_1_ngpermgCr     8.3 
log_OH_2_E2_0_ngpermgCr     8.3 
log_OH_2_E2_1_ngpermgCr     8.3 
log_OH_4_E2_0_ngpermgCr     8.3 
log_OH_4_E2_1_ngpermgCr     8.3 
log_MeO_2_E1_0_ngpermgCr    8.3 
log_MeO_2_E1_1_ngpermgCr    8.3 
log_MeO_4_E1_0_ngpermgCr    8.3 
log_MeO_4_E1_1_ngpermgCr    8.3  
log_MeO_2_E2_0_ngpermgCr    8.3 
log_MeO_2_E2_1_ngpermgCr    8.3 
log_MeO_4_E2_0_ngpermgCr    8.3 
log_MeO_4_E2_1_ngpermgCr    8.3 
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log_R_2to16E1_0_ngpermgCr    8.3 
log_R_2to16E1_1_ngpermgCr    8.3 
log_R_2to4E1_0_ngpermgCr    8.3 
log_R_2to4E1_1_ngpermgCr    8.3 
log_R_tot_2to4OHE_0_ngpermgCr   8.3 
log_R_tot_2to4OHE_1_ngpermgCr   8.3 
log_R_tot_2to4MeOE_0_ngpermgCr   8.3 
log_R_tot_2to4MeOE_1_ngpermgCr   8.3 
log_Total_2OHE_0_ngpermgCr    8.3 
log_Total_2OHE_1_ngpermgCr    8.3 
log_Total_4OHE_0_ngpermgCr    8.3 
log_Total_4OHE_1_ngpermgCr    8.3 
log_Total_2MeOE_0_ngpermgCr    8.3 
log_Total_2MeOE_1_ngpermgCr    8.3 
log_Total_4MeOE_0_ngpermgCr    8.3 
log_Total_4MeOE_1_ngpermgCr    8.3; 
run; 
proc means; 
run; 
 
/*PURPOSE: Calculate change in concentration*/ 
Data EM.D_EM_ngpermgCr_LowSTD; 
Set EM.Log_EM_ngpermgCr_LowSTD; 
 
array a[20]  E1_0_ngpermgCr E2_0_ngpermgCr E3_0_ngpermgCr   
_16_OH_E1_0_ngpermgCr 
OH_2_E1_0_ngpermgCr OH_4_E1_0_ngpermgCr OH_2_E2_0_ngpermgCr 
OH_4_E2_0_ngpermgCr  
MeO_2_E1_0_ngpermgCr MeO_4_E1_0_ngpermgCr 
MeO_2_E2_0_ngpermgCr MeO_4_E2_0_ngpermgCr  
R_2to16E1_0_ngpermgCr R_2to4E1_0_ngpermgCr 
R_tot_2to4OHE_0_ngpermgCr R_tot_2to4MeOE_0_ngpermgCr 
Total_2OHE_0_ngpermgCr Total_4OHE_0_ngpermgCr 
Total_2MeOE_0_ngpermgCr Total_4MeOE_0_ngpermgCr; 
 
array b[20]   E1_1_ngpermgCr E2_1_ngpermgCr E3_1_ngpermgCr 
_16_OH_E1_1_ngpermgCr 
OH_2_E1_1_ngpermgCr OH_4_E1_1_ngpermgCr OH_2_E2_1_ngpermgCr 
OH_4_E2_1_ngpermgCr  
MeO_2_E1_1_ngpermgCr MeO_4_E1_1_ngpermgCr 
MeO_2_E2_1_ngpermgCr MeO_4_E2_1_ngpermgCr  
R_2to16E1_1_ngpermgCr R_2to4E1_1_ngpermgCr 
R_tot_2to4OHE_1_ngpermgCr R_tot_2to4MeOE_1_ngpermgCr 
Total_2OHE_1_ngpermgCr Total_4OHE_1_ngpermgCr 
Total_2MeOE_1_ngpermgCr Total_4MeOE_1_ngpermgCr; 
 
array c[20]  D_E1_ngpermgCr D_E2_ngpermgCr D_E3_ngpermgCr 
D__16_OH_E1_ngpermgCr 
D_OH_2_E1_ngpermgCr D_OH_4_E1_ngpermgCr D_OH_2_E2_ngpermgCr 
D_OH_4_E2_ngpermgCr  
D_MeO_2_E1_ngpermgCr D_MeO_4_E1_ngpermgCr 
D_MeO_2_E2_ngpermgCr D_MeO_4_E2_ngpermgCr  
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D_R_2to16E1_ngpermgCr D_R_2to4E1_ngpermgCr 
D_R_tot_2to4OHE_ngpermgCr D_R_tot_2to4MeOE_ngpermgCr 
D_Total_2OHE_ngpermgCr D_Total_4OHE_ngpermgCr 
D_Total_2MeOE_ngpermgCr D_Total_4MeOE_ngpermgCr; 
 
 
do j=1 to 20; 
 c[j]= b[j]-a[j]; 
 end;  
Drop j; 
 
 
Format  D_E1_ngpermgCr      8.3 
  D_E2_ngpermgCr     8.3 
  D_E3_ngpermgCr    8.3 
  D_MeO_2_E1_ngpermgCr   8.3 
  D_MeO_4_E1_ngpermgCr   8.3 
  D_MeO_2_E2_ngpermgCr   8.3  
  D_MeO_4_E2_ngpermgCr   8.3 
  D__16_OH_E1_ngpermgCr  8.3 
  D_OH_2_E1_ngpermgCr    8.3 
  D_OH_4_E1_ngpermgCr    8.3 
  D_OH_2_E2_ngpermgCr    8.3 
  D_OH_4_E2_ngpermgCr    8.3 
  D_R_2to16E1_ngpermgCr   8.3 
  D_R_2to4E1_ngpermgCr   8.3 
  D_Total_2OHE_ngpermgCr  8.3  
  D_Total_4OHE_ngpermgCr  8.3  
  D_Total_2MeOE_ngpermgCr  8.3 
  D_Total_4MeOE_ngpermgCr  8.3  
  D_R_tot_2to4OHE_ngpermgCr 8.3 
  D_R_tot_2to4MeOE_ngpermgCr 8.3; 
RUN; 
proc means DATA=EM.D_EM_ngpermgCr_LowSTD; 
RUN; 
 
/*PURPOSE: Check the distribution of data, if skewed then need to log transform*/ 
proc univariate plot data=EM.D_EM_ngpermgCr_LowSTD; 
var  D_E1_ngpermgCr D_E2_ngpermgCr D_E3_ngpermgCr D__16_OH_E1_ngpermgCr 
D_OH_2_E1_ngpermgCr D_OH_4_E1_ngpermgCr D_OH_2_E2_ngpermgCr 
D_OH_4_E2_ngpermgCr  
D_MeO_2_E1_ngpermgCr D_MeO_4_E1_ngpermgCr D_MeO_2_E2_ngpermgCr 
D_MeO_4_E2_ngpermgCr  
D_R_2to16E1_ngpermgCr D_R_2to4E1_ngpermgCr D_R_tot_2to4OHE_ngpermgCr 
D_R_tot_2to4MeOE_ngpermgCr 
D_Total_2OHE_ngpermgCr D_Total_4OHE_ngpermgCr D_Total_2MeOE_ngpermgCr 
D_Total_4MeOE_ngpermgCr; 
/*Distributions are normally distributed so no need to log transform changes from baseline*/ 
run; 
 
/*PURPOSE: Merge all datasets into one*/ 
Data Merged_A_LowSTD; 
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Merge EM.Ratios_EM_ngpermgCr_LowSTD EM.D_EM_ngpermgCr_LowSTD 
EM.LOG_EM_ngpermgCr_LowSTD; 
RUN; 
 
/*Create a dataset with ID, trt, age_strata and bmi_strata to merge to EM.EM_318*/ 
Data Merged_B_LowSTD; 
Set WISER.Table1; 
keep id trt age_strata bmi_strata bmi_class bmi_over25; 
run; 
 
Data Merged_B_LowSTD; 
Set Merged_B_LowSTD; 
If ID= '2622' then DELETE; 
if ID= '2601' then DELETE; 
RUN; 
 
/*PURPOSE: Add to merged data set id, trt and age & bmi strata*/ 
Data EM.EM_Merged_ngpermgCr_LowSTD; 
Merge Merged_B_LowSTD Merged_A_LowSTD; 
RUN; 
 
/*PURPOSE: Calculate EM ratios (nmol EM/day)*/ 
Data EM.Ratios_EM_nmolperday_LowSTD; 
Set EM.EM_nmolperday_LowSTD; 
 
R_2to16E1_0_nmolperday    = 
OH_2_E1_0_nmolperday/_16_OH_E1_0_nmolperday; 
R_2to16E1_1_nmolperday    = 
OH_2_E1_1_nmolperday/_16_OH_E1_1_nmolperday; 
R_2to4E1_0_nmolperday    = OH_2_E1_0_nmolperday/OH_4_E1_0_nmolperday; 
R_2to4E1_1_nmolperday    = OH_2_E1_1_nmolperday/OH_4_E1_1_nmolperday; 
Total_2OHE_0_nmolperday   = (OH_2_E1_0_nmolperday + 
OH_2_E2_0_nmolperday); 
Total_2OHE_1_nmolperday   = (OH_2_E1_1_nmolperday + 
OH_2_E2_1_nmolperday);  
Total_4OHE_0_nmolperday   = (OH_4_E1_0_nmolperday + 
OH_4_E2_0_nmolperday); 
Total_4OHE_1_nmolperday   = (OH_4_E1_1_nmolperday + 
OH_4_E2_1_nmolperday);  
Total_2MeOE_0_nmolperday   = (MeO_2_E1_0_nmolperday + 
MeO_2_E2_0_nmolperday); 
Total_2MeOE_1_nmolperday   = (MeO_2_E1_1_nmolperday + 
MeO_2_E2_1_nmolperday);  
Total_4MeOE_0_nmolperday   = (MeO_4_E1_0_nmolperday + 
MeO_4_E2_0_nmolperday); 
Total_4MeOE_1_nmolperday   = (MeO_4_E1_1_nmolperday + 
MeO_4_E2_1_nmolperday);  
R_tot_2to4OHE_0_nmolperday  = (Total_2OHE_0_nmolperday/Total_4OHE_0_nmolperday); 
R_tot_2to4OHE_1_nmolperday  = (Total_2OHE_1_nmolperday/Total_4OHE_1_nmolperday); 
R_tot_2to4MeOE_0_nmolperday = (Total_2MeOE_0_nmolperday/Total_4MeOE_0_nmolperday); 
R_tot_2to4MeOE_1_nmolperday = (Total_2MeOE_1_nmolperday/Total_4MeOE_1_nmolperday);  
 
FORMAT   
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R_2to16E1_0_nmolperday    8.3 
R_2to16E1_1_nmolperday    8.3 
R_2to4E1_0_nmolperday    8.3 
R_2to4E1_1_nmolperday    8.3 
Total_2OHE_0_nmolperday   8.3 
Total_2OHE_1_nmolperday   8.3  
Total_4OHE_0_nmolperday   8.3 
Total_4OHE_1_nmolperday   8.3  
Total_2MeOE_0_nmolperday   8.3 
Total_2MeOE_1_nmolperday   8.3  
Total_4MeOE_0_nmolperday   8.3 
Total_4MeOE_1_nmolperday   8.3  
R_tot_2to4OHE_0_nmolperday  8.3 
R_tot_2to4OHE_1_nmolperday  8.3 
R_tot_2to4MeOE_0_nmolperday  8.3 
R_tot_2to4MeOE_1_nmolperday  8.3  
; 
RUN; 
proc print; 
run; 
proc means data=em.Ratios_EM_nmolperday_LowSTD; 
run; 
 
/*RESULT: All hormones are right-skewed (max/min >10) so need to log transform*/ 
Data EM.Log_EM_nmolperday_LowSTD; 
Set EM.Ratios_EM_nmolperday_LowSTD; 
 
log_E1_0_nmolperday           = log(E1_0_nmolperday) ; 
log_E1_1_nmolperday           = log(E1_1_nmolperday) ;   
log_E2_0_nmolperday           = log(E2_0_nmolperday) ; 
log_E2_1_nmolperday           = log(E2_1_nmolperday) ;   
log_E3_0_nmolperday           = log(E3_0_nmolperday) ; 
log_E3_1_nmolperday           = log(E3_1_nmolperday) ;  
log__16_OH_E1_0_nmolperday    = log(_16_OH_E1_0_nmolperday); 
log__16_OH_E1_1_nmolperday    = log(_16_OH_E1_1_nmolperday); 
log_OH_2_E1_0_nmolperday      = log(OH_2_E1_0_nmolperday); 
log_OH_2_E1_1_nmolperday      = log(OH_2_E1_1_nmolperday); 
log_OH_4_E1_0_nmolperday      = log(OH_4_E1_0_nmolperday); 
log_OH_4_E1_1_nmolperday      = log(OH_4_E1_1_nmolperday); 
log_OH_2_E2_0_nmolperday      = log(OH_2_E2_0_nmolperday); 
log_OH_2_E2_1_nmolperday      = log(OH_2_E2_1_nmolperday); 
log_OH_4_E2_0_nmolperday      = log(OH_4_E2_0_nmolperday); 
log_OH_4_E2_1_nmolperday      = log(OH_4_E2_1_nmolperday); 
log_MeO_2_E1_0_nmolperday     = log(MeO_2_E1_0_nmolperday); 
log_MeO_2_E1_1_nmolperday     = log(MeO_2_E1_1_nmolperday); 
log_MeO_4_E1_0_nmolperday     = log(MeO_4_E1_0_nmolperday); 
log_MeO_4_E1_1_nmolperday     = log(MeO_4_E1_1_nmolperday); 
log_MeO_2_E2_0_nmolperday     = log(MeO_2_E2_0_nmolperday); 
log_MeO_2_E2_1_nmolperday     = log(MeO_2_E2_1_nmolperday); 
log_MeO_4_E2_0_nmolperday     = log(MeO_4_E2_0_nmolperday); 
log_MeO_4_E2_1_nmolperday     = log(MeO_4_E2_1_nmolperday); 
log_R_2to16E1_0_nmolperday   = log(R_2to16E1_0_nmolperday); 
log_R_2to16E1_1_nmolperday   = log(R_2to16E1_1_nmolperday); 
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log_R_2to4E1_0_nmolperday   = log(R_2to4E1_0_nmolperday); 
log_R_2to4E1_1_nmolperday   = log(R_2to4E1_1_nmolperday); 
log_R_tot_2to4OHE_0_nmolperday  = log(R_tot_2to4OHE_0_nmolperday); 
log_R_tot_2to4OHE_1_nmolperday  = log(R_tot_2to4OHE_1_nmolperday); 
log_R_tot_2to4MeOE_0_nmolperday = log(R_tot_2to4MeOE_0_nmolperday); 
log_R_tot_2to4MeOE_1_nmolperday = log(R_tot_2to4MeOE_1_nmolperday); 
log_Total_2OHE_0_nmolperday   = log(Total_2OHE_0_nmolperday); 
log_Total_2OHE_1_nmolperday   = log(Total_2OHE_1_nmolperday); 
log_Total_4OHE_0_nmolperday   = log(Total_4OHE_0_nmolperday); 
log_Total_4OHE_1_nmolperday   = log(Total_4OHE_1_nmolperday); 
log_Total_2MeOE_0_nmolperday   = log(Total_2MeOE_0_nmolperday); 
log_Total_2MeOE_1_nmolperday   = log(Total_2MeOE_1_nmolperday); 
log_Total_4MeOE_0_nmolperday   = log(Total_4MeOE_0_nmolperday); 
log_Total_4MeOE_1_nmolperday   = log(Total_4MeOE_1_nmolperday); 
 
Format 
log_E1_0_nmolperday          8.3 
log_E1_1_nmolperday          8.3   
log_E2_0_nmolperday          8.3 
log_E2_1_nmolperday          8.3   
log_E3_0_nmolperday          8.3 
log_E3_1_nmolperday          8.3  
log__16_OH_E1_0_nmolperday    8.3 
log__16_OH_E1_1_nmolperday    8.3 
log_OH_2_E1_0_nmolperday     8.3 
log_OH_2_E1_1_nmolperday     8.3 
log_OH_4_E1_0_nmolperday     8.3 
log_OH_4_E1_1_nmolperday     8.3 
log_OH_2_E2_0_nmolperday     8.3 
log_OH_2_E2_1_nmolperday     8.3 
log_OH_4_E2_0_nmolperday     8.3 
log_OH_4_E2_1_nmolperday     8.3 
log_MeO_2_E1_0_nmolperday    8.3 
log_MeO_2_E1_1_nmolperday    8.3 
log_MeO_4_E1_0_nmolperday    8.3 
log_MeO_4_E1_1_nmolperday    8.3  
log_MeO_2_E2_0_nmolperday    8.3 
log_MeO_2_E2_1_nmolperday    8.3 
log_MeO_4_E2_0_nmolperday    8.3 
log_MeO_4_E2_1_nmolperday    8.3 
log_R_2to16E1_0_nmolperday    8.3 
log_R_2to16E1_1_nmolperday    8.3 
log_R_2to4E1_0_nmolperday    8.3 
log_R_2to4E1_1_nmolperday    8.3 
log_R_tot_2to4OHE_0_nmolperday   8.3 
log_R_tot_2to4OHE_1_nmolperday   8.3 
log_R_tot_2to4MeOE_0_nmolperday   8.3 
log_R_tot_2to4MeOE_1_nmolperday   8.3 
log_Total_2OHE_0_nmolperday    8.3 
log_Total_2OHE_1_nmolperday    8.3 
log_Total_4OHE_0_nmolperday    8.3 
log_Total_4OHE_1_nmolperday    8.3 
log_Total_2MeOE_0_nmolperday    8.3 
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log_Total_2MeOE_1_nmolperday    8.3 
log_Total_4MeOE_0_nmolperday    8.3 
log_Total_4MeOE_1_nmolperday    8.3; 
run; 
proc means; 
run; 
 
/*PURPOSE: Calculate change in concentration*/ 
Data EM.D_EM_nmolperday_LowSTD; 
Set EM.Log_EM_nmolperday_LowSTD; 
 
array a[20]  E1_0_nmolperday E2_0_nmolperday E3_0_nmolperday 
_16_OH_E1_0_nmolperday 
OH_2_E1_0_nmolperday OH_2_E2_0_nmolperday OH_4_E1_0_nmolperday 
OH_4_E2_0_nmolperday  
MeO_2_E1_0_nmolperday MeO_2_E2_0_nmolperday 
MeO_4_E1_0_nmolperday MeO_4_E2_0_nmolperday  
   R_2to16E1_0_nmolperday R_2to4E1_0_nmolperday  
R_tot_2to4OHE_0_nmolperday R_tot_2to4MeOE_0_nmolperday 
Total_2OHE_0_nmolperday Total_4OHE_0_nmolperday 
Total_2MeOE_0_nmolperday Total_4MeOE_0_nmolperday; 
 
array b[20]  E1_1_nmolperday E2_1_nmolperday E3_1_nmolperday 
_16_OH_E1_1_nmolperday 
OH_2_E1_1_nmolperday OH_2_E2_1_nmolperday OH_4_E1_1_nmolperday 
OH_4_E2_1_nmolperday  
MeO_2_E1_1_nmolperday MeO_2_E2_1_nmolperday 
MeO_4_E1_1_nmolperday MeO_4_E2_1_nmolperday  
   R_2to16E1_1_nmolperday R_2to4E1_1_nmolperday  
R_tot_2to4OHE_1_nmolperday R_tot_2to4MeOE_1_nmolperday 
Total_2OHE_1_nmolperday Total_4OHE_1_nmolperday 
Total_2MeOE_1_nmolperday Total_4MeOE_1_nmolperday; 
 
array c[20]  D_E1_nmolperday D_E2_nmolperday D_E3_nmolperday 
D__16_OH_E1_nmolperday 
D_OH_2_E1_nmolperday D_OH_2_E2_nmolperday D_OH_4_E1_nmolperday 
D_OH_4_E2_nmolperday  
D_MeO_2_E1_nmolperday D_MeO_2_E2_nmolperday 
D_MeO_4_E1_nmolperday D_MeO_4_E2_nmolperday  
   D_R_2to16E1_nmolperday D_R_2to4E1_nmolperday  
D_R_tot_2to4OHE_nmolperday D_R_tot_2to4MeOE_nmolperday 
D_Total_2OHE_nmolperday D_Total_4OHE_nmolperday 
D_Total_2MeOE_nmolperday D_Total_4MeOE_nmolperday; 
 
 
do j=1 to 20; 
c[j]= b[j]-a[j]; 
end;  
Drop j; 
 
Format  D_E1_nmolperday     8.3 
  D_E2_nmolperday     8.3 
  D_E3_nmolperday    8.3 
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  D__16_OH_E1_nmolperday  8.3 
  D_OH_2_E1_nmolperday    8.3 
  D_OH_2_E2_nmolperday    8.3 
  D_OH_4_E1_nmolperday    8.3 
  D_OH_4_E2_nmolperday    8.3 
  D_MeO_2_E1_nmolperday   8.3 
  D_MeO_2_E2_nmolperday   8.3 
  D_MeO_4_E1_nmolperday   8.3  
  D_MeO_4_E2_nmolperday   8.3 
  D_R_2to16E1_nmolperday   8.3 
  D_R_2to4E1_nmolperday   8.3 
  D_Total_2OHE_nmolperday  8.3  
  D_Total_4OHE_nmolperday  8.3  
  D_Total_2MeOE_nmolperday  8.3 
  D_Total_4MeOE_nmolperday  8.3  
  D_R_tot_2to4OHE_nmolperday 8.3 
  D_R_tot_2to4MeOE_nmolperday 8.3; 
RUN; 
 
proc means DATA=EM.D_EM_nmolperday_LowSTD; 
RUN; 
 
/*PURPOSE: Check the distribution of data, if skewed then need to log transform*/ 
proc univariate plot data=EM.D_EM_nmolperday_LowSTD; 
var  D_E1_nmolperday D_E2_nmolperday D_E3_nmolperday D__16_OH_E1_nmolperday 
D_OH_2_E1_nmolperday D_OH_2_E2_nmolperday D_OH_4_E1_nmolperday 
D_OH_4_E2_nmolperday  
D_MeO_2_E1_nmolperday D_MeO_2_E2_nmolperday D_MeO_4_E1_nmolperday 
D_MeO_4_E2_nmolperday  
 D_R_2to16E1_nmolperday D_R_2to4E1_nmolperday  
     D_R_tot_2to4OHE_nmolperday D_R_tot_2to4MeOE_nmolperday 
D_Total_2OHE_nmolperday D_Total_4OHE_nmolperday D_Total_2MeOE_nmolperday 
D_Total_4MeOE_nmolperday; 
/*Distributions are normally distributed so no need to log transform changes from baseline*/ 
run; 
 
/*PURPOSE: Merge all datasets into one*/ 
Data Merged_A_LowSTD; 
Merge  EM.Ratios_EM_nmolperday_LowSTD EM.D_EM_nmolperday_LowSTD 
EM.LOG_EM_nmolperday_LowSTD; 
RUN; 
 
/*Create a dataset with ID, trt, age_strata and bmi_strata to merge to EM.EM_318*/ 
Data Merged_B_LowSTD; 
Set WISER.Table1; 
keep id trt age_strata bmi_strata bmi_class bmi_over25 lean_mass_0; 
run; 
 
Data Merged_B_LowSTD; 
Set Merged_B_LowSTD; 
If ID= '2622' then DELETE; 
if ID= '2601' then DELETE; 
RUN; 
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/*PURPOSE: Add to merged EM data, id, trt and age & bmi strata, lean_mass_0*/ 
Data EM.EM_Merged_nmolperday_LowSTD; 
Merge Merged_B_LowSTD Merged_A_LowSTD; 
RUN; 
 
/*PURPOSE: To investigate baseline associations between EM and suggested covariates based on lit 
review*/ 
 
Data EM.BaselineAssoc_ngpermgcr; 
Merge WISER.Demographics_319 WISER.Bodycomp_319 Wiser.Bodyweights_319 
WISER.Menarche_310 WISER.Familyhistory_251  
WISER.FoodRecords_312 WISER.Fitness_319 WISER.SRPA_319 EM.EM_Merged_ngpermgcr; 
by ID; 
If ID= '2601' then DELETE; 
If ID= '2622' then DELETE; 
 
KEEP ID trt  
 age age_strata bmi_strata bmi_class 
Weight_0 D_weight BMI_0 D_BMI fat_mass_0 D_fat_mass lean_mass_0 D_lean_mass  
     Menarche_age  
Kcal_0 Fat_g_0 Carb_g_0 Prot_g_0 Fib_g_0 Caff_mg_0 Alc_g_0 
 Mets_0 total_mets_week_0  
log_E1_0_ngpermgCr log_E2_0_ngpermgCr log_E3_0_ngpermgCr 
log__16_OH_E1_0_ngpermgCr 
log_OH_2_E1_0_ngpermgCr log_OH_4_E1_0_ngpermgCr log_MeO_2_E1_0_ngpermgCr 
log_MeO_2_E2_0_ngpermgCr  
 log_R_2to16E1_0_ngpermgCr log_R_2to4E1_0_ngpermgCr 
D_E1_ngpermgCr D_E2_ngpermgCr D_E3_ngpermgCr D__16_OH_E1_ngpermgCr 
 D_OH_2_E1_ngpermgCr D_OH_4_E1_ngpermgCr   
     D_MeO_2_E1_ngpermgCr D_MeO_2_E2_ngpermgCr   
     D_R_2to16E1_ngpermgCr D_R_2to4E1_ngpermgCr  
; 
 RUN; 
 
PROC means DATA=EM.BASELINEassoc_ngpermgcr; 
/*since caff_mg_0 and alc_g_0 have a min value=0 these need to be log transformed*/ 
run; 
 
 
Data EM.BaselineAssoc_ngpermgcr; 
Set EM.BaselineAssoc_ngpermgcr; 
log_caff = log(caff_mg_0 +1.0); 
log_alc= log(alc_g_0 + 1.0); 
DROP caff_mg_0 alc_g_0; 
run; 
 
PROC means DATA=EM.BASELINEassoc_ngpermgcr n nmiss max min; 
/*since caff_mg_0 and alc_g_0 have a min value=0 these need to be log transformed*/ 
run; 
 
Proc Corr Data=EM.BaselineAssoc_ngpermgCr; 
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var  log_E1_0_ngpermgCr log_E2_0_ngpermgCr log_E3_0_ngpermgCr 
log__16_OH_E1_0_ngpermgCr 
log_OH_2_E1_0_ngpermgCr log_OH_4_E1_0_ngpermgCr log_MeO_2_E1_0_ngpermgCr 
log_MeO_2_E2_0_ngpermgCr  
 log_R_2to16E1_0_ngpermgCr log_R_2to4E1_0_ngpermgCr; 
with age Weight_0 D_weight BMI_0 D_BMI fat_mass_0 D_fat_mass lean_mass_0 D_lean_mass  
     Menarche_age  
Kcal_0 Fat_g_0 Carb_g_0 Prot_g_0 Fib_g_0 log_Caff log_Alc 
 Mets_0 total_mets_week_0; 
run; 
 
Proc Reg data=em.baselineassoc_ngpermgcr; 
model /*log_OH_2_E1_0_ngpermgCr log__16_OH_E1_0_ngpermgCr*/ log_R_2to16E1_0_ngpermgCr= 
age 
Weight_0 BMI_0 fat_mass_0 lean_mass_0  
Menarche_age Kcal_0 Fat_g_0 Carb_g_0 Prot_g_0 Fib_g_0 log_Caff log_Alc 
Mets_0 total_mets_week_0/ VIF; 
 
plot cookd. * obs.; 
output out=c cookd=cook_dist; 
run; 
proc print data=c; 
where (cook_dist> 0.1); 
run; 
    
Proc Corr data=em.baselineassoc_ngpermgcr; 
var weight_0 bmi_0 fat_mass_0 lean_mass_0 kcal_0 fat_g_0 carb_g_0; 
run; 
 
Proc Insight data=em.baselineassoc_ngpermgcr; 
/*scatter weight_0 * fat_mass_0 bmi_0 lean_mass_0;/*remove weight*/ 
scatter bmi_0 * fat_mass_0 lean_mass_0; /*remove bmi*/ 
/*scatter fat_mass_0 * lean_mass_0; /*no colinearity 
scatter kcal_0 * fat_g_0 carb_g_0; /*remove kcal_0*/ 
run; 
/*predictors are highly correlated so remove one (bmi_0)*/ 
quit; 
 
Proc Reg data=em.baselineassoc_ngpermgcr; 
model /*log_OH_2_E1_0_ngpermgCr log__16_OH_E1_0_ngpermgCr */ log_R_2to16E1_0_ngpermgCr = 
age fat_mass_0 lean_mass_0  
     Menarche_age  
  Fat_g_0 Carb_g_0 Prot_g_0 Fib_g_0 log_Caff log_Alc 
  Mets_0 total_mets_week_0/ selection=cp; 
run; 
plot student. * predicted.; 
output out=c predicted=yhat student=resid; 
run; 
 
Proc corr data=em.baselineassoc_ngpermgcr; 
var log_OH_2_E1_0_ngpermgCr; 
with total_mets_week_0 Fib_g_0; 
run; 
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Proc Reg data=em.baselineassoc_ngpermgcr; 
model log_OH_2_E1_0_ngpermgCr = Fib_g_0; /*r squared= 0.03*/ 
run; 
 
Proc corr data=em.baselineassoc_ngpermgcr; 
var log__16_OH_E1_0_ngpermgCr; 
with Fat_mass_0 Lean_mass_0 Carb_g_0 Fib_g_0 log_alc Mets_0; 
run; 
 
Proc Reg data=em.baselineassoc_ngpermgcr; 
model log__16_OH_E1_0_ngpermgCr = log_alc Mets_0; /*r squared= 0.04*/ 
run; 
 
Proc corr data=em.baselineassoc_ngpermgcr; 
var log_R_2to16E1_0_ngpermgCr; 
with Fat_mass_0 Fat_g_0 Prot_g_0 Carb_g_0 Fib_g_0 log_alc Mets_0 total_mets_week_0; 
run; 
 
Proc Reg data=em.baselineassoc_ngpermgcr; 
model log_R_2to16E1_0_ngpermgCr = log_alc total_Mets_week_0; /*r squared= 0.04*/ 
run; 
 
/*PURPOSE: To investigate baseline associations between EM and suggested covariates based on lit 
review 
inverse relationship with age, age at menarche*/ 
 
Proc Sort Data=EM.EM_Merged_nmolperday_LowSTD; 
By id; 
run; 
 
Data EM.BaselineAssoc_nmolperday; 
Merge WISER.Demographics_319 WISER.Bodycomp_319 Wiser.Bodyweights_319 
WISER.Menarche_310 WISER.Familyhistory_251  
WISER.FoodRecords_312 WISER.Fitness_319 WISER.SRPA_319 
EM.EM_Merged_nmolperday_LowSTD; 
by ID; 
If ID= '2601' then DELETE; 
If ID= '2622' then DELETE; 
KEEP ID trt age age_strata bmi_strata 
Weight_0 D_weight BMI_0 D_BMI fat_mass_0 D_fat_mass lean_mass_0 D_lean_mass  
  Menarche_age  
Kcal_0 Fat_g_0 Carb_g_0 Prot_g_0 Fib_g_0 Caff_mg_0 Alc_g_0 
 Mets_0 total_mets_week_0  
log_E1_0_nmolperday log_E2_0_nmolperday log_E3_0_nmolperday 
log__16_OH_E1_0_nmolperday 
log_OH_2_E1_0_nmolperday log_OH_4_E1_0_nmolperday log_MeO_2_E1_0_nmolperday 
log_MeO_2_E2_0_nmolperday  
 log_R_2to16E1_0_nmolperday log_R_2to4E1_0_nmolperday; 
 RUN; 
 
PROC means DATA=EM.BASELINEassoc_nmolperday; 
/*since caff_mg_0 and alc_g_0 have a min value=0 these need to be log transformed*/ 
  252
run; 
 
Data EM.BaselineAssoc_nmolperday; 
Set EM.BaselineAssoc_nmolperday; 
log_caff = log(caff_mg_0 +1.0); 
log_alc= log(alc_g_0 + 1.0); 
 
 
DROP caff_mg_0 alc_g_0; 
run; 
PROC means DATA=EM.BASELINEassoc_nmolperday n nmiss max min; 
/*since caff_mg_0 and alc_g_0 have a min value=0 these need to be log transformed*/ 
run; 
/* Purpose: to check any correlation between EM and body composition measures*/ 
Proc Corr Data=EM.BaselineAssoc_nmolperday; 
var  age Weight_0 D_weight BMI_0 D_BMI fat_mass_0 D_fat_mass lean_mass_0 D_lean_mass  
     Menarche_age 
Kcal_0 Fat_g_0 Carb_g_0 Prot_g_0 Fib_g_0 log_Caff log_Alc 
 Mets_0 total_mets_week_0 ;  
with /*log_E1_0_nmolperday log_E2_0_nmolperday log_E3_0_nmolperday 
*/log__16_OH_E1_0_nmolperday 
  log_OH_2_E1_0_nmolperday /*log_OH_4_E1_0_nmolperday log_MeO_2_E1_0_nmolperday 
log_MeO_2_E2_0_nmolperday*/  
  log_R_2to16E1_0_nmolperday /*log_R_2to4E1_0_nmolperday*/; 
run; 
/*2OHE1 r=0.216 p=0.0001 with leanmass*/ 
 
Proc GLM data=em.baselineassoc_nmolperday; 
class trt age_strata bmi_strata ; 
model log_OH_2_E1_0_nmolperday = 
  age 
  lean_mass_0  
  Kcal_0 Fat_g_0 Carb_g_0 Fib_g_0 
  /ss3; 
  run; 
 
Proc Reg data=em.baselineassoc_nmolperday; 
model log_E2_0_nmolperday 
  = age 
  Weight_0 BMI_0 fat_mass_0 lean_mass_0   
  Kcal_0 Carb_g_0 log_Caff/ VIF; 
 
plot cookd. * obs.; 
output out=c cookd=cook_dist; 
run; 
proc print data=c; 
where (cook_dist> 0.10); 
run; 
    
Proc Corr data=em.baselineassoc_nmolperday; 
var weight_0 bmi_0 fat_mass_0 lean_mass_0 kcal_0 fat_g_0 carb_g_0; 
run; 
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Proc Insight data=em.baselineassoc_nmolperday; 
/*scatter weight_0 * fat_mass_0 bmi_0 lean_mass_0;/*remove weight*/ 
/*scatter bmi_0 * fat_mass_0 lean_mass_0; /*remove bmi*/ 
scatter fat_mass_0 * lean_mass_0; /*no colinearity*/ 
run; 
/*predictors are highly correlated so remove one (bmi_0)*/ 
quit; 
 
Proc Reg data=em.baselineassoc_nmolperday; 
model /*log_E2_0_nmolperday log_E1_0_nmolperday log_R_2to16E1_0_nmolperday*/ 
log_OH_2_E1_0_nmolperday 
 = age 
Weight_0 D_weight BMI_0 D_BMI fat_mass_0 D_fat_mass lean_mass_0 D_lean_mass  
     Menarche_age 
Kcal_0 Fat_g_0 Carb_g_0 Prot_g_0 Fib_g_0 log_Caff log_Alc 
 Mets_0 total_mets_week_0    
  / selection=cp; 
run; 
plot student. * predicted.; 
output out=c predicted=yhat student=resid; 
run; 
 
 
/*Table 1. Baseline characteristics of Randomized participants (n=318) ID 2622 Did not complete CV8 due 
to travel*/ 
Proc Sort Data=WISER.SRPA_319; 
BY ID; 
RUN; 
Data WISER.EM_Table1; 
Merge WISER.Demographics_319 WISER.Bodycomp_319 WISER.Menarche_310 
WISER.Familyhistory_251 WISER.FoodRecords_312 
WISER.Fitness_319 wiser.srpa_319; 
By id; 
 
KEEP ID trt age age_strata Ht_CV1 Wt_CV1 fat_mass_0 Percent_bodyfat_0 lean_mass_0 BMI BMI_class 
BMI_class4 
     race Hispanic EDU MarStat status 
     Menarche_age BC_history BCuse Parity 
Kcal_0 FatCals_0 Fib_g_0 Caff_mg_0 Alc_g_0 total_mets_week_0 
 Mets_0 
; 
run; 
 
Data WISER.EM_Table1; 
Set WISER.EM_Table1; 
IF ID = '2622' THEN DELETE; 
If EDU = 'College/University degree' then Education = 'Beyond HS'; 
If EDU = 'Graduate or Professional degree' then Education= 'Beyond HS'; 
If EDU = 'Some college (less than 4 years)' then Education= 'Beyond HS'; 
If EDU = 'Vocational training (beyond high school)' then Education= 'Beyond HS'; 
If EDU = 'Completed high school diploma (or GED)' then Education ='HS or less'; 
IF EDU = 'Less than high school diploma' then Education='HS or less'; 
RUN;  
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Proc Ttest Data=wiser.EM_Table1 ci=none; 
class trt; 
var age Wt_CV1 BMI fat_mass_0 Percent_bodyfat_0 lean_mass_0 Kcal_0 Alc_g_0 Mets_0 
total_mets_week_0 menarche_age; 
run; 
 
Proc Freq Data=wiser.EM_Table1; 
tables trt*(BMI_class4 race Hispanic Education menarche_age MarStat status BC_history BCuse Parity 
BMI_class age_strata) 
/ nocol chisq; 
run; 
 
/*Table 2. Baseline EM characteristics of Randomized participants (n=318) 
  ID 2622 Did not complete CV8 due to travel*/ 
Proc sort Data=EM.EM_Merged_ngpermgCr_LowSTD; 
by trt; 
run; 
 
Proc Ttest Data=EM.EM_Merged_ngpermgCr_LowSTD ci=none; 
class trt; 
var  E1_0_ngpermgCr E2_0_ngpermgCr E3_0_ngpermgCr _16_OH_E1_0_ngpermgCr 
OH_2_E1_0_ngpermgCr OH_4_E1_0_ngpermgCr OH_2_E2_0_ngpermgCr 
OH_4_E2_0_ngpermgCr  
MeO_2_E1_0_ngpermgCr MeO_4_E1_0_ngpermgCr MeO_2_E2_0_ngpermgCr 
MeO_4_E2_0_ngpermgCr  
 R_2to16E1_0_ngpermgCr R_2to4E1_0_ngpermgCr; 
/*No differences in baseline levels*/ 
run; 
 
proc means mean median Q1 Q3 data=EM.EM_Merged_ngpermgCr_LowSTD; 
var  E1_0_ngpermgCr E2_0_ngpermgCr E3_0_ngpermgCr _16_OH_E1_0_ngpermgCr 
OH_2_E1_0_ngpermgCr OH_4_E1_0_ngpermgCr OH_2_E2_0_ngpermgCr 
OH_4_E2_0_ngpermgCr  
MeO_2_E1_0_ngpermgCr MeO_4_E1_0_ngpermgCr MeO_2_E2_0_ngpermgCr 
MeO_4_E2_0_ngpermgCr  
 R_2to16E1_0_ngpermgCr R_2to4E1_0_ngpermgCr; 
by trt; 
   run; 
 
/*PURPOSE; Generate Table 2. Distribution of Baseline urinary levels of wiser participants by group 
(n=318) 
ID 2622 Did not complete CV8 due to travel*/ 
 
 
/*Calculate baseline median, 10th and 90th percentile levels per group*/ 
Proc sort Data=EM.EM_Merged_nmolperday_LowSTD; 
by trt; 
run; 
proc means P50 P10 P90 data=EM.EM_Merged_nmolperday_LowSTD; 
var  E1_0_nmolperday E2_0_nmolperday E3_0_nmolperday _16_OH_E1_0_nmolperday 
OH_2_E1_0_nmolperday OH_2_E2_0_nmolperday OH_4_E1_0_nmolperday 
OH_4_E2_0_nmolperday  
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MeO_2_E1_0_nmolperday MeO_2_E2_0_nmolperday MeO_4_E1_0_nmolperday 
MeO_4_E2_0_nmolperday  
 R_2to16E1_0_nmolperday R_2to4E1_0_nmolperday ; 
by trt; 
run; 
 
/*Determine if there are significant differences at baseline in urinary levels of EM 
Given non-normality, comparisons must be made using log transformed values*/ 
 
Proc Ttest Data=EM.EM_Merged_nmolperday_LowSTD ci=none; 
class trt; 
var log_E1_0_nmolperday log_E2_0_nmolperday log_E3_0_nmolperday log__16_OH_E1_0_nmolperday 
log_OH_2_E1_0_nmolperday log_OH_2_E2_0_nmolperday log_OH_4_E1_0_nmolperday 
log_OH_4_E2_0_nmolperday 
log_MeO_2_E1_0_nmolperday log_MeO_2_E2_0_nmolperday log_MeO_4_E1_0_nmolperday 
log_MeO_4_E2_0_nmolperday 
log_R_2to16E1_0_nmolperday log_R_2to4E1_0_nmolperday;  
/*No differences in baseline levels*/ 
run; 
 
/* PURPOSE: To conduct baseline comparisons (ng/mg Cr) using a full model*/ 
 
Proc GLM data=EM.EM_Merged_ngpermgCr_LowSTD; 
class age_strata bmi_strata trt; 
model log_E1_0_ngpermgCr log_E2_0_ngpermgCr log_E3_0_ngpermgCr 
log__16_OH_E1_0_ngpermgCr 
log_OH_2_E1_0_ngpermgCr log_OH_2_E2_0_ngpermgCr log_OH_4_E1_0_ngpermgCr 
log_OH_4_E2_0_ngpermgCr 
log_MeO_2_E1_0_ngpermgCr log_MeO_2_E2_0_ngpermgCr log_MeO_4_E1_0_ngpermgCr 
log_MeO_4_E2_0_ngpermgCr 
log_R_2to16E1_0_ngpermgCr log_R_2to4E1_0_ngpermgCr 
log_R_tot_2to4OHE_0_ngpermgCr log_R_tot_2to4MeOE_0_ngpermgCr  
log_Total_2OHE_0_ngpermgCr log_Total_4OHE_0_ngpermgCr log_Total_2MeOE_0_ngpermgCr 
log_Total_4MeOE_0_ngpermgCr 
= age_strata | BMI_strata | trt/ ss3; 
run;   
/*SIGNIFICANT TRT INTERACTIONS*/        
quit;  
 
/*Per Will Thomas, these variables should be run with a simplified model. Keeping the trt interaction 
means 
we should present the comparisons in each of 6 age-bmi strata separatedly*/ 
 
/*PURPOSE: Conduct baseline comparisons (ng/mg Cr) using a reduced model for all variables*/ 
Proc GLM Data =EM.EM_Merged_ngpermgCr_LowSTD;  
class age_strata bmi_strata trt; 
model log_E1_0_ngpermgCr log_E2_0_ngpermgCr log_E3_0_ngpermgCr 
log__16_OH_E1_0_ngpermgCr 
log_OH_2_E1_0_ngpermgCr log_OH_2_E2_0_ngpermgCr log_OH_4_E1_0_ngpermgCr 
log_OH_4_E2_0_ngpermgCr 
log_MeO_2_E1_0_ngpermgCr log_MeO_2_E2_0_ngpermgCr log_MeO_4_E1_0_ngpermgCr 
log_MeO_4_E2_0_ngpermgCr 
log_R_2to16E1_0_ngpermgCr log_R_2to4E1_0_ngpermgCr 
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log_R_tot_2to4OHE_0_ngpermgCr log_R_tot_2to4MeOE_0_ngpermgCr  
log_Total_2OHE_0_ngpermgCr log_Total_4OHE_0_ngpermgCr log_Total_2MeOE_0_ngpermgCr 
log_Total_4MeOE_0_ngpermgCr 
= trt age_strata | BMI_strata/ ss3; 
lsmeans trt / CL pdiff; 
ODS output LSMeanCL=logCI_0; 
run;  
/*Significant difference at baseline in log(2/16OHE1) p=0.044 so will need to adjust change from baseline 
comparisons*/ 
quit; 
 
Data a; 
Set logCI_0; 
geometric_mean= exp(lsmean); 
left_CI= exp(LowerCL); 
right_CI= exp(UpperCL); 
drop lsmean LowerCL UpperCL; 
run; 
proc print data =a; 
run; 
 
/* PURPOSE: To conduct changes from baseline comparisons (ng/mg Cr)using a full model. 
Since there were significant differences at baseline in 2/16 ratio, include baseline term in the model*/ 
 
Proc GLM Data =EM.EM_Merged_ngpermgCr_LowSTD; 
class age_strata bmi_strata trt; 
model  D_E1_ngpermgCr D_E2_ngpermgCr D_E3_ngpermgCr D__16_OH_E1_ngpermgCr 
D_OH_2_E1_ngpermgCr D_OH_2_E2_ngpermgCr D_OH_4_E1_ngpermgCr 
D_OH_4_E2_ngpermgCr 
D_MeO_2_E1_ngpermgCr D_MeO_2_E2_ngpermgCr D_MeO_4_E1_ngpermgCr 
D_MeO_4_E2_ngpermgCr  
  D_R_2to4E1_ngpermgCr  
D_R_tot_2to4OHE_ngpermgCr D_R_tot_2to4MeOE_ngpermgCr  
D_Total_2OHE_ngpermgCr D_Total_4OHE_ngpermgCr D_Total_2MeOE_ngpermgCr 
D_Total_4MeOE_ngpermgCr 
      = age_strata | bmi_strata | trt /ss3; 
lsmeans trt / stderr pdiff; 
run;  
quit; 
 
Proc GLM Data =EM.EM_Merged_ngpermgCr_LowSTD; 
class age_strata bmi_strata trt; 
model D_R_2to16E1_ngpermgCr = log_R_2to16E1_0_ngpermgCr age_strata | bmi_strata | trt /ss3; 
lsmeans trt / stderr pdiff; 
run;  
quit; 
 
/* PURPOSE: To conduct changes from baseline comparisons (ng/mg Cr)using a reduced model. 
 Since there were significant differences at baseline in 2/16 ratio, include baseline term in the 
model*/ 
Proc GLM Data =EM.EM_Merged_ngpermgCr_LowSTD; 
class age_strata bmi_strata trt; 
model  D_E1_ngpermgCr D_E2_ngpermgCr D_E3_ngpermgCr D__16_OH_E1_ngpermgCr 
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D_OH_2_E1_ngpermgCr D_OH_2_E2_ngpermgCr D_OH_4_E1_ngpermgCr 
D_OH_4_E2_ngpermgCr 
D_MeO_2_E1_ngpermgCr D_MeO_2_E2_ngpermgCr D_MeO_4_E1_ngpermgCr 
D_MeO_4_E2_ngpermgCr  
  D_R_2to4E1_ngpermgCr  
D_R_tot_2to4OHE_ngpermgCr D_R_tot_2to4MeOE_ngpermgCr  
D_Total_2OHE_ngpermgCr D_Total_4OHE_ngpermgCr D_Total_2MeOE_ngpermgCr 
D_Total_4MeOE_ngpermgCr 
       = trt age_strata | bmi_strata /ss3;   
lsmeans trt / stderr pdiff CL; 
run;  
/*Significant within change in controls in E2 p=0.028*/ 
quit; 
 
Proc GLM Data =EM.EM_Merged_ngpermgCr_LowSTD; 
class age_strata bmi_strata trt; 
model D_R_2to16E1_ngpermgCr = trt log_R_2to16E1_0_ngpermgCr age_strata | bmi_strata /ss3; 
lsmeans trt / stderr pdiff CL; 
run;  
/*Exercisers significantly increase their ratio (p=0.034)  
which was different from the controls (p=0.033) 
Significant change between groups in 2/16 p=0.045*/ 
quit; 
 
/* PURPOSE: To conduct baseline comparisons (nmol/day) using a full model*/ 
 
Proc GLM data=EM.EM_Merged_nmolperday_LowSTD; 
class age_strata bmi_strata trt; 
model log_E1_0_nmolperday log_E2_0_nmolperday log_E3_0_nmolperday 
log__16_OH_E1_0_nmolperday 
log_OH_2_E1_0_nmolperday log_OH_2_E2_0_nmolperday log_OH_4_E1_0_nmolperday 
log_OH_4_E2_0_nmolperday 
log_MeO_2_E1_0_nmolperday log_MeO_2_E2_0_nmolperday log_MeO_4_E1_0_nmolperday 
log_MeO_4_E2_0_nmolperday  
log_R_2to16E1_0_nmolperday log_R_2to4E1_0_nmolperday  
log_R_tot_2to4MeOE_0_nmolperday log_R_tot_2to4OHE_0_nmolperday  
log_Total_2OHE_0_nmolperday log_Total_4OHE_0_nmolperday log_Total_2MeOE_0_nmolperday 
log_Total_4MeOE_0_nmolperday 
= age_strata | BMI_strata | trt/ ss3; 
run;    
quit;  
 
/*Per Will Thomas, these variables should be run with a simplified model. Keeping the trt interaction 
means 
we should present the comparisons in each of 6 age-bmi strata separatedly*/ 
 
/*PURPOSE: Conduct baseline comparisons (nmol/day) using a reduced model for all variables*/ 
Proc GLM Data =EM.EM_Merged_nmolperday_LowSTD;  
class age_strata bmi_strata trt; 
model log_E1_0_nmolperday log_E2_0_nmolperday log_E3_0_nmolperday 
log__16_OH_E1_0_nmolperday 
log_OH_2_E1_0_nmolperday log_OH_2_E2_0_nmolperday log_OH_4_E1_0_nmolperday 
log_OH_4_E2_0_nmolperday 
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log_MeO_2_E1_0_nmolperday log_MeO_2_E2_0_nmolperday log_MeO_4_E1_0_nmolperday 
log_MeO_4_E2_0_nmolperday 
log_R_2to16E1_0_nmolperday log_R_2to4E1_0_nmolperday  
log_R_tot_2to4OHE_0_nmolperday log_R_tot_2to4MeOE_0_nmolperday  
log_Total_2OHE_0_nmolperday log_Total_4OHE_0_nmolperday log_Total_2MeOE_0_nmolperday 
log_Total_4MeOE_0_nmolperday 
= trt lean_mass_0 age_strata | BMI_strata/ ss3; 
lsmeans trt / CL pdiff; 
ODS output LSMeanCL=logCI_0; 
run;  
/*Significant difference at baseline in 2/16 p=0.0443, 2OHE1 p=0.084*/ 
quit; 
Data a; 
Set logCI_0; 
geometric_mean= exp(lsmean); 
left_CI= exp(LowerCL); 
right_CI= exp(UpperCL); 
drop lsmean LowerCL UpperCL; 
run; 
proc print data =a; 
run; 
 
/* PURPOSE: To conduct follow up comparisons (nmol/day) using a full model 
Also, adjustement for baseline 2OHE1 and 2/16 is necessary*/ 
 
Proc GLM data=EM.EM_Merged_nmolperday_LowSTD; 
class age_strata bmi_strata trt; 
model log_E1_1_nmolperday log_E2_1_nmolperday log_E3_1_nmolperday 
log__16_OH_E1_1_nmolperday 
log_OH_2_E1_1_nmolperday log_OH_2_E2_1_nmolperday log_OH_4_E1_1_nmolperday 
log_OH_4_E2_1_nmolperday 
log_MeO_2_E1_1_nmolperday log_MeO_2_E2_1_nmolperday log_MeO_4_E1_1_nmolperday 
log_MeO_4_E2_1_nmolperday 
log_R_2to16E1_1_nmolperday log_R_2to4E1_1_nmolperday  
log_R_tot_2to4OHE_1_nmolperday log_R_tot_2to4MeOE_1_nmolperday  
log_Total_2OHE_1_nmolperday log_Total_4OHE_1_nmolperday log_Total_2MeOE_1_nmolperday 
log_Total_4MeOE_1_nmolperday 
= age_strata | BMI_strata | trt/ ss3; 
run;   
quit;  
 
/*Per Will Thomas, these variables should be run with a simplified model. Keeping the trt interaction 
means 
we should present the comparisons in each of 6 age-bmi strata separatedly*/ 
 
/*PURPOSE: Conduct follow up comparisons (nmol/day) using a reduced model for all variables. 
Also, adjustement for baseline 2OHE1 and 2/16 is necessary*/ 
Proc GLM Data =EM.EM_Merged_nmolperday_LowSTD;  
class age_strata bmi_strata trt; 
model log_E1_1_nmolperday log_E2_1_nmolperday log_E3_1_nmolperday 
log__16_OH_E1_1_nmolperday 
log_OH_2_E2_1_nmolperday log_OH_4_E1_1_nmolperday log_OH_4_E2_1_nmolperday 
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log_MeO_2_E1_1_nmolperday log_MeO_2_E2_1_nmolperday log_MeO_4_E1_1_nmolperday 
log_MeO_4_E2_1_nmolperday 
log_R_2to4E1_1_nmolperday  
log_R_tot_2to4OHE_1_nmolperday log_R_tot_2to4MeOE_1_nmolperday  
log_Total_2OHE_1_nmolperday log_Total_4OHE_1_nmolperday log_Total_2MeOE_1_nmolperday 
log_Total_4MeOE_1_nmolperday 
= trt lean_mass_0 age_strata | BMI_strata/ ss3; 
lsmeans trt / CL pdiff; 
ODS output LSMeanCL=logCI_1; 
run;  
quit; 
Data b; 
Set logCI_1; 
geometric_mean= exp(lsmean); 
left_CI= exp(LowerCL); 
right_CI= exp(UpperCL); 
drop lsmean LowerCL UpperCL; 
run; 
proc print data =b; 
run; 
 
Proc GLM Data =EM.EM_Merged_nmolperday_LowSTD;  
class age_strata bmi_strata trt; 
model log_OH_2_E1_1_nmolperday = trt log_OH_2_E1_0_nmolperday age_strata | BMI_strata/ ss3; 
lsmeans trt / CL pdiff; 
ODS output LSMeanCL=logCI_2; 
run;  
/*Significant difference at baseline in 2/16 p=0.048*/ 
quit; 
 
Data c; 
Set logCI_2; 
geometric_mean= exp(lsmean); 
left_CI= exp(LowerCL); 
right_CI= exp(UpperCL); 
drop lsmean LowerCL UpperCL; 
run; 
proc print data =c; 
run; 
 
Proc GLM Data =EM.EM_Merged_nmolperday_LowSTD;  
class age_strata bmi_strata trt; 
model log_R_2to16E1_1_nmolperday = trt log_R_2to16E1_0_nmolperday age_strata | BMI_strata/ ss3; 
lsmeans trt / CL pdiff; 
ODS output LSMeanCL=logCI_3; 
run;  
/*Significant difference at baseline in 2/16 p=0.048*/ 
quit; 
 
Data d; 
Set logCI_3; 
geometric_mean= exp(lsmean); 
left_CI= exp(LowerCL); 
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right_CI= exp(UpperCL); 
drop lsmean LowerCL UpperCL; 
run; 
proc print data =d; 
run; 
 
/* PURPOSE: To conduct changes from baseline comparisons (nmol/day)using a full model. 
 Since there were significant differences at baseline in 2OHE1 and 2/16 ratio, include baseline term 
in the model*/ 
 
Proc GLM Data =EM.EM_Merged_nmolperday_LowSTD; 
class age_strata bmi_strata trt; 
model  D_E1_nmolperday D_E2_nmolperday D_E3_nmolperday 
D__16_OH_E1_nmolperday 
D_OH_2_E2_nmolperday D_OH_4_E1_nmolperday D_OH_4_E2_nmolperday  
D_MeO_2_E1_nmolperday D_MeO_2_E2_nmolperday D_MeO_4_E1_nmolperday 
D_MeO_4_E2_nmolperday   
  D_R_2to4E1_nmolperday  
D_R_tot_2to4OHE_nmolperday D_R_tot_2to4MeOE_nmolperday  
D_Total_2OHE_nmolperday D_Total_4OHE_nmolperday 
D_Total_2MeOE_nmolperday D_Total_4MeOE_nmolperday 
       = age_strata | bmi_strata | trt /ss3; 
lsmeans trt / stderr pdiff; 
run;  
quit; 
 
Proc GLM Data =EM.EM_Merged_nmolperday_LowSTD; 
class age_strata bmi_strata trt; 
model D_OH_2_E1_nmolperday = log_OH_2_E1_0_nmolperday age_strata | bmi_strata |trt /ss3; 
lsmeans trt / stderr pdiff CL; 
run;  
quit; 
 
Proc GLM Data =EM.EM_Merged_nmolperday_LowSTD; 
class age_strata bmi_strata trt; 
model D_R_2to16E1_nmolperday = log_R_2to16E1_0_nmolperday age_strata | bmi_strata | trt /ss3; 
lsmeans trt / stderr pdiff; 
run;  
quit; 
 
/* PURPOSE: To conduct changes from baseline comparisons (nmol/daymol)using a reduced model. 
Since there were significant differences at baseline in 2/16 ratio, include baseline term in the model*/ 
 
Proc GLM Data =EM.EM_Merged_nmolperday_LowSTD; 
class age_strata bmi_strata trt; 
model  D_E1_nmolperday D_E2_nmolperday D_E3_nmolperday D__16_OH_E1_nmolperday 
D_OH_2_E2_nmolperday D_OH_4_E1_nmolperday D_OH_4_E2_nmolperday  
D_MeO_2_E1_nmolperday D_MeO_2_E2_nmolperday D_MeO_4_E1_nmolperday 
D_MeO_4_E2_nmolperday   
  D_R_2to4E1_nmolperday  
D_R_tot_2to4OHE_nmolperday D_R_tot_2to4MeOE_nmolperday  
D_Total_2OHE_nmolperday D_Total_4OHE_nmolperday 
D_Total_2MeOE_nmolperday D_Total_4MeOE_nmolperday 
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       = trt lean_mass_0 age_strata | bmi_strata /ss3;   
lsmeans trt / stderr pdiff CL; 
 
run;  
quit; 
 
Proc GLM Data =EM.EM_Merged_nmolperday_LowSTD; 
class age_strata bmi_strata trt; 
model D_OH_2_E1_nmolperday = trt log_OH_2_E1_0_nmolperday age_strata | bmi_strata /ss3; 
lsmeans trt / stderr pdiff CL; 
run;  
quit; 
 
Proc GLM Data =EM.EM_Merged_nmolperday_LowSTD; 
class age_strata bmi_strata trt; 
model D_R_2to16E1_nmolperday = trt log_R_2to16E1_0_nmolperday age_strata | bmi_strata /ss3; 
lsmeans trt / stderr pdiff CL; 
run;  
quit; 
 
/*PURPOSE: Investigate associations between changes in EM and changes in body composition*/ 
 
Data EM.bodycomp_covariates; 
Set WISER.Bodycomp_319;  
Keep ID D_fat_mass D_percent_bodyfat D_lean_mass D_percent_leanmass; 
run; 
 
Data EM_changes; 
Set EM.EM_Merged_nmolperday_LowSTD; 
KEEP  ID D_E1_nmolperday D_E2_nmolperday D_E3_nmolperday 
D__16_OH_E1_nmolperday 
D_OH_2_E1_nmolperday D_OH_2_E2_nmolperday D_OH_4_E1_nmolperday 
D_OH_4_E2_nmolperday  
D_MeO_2_E1_nmolperday D_MeO_2_E2_nmolperday D_MeO_4_E1_nmolperday 
D_MeO_4_E2_nmolperday   
  D_R_2to16E1_nmolperday D_R_2to4E1_nmolperday  
D_R_tot_2to4OHE_nmolperday D_R_tot_2to4MeOE_nmolperday  
D_Total_2OHE_nmolperday D_Total_4OHE_nmolperday 
D_Total_2MeOE_nmolperday D_Total_4MeOE_nmolperday; 
RUN; 
 
Data WISER.EM_Assoc_changes; 
Merge EM_changes EM.bodycomp_covariates; 
run; 
 
Proc Corr Data= wiser.em_assoc_changes; 
var  D_E1_nmolperday D_E2_nmolperday D_E3_nmolperday D__16_OH_E1_nmolperday 
D_OH_2_E1_nmolperday D_OH_2_E2_nmolperday D_OH_4_E1_nmolperday 
D_OH_4_E2_nmolperday  
D_MeO_2_E1_nmolperday D_MeO_2_E2_nmolperday D_MeO_4_E1_nmolperday 
D_MeO_4_E2_nmolperday   
  D_R_2to16E1_nmolperday D_R_2to4E1_nmolperday  
D_R_tot_2to4OHE_nmolperday D_R_tot_2to4MeOE_nmolperday  
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D_Total_2OHE_nmolperday D_Total_4OHE_nmolperday 
D_Total_2MeOE_nmolperday D_Total_4MeOE_nmolperday; 
with D_fat_mass D_percent_bodyfat D_lean_mass D_percent_leanmass; 
run; 
 
Proc GLM Data =EM.EM_Merged_nmolperday;  
class trt age_strata bmi_strata; 
model /*log_E1_0_nmolperday log_E2_0_nmolperday log_E3_0_nmolperday 
log__16_OH_E1_0_nmolperday 
log_OH_2_E1_0_nmolperday log_OH_4_E1_0_nmolperday log_MeO_2_E1_0_nmolperday 
log_MeO_2_E2_0_nmolperday  
log_R_2to4E1_0_nmolperday */ log_R_2to16E1_0_nmolperday 
= trt age_strata | BMI_strata / ss3; 
run; 
lsmeans trt / stderr pdiff CL; 
ODS output LSMeanCL=logCI_0; 
run;  
/*Significant difference at baseline in log(2/16OHE1) p=0.048. Changes from baseline in 2/16 will need to 
be 
additionally adjusted for baseline 2/16*/ 
quit; 
 
Data a; 
Set logCI_0; 
geometric_mean= exp(lsmean); 
left_CI= exp(LowerCL); 
right_CI= exp(UpperCL); 
drop lsmean LowerCL UpperCL; 
run; 
proc print data =a; 
run; 
 
Proc GLM Data =EM.EM_Merged_nmolperday; 
class trt age_strata bmi_strata; 
model D_R_2to16E1_nmolperday = log_R_2to16E1_0_nmolperday trt age_strata | bmi_strata /ss3; 
lsmeans trt / stderr pdiff; 
run;  
 
/*Exercisers significantly increase their ratio (p=0.034) which was different from the controls (p=0.033)*/ 
quit; 
 
Proc Freq Data=EM.EM_Merged_ngpermgCr; 
Tables bmi_class * trt /nopercent norow nocol;; 
run;    
 
Data normalBMI_nmolperday; 
Set EM.EM_Merged_nmolperday; 
if bmi_class = '1_Normal'; 
run; 
  
Proc GLM Data =normalBMI_nmolperday;  
class trt age_strata bmi_strata; 
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model log_E1_0_nmolperday /*log_E2_0_nmolperday log_E3_0_nmolperday 
log__16_OH_E1_0_nmolperday*/ 
log_OH_2_E1_0_nmolperday /*log_OH_4_E1_0_nmolperday log_MeO_2_E1_0_nmolperday 
log_MeO_2_E2_0_nmolperday  
log_R_2to4E1_0_nmolperday*/ log_R_2to16E1_0_nmolperday 
= trt age_strata | bmi_strata/ ss3; 
lsmeans trt / CL pdiff; 
ODS output LSMeanCL=logCI_0; 
run;  
quit; 
 
Data normal; 
Set logCI_0; 
geometric_mean= exp(lsmean); 
left_CI= exp(LowerCL); 
right_CI= exp(UpperCL); 
drop lsmean LowerCL UpperCL; 
run; 
proc print data =normal; 
run; 
 
Proc GLM Data = normalBMI_nmolperday; 
class trt age_strata bmi_strata; 
model  D_E1_nmolperday /*D_E2_nmolperday D_E3_nmolperday D__16_OH_E1_nmolperday 
*/D_OH_2_E1_nmolperday /*D_OH_4_E1_nmolperday D_MeO_2_E1_nmolperday 
D_MeO_2_E2_nmolperday   
  D_R_2to4E1_nmolperday*/ D_R_2to16E1_nmolperday 
       = trt age_strata | bmi_strata  /ss3; 
lsmeans trt / stderr pdiff; 
run;  
quit; 
 
Data overwtBMI_nmolperday; 
Set EM.EM_Merged_nmolperday; 
if bmi_class = '2_Overwt'; 
run; 
  
Proc GLM Data =overwtBMI_nmolperday;  
class trt age_strata bmi_strata; 
model log_E1_0_nmolperday /*log_E2_0_nmolperday log_E3_0_nmolperday 
log__16_OH_E1_0_nmolperday*/ 
log_OH_2_E1_0_nmolperday /*log_OH_4_E1_0_nmolperday log_MeO_2_E1_0_nmolperday 
log_MeO_2_E2_0_nmolperday  
log_R_2to4E1_0_nmolperday*/ log_R_2to16E1_0_nmolperday 
= trt age_strata | bmi_strata/ ss3; 
lsmeans trt / CL pdiff; 
ODS output LSMeanCL=logCI_0; 
run;  
quit; 
 
Data overwt; 
Set logCI_0; 
geometric_mean= exp(lsmean); 
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left_CI= exp(LowerCL); 
right_CI= exp(UpperCL); 
drop lsmean LowerCL UpperCL; 
run; 
proc print data =overwt; 
run; 
 
Proc GLM Data = overwtBMI_nmolperday; 
class trt age_strata bmi_strata; 
model  D_E1_nmolperday /*D_E2_nmolperday D_E3_nmolperday D__16_OH_E1_nmolperday 
*/D_OH_2_E1_nmolperday /*D_OH_4_E1_nmolperday D_MeO_2_E1_nmolperday 
D_MeO_2_E2_nmolperday   
  D_R_2to4E1_nmolperday*/ D_R_2to16E1_nmolperday 
       = trt age_strata |bmi_strata /ss3; 
lsmeans trt / stderr pdiff; 
run;  
quit; 
 
Data obeseBMI_nmolperday; 
Set EM.EM_Merged_nmolperday; 
if bmi_class = '3_Obese'; 
run; 
  
Proc GLM Data =obeseBMI_nmolperday;  
class trt age_strata bmi_strata; 
model log_E1_0_nmolperday /*log_E2_0_nmolperday log_E3_0_nmolperday 
log__16_OH_E1_0_nmolperday*/ 
log_OH_2_E1_0_nmolperday /*log_OH_4_E1_0_nmolperday log_MeO_2_E1_0_nmolperday 
log_MeO_2_E2_0_nmolperday  
log_R_2to4E1_0_nmolperday*/ log_R_2to16E1_0_nmolperday 
= trt age_strata | bmi_strata/ ss3; 
lsmeans trt / CL pdiff; 
ODS output LSMeanCL=logCI_0; 
run;  
quit; 
 
 
Data obese; 
Set logCI_0; 
geometric_mean= exp(lsmean); 
left_CI= exp(LowerCL); 
right_CI= exp(UpperCL); 
drop lsmean LowerCL UpperCL; 
run; 
proc print data =obese; 
run; 
 
Proc GLM Data = obeseBMI_nmolperday; 
class trt age_strata bmi_strata; 
model  D_E1_nmolperday /*D_E2_nmolperday D_E3_nmolperday D__16_OH_E1_nmolperday 
*/D_OH_2_E1_nmolperday /*D_OH_4_E1_nmolperday D_MeO_2_E1_nmolperday 
D_MeO_2_E2_nmolperday   
  D_R_2to4E1_nmolperday*/ D_R_2to16E1_nmolperday  
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          = trt age_strata | bmi_strata /ss3; 
lsmeans trt / stderr pdiff; 
run;  
quit; 
 
Data quartiles; 
Set EM.EM_Merged_nmolperday; 
strata_2to16E1 = ROUND (log_R_2to16E1_0_nmolperday,0.1); 
run; 
 
Proc Freq Data=quartiles; 
tables trt*strata_2to16E1/ nopercent norow nocol; 
run; 
 
proc univariate data=quartiles; 
var strata_2to16E1; 
run; 
 
/* Table 2. Changes in body weight, anthropometry, fitness,PA*/ 
Data EM.Table2_ngpermgcr; 
Merge WISER.Demographics_319 WISER.Bodycomp_319 Wiser.Bodyweights_319  
WISER.FoodRecords_312 WISER.Fitness_319 WISER.SRPA_319; 
by ID; 
If ID= '2601' then DELETE; 
If ID= '2622' then DELETE; 
KEEP ID trt  
 age age_strata bmi_strata bmi_class 
Weight_0 weight_1 D_weight PD_weight BMI_0 BMI_1 D_BMI PD_BMI 
fat_mass_0 fat_mass_1 D_fat_mass PD_fat_mass lean_mass_0 lean_mass_1 D_lean_mass 
PD_lean_mass  
 kcal_0 kcal_1 D_kcal PD_kcal 
     Mets_0 Mets_1 D_Mets PD_Mets  
total_mets_week_0 total_mets_week_1 D_SRPA D_percent_SRPA ; 
 RUN; 
 
 
Proc GLM Data=EM.Table2_ngpermgCr; 
class trt bmi_strata age_strata; 
/*model Mets_0 Mets_1 D_mets PD_mets = trt | bmi_strata | age_strata ss3;*/  
model Mets_0 Mets_1 D_mets PD_mets = trt bmi_strata | age_strata; 
lsmeans trt /stderr pdiff ; 
/* none of the trt*strata interactions were significant so will be removed from model*/ 
ods select lsmeans; 
run; 
 
Proc GLM Data=EM.Table2_ngpermgCr; 
class trt bmi_strata age_strata; 
*model weight_0 weight_1 D_weight PD_weight = trt | bmi_strata | age_strata; 
model weight_0 weight_1 D_weight PD_weight = trt bmi_strata | age_strata; 
lsmeans trt /stderr pdiff; 
/* none of the trt*strata interactions were significant so will be removed from model*/ 
ods select lsmeans; 
run; 
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Proc GLM Data=EM.Table2_ngpermgCr; 
class trt bmi_strata age_strata; 
*model bmi_0 bmi_1 D_bmi PD_bmi = trt | bmi_strata | age_strata; 
model bmi_0 bmi_1 D_bmi PD_BMI = trt bmi_strata | age_strata; 
lsmeans trt /stderr pdiff; 
/* none of the trt*strata interactions were significant so will be removed from model*/ 
ods select lsmeans; 
run; 
 
Proc GLM Data=EM.Table2_ngpermgCr; 
class trt bmi_strata age_strata; 
*model fat_mass_0 fat_mass_1 D_fat_mass PD_fat_mass= trt|bmi_strata|age_strata; 
model fat_mass_0 fat_mass_1 D_fat_mass PD_fat_mass= trt bmi_strata | age_strata; 
lsmeans trt /stderr pdiff; 
/* none of the trt*strata interactions were significant so will be removed from model*/ 
ods select lsmeans; 
run; 
 
Proc GLM Data=EM.Table2_ngpermgCr; 
class trt bmi_strata age_strata; 
*model lean_mass_0 lean_mass_1 D_lean_mass PD_lean_mass= trt|bmi_strata|age_strata; 
model lean_mass_0 lean_mass_1 D_lean_mass PD_lean_mass= trt bmi_strata | age_strata; 
lsmeans trt /stderr pdiff; 
/* none of the trt*strata interactions were significant so will be removed from model*/ 
ods select lsmeans; 
run; 
 
Proc GLM Data=EM.Table2_ngpermgCr; 
class trt bmi_strata age_strata; 
*model kcal_0 kcal_1 D_kcal PD_kcal= trt|bmi_strata|age_strata; 
model kcal_0 kcal_1 D_kcal PD_kcal = trt bmi_strata | age_strata; 
lsmeans trt /stderr pdiff; 
/* none of the trt*strata interactions were significant so will be removed from model*/ 
ods select lsmeans; 
run; 
 
/*Self-reported physical activity won't be reported*/ 
Proc GLM Data=EM.Table2_ngpermgCr; 
class trt bmi_strata age_strata; 
*model total_mets_week_0 total_mets_week_1 D_srpa D_percent_SRPA = trt bmi_strata | age_strata; 
model total_mets_week_0 total_mets_week_1 D_srpa D_percent_SRPA = trt bmi_strata | age_strata; 
lsmeans trt /stderr pdiff; 
/* none of the trt*strata interactions were significant so will be removed from model*/ *ods select lsmeans; 
run;; 
 
 
 
 
